x	y	score	nptumor	nphit	tumor	name	status	top	cx	cy
1453.6333166516968	1.1526071822040365	0.892	89	20	ACC	TRAMETINIB	Approved in cancer	NF1|RB1|STK11	1456.3078089853377	69.71161637903302
1385.686748323648	-2.6512980538048794	0.8420000000000001	89	14	ACC	CICLOPHOSPHAMIDE	Approved in same tumor type	CTNNB1|TP53|ATM	1327.4635399620306	211.16886596619327
255.21065482578788	4.1763727899678145	0.0004	89	14	ACC	SMR000031817	Experimental	CTNNB1|TP53	246.82035608328476	46.33515316351432
1364.810102856892	6.9087959878889365	0.8230000000000001	89	11	ACC	TEMSIROLIMUS	Approved in cancer	CTNNB1|BRAF|PIK3CA	1407.7172112762853	-77.90059243827183
1370.658605001167	-6.597488634980607	0.8310000000000001	89	11	ACC	DEXAMETHASONE	Approved in cancer	CTNNB1|RB1	1292.1877386206656	64.37811552370363
1172.2039760146217	0.4314296405181892	0.6829999999999999	89	10	ACC	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	TP53|NF1|STK11	1097.865213035433	5.687818275096191
900.6308844114557	0.4343142204542687	0.482	89	10	ACC	PIMASERTIB	Clinical trials in cancer	NRAS|TP53|NF1	874.0843592015215	-6.008457587386687
1368.452939153523	2.3747735548068647	0.8310000000000001	89	10	ACC	TOPOTECAN	Approved in cancer	PIK3CA|TP53|RB1	1252.6090150019716	151.892648347075
1117.9856846439166	0.4223950523025337	0.643	89	10	ACC	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	TP53|RB1|STK11	1009.4708210605728	31.994585673623533
846.8478399500892	2.025969342146311	0.442	89	10	ACC	SAPANISERTIB	Clinical trials in cancer	TP53|RB1|STK11	741.659992233996	-55.09826382284034
1389.6415304769441	2.375956114254194	0.8420000000000001	89	10	ACC	IMATINIB	Approved in cancer	CTNNB1|BRAF	1312.525741085277	-90.56736607821163
249.07745578351754	-10.544331053148028	0.0004	89	10	ACC	DITHIAZANINE IODIDE	Experimental	CTNNB1|ATM	169.5799671669485	18.169630819870974
1505.126627248277	0.4317187448390314	0.93	89	9	ACC	ALPELISIB	Approved in cancer	PIK3CA|NRAS|TP53	1489.9206098770162	5.361513706449358
1386.9769346662815	7.085957607808609	0.8420000000000001	89	9	ACC	BORTEZOMIB	Approved in cancer	PIK3CA|TP53|RB1	1401.6710080775185	-159.81856182950975
1559.1743695635835	0.4323558192293149	0.97	89	9	ACC	DABRAFENIB	Approved in cancer	PIK3CA|NRAS|TP53	1560.9326236963725	27.979844214826898
1545.7509590892669	0.4322967369238029	0.96	89	9	ACC	VEMURAFENIB	Approved in cancer	PIK3CA|NRAS|TP53	1526.7882596895574	-16.43204809803106
1343.2312006388509	-1.516112000358902	0.812	89	9	ACC	VORINOSTAT	Approved in cancer	BRAF|TP53|RB1	1260.154454431198	-15.533884636720103
961.3381585124706	0.43204663458183745	0.527	89	9	ACC	GEDATOLISIB	Clinical trials in cancer	NRAS|TP53|STK11	922.0474461612329	-78.72783250682828
859.6745730456232	-1.825594481962213	0.452	89	9	ACC	MIRDAMETINIB	Clinical trials in cancer	NRAS|TP53|STK11	805.4010919368263	-41.246239285672544
563.2349154234191	0.43206912653536733	0.2319999999999999	89	9	ACC	GEMCITABINE	Approved in other pathologies	PIK3CA|NRAS|TP53	503.84139841411223	-7.663566562764288
243.79509138249273	-3.065906421374507	0.0004	89	9	ACC	93718-83-3	Experimental	GNAS|MEN1|TP53	211.25194877051416	77.19278941036293
1380.7335263607729	1.024720599892646	0.8410000000000001	89	9	ACC	THALIDOMIDE	Approved in cancer	CTNNB1	1326.2281608425412	-49.04862659136967
819.8991128838221	-4.178841238475201	0.422	89	9	ACC	TRICIRIBINE	Clinical trials in cancer	CTNNB1	738.891485424522	12.49692149601978
819.7230251370133	0.8603865270327162	0.422	89	9	ACC	VANTICTUMAB	Clinical trials in cancer	CTNNB1	709.5048811179504	54.71267654499442
536.2954449905236	0.43199167646787373	0.212	89	9	ACC	FLUORESCEIN SODIUM	Approved in other pathologies	CTNNB1	466.4766746229107	33.724468596160676
253.2515880912826	10.02525856009484	0.0004	89	9	ACC	(+/-)-HYDNOCARPIN	Experimental	CTNNB1	275.65531876303373	-39.86615525237414
257.888209848649	-1.3747755276654061	0.0004	89	9	ACC	CID 5718631	Experimental	CTNNB1	308.1395511004365	-64.10575586685431
245.00133479405477	6.388728382642569	0.0004	89	9	ACC	EOSIN_Y	Experimental	CTNNB1	219.7391492723212	2.6446538928902896
252.84982039094274	-1.5235213308146172	0.0004	89	9	ACC	SODIUM 2-PHENOXYBENZOATE	Experimental	CTNNB1	258.1169520824143	-67.90512868337288
1398.5036113869353	-1.383790753014864	0.8520000000000001	89	8	ACC	METHOTREXATE	Approved in cancer	TP53|RB1	1401.9776489754734	32.52567478935049
1375.7846637376983	-5.3855292424261165	0.8330000000000001	89	8	ACC	DOXORUBICIN	Approved in same tumor type	PIK3CA|TP53|ATM	1278.9356180311381	64.36725662851751
1376.3013123620547	-0.8189140325972346	0.8330000000000001	89	8	ACC	CISPLATIN	Approved in cancer	TP53|ATM|STK11	1260.319706169838	146.1965293635729
1373.4760525531535	2.8104793567230786	0.8320000000000001	89	8	ACC	BEVACIZUMAB	Approved in cancer	BRAF|PIK3CA|TP53	1402.3830159281565	32.76890839134421
1375.3734467725283	6.996673395841071	0.8320000000000001	89	8	ACC	CARBOPLATIN	Approved in cancer	PIK3CA|NRAS|TP53	1336.420865072242	-66.88263162950497
1371.7529751129593	-1.4418270607897625	0.8320000000000001	89	8	ACC	FLUOROURACIL	Approved in cancer	PIK3CA|TP53|ATM	1316.0057670414537	116.50784911564034
1356.1078358557086	-6.42665947103913	0.8220000000000001	89	8	ACC	IRINOTECAN	Approved in cancer	PIK3CA|TP53|ATM	1288.2941057949508	55.66690775225308
1350.2426346869527	3.205378178468777	0.812	89	8	ACC	LORLATINIB	Approved in cancer	TP53|RB1	1270.2116870777909	74.42402204704808
1367.3062890807455	-2.5455057673128465	0.8250000000000001	89	8	ACC	OLAPARIB	Approved in cancer	CHEK2|TP53|ATM	1306.35606014988	-109.74107239815842
1357.7862050370336	2.4976679515783644	0.8230000000000001	89	8	ACC	PEMBROLIZUMAB	Approved in cancer	MSH6|NRAS|TP53	1343.3603540198503	-135.5443299305125
1360.082418585605	-8.738778142928453	0.8220000000000001	89	8	ACC	VENETOCLAX	Approved in cancer	BRAF|PIK3CA|TP53	1227.131663749153	-27.245423471277917
1186.9561663058541	0.4319617215365099	0.694	89	8	ACC	DASATINIB	Approved in other pathologies and in clinical trials in cancer	BRAF|PIK3CA|TP53	1137.4947057284696	67.09116940390234
1089.617432450647	3.3617841694691606	0.622	89	8	ACC	MERCAPTOPURINE	Approved in other pathologies and in clinical trials in cancer	TP53|RB1	1058.6492364261935	-132.49231782960524
863.0485380454874	1.6178203216593658	0.453	89	8	ACC	SELICICLIB	Clinical trials in cancer	TP53|RB1	763.8286658072875	-20.619958094027368
954.8847228220146	0.4320880612591509	0.522	89	8	ACC	NVP-CGM097	Clinical trials in cancer	BRAF|PIK3CA|TP53	895.9830374795308	-102.58148947864939
873.4495072155245	0.45024543009051854	0.462	89	8	ACC	NAVITOCLAX	Clinical trials in cancer	BRAF|PIK3CA|TP53	852.0537373634835	-98.80720086502771
819.9080383022919	5.676834401595983	0.422	89	8	ACC	ADAVOSERTIB	Clinical trials in cancer	NRAS|TP53|STK11	720.864492397716	23.54233053610392
268.82626867801264	0.25625338370471695	0.014	89	8	ACC	LY3009120	Clinical trials	BRAF|NRAS|TP53	207.78077084107167	1.2737554271086537
249.8153809412278	6.6568354645467025	0.0004	89	8	ACC	1173900-33-8	Experimental	PIK3CA|TP53|ATM	200.11056264047824	84.08253604956712
253.98704701133772	-9.394092345348298	0.0004	89	8	ACC	GNF-PF-4029	Experimental	MEN1|TP53	225.93262114542827	-4.180266952076721
249.65520776870002	2.0733932360583083	0.0004	89	8	ACC	PF-477736	Experimental	BRAF|CHEK2|TP53	218.66919625007554	2.6313939380380873
245.08522712174482	1.5689196860277264	0.0004	89	8	ACC	SMR000065948	Experimental	MEN1|TP53	199.00360806508075	82.53859738976757
248.54094426954947	11.066295508519204	0.0004	89	8	ACC	TRACAZOLATE	Experimental	MEN1|TP53	205.8267639482684	-80.54338123435934
1356.0117097323102	8.081685423226418	0.8220000000000001	89	7	ACC	ABEMACICLIB	Approved in cancer	NRAS|TP53	1323.8091703888954	19.3916057028612
1571.2134877345225	0.43238998537006523	0.979	89	7	ACC	ENCORAFENIB	Approved in cancer	BRAF|TP53	1578.8193859815653	4.56936135308257
1384.8697408774108	3.012273962725857	0.8420000000000001	89	7	ACC	DOCETAXEL	Approved in cancer	PIK3CA|TP53	1306.4583572683975	-109.97550846709751
1453.638564356558	-5.915390869691095	0.892	89	7	ACC	TAMOXIFEN	Approved in cancer	PIK3CA|TP53	1412.68549463508	170.64540183522706
1401.6282230697268	1.6752865500123164	0.8530000000000001	89	7	ACC	PACLITAXEL	Approved in cancer	PIK3CA|TP53|ATM	1447.0311359445816	101.19414328203959
1357.0903822398045	-1.8186652191552923	0.8220000000000001	89	7	ACC	CAPMATINIB	Approved in cancer	BRAF|TP53	1314.630639809337	-69.15480771156105
1426.4531486632466	0.4246431891263569	0.8720000000000001	89	7	ACC	DUVELISIB	Approved in cancer	PIK3CA|TP53	1409.8092414687999	-18.801585998456858
1371.0368225111504	6.441629277955769	0.8320000000000001	89	7	ACC	ERLOTINIB	Approved in cancer	BRAF|TP53	1285.0094636959543	86.6819038796084
1359.7897323164043	6.385089798127808	0.8220000000000001	89	7	ACC	RALOXIFENE	Approved in cancer	PIK3CA|TP53	1295.7826131217048	119.17698998276705
846.8275352725354	-2.795987907774304	0.442	89	7	ACC	DS-7423	Clinical trials in cancer	PIK3CA|TP53	739.4802134145292	-143.5279636117241
833.287413819256	0.42319858750647654	0.432	89	7	ACC	CAPIVASERTIB	Clinical trials in cancer	PIK3CA|TP53	747.8019533320166	-104.79583051433961
806.168996607538	-3.432454039733642	0.412	89	7	ACC	DEMCIZUMAB	Clinical trials in cancer	PIK3CA|TP53	764.1840161656586	-18.07929513401936
806.1784199088634	4.339457035189554	0.412	89	7	ACC	GANETESPIB	Clinical trials in cancer	BRAF|TP53	742.2500436606499	11.94604761519011
858.8099185004927	2.6894958101439386	0.452	89	7	ACC	RESVERATROL	Clinical trials in cancer	PIK3CA|TP53	810.2848092808194	83.22429913957637
807.6228292415291	0.4510658951415678	0.412	89	7	ACC	TANESPIMYCIN	Clinical trials in cancer	PIK3CA|TP53	744.7293308204797	10.979198895421888
264.98798083067675	2.35097487385039	0.012	89	7	ACC	EMODIN	Clinical trials	PIK3CA|TP53	210.03791865030774	-131.14115218445403
264.9656083484125	-1.7969647920530178	0.012	89	7	ACC	INOSITOL	Clinical trials	NRAS|TP53	199.35986641772152	-58.964482819131476
279.0077661249144	0.3724671466034124	0.022	89	7	ACC	PF-04217903	Clinical trials	BRAF|TP53	279.91643340688074	57.71325996218542
251.3845267930358	-5.879301813514786	0.0004	89	7	ACC	ABT-737	Experimental	PIK3CA|TP53	201.6882730307136	-29.96393282446104
248.28377389664067	-2.07775390719803	0.0004	89	7	ACC	AZD7762	Experimental	CHEK2|TP53	233.5844531577719	-112.19105539225258
247.24633476627145	-6.093924209956299	0.0004	89	7	ACC	CHEMBL2002487	Experimental	GNAS|TP53	267.0571716335948	3.594720698188155
1353.8094362774782	0.6983291895062109	0.8210000000000001	89	7	ACC	LENALIDOMIDE	Approved in cancer	CTNNB1	1268.319488066647	113.37919399997065
255.481794892014	-5.282471723384987	0.0004	89	7	ACC	NUTLIN-3A (-)	Experimental	CTNNB1	263.6539571958376	145.95093359441074
1354.218448305997	4.5966244223411366	0.8220000000000001	89	6	ACC	DAUNORUBICIN HYDROCHLORIDE	Approved in cancer	TP53	1289.9953850742966	-38.3143290454131
1361.8820853664934	3.0996622805978973	0.8220000000000001	89	6	ACC	ETOPOSIDE	Approved in cancer	TP53|ATM	1373.843096826584	123.13288420303257
1363.7536968554152	-6.8130346576258205	0.8220000000000001	89	6	ACC	CRIZOTINIB	Approved in cancer	TP53	1282.115298231583	-14.10700340249781
1344.5482550562601	-5.6857821912648205	0.812	89	6	ACC	DOXORUBICIN HYDROCHLORIDE	Approved in same tumor type	TP53	1258.9415367525783	-14.668700279298236
1353.4540957225424	-3.245596903481129	0.8220000000000001	89	6	ACC	IBRUTINIB	Approved in cancer	TP53|ATM	1388.7083464648804	33.93598837619689
1347.2653720789924	-3.1931022049754745	0.812	89	6	ACC	IFOSFAMIDE	Approved in cancer	TP53	1302.8334759163054	202.56481168944435
1346.1846118840276	4.065945317325799	0.812	89	6	ACC	MECHLORETHAMINE HYDROCHLORIDE	Approved in cancer	TP53	1259.752029580018	33.86485383954803
1359.2750814857652	10.263644132984211	0.8220000000000001	89	6	ACC	MELPHALAN	Approved in same tumor type	TP53	1337.6800312630808	-66.68517051920017
1347.1015585773982	0.4953847596520973	0.812	89	6	ACC	METHYLPREDNISOLONE	Approved in cancer	TP53	1334.3377749700567	-16.108790411917738
1360.7263575095365	-0.41992798160026723	0.8220000000000001	89	6	ACC	MITOXANTRONE	Approved in cancer	TP53	1275.555618878646	8.435415633835277
1363.220153550826	-3.1649666158299965	0.8220000000000001	89	6	ACC	MITOXANTRONE HYDROCHLORIDE	Approved in cancer	TP53	1351.587864486221	93.21537552958313
1359.824254331873	-4.613480157676662	0.8220000000000001	89	6	ACC	PANITUMUMAB	Approved in cancer	TP53	1326.6833820672298	-47.111695470969295
1397.845347820342	2.7106313464559832	0.8520000000000001	89	6	ACC	PAZOPANIB	Approved in cancer	TP53	1414.0537863712693	-5.072564301408363
1344.829479650096	7.498627564423117	0.812	89	6	ACC	RITUXIMAB	Approved in cancer	TP53	1352.7796895227661	20.043844285165704
1350.3425990882379	-5.2397895405205475	0.812	89	6	ACC	TAMOXIFEN CITRATE	Approved in cancer	TP53	1311.3916912648906	-72.99356410315515
1364.3508930664293	0.34224028435227183	0.8230000000000001	89	6	ACC	TEMOZOLOMIDE	Approved in cancer	MSH6|TP53	1314.960253046594	-169.6834338986345
1350.386208575926	-1.1991624635484186	0.812	89	6	ACC	TRABECTEDIN	Approved in cancer	TP53	1271.3687502557134	6.140229582260446
1348.4855544298641	6.956840906173568	0.812	89	6	ACC	TRIFLURIDINE	Approved in cancer	TP53	1349.2038476851021	-21.661406357938745
1306.4169277276887	0.43743153355438835	0.782	89	6	ACC	ASPIRIN	Approved in other pathologies and in clinical trials in cancer	TP53	1215.1480178497595	41.43300340057431
1089.612177647121	-3.5522547421280706	0.622	89	6	ACC	CLADRIBINE	Approved in other pathologies and in clinical trials in cancer	TP53	1053.857787972924	-97.92631429297255
1091.4625921695797	-0.35148889816687756	0.622	89	6	ACC	AZACITIDINE	Approved in other pathologies and in clinical trials in cancer	TP53	1052.810521228998	-35.98241253654979
1076.4624351843559	-1.7373991751701396	0.612	89	6	ACC	CHLORAMBUCIL	Approved in other pathologies and in clinical trials in cancer	TP53	1070.5419216258306	-61.149645119851115
1087.7665932325199	-0.3486858190557598	0.622	89	6	ACC	DAUNORUBICIN	Approved in other pathologies and in clinical trials in cancer	TP53	1012.3705663947128	19.08358915018559
1074.8459865755224	1.587868627522539	0.612	89	6	ACC	ENALAPRIL	Approved in other pathologies and in clinical trials in cancer	TP53	1034.3283843842064	-77.94047081416468
1078.5326885328018	1.3258673340061478	0.612	89	6	ACC	FENOFIBRATE	Approved in other pathologies and in clinical trials in cancer	TP53	1035.7373973544304	-110.06406750236319
1326.9832146323906	-3.42126121089035	0.797	404	228	BLCA	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	CDH1|NF1|PTEN	1179.7192121851563	140.3417986481445
1603.1421871396678	-1.913392624774957	1	404	224	BLCA	ALPELISIB	Approved in cancer	HRAS|TP53|PTEN	1596.2548161886803	-170.64079069858312
1528.597432244796	0.4580132762997948	0.949	404	219	BLCA	TRAMETINIB	Approved in cancer	TP53|NF1|RB1	1578.634341528464	-133.5127054910502
1453.5545091906092	-40.83485991391049	0.893	404	215	BLCA	BORTEZOMIB	Approved in cancer	KRAS|TP53|RB1	1483.5055700322005	-241.81054641493165
1189.6580407425804	0.11363586190481101	0.694	404	215	BLCA	DASATINIB	Approved in other pathologies and in clinical trials in cancer	KRAS|HRAS|TP53	1135.0775313227698	143.26254593945902
989.543276405927	-1.9352385809707755	0.546	404	204	BLCA	CAPIVASERTIB	Clinical trials in cancer	KRAS|TP53|PTEN	897.642355622154	3.488142529421509
1472.4396795282091	11.838422796703497	0.893	404	196	BLCA	CISPLATIN	Approved in same tumor type	PTEN|BRCA1|ATM	1402.3321023275053	-148.0302891482587
1452.4184876836637	9.637839686104059	0.893	404	191	BLCA	PACLITAXEL	Approved in cancer	PTEN|BRCA1|ATM	1367.0202782896815	-257.93435015987575
1168.5704683730246	0.8377156631616458	0.6829999999999999	404	191	BLCA	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	HRAS|TP53|RB1	1116.5100237689182	-52.47348845873307
1470.3698650348713	-8.164002017393386	0.892	404	190	BLCA	FLUOROURACIL	Approved in cancer	TP53|PTEN|ATM	1502.4921550441502	-152.69120562628893
914.9237443942116	15.623265900418659	0.493	404	190	BLCA	SAPANISERTIB	Clinical trials in cancer	TP53|PTEN|RB1	858.3130710904061	-26.95150658059117
1429.137961142643	32.72884889045997	0.8730000000000001	404	189	BLCA	DOXORUBICIN	Approved in same tumor type	KMT2A|BRCA1|ATM	1397.891492875581	-110.44147993763492
1424.7354335103425	-6.795987289415109	0.8720000000000001	404	189	BLCA	OLAPARIB	Approved in cancer	PTEN|BRCA1|ATM	1289.6051782071972	41.14040833173445
1440.2631874360911	-18.8440792464026	0.882	404	188	BLCA	BEVACIZUMAB	Approved in cancer	KRAS|HRAS|TP53	1462.5954031384185	40.06980994650439
644.2694744423313	-4.6586132516004	0.292	404	188	BLCA	GEMCITABINE	Approved in other pathologies	TP53|PTEN|BRCA1	607.2425499644753	18.25328638156904
1571.9175762440725	-1.754737519057386	0.98	404	187	BLCA	DABRAFENIB	Approved in cancer	NRAS|HRAS|TP53	1585.2540013758867	109.9015818337956
1432.9596728738834	12.758724784000975	0.8730000000000001	404	187	BLCA	CARBOPLATIN	Approved in cancer	BRCA2|PTEN|BRCA1	1321.488117747237	173.75569312381128
1062.9146720319857	6.282461199557616	0.597	404	185	BLCA	GEDATOLISIB	Clinical trials in cancer	NRAS|TP53|PTEN	1045.0584751172573	77.17207725194788
1422.3182938120606	-26.191769931776037	0.8720000000000001	404	184	BLCA	IRINOTECAN	Approved in cancer	BRCA2|BRCA1|ATM	1298.3251526696283	72.57156156126959
1053.9223124646437	-10.593793805087074	0.595	404	181	BLCA	PIMASERTIB	Clinical trials in cancer	NRAS|TP53|NF1	1007.5290419131702	65.196880835385
1043.8663501633287	5.373501582244046	0.594	404	180	BLCA	MIRDAMETINIB	Clinical trials in cancer	NRAS|TP53|PTEN	1031.47922987724	-143.47081933414316
1586.4169434339922	10.70720991340525	0.993	404	179	BLCA	PAZOPANIB	Approved in cancer	TP53|BRCA2|BRCA1	1579.4863728085804	53.58347199326312
1467.3772227104582	42.05240102726654	0.892	404	179	BLCA	VENETOCLAX	Approved in cancer	KRAS|TP53|PTEN	1432.1530579623206	-17.566390894809217
924.1103821370369	-1.2015760328791885	0.494	404	177	BLCA	DS-7423	Clinical trials in cancer	KRAS|TP53|PTEN	899.6842286964745	69.39634551146733
1549.1514046540588	0.4243354015395937	0.96	404	176	BLCA	VEMURAFENIB	Approved in cancer	HRAS|TP53|PTEN	1549.4762291000895	94.75533488678212
912.3008706341624	-15.411783140197201	0.492	404	176	BLCA	NAVITOCLAX	Clinical trials in cancer	KRAS|TP53|PTEN	862.4662938327873	-58.51458156717642
244.04606771280064	27.8330759920359	0.0004	404	176	BLCA	1173900-33-8	Experimental	TP53|PTEN|ATM	99.60564323718522	-50.9432048776423
1402.4392825945913	-1.1263735389587168	0.8620000000000001	404	175	BLCA	TOPOTECAN	Approved in cancer	TP53|PTEN|RB1	1371.4802558665879	248.90604029895673
257.7830217009857	-36.24537680146884	0.0004	404	175	BLCA	ABT-737	Experimental	KRAS|TP53|PTEN	128.08594509409028	12.7868468626273
1024.992455897067	-1.3821168252447364	0.5720000000000001	404	172	BLCA	NVP-CGM097	Clinical trials in cancer	PIK3CA|KRAS|TP53	943.4272438599546	-100.13995353929926
833.3571800919858	-6.834451931367113	0.432	404	171	BLCA	DEMCIZUMAB	Clinical trials in cancer	PIK3CA|KRAS|TP53	730.4823253928884	-26.635371959007813
333.4756304595164	0.42305518879445003	0.062	404	165	BLCA	EMODIN	Clinical trials	PIK3CA|TP53|BRCA1	333.5734555767337	-11.860349734444839
1449.4493572385134	40.66747786397599	0.892	404	164	BLCA	TAMOXIFEN	Approved in cancer	PIK3CA|TP53|BRCA1	1440.2422540701232	239.56115020941053
1008.0115062710175	3.183450543585934	0.5630000000000001	404	163	BLCA	RESVERATROL	Clinical trials in cancer	PIK3CA|TP53|BRCA1	950.8896139740019	-37.73596869649765
1473.6604628779814	-26.148702064335538	0.892	404	159	BLCA	DUVELISIB	Approved in cancer	PIK3CB|PIK3CA|TP53	1385.1671116164503	-260.5116648715591
1402.4250509649428	16.352174257676097	0.8620000000000001	404	158	BLCA	RALOXIFENE	Approved in cancer	PIK3CA|TP53	1444.5996064940332	-51.837904123708284
847.7790804193747	2.699044464749079	0.442	404	158	BLCA	TANESPIMYCIN	Clinical trials in cancer	PIK3CA|TP53	715.4974303856008	-58.980443200545935
1460.469189684107	25.879008927409757	0.892	404	156	BLCA	DOCETAXEL	Approved in cancer	KRAS|HRAS|TP53	1348.8892020847875	-87.83926142482345
1457.7765008773363	-22.174383450653437	0.893	404	152	BLCA	EVEROLIMUS	Approved in cancer	BRCA1|RB1|ATM	1425.393030559404	-274.0954881937656
980.8749790019542	14.380082935615349	0.543	404	149	BLCA	BERZOSERTIB	Clinical trials in cancer	BRCA2|BRCA1|ATM	937.8665271371306	57.53330080911823
1416.2032919420838	8.387789909175524	0.8720000000000001	404	143	BLCA	CICLOPHOSPHAMIDE	Approved in cancer	BRCA2|BRCA1|ATM	1313.51018805049	57.29225929550125
1444.7793539980828	25.26106065078548	0.892	404	141	BLCA	ABEMACICLIB	Approved in cancer	CDKN2A|NRAS|TP53	1468.7656429773926	100.40815771140831
1396.0393063193353	-16.48399220159297	0.8520000000000001	404	141	BLCA	VORINOSTAT	Approved in cancer	TP53|PTEN|RB1	1394.1316503891217	183.19735927325826
1595.8172811466438	-19.35797825095247	0.999	404	138	BLCA	ENCORAFENIB	Approved in cancer	KRAS|TP53|PTEN	1599.0188045694772	115.32460022793157
1453.168706726354	-7.540483199317947	0.892	404	138	BLCA	METHOTREXATE	Approved in cancer	IDH1|TP53|RB1	1436.162476861793	228.31632831433978
873.7664758163039	0.4403713444835944	0.462	404	138	BLCA	ADAVOSERTIB	Clinical trials in cancer	NRAS|TP53|BRCA1	794.2388824651009	76.35027652448531
283.0340080425331	6.654439964913195	0.024	404	138	BLCA	LY3009120	Clinical trials	KRAS|NRAS|TP53	183.35626946351627	112.0655873516593
1405.5619495604465	-28.371593893331976	0.8620000000000001	404	137	BLCA	CRIZOTINIB	Approved in cancer	KRAS|CDKN2A|TP53	1315.9033671266643	100.86075349998481
1144.0665413964366	0.43630792179808964	0.6619999999999999	404	137	BLCA	MERCAPTOPURINE	Approved in other pathologies and in clinical trials in cancer	IDH1|TP53|RB1	1112.2134104002635	54.3920667652628
255.32111592162443	39.734741559187455	0.0004	404	135	BLCA	PF-477736	Experimental	KRAS|CDKN2A|TP53	217.77161648989585	44.79507761531167
1375.3384178231036	1.5047762932118474	0.8330000000000001	404	134	BLCA	PEMBROLIZUMAB	Approved in same tumor type	TP53|MSH2|MSH6	1373.5381005100123	100.8809671411446
260.3257240211388	26.342633817410217	0.0004	404	134	BLCA	167869-21-8	Experimental	ERBB2|HRAS|TP53	218.0628298248943	105.55856550663538
270.94647624538584	-16.358997213234858	0.0004	404	133	BLCA	PLUMBAGIN	Experimental	ERBB2|TP53|EP300	181.716902292175	51.09563427102282
227.20580634132912	6.420594571821994	0.0004	404	133	BLCA	RUFOCROMOMYCIN	Experimental	IDH1|TP53|ATM	255.3278960064146	73.68173435585908
1436.2864609570213	-35.206070641385	0.8720000000000001	404	132	BLCA	ETOPOSIDE	Approved in cancer	TP53|BRCA2|ATM	1431.848427746811	-196.89257629530593
1377.9047643901667	15.457598207566065	0.8320000000000001	404	132	BLCA	LORLATINIB	Approved in cancer	TP53|RB1	1303.4515606535922	-141.31631614817474
907.8729503699516	0.21914895401039303	0.493	404	132	BLCA	SELICICLIB	Clinical trials in cancer	TP53|RB1	882.1714862907781	20.131867055320043
833.5100809466163	9.11753815738183	0.432	404	131	BLCA	AZD6738	Clinical trials in cancer	TP53|BRCA2|ATM	708.3559987135782	105.14489370064075
257.5554465342887	-20.23930474794679	0.0004	404	129	BLCA	COUMARIN 7	Experimental	NPC1|TP53|ATM	199.4878132753982	-80.68614545360015
1410.2749787945093	-15.063503157988805	0.8620000000000001	404	128	BLCA	PANITUMUMAB	Approved in cancer	HRAS|TP53|PTEN	1408.2581735904519	-35.486882674444956
1317.1911069628918	12.364251241638385	0.792	404	127	BLCA	ASPIRIN	Approved in other pathologies and in clinical trials in cancer	GFAP|TSC1|TP53	1198.3879538144115	-110.37174802268801
1116.5210034392499	0.4368767966258531	0.642	404	127	BLCA	CHLORAMBUCIL	Approved in other pathologies and in clinical trials in cancer	TP53|BRCA2|BRCA1	1103.8251764249076	-88.37083755210271
241.92948755277098	43.679486500537735	0.0004	404	127	BLCA	TRACAZOLATE	Experimental	TP53|KMT2A|CREBBP	100.73941046644858	-167.39945346558628
1389.6903827434094	8.344172448973268	0.8530000000000001	404	126	BLCA	IBRUTINIB	Approved in cancer	ERBB2|TP53|ATM	1257.3404280928999	228.0033989107465
1130.0468881159663	0.43545874195692136	0.652	404	126	BLCA	AZACITIDINE	Approved in other pathologies and in clinical trials in cancer	IDH1|ASXL1|TP53	1094.0435508752207	77.2042088587288
1416.0650015413044	22.64877951749918	0.8620000000000001	404	125	BLCA	DOXORUBICIN HYDROCHLORIDE	Approved in same tumor type	IDH1|TP53|BRCA1	1303.8332186541973	42.067810080686144
977.3638936692925	-14.202656520048265	0.542	404	125	BLCA	GENISTEIN	Clinical trials in cancer	AKT1|NPC1|TP53	928.9763518370635	-97.01187631968864
817.7407743545482	-5.75824302184526	0.422	404	125	BLCA	ONC201	Clinical trials in cancer	AKT1|TP53|PTEN	684.7105866840227	94.11243337030368
675.2534863049029	0.4501854070733202	0.315	404	125	BLCA	TRIAMTERENE	Approved in other pathologies	NFE2L2|IDH1|TP53	607.9372654309275	-29.819527560450183
268.9481427522072	37.10661802781095	0.0004	404	125	BLCA	1,10-PHENANTHROLINE	Experimental	RUNX1|IDH1|TP53	157.5435202316019	-99.16566530437109
240.26894782247516	10.794171511222714	0.0004	404	125	BLCA	3-METHYLTOXOFLAVIN	Experimental	NFE2L2|IDH1|TP53	182.21640879516417	-8.412223912271003
241.94230523405196	-36.98493110411127	0.0004	404	125	BLCA	SMR000031817	Experimental	CTNNB1|IDH1|TP53	155.6973308359667	-1.0762910891081958
644.2658373202321	11.785386346166064	0.292	404	124	BLCA	AZATHIOPRINE	Approved in other pathologies	NFE2L2|IDH1|TP53	602.673018689905	-16.89868225004588
590.2594459902341	0.43922839051552387	0.252	404	124	BLCA	HEXACHLOROPHENE	Approved in other pathologies	NFE2L2|IDH1|TP53	535.9006621159723	-37.54006475008475
232.04560872503353	-28.060924415311717	0.0004	404	124	BLCA	BENZETHONIUM CHLORIDE	Experimental	NFE2L2|IDH1|TP53	229.76735772574267	-10.261701775460722
270.2984185603103	16.84255552229456	0.0004	404	124	BLCA	CHEMBL2002487	Experimental	NFE2L2|IDH1|TP53	294.1523243663208	53.82509575540405
230.43220102254466	19.75391041184605	0.0004	404	124	BLCA	DICHLOROPHEN	Experimental	NFE2L2|IDH1|TP53	313.6032074187888	97.6502482524254
248.14423509643154	-48.75797073929837	0.0004	404	124	BLCA	ELLIPTICINE	Experimental	NFE2L2|IDH1|TP53	188.92365134944384	64.43936534381263
252.96970883550986	14.77727719536611	0.0004	404	124	BLCA	FENTICLOR	Experimental	NFE2L2|IDH1|TP53	180.51297444781454	-34.93809616678567
234.86299503724035	-15.10170191943962	0.0004	404	124	BLCA	KINETIN RIBOSIDE	Experimental	NFE2L2|IDH1|TP53	226.236362936622	97.09502468341401
247.55182970573134	-11.122413685327246	0.0004	404	124	BLCA	MALONOBEN	Experimental	NFE2L2|IDH1|TP53	143.83667613998185	100.9892397209104
272.75487719969306	-2.776249091658798	0.0004	404	124	BLCA	PROPACHLOR	Experimental	NFE2L2|IDH1|TP53	148.4924951720337	-60.25649200348337
260.15287320085673	-7.0023506033127205	0.0004	404	124	BLCA	TOXOFLAVIN	Experimental	NFE2L2|IDH1|TP53	187.3900691755231	123.61896668831201
1601.4319051664243	16.234498956914877	1	404	124	BLCA	SORAFENIB	Approved in cancer	KRAS|NRAS|PTEN	1588.2719062626134	9.518924753788923
1440.4274802434272	-1.8114308335647422	0.892	404	124	BLCA	PALBOCICLIB	Approved in cancer	NRAS|PTEN|RB1	1538.26552283029	99.01566540028313
549.7691497952237	0.4345501292970084	0.2219999999999999	404	123	BLCA	NITAZOXANIDE	Approved in other pathologies	NFE2L2|NPC1|TP53	466.3626501884872	-55.50939931753901
294.3185106751961	-1.498214867568123	0.032	404	123	BLCA	INOSITOL	Clinical trials	NRAS|TP53	327.1467085857151	-37.37811926488715
244.6422986147966	-24.000504659109083	0.0004	404	123	BLCA	DAIDZEIN	Experimental	NFE2L2|NPC1|TP53	157.50133810848064	132.49293220958384
237.76616265756292	-2.2055552729307237	0.0004	404	123	BLCA	HOMIDIUM BROMIDE	Experimental	NFE2L2|RUNX1|TP53	288.81827020351074	-25.239554901620465
250.30166054649774	1.8317342614396068	0.0004	404	123	BLCA	MLS000541562	Experimental	NFE2L2|RUNX1|TP53	92.35899585727704	11.684018161159287
262.816023729988	5.967325378520059	0.0004	404	123	BLCA	SMR000060445	Experimental	NFE2L2|NPC1|TP53	153.79427810677495	-167.2269607254239
1405.6925398238736	30.858043908012064	0.8620000000000001	404	122	BLCA	DAUNORUBICIN HYDROCHLORIDE	Approved in cancer	TP53|KMT2A|BRCA1	1457.4299027080187	-52.349719641111705
1369.8604067367285	-12.529151955405212	0.8320000000000001	404	122	BLCA	MECHLORETHAMINE HYDROCHLORIDE	Approved in cancer	NFE2L2|TP53	1215.3948971824493	-172.06024194008398
1387.2766741812504	-5.15954648336475	0.8420000000000001	404	122	BLCA	MELPHALAN	Approved in cancer	NFE2L2|TP53	1424.8133225185538	89.353692852515
1362.1161964890357	-2.0092512955289976	0.8320000000000001	404	122	BLCA	METHYLPREDNISOLONE	Approved in cancer	NFE2L2|TP53	1297.960934891629	3.2255170955088204
1382.0679716070943	-17.198138922049907	0.8420000000000001	404	122	BLCA	TEMOZOLOMIDE	Approved in cancer	MSH6|PTEN|BRCA1	1376.304617009646	-164.8363761928873
1365.199670567903	10.702105343514347	0.8320000000000001	404	122	BLCA	TRIFLURIDINE	Approved in cancer	ERBB2|TP53	1313.8478406307765	84.35254833900143
1103.1933450495335	0.4372458109221782	0.632	404	122	BLCA	CLADRIBINE	Approved in other pathologies and in clinical trials in cancer	NFE2L2|TP53	1089.0093871615284	168.50029346803768
1238.265277719613	0.4351825205181683	0.7320000000000001	404	122	BLCA	HALOPERIDOL	Approved in other pathologies and in clinical trials in cancer	GRIN2B|LDLR|TP53	1170.3109016899098	128.98995747337267
820.1136210843788	7.255195509024276	0.422	404	122	BLCA	CARBENDAZIM	Clinical trials in cancer	NFE2L2|TP53	793.0009596412644	-26.996469135935456
1464.9680828808307	29.055466793420948	0.893	966	483	BRCA	PACLITAXEL	Approved in same tumor type	BRCA2|ATM|BRCA1	1503.752501977343	32.64648815313794
1425.3673396799247	26.16891157110615	0.8720000000000001	966	480	BRCA	CARBOPLATIN	Approved in cancer	TP53|BRCA2|BRCA1	1446.6815211577111	-115.2330838637162
1446.0508939657072	-12.209719592479416	0.893	966	478	BRCA	CISPLATIN	Approved in cancer	ATM|BRCA1|STK11	1495.15902055776	151.19225213500061
1600.6387820323873	-5.417881923181653	1	966	465	BRCA	ALPELISIB	Approved in same tumor type	HRAS|PTEN|TP53	1602.5669057402918	-10.71090776045017
1461.5993171280356	-43.44536236548376	0.893	966	463	BRCA	DOXORUBICIN	Approved in same tumor type	TP53|ATM|BRCA1	1461.676583002919	286.1141398621103
1059.7650782012715	-8.46466498647635	0.597	966	463	BRCA	GEDATOLISIB	Clinical trials in cancer	PTEN|TP53|STK11	1006.7903014701697	117.95818687951811
617.3299454241194	0.43272865003925176	0.272	966	462	BRCA	GEMCITABINE	Approved in other pathologies	PTEN|TP53|BRCA1	580.5334264025126	51.62372090292024
1407.7712856537999	-1.4179399233890706	0.8620000000000001	966	460	BRCA	IRINOTECAN	Approved in cancer	BRCA2|ATM|BRCA1	1351.5102690899266	-227.3940271983451
1187.8410710633016	9.531497247175821	0.693	966	460	BRCA	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	NF1|STK11|CDH1	1137.0024118760002	-212.39929162325106
974.2626110446015	-5.4913072682719815	0.536	966	459	BRCA	CAPIVASERTIB	Clinical trials in cancer	KRAS|PTEN|TP53	907.340887860074	235.72516132349818
1397.522143415858	-18.579334235981634	0.8620000000000001	966	457	BRCA	TOPOTECAN	Approved in cancer	PTEN|TP53|RB1	1392.060640596911	-121.22850891095976
1444.808937052403	-32.53497214813743	0.892	966	456	BRCA	VEMURAFENIB	Approved in cancer	HRAS|PTEN|TP53	1488.297674842785	-194.0334327901933
998.0834050265014	-4.282118129735409	0.553	966	452	BRCA	RESVERATROL	Clinical trials in cancer	PIK3CA|TP53|BRCA1	891.5781942869826	-86.90848855177823
1426.9001420767497	-6.206919227931394	0.8720000000000001	966	444	BRCA	FLUOROURACIL	Approved in same tumor type	PTEN|TP53|ATM	1404.089009552347	156.8488369130136
1406.8888800180207	18.266549733355646	0.8620000000000001	966	443	BRCA	OLAPARIB	Approved in same tumor type	CHEK2|ATM|BRCA1	1384.5511956441321	73.01222659873193
1158.2925998583028	0.4291324520433193	0.6729999999999999	966	443	BRCA	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	TP53|RB1|STK11	1129.7550847000866	-83.23333749850195
888.7287861541688	-16.334929769269365	0.473	966	442	BRCA	SAPANISERTIB	Clinical trials in cancer	TP53|RB1|STK11	821.9952363442054	83.44096004484572
1444.91557032841	30.51354268211017	0.892	966	440	BRCA	VENETOCLAX	Approved in cancer	KRAS|PTEN|TP53	1543.8986024054773	-89.50324898702189
262.06358475203484	2.022555481305261	0.0004	966	440	BRCA	1173900-33-8	Experimental	PTEN|TP53|ATM	237.38585860509073	132.60945037914883
955.8579369126727	1.1660110596688469	0.526	966	438	BRCA	MIRDAMETINIB	Clinical trials in cancer	PTEN|TP53|STK11	963.7069975168463	112.1910455615207
889.207939652838	19.75297549150352	0.474	966	438	BRCA	DS-7423	Clinical trials in cancer	KRAS|PTEN|TP53	812.4573147207378	-145.65080284931446
915.4084154502293	2.2200858093397926	0.492	966	438	BRCA	NAVITOCLAX	Clinical trials in cancer	KRAS|PTEN|TP53	865.8353980050803	233.55288197753555
251.94829711398214	-25.479020286549144	0.0004	966	438	BRCA	ABT-737	Experimental	KRAS|PTEN|TP53	272.0762924651098	24.55153167716324
1468.078608533624	9.268585672176812	0.892	966	437	BRCA	TAMOXIFEN	Approved in same tumor type	PIK3CA|TP53|BRCA1	1550.454357800479	79.39242821565801
1462.1949398195345	-23.876546052673717	0.892	966	435	BRCA	BEVACIZUMAB	Approved in same tumor type	KRAS|HRAS|TP53	1470.9779790893635	175.7138891697711
306.6390662705787	0.4507015252403619	0.042	966	435	BRCA	EMODIN	Clinical trials	PIK3CA|TP53|BRCA1	355.848879172175	-52.57739001521168
1185.9272136517072	-9.865717138385492	0.692	966	433	BRCA	DASATINIB	Approved in other pathologies and in clinical trials in cancer	KRAS|HRAS|TP53	1123.0606179746878	-37.37342000065371
1518.6966055207092	-5.918042099911645	0.94	966	432	BRCA	TRAMETINIB	Approved in cancer	NF1|RB1|STK11	1535.286526120813	-45.837073281763395
1455.290213273729	46.46391897791523	0.892	966	431	BRCA	BORTEZOMIB	Approved in cancer	KRAS|TP53|RB1	1439.0216164016988	-298.8398401418035
956.072800875691	20.157126709827253	0.526	966	431	BRCA	PIMASERTIB	Clinical trials in cancer	KRAS|TP53|NF1	886.3263488817946	-177.05217851681542
1478.3462936702608	-13.996408259110268	0.892	966	430	BRCA	DABRAFENIB	Approved in cancer	KRAS|HRAS|TP53	1406.7607163536218	51.730867592187934
1438.7134968002217	8.72660683715793	0.892	966	428	BRCA	DUVELISIB	Approved in cancer	PIK3CA|TP53	1374.2819169720908	233.613024144149
1384.0888666602596	-4.721750910777473	0.8420000000000001	966	428	BRCA	RALOXIFENE	Approved in same tumor type	PIK3CA|TP53	1283.780522915006	169.13867789387234
985.5276637677267	10.265371070750973	0.542	966	428	BRCA	NVP-CGM097	Clinical trials in cancer	PIK3CA|KRAS|TP53	949.788082656836	-117.29873884987379
831.7335420514851	2.280449611859524	0.432	966	428	BRCA	DEMCIZUMAB	Clinical trials in cancer	PIK3CA|KRAS|TP53	745.3409201082977	-86.34676945088566
849.9948229262222	-1.861023062747961	0.442	966	428	BRCA	TANESPIMYCIN	Clinical trials in cancer	PIK3CA|TP53	741.6966929194235	175.5738484884708
1416.1641758631247	-21.426762230625343	0.8620000000000001	966	407	BRCA	DOCETAXEL	Approved in same tumor type	KRAS|HRAS|TP53	1341.1623135440523	150.91288906421687
1463.0637076012845	-6.937233393228809	0.893	966	336	BRCA	EVEROLIMUS	Approved in same tumor type	ATM|BRCA1|STK11	1451.8979691775937	148.23544494391416
1054.1225782184542	7.684584836131279	0.597	966	315	BRCA	PICTILISIB	Clinical trials in cancer	PTEN|RB1|STK11	1042.074247514247	-70.81202746417563
1420.9469381274805	9.346730728736901	0.8630000000000001	966	313	BRCA	TEMSIROLIMUS	Approved in cancer	PIK3CA|KRAS|PTEN	1253.276708772262	28.81566815990402
960.0835826656016	-14.776625211136547	0.53	966	311	BRCA	MK-2206	Clinical trials in cancer	PIK3CA|HRAS|PTEN	884.5435319637578	-145.0271861708399
1453.172437202467	16.239138493636574	0.892	966	310	BRCA	SORAFENIB	Approved in cancer	PIK3CA|KRAS|PTEN	1517.3145351317196	-30.92852706159431
971.76467080517	-22.22920301124708	0.529	966	310	BRCA	IPATASERTIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	868.7106399652473	-92.03126621633034
909.1949754443613	-13.031546130848852	0.492	966	309	BRCA	AFURESERTIB	Clinical trials in cancer	AKT1|PIK3CA|PTEN	823.0231354861227	138.98921247818396
380.425476427915	5.956225642239559	0.096	966	309	BRCA	OMIPALISIB	Clinical trials	PIK3CA|MAP2K1|PTEN	379.98825905503134	-35.22196673408703
1040.5480256722226	10.680121748180653	0.595	966	308	BRCA	APITOLISIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	997.430350791027	6.540907502290679
969.293910532681	10.636719572264127	0.532	966	308	BRCA	M2698 FREE BASE	Clinical trials in cancer	AKT1|PIK3CA|PTEN	986.0648689793491	24.948055973768504
1393.9048508491637	8.132980664509375	0.8520000000000001	966	305	BRCA	CAPECITABINE	Approved in same tumor type	KRAS|PTEN|CDH1	1315.9304864305602	-99.30888206352527
1431.8958142652739	-21.93974533579626	0.8720000000000001	966	305	BRCA	CETUXIMAB	Approved in cancer	MAP2K1|HRAS|PTEN	1395.276699640518	-3.5278051761886786
1479.8070866191763	20.423677626728676	0.892	966	298	BRCA	PALBOCICLIB	Approved in same tumor type	PTEN|RPS6KA3|RB1	1425.6127758000566	-184.24298887611363
1130.1338260431073	0.4385544489009021	0.652	966	297	BRCA	METFORMIN	Approved in other pathologies and in clinical trials in cancer	PTEN|ATM|STK11	1110.6387517829492	-106.70423410553855
263.25444543233453	18.22939878349453	0.0008	966	297	BRCA	ADENOSINE TRIPHOSPHATE	Experimental	ALK|AKT1|PIK3CA	215.70104305589248	-25.713640874613844
250.39287914430065	14.853032345342797	0.0004	966	297	BRCA	A-443654	Experimental	IDH1|PIK3CA|KRAS	253.96491461016473	127.30711077552593
239.33036879015364	-15.321019854214398	0.0008	966	296	BRCA	WORTMANNIN	Experimental	AKT1|PIK3CA	284.97142456215994	126.45056357186513
245.8414397454551	2.397173286186046	0.0004	966	296	BRCA	154447-36-6	Experimental	AKT1|PIK3CA	308.871400533141	-96.4631336043322
878.4939939516992	-3.7570440415405812	0.472	966	293	BRCA	AZD8055	Clinical trials in cancer	HRAS|PTEN|STK11	832.702283520622	-61.68621221318364
922.6319050043364	-12.20639794399861	0.492	966	293	BRCA	UPROSERTIB	Clinical trials in cancer	AKT1|PIK3CA|PTEN	841.723811653337	163.28377952786798
1062.4215019932867	18.38272961769789	0.597	966	291	BRCA	PILARALISIB	Clinical trials in cancer	KRAS|PTEN|STK11	1063.5297851187079	-116.26580521634872
865.1399491886783	2.9275158507208516	0.454	966	291	BRCA	FIMEPINOSTAT	Clinical trials in cancer	HDAC8|KRAS|PTEN	884.0515457448989	-4.809118953299986
1598.581458600187	11.087474980997513	0.999	966	290	BRCA	COPANLISIB	Approved in cancer	PIK3CA|KRAS|PTEN	1635.8518020087536	53.37917297121615
1053.4007929087234	-23.786433023837645	0.593	966	290	BRCA	IZORLISIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	1023.2933388619845	-19.01486671704569
899.247422753914	-4.073010481915844	0.474	966	290	BRCA	VS-5584	Clinical trials in cancer	ERBB2|PIK3CA|PTEN	876.2058107036668	-119.64024511088004
832.0346558454555	18.14245689307043	0.433	966	290	BRCA	PKI-179	Clinical trials in cancer	ERBB2|PIK3CA|PTEN	771.0579255344032	137.23971093199089
253.94144272678008	27.516184223630546	0.0004	966	290	BRCA	1056901-62-2	Experimental	PIK3CA|KRAS|PTEN	231.05367510739302	18.183142752951966
1518.839440378987	19.62840517029781	0.94	966	288	BRCA	TRASTUZUMAB	Approved in same tumor type	PIK3CA|KRAS|PTEN	1506.0096866134265	-117.9293705281929
513.3385985086729	0.4334557146933946	0.195	966	288	BRCA	TASELISIB	Clinical trials	PIK3CA|KRAS|PTEN	458.8652951815225	-44.93186434176232
849.3412851081636	-17.649128525578845	0.443	966	287	BRCA	RIGOSERTIB	Clinical trials in cancer	KRAS|HRAS|PTEN	684.4331269921641	-62.72047939643613
1512.2277897971076	8.566932918693766	0.94	966	286	BRCA	LAPATINIB	Approved in same tumor type	ERBB2|PIK3CA|CDH1	1447.1517671425347	-39.85929543225882
1369.1988658610621	0.5147016962089879	0.8320000000000001	966	286	BRCA	FULVESTRANT	Approved in same tumor type	ERBB2|PIK3CA|PTEN	1431.3079709876977	139.8461848076081
900.8281768717032	8.76653389817534	0.473	966	286	BRCA	VOXTALISIB	Clinical trials in cancer	KRAS|PTEN|STK11	827.7147268239424	-99.68451964582245
241.41201152455042	24.35838249077625	0.0004	966	286	BRCA	PKI-402	Experimental	KRAS|PTEN|STK11	245.0870968343998	-5.734607244534146
1587.4548847541605	4.551989501808123	0.993	966	285	BRCA	INFIGRATINIB	Approved in cancer	PIK3CA|KRAS|PTEN	1574.9516501692726	-114.81727977148212
1453.3474131292949	2.9222879866683797	0.893	966	285	BRCA	IDELALISIB	Approved in cancer	PIK3CA|PTEN	1395.8517673293697	192.31772256196098
1067.4371697462016	6.130762123991417	0.596	966	285	BRCA	PF-04691502	Clinical trials in cancer	PIK3CA|KRAS|PTEN	994.9581313671723	115.73018775558677
867.1009720540204	-9.914951400808292	0.462	966	285	BRCA	ONATASERTIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	757.6867501876714	102.01656176849554
1044.424064504052	-14.525165241958547	0.594	966	285	BRCA	SAMOTOLISIB	Clinical trials in cancer	PIK3CA|PTEN	1040.1451341975771	-104.5422700235479
889.0164113550715	3.7903279608023865	0.473	966	285	BRCA	BGT-226 FREE BASE	Clinical trials in cancer	PIK3CA|PTEN	827.1374123658701	-154.36741254694616
1049.6469927063486	20.342751212104048	0.592	966	285	BRCA	GSK2636771	Clinical trials in cancer	PIK3CA|PTEN	979.388675421669	133.06880886749252
856.4698466168369	12.509670392190827	0.444	966	285	BRCA	PANULISIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	785.4780358632529	-130.45957038420607
825.5660997451295	-12.226285214932744	0.433	966	285	BRCA	AZD8835	Clinical trials in cancer	PIK3CA|KRAS|PTEN	777.2431697092594	-12.555221758584338
913.4539521831352	18.06525618828445	0.492	966	285	BRCA	LINSITINIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	849.4004361501895	22.281954465516264
843.6700072683218	12.573800229537142	0.442	966	285	BRCA	PAXALISIB	Clinical trials in cancer	PIK3CA|PTEN	813.3690677491356	26.027559847625355
374.6211866255014	-6.008180899231576	0.093	966	285	BRCA	ACALISIB	Clinical trials	PIK3CA|PTEN	362.341997759068	-23.810259634760456
263.0142980925582	-13.957583075095869	0.0008	966	285	BRCA	SAR-260301	Experimental	PIK3CA|PTEN	152.52641879828548	143.00975384646506
250.99941590323635	-9.543672566633973	0.0004	966	285	BRCA	CCT128930	Experimental	PIK3CA|PTEN	272.5214118025266	-123.96997329873298
234.15244390912565	-3.3664829179146523	0.0004	966	285	BRCA	GSK2334470	Experimental	PIK3CA|PTEN	125.56662863492792	-11.213056061202167
237.3000783405367	12.213602152387267	0.0004	966	285	BRCA	NVP-AEW541	Experimental	PIK3CA|PTEN	174.51207561137204	-68.27538054241228
1044.762791052654	-1.8116774880966773	0.596	966	281	BRCA	BUPARLISIB	Clinical trials in cancer	KRAS|HRAS|PTEN	1020.238981482764	16.976490820307987
1366.1241604333104	12.859996278713794	0.8320000000000001	966	280	BRCA	LETROZOLE	Approved in same tumor type	ERBB2|GATA3|PIK3CA	1393.427894030839	164.91285136301792
877.4698847890526	9.073975210485571	0.472	966	280	BRCA	OSI-027	Clinical trials in cancer	PIK3CA|KRAS|PTEN	837.696102293657	-92.55280187924416
1378.3242864566769	9.816576986273844	0.8320000000000001	966	279	BRCA	FLOXURIDINE	Approved in cancer	ERBB2|IDH1|PIK3CA	1227.1976278334937	-195.23241894075503
1491.6165681806806	0.5628368689229433	0.92	966	278	BRCA	COBIMETINIB	Approved in cancer	MAP2K1|KRAS|NF1	1485.3383804037367	-114.47638634700873
1518.543282217356	-21.612125332452962	0.94	966	278	BRCA	PERTUZUMAB	Approved in same tumor type	ERBB2|PIK3CA	1517.9389596002302	30.903501088848458
1174.2148802338525	0.6194936798538606	0.692	966	278	BRCA	PONATINIB	Approved in other pathologies and in clinical trials in cancer	ERBB2|PIK3CA|KRAS	1120.4138157296293	-9.018909735762207
1524.8634325254748	8.471912705264003	0.94	966	276	BRCA	NERATINIB	Approved in cancer	ERBB2|PIK3CA|KRAS	1521.8080068260667	-173.98435587059092
1370.3575754447472	-12.06511803702719	0.8320000000000001	966	276	BRCA	STREPTOZOCIN	Approved in cancer	PIK3CA|CDKN1B|HRAS	1327.7824370425362	-19.793658821657488
1319.363571344473	0.4337819387016566	0.792	966	275	BRCA	CAFFEINE	Approved in other pathologies and in clinical trials in cancer	PIK3CA|ATM	1186.429440457895	69.67192715845559
986.8186192596378	-15.717367275588146	0.542	966	275	BRCA	SURAMIN	Clinical trials in cancer	F2|KMT2A|PIK3CA	974.6082832867648	-132.0696214465019
941.4280526157912	7.443955743711996	0.516	966	274	BRCA	TAK-733	Clinical trials in cancer	PIK3CA|MAP2K1|KRAS	932.5788948763357	44.98187264519294
838.1332959178635	-11.878773636466605	0.432	966	274	BRCA	GM-CSF	Clinical trials in cancer	PIK3CA|RPS6KA3	764.7893602779262	58.35930628421522
1455.9138414873416	-28.631252972084127	0.893	281	102	CESC	PACLITAXEL	Approved in cancer	BRCA2|SMAD4|ATM	1390.0458320128803	57.39356878471011
1462.421967561591	19.759409944104675	0.893	281	101	CESC	CARBOPLATIN	Approved in cancer	TP53|BRCA2|SMAD4	1477.707839019669	67.4786129047555
1446.493549411248	-16.38526397411519	0.893	281	101	CESC	CISPLATIN	Approved in cancer	SMAD4|ATM|STK11	1429.3967262406027	111.76117641776227
1003.2720076740543	-11.871914599837481	0.554	281	101	CESC	SAPANISERTIB	Clinical trials in cancer	SMAD4|RB1|STK11	958.5330163693825	-76.01856632343865
1598.6241823632793	-12.542765547603238	1	281	99	CESC	EVEROLIMUS	Approved in cancer	ATM|RB1|STK11	1627.849702024211	11.71705736586847
1060.263037925763	-20.271824000555085	0.597	281	98	CESC	GEDATOLISIB	Clinical trials in cancer	PTEN|TP53|STK11	992.9365689393796	-42.539702315724526
1598.5124531573852	14.185252556037256	1	281	95	CESC	ALPELISIB	Approved in cancer	NRAS|PTEN|TP53	1626.512908178568	-107.10100839351357
1454.533511535443	-3.7852731449028454	0.892	281	95	CESC	IRINOTECAN	Approved in cancer	SMAD4|TGFBR2|ATM	1474.1520196422136	49.07831181942137
919.5117559131232	0.12134030239562321	0.492	281	94	CESC	MIRDAMETINIB	Clinical trials in cancer	PTEN|TP53|STK11	846.7947198803766	-33.28979890150586
1184.1130614526528	0.43599961524535047	0.692	281	93	CESC	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	TP53|NF1|STK11	1118.8383410720267	85.53982102059649
1413.4956493462687	4.938479712158113	0.8620000000000001	281	93	CESC	FLUOROURACIL	Approved in cancer	PTEN|TP53|ATM	1459.3971270519924	-123.45010245872717
603.8145301941515	0.4331408686989846	0.262	281	92	CESC	GEMCITABINE	Approved in other pathologies	BRCA1|TP53|SMAD4	568.6595189850794	17.97715788239782
955.6366849832278	1.4369319088523866	0.526	281	91	CESC	CAPIVASERTIB	Clinical trials in cancer	KRAS|PTEN|TP53	913.1444973599896	-5.12637649710129
1433.6149200612672	-9.386812748403798	0.883	281	91	CESC	DOXORUBICIN	Approved in cancer	BRCA1|TP53|ATM	1324.760279127147	-266.2722416153043
976.4917579096326	10.88546724534018	0.542	281	90	CESC	DS-7423	Clinical trials in cancer	KRAS|PTEN|TP53	920.3082547967362	198.86578609610297
1456.4311603456995	32.98476045628448	0.892	281	89	CESC	VENETOCLAX	Approved in cancer	KRAS|PTEN|TP53	1385.5079445467934	-96.35138102368565
1064.80093638909	6.682986569713563	0.597	281	89	CESC	PICTILISIB	Clinical trials in cancer	PTEN|RB1|STK11	992.2617077587694	49.077655642457046
915.9607799263918	13.689527877483613	0.492	281	89	CESC	NAVITOCLAX	Clinical trials in cancer	KRAS|PTEN|TP53	912.8665770260235	76.79163538543003
1573.3360886346838	-3.9127764456333978	0.98	281	88	CESC	SORAFENIB	Approved in cancer	KIT|NRAS|PTEN	1669.775869183233	15.793549814493133
1427.2094007762194	2.7720991274483993	0.8720000000000001	281	88	CESC	OLAPARIB	Approved in cancer	TP53|BRCA2|ATM	1382.4671121236383	243.12327854729517
1130.0026011023244	0.4418791023526296	0.652	281	88	CESC	METFORMIN	Approved in other pathologies and in clinical trials in cancer	PTEN|ATM|STK11	1069.237350345064	-81.78110712408751
250.32686976896932	-22.312898126081222	0.0004	281	88	CESC	ABT-737	Experimental	KRAS|PTEN|TP53	175.54238187616048	-17.699575138178886
1558.935385654848	-0.5449457006335194	0.97	281	87	CESC	TEMSIROLIMUS	Approved in cancer	PIK3CA|KRAS|PTEN	1577.5554671470577	39.121589129703096
1464.8519489779558	5.606379507826745	0.892	281	87	CESC	PALBOCICLIB	Approved in cancer	NRAS|PTEN|RB1	1444.7554537022536	140.87947062519805
1232.186409259244	0.43460467744577613	0.7280000000000001	281	87	CESC	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	TP53|RB1|STK11	1168.4126012675126	-40.57182376180674
1448.337297367189	22.256254592972283	0.892	281	86	CESC	TRAMETINIB	Approved in cancer	NF1|RB1|STK11	1441.3675652834042	-234.77664241951857
989.4126274510293	6.878965307431912	0.545	281	86	CESC	AZD8055	Clinical trials in cancer	KRAS|PTEN|STK11	986.3647484768574	-57.194630434300606
1063.5508747600206	-6.638216235760581	0.597	281	85	CESC	PILARALISIB	Clinical trials in cancer	KRAS|PTEN|STK11	981.7207857324373	-22.638472212908738
979.8320460198294	-2.1454570430109072	0.542	281	85	CESC	VOXTALISIB	Clinical trials in cancer	KRAS|PTEN|STK11	923.3891539435438	74.07530555747962
1386.9597312860917	0.44165628341710317	0.8420000000000001	281	84	CESC	TOPOTECAN	Approved in cancer	PTEN|TP53|RB1	1367.1933737244196	70.62960491929809
1046.3126062896536	-20.80278520866878	0.595	281	84	CESC	APITOLISIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	1020.6805631338469	78.5083376755939
1452.35643862052	9.782209376985037	0.892	281	84	CESC	BORTEZOMIB	Approved in cancer	KRAS|TP53|RB1	1312.3462191907486	170.66251408394277
908.2644249557152	-7.529784789432199	0.492	281	83	CESC	PIMASERTIB	Clinical trials in cancer	NRAS|TP53|NF1	831.2048453650232	-166.99788164092087
1602.047086111786	0.9799201827004254	0.999	281	83	CESC	COPANLISIB	Approved in cancer	PIK3CA|KRAS|PTEN	1588.2383318186069	-89.35948867634804
1589.2504241537893	0.2761455525964607	0.993	281	83	CESC	INFIGRATINIB	Approved in cancer	KRAS|KIT|PTEN	1566.1658551326968	-61.628452971053264
1504.1269575747478	-6.264263428641129	0.93	281	83	CESC	TRASTUZUMAB	Approved in cancer	PIK3CA|KRAS|PTEN	1426.3801083431833	47.30352430480775
963.2748251427457	12.432106988318253	0.529	281	83	CESC	IPATASERTIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	940.3007658453844	-115.84758190369291
261.3038485749345	-15.018014878573126	0.0004	281	83	CESC	PKI-402	Experimental	KRAS|PTEN|STK11	219.90484034011752	-157.59082296774437
1545.8506539505108	0.4329435731535227	0.96	281	83	CESC	DABRAFENIB	Approved in cancer	KRAS|NRAS|TP53	1546.3878877646225	-50.55647042636528
1441.8222402283257	1.1724603574832315	0.892	281	83	CESC	BEVACIZUMAB	Approved in cancer	KRAS|KIT|TP53	1344.3016483519384	65.26218312984616
1289.4473888086347	0.43396356435931693	0.77	281	83	CESC	DASATINIB	Approved in other pathologies and in clinical trials in cancer	KRAS|KIT|TP53	1199.4775532694157	84.97712788129087
1053.283101777764	23.983988288979845	0.596	281	82	CESC	PF-04691502	Clinical trials in cancer	PIK3CA|KRAS|PTEN	1030.643464211376	-40.69226886548353
1042.594185183185	17.181767721783615	0.593	281	82	CESC	IZORLISIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	963.8221948639565	-116.88803056071463
983.8638050000476	-14.388596142715329	0.544	281	82	CESC	ONATASERTIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	950.1611159229665	-149.7729765752163
839.6690429605369	6.110793009241547	0.434	281	82	CESC	PANULISIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	717.7957465978642	-125.41117610259778
1400.4276631747468	-4.643838842085529	0.8520000000000001	281	81	CESC	CAPECITABINE	Approved in cancer	PIK3CA|KRAS|PTEN	1364.2687210502916	143.459402926304
839.3547059611174	-6.4872804690667465	0.434	281	81	CESC	FIMEPINOSTAT	Clinical trials in cancer	PIK3CA|KRAS|PTEN	784.2618063591046	72.20381739688412
513.3341824448628	0.43317631011859703	0.195	281	81	CESC	TASELISIB	Clinical trials	PIK3CA|KRAS|PTEN	446.53815522100166	-40.488839426720915
251.53881140969915	12.180242497095065	0.0004	281	81	CESC	1056901-62-2	Experimental	PIK3CA|KRAS|PTEN	244.3431702025539	-89.514633842501
250.6022060149482	24.66437671254414	0.0004	281	81	CESC	1173900-33-8	Experimental	PTEN|TP53|ATM	245.1362197029379	30.311492797239765
969.9501535778782	-10.29842424550705	0.532	281	81	CESC	NVP-CGM097	Clinical trials in cancer	PIK3CA|KRAS|TP53	917.4523631174324	-54.542606650582115
828.3549058716715	11.513393663358329	0.432	281	80	CESC	AZD8835	Clinical trials in cancer	PIK3CA|KRAS|PTEN	751.1395332710022	-3.674699917509116
859.9006183549923	5.980803930869911	0.452	281	80	CESC	LINSITINIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	884.962842169951	60.15872202393916
957.5627577876758	-11.594395995492363	0.524	281	80	CESC	OSI-027	Clinical trials in cancer	PIK3CA|KRAS|PTEN	899.1086722040891	-45.86620343725971
838.5215925509161	18.586174558337433	0.433	281	80	CESC	RIGOSERTIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	729.7068607343854	-41.22383296721861
1001.2059241038619	1.859710482511872	0.553	281	80	CESC	VISTUSERTIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	891.8059060973324	141.43137041953582
836.5104110509226	-18.618438307385645	0.432	281	80	CESC	DEMCIZUMAB	Clinical trials in cancer	PIK3CA|KRAS|TP53	729.0694359664705	170.5136925176045
1500.4380938660759	5.640834864723786	0.93	281	78	CESC	VEMURAFENIB	Approved in cancer	NRAS|PTEN|TP53	1539.4362729983802	-55.58220760896732
1459.9881235431617	-15.672561646512634	0.892	281	75	CESC	COBIMETINIB	Approved in cancer	KRAS|NRAS|NF1	1423.9778075823465	-13.814295616006206
380.4116530028816	4.870364666829744	0.096	281	75	CESC	OMIPALISIB	Clinical trials	PIK3CA|NRAS|PTEN	371.8818254140596	-0.057518178330184355
1568.3896212168374	7.678090839373624	0.977	281	75	CESC	REGORAFENIB	Approved in cancer	KRAS|KIT|NRAS	1530.7565880344525	29.09862407832432
946.3079414473328	-7.340205926887194	0.523	281	75	CESC	RESVERATROL	Clinical trials in cancer	PIK3CA|BRCA1|TP53	900.0296810662328	-95.26696925443558
861.9155433735503	-5.88128278140735	0.453	281	75	CESC	CAMPTOTHECIN	Clinical trials in cancer	MTOR|PIK3CA|KRAS	831.4600288569571	33.7305283168096
1467.2512422440834	-6.610626889053208	0.892	281	74	CESC	TAMOXIFEN	Approved in cancer	PIK3CA|BRCA1|TP53	1480.4995691021998	20.439325153548452
250.32568757729362	-9.794542987224133	0.0004	281	74	CESC	A-443654	Experimental	AKT1|PIK3CA|KRAS	159.52428822213363	-107.66461580518215
1511.8911782811267	3.0250440914585113	0.93	281	73	CESC	NERATINIB	Approved in cancer	ERBB2|PIK3CA|KRAS	1423.9238713966324	-30.91716753783848
1258.3455162621435	0.434191288442463	0.7470000000000001	281	73	CESC	PONATINIB	Approved in other pathologies and in clinical trials in cancer	PIK3CA|KRAS|KIT	1180.845682816996	6.2234346597404056
907.4018045172937	4.541355343553619	0.492	281	73	CESC	TAK-733	Clinical trials in cancer	PIK3CA|KRAS|NRAS	843.2186508691337	-74.94399227026216
1053.4305332856945	11.95257181702334	0.595	281	73	CESC	SERABELISIB	Clinical trials in cancer	MTOR|PIK3CA|KRAS	991.7920482476948	-48.95882691804704
991.667226427486	-5.237091447407664	0.548	281	73	CESC	RIDAFOROLIMUS	Clinical trials in cancer	MTOR|PIK3CA|KRAS	920.1162844199883	-121.58072387701996
320.16410668871737	0.44008127465278335	0.052	281	73	CESC	EMODIN	Clinical trials	PIK3CA|BRCA1|TP53	327.7718545227104	-116.72722809414672
968.2209389685473	1.4654056203617358	0.53	281	72	CESC	MK-2206	Clinical trials in cancer	KIT|NRAS|PTEN	918.3964855372328	-100.45218398186258
919.1331665462934	-12.688157722708894	0.492	281	72	CESC	AFURESERTIB	Clinical trials in cancer	AKT1|PIK3CA|PTEN	883.0982587242074	-65.4105176774536
951.2725361294273	13.252076843061673	0.522	281	72	CESC	M2698 FREE BASE	Clinical trials in cancer	AKT1|PIK3CA|PTEN	924.3296143150783	-184.89748890578088
818.7616469355347	1.8189909110491271	0.423	281	72	CESC	PKI-179	Clinical trials in cancer	ERBB2|PIK3CA|PTEN	797.5574360976121	-38.67859409705335
999.6594964827996	13.573870948182162	0.553	281	72	CESC	VS-5584	Clinical trials in cancer	ERBB2|PIK3CA|PTEN	963.9349252449078	-165.19359329580666
1244.5024092552933	0.4342927221736943	0.7360000000000001	281	72	CESC	MIDOSTAURIN	Approved in other pathologies and in clinical trials in cancer	PIK3CA|KRAS|KIT	1175.2249504891624	24.545872271407177
827.6043105457003	-10.856385883793138	0.432	281	72	CESC	TANESPIMYCIN	Clinical trials in cancer	MTOR|PIK3CA|TP53	740.6326838010858	-150.04708764831693
1053.9471090836932	0.7241679734482034	0.596	281	71	CESC	BUPARLISIB	Clinical trials in cancer	KRAS|NRAS|PTEN	1014.7776184265343	-48.632034429197404
1041.9853506069594	-5.397831767330445	0.594	281	71	CESC	SAMOTOLISIB	Clinical trials in cancer	MTOR|PIK3CA|PTEN	1074.5172342775797	-66.58313154170717
986.252236469712	18.63056023349168	0.543	281	71	CESC	BGT-226 FREE BASE	Clinical trials in cancer	MTOR|PIK3CA|PTEN	891.3459731461307	-9.686418888416824
1051.9943097837106	-10.211368305652258	0.596	281	71	CESC	SONOLISIB	Clinical trials in cancer	PIK3CA|KRAS	994.5993015064042	83.11903202881632
240.33442036222272	-15.09500136559069	0.0004	281	71	CESC	DEGUELIN	Experimental	PIK3CA|KRAS	175.13050788496778	158.9032297683449
1440.5664813062765	12.995961068194958	0.893	281	70	CESC	IDELALISIB	Approved in cancer	BRAF|PIK3CA|PTEN	1457.3575166174307	180.06620742703342
1043.97821385203	5.454017820806769	0.592	281	70	CESC	GSK2636771	Clinical trials in cancer	BRAF|PIK3CA|PTEN	971.7728011089466	-91.60292138846476
259.4823405460249	-3.26899033811182	0.0008	281	70	CESC	SAR-260301	Experimental	BRAF|PIK3CA|PTEN	224.50750726479475	-76.39254871140731
240.63113860413586	-4.059885500861668	0.0004	281	70	CESC	NVP-AEW541	Experimental	BRAF|PIK3CA|PTEN	237.70940872792332	-152.43974826814627
1471.2182511298738	-17.1358510907136	0.892	281	70	CESC	DUVELISIB	Approved in cancer	PIK3CA|TP53	1487.1775697675846	70.13704046057015
1400.414301380889	7.10415355927438	0.8520000000000001	281	70	CESC	RALOXIFENE	Approved in cancer	PIK3CA|TP53	1298.4845814619755	-174.4206921283422
829.6450813695121	-0.010716221533073167	0.432	281	69	CESC	PAXALISIB	Clinical trials in cancer	PIK3CA|PTEN	729.8742781568548	125.74289264943599
374.6040565100246	-4.764692311525664	0.093	281	69	CESC	ACALISIB	Clinical trials	PIK3CA|PTEN	358.3018460126515	32.38902176928002
241.1579691404303	6.8270668489899435	0.0004	281	69	CESC	CCT128930	Experimental	PIK3CA|PTEN	221.02522312011925	78.29596543141145
241.2299724682445	17.647449946706843	0.0004	281	69	CESC	GSK2334470	Experimental	PIK3CA|PTEN	210.00818936715876	-83.02150896302057
1413.9383425486474	-7.5137006910095465	0.8620000000000001	281	68	CESC	CETUXIMAB	Approved in cancer	ERBB2|PIK3CA|PTEN	1383.5407547236728	30.113987597799593
1373.474506723501	0.43942897092190947	0.8320000000000001	281	68	CESC	FULVESTRANT	Approved in cancer	ERBB2|PIK3CA|PTEN	1345.7360757326007	215.35371625313854
849.2915743537924	-0.49831691103031517	0.442	281	68	CESC	UPROSERTIB	Clinical trials in cancer	AKT1|PIK3CA|PTEN	840.5910072223686	-186.2290995403603
249.8679275867906	1.021045040074	0.0004	281	64	CESC	154447-36-6	Experimental	MTOR|AKT1|PIK3CA	181.67185934909526	-184.91521058354516
260.57239836232617	18.986216691954297	0.0008	281	64	CESC	ADENOSINE TRIPHOSPHATE	Experimental	ASS1|AKT1|PIK3CA	264.032800192587	-3.0411569197561903
261.6234503159725	7.050689634304547	0.0008	281	64	CESC	WORTMANNIN	Experimental	MTOR|AKT1|PIK3CA	277.3070902961569	100.68013467182436
1063.1101367178826	18.367048179389116	0.598	281	63	CESC	DACTOLISIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	1010.4147857570008	-20.7405605437055
1440.0735411017754	5.503526702068427	0.882	48	17	CHOL	VENETOCLAX	Approved in cancer	TP53|PTEN|KRAS	1445.6782547421785	203.39239319259008
1184.1212498579105	-4.615293570233206	0.692	48	17	CHOL	DASATINIB	Approved in other pathologies and in clinical trials in cancer	IDH1|TP53|KRAS	1117.0330859791839	24.847380327188034
617.1999085971495	0.43175341821796565	0.272	48	15	CHOL	GEMCITABINE	Approved in other pathologies	PTEN|KRAS|NRAS	590.8783076795435	-12.702930267021827
1399.2384791496982	4.978522072367582	0.8520000000000001	48	14	CHOL	BEVACIZUMAB	Approved in cancer	IDH1|TP53|KRAS	1369.5053876637846	-12.500037863763907
1435.5794052625486	-7.67235638701257	0.881	48	14	CHOL	CISPLATIN	Approved in cancer	PTEN|KRAS|NRAS	1472.04645062767	80.8381231461334
1426.7681821531962	1.4254007119536425	0.8720000000000001	48	14	CHOL	OLAPARIB	Approved in cancer	TP53|PTEN|KRAS	1249.7226406794425	172.04677584078138
1184.1250102709669	8.884705906036913	0.692	48	13	CHOL	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	KRAS|NRAS|NF1	1147.1415936177696	-178.80711494117946
1116.4678089716695	0.40587704928543644	0.642	48	13	CHOL	METFORMIN	Approved in other pathologies and in clinical trials in cancer	IDH1|PTEN|KRAS	1035.12748075205	130.66402711545368
1599.8235392890144	3.3006658483681406	1	48	12	CHOL	ALPELISIB	Approved in cancer	PTEN|KRAS|NRAS	1626.853553130073	23.16347516300013
1452.8410660629097	2.6589737981154826	0.892	48	12	CHOL	TRAMETINIB	Approved in cancer	KRAS|NRAS|NF1	1418.6992937578182	-11.483669905827128
847.5680029120797	0.23970874852466295	0.442	48	12	CHOL	SARACATINIB	Clinical trials in cancer	IDH2|IDH1|KRAS	786.8328989267818	-20.5594352663974
254.97959323871325	10.065640976461736	0.0004	48	12	CHOL	A-443654	Experimental	PIK3CA|IDH1|KRAS	228.81220576889024	106.43352007861046
1499.993469761416	-3.0025646248394935	0.927	48	11	CHOL	REGORAFENIB	Approved in cancer	PIK3CA|KRAS|NRAS	1569.369455050636	-120.17359369385497
1408.9347490861933	-1.0417911911911233	0.8610000000000001	48	11	CHOL	FLUOROURACIL	Approved in cancer	TP53|PTEN|KRAS	1214.80722169933	135.55453854680883
1056.6068213298367	-0.8334650566191328	0.597	48	11	CHOL	GEDATOLISIB	Clinical trials in cancer	PTEN|KRAS|NRAS	1028.283413142191	-89.95751744288876
910.2686075396866	3.917390041521145	0.492	48	11	CHOL	MIRDAMETINIB	Clinical trials in cancer	PTEN|KRAS|NRAS	856.2767701502215	-159.1783082393877
914.3162119984172	13.243289025447922	0.492	48	11	CHOL	PIMASERTIB	Clinical trials in cancer	KRAS|NRAS|NF1	889.6365349032981	133.39504727320315
871.3659289988818	5.603681759170371	0.462	48	11	CHOL	SAPANISERTIB	Clinical trials in cancer	TP53|PTEN|KRAS	798.0294430927183	46.39158779362634
915.2548915899945	-12.183933095550515	0.492	48	11	CHOL	BERZOSERTIB	Clinical trials in cancer	IDH1|TP53|KRAS	895.8623886603856	-35.731894990363315
1462.0535532635474	-2.5492771055156425	0.893	48	11	CHOL	VANDETANIB	Approved in cancer	IDH1|PTEN|KRAS	1492.9811533671784	-17.578310373579654
1506.028124062743	4.6554669410052725	0.93	48	10	CHOL	SORAFENIB	Approved in cancer	PTEN|KRAS|NRAS	1456.4552108475325	-0.6661552395038086
1416.011125513261	-12.851384645539127	0.8620000000000001	48	10	CHOL	TRASTUZUMAB	Approved in cancer	PIK3CA|PTEN|KRAS	1299.6098449368549	-61.694003545103584
1454.7302386048066	-8.983660773172943	0.892	48	10	CHOL	COBIMETINIB	Approved in cancer	KRAS|NRAS|NF1	1448.8193018715224	-1.6000164325024002
1491.9122049358787	3.6421048167521803	0.92	48	10	CHOL	DABRAFENIB	Approved in cancer	TP53|KRAS|NRAS	1418.4621803160496	-197.7758324114066
1446.254819240228	-5.078089112473435	0.882	48	10	CHOL	PALBOCICLIB	Approved in cancer	PTEN|KRAS|NRAS	1403.7538310308978	-21.83260201283926
1424.7619886584073	-9.607079005479648	0.8730000000000001	48	10	CHOL	EVEROLIMUS	Approved in cancer	PTEN|KRAS|NRAS	1415.9441589897292	-96.28266681448335
1060.991995280206	7.874748873247114	0.597	48	10	CHOL	PICTILISIB	Clinical trials in cancer	PIK3R1|PTEN|KRAS	1018.7180189002943	-166.56554326003754
917.4474263440785	-2.6840025823753706	0.492	48	10	CHOL	NAVITOCLAX	Clinical trials in cancer	TP53|PTEN|KRAS	833.2963368964502	130.31138346119803
1459.1824949307336	10.601724164634192	0.892	48	10	CHOL	TAMOXIFEN	Approved in cancer	PIK3CA|IDH1|TP53	1353.7675006233433	-23.180344616842262
1400.5160957251212	-5.948602818904959	0.8530000000000001	48	10	CHOL	CARBOPLATIN	Approved in cancer	PTEN|KRAS|NRAS	1244.8082981280374	-66.01345554426929
1416.5881748244628	4.30399565642378	0.8620000000000001	48	9	CHOL	BINIMETINIB	Approved in cancer	KRAS|NRAS|NF1	1308.81488863708	-84.63700878592147
1417.7486362557788	-4.108522247692122	0.8630000000000001	48	9	CHOL	TEMSIROLIMUS	Approved in cancer	PIK3CA|PTEN|KRAS	1421.1834087887005	140.35827850277536
1375.2991562798568	-2.786111977775562	0.8330000000000001	48	9	CHOL	DOXORUBICIN	Approved in cancer	PIK3CA|TP53|KRAS	1397.7202409594556	116.84970610792612
1417.6907234870243	12.727047645367747	0.8620000000000001	48	9	CHOL	IRINOTECAN	Approved in cancer	PIK3CA|TP53|KRAS	1376.9720928067054	70.93073333381105
1052.0935563590645	7.3409477001030154	0.597	48	9	CHOL	PILARALISIB	Clinical trials in cancer	PIK3R1|PTEN|KRAS	1006.3252046192671	203.24382937868336
946.3887044447064	0.43867453881389906	0.516	48	9	CHOL	BUPARLISIB	Clinical trials in cancer	PIK3CA|KRAS|NRAS	907.1783969932687	-151.9852936957597
1047.339388947651	0.29626595899813424	0.593	48	9	CHOL	IZORLISIB	Clinical trials in cancer	PIK3R1|PTEN|KRAS	972.365093510645	34.791212309927886
900.7573167100841	0.38579045975600934	0.482	48	9	CHOL	TAK-733	Clinical trials in cancer	PIK3CA|KRAS|NRAS	882.4282399157182	39.48664415231187
981.6254577032732	0.43038813010232957	0.542	48	9	CHOL	NVP-CGM097	Clinical trials in cancer	PIK3CA|TP53|KRAS	962.9019434762473	-87.22826234358747
1450.3920884783176	12.092968681415897	0.892	48	9	CHOL	PACLITAXEL	Approved in cancer	TP53|PTEN|KRAS	1381.3961738388816	82.47373417876486
1590.4448566784308	0.31535542048101206	0.993	48	9	CHOL	INFIGRATINIB	Approved in same tumor type	PIK3R1|PTEN|KRAS	1621.9033548636858	-135.2713028810428
1158.517003007073	0.4445903685627286	0.6729999999999999	48	9	CHOL	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	PIK3CA|TP53|KRAS	1111.4979050178322	10.933490458458976
908.9302080045408	-5.3162724626288025	0.492	48	9	CHOL	CAPIVASERTIB	Clinical trials in cancer	TP53|PTEN|KRAS	832.5784829520609	-126.09959770540046
889.8357454583349	0.4425401633514525	0.474	48	9	CHOL	DS-7423	Clinical trials in cancer	PIK3R1|PTEN|KRAS	844.3371885329527	-51.12871361880201
248.9729312195631	-15.73615907178629	0.0004	48	9	CHOL	ABT-737	Experimental	TP53|PTEN|KRAS	232.89436556004483	50.25929643877066
1386.8715682957227	-3.1658783129509516	0.8420000000000001	48	9	CHOL	TEMOZOLOMIDE	Approved in cancer	IDH1|TP53|PTEN	1337.3758885824943	-69.33115079766912
1409.3322764940644	7.861851682042953	0.8620000000000001	48	8	CHOL	NERATINIB	Approved in cancer	BRAF|PIK3CA|KRAS	1329.713314128286	-42.21718874479444
1489.9082614202553	-4.618295317998587	0.919	48	8	CHOL	ENCORAFENIB	Approved in cancer	TP53|PTEN|KRAS	1444.1430186341454	-124.90386285170686
1364.6012574239428	-3.0115450358710802	0.8230000000000001	48	8	CHOL	PEMBROLIZUMAB	Approved in cancer	TP53|KRAS|NRAS	1340.7071773359294	-111.43113928368497
832.1068713905269	-3.5333484518584157	0.432	48	8	CHOL	CAMPTOTHECIN	Clinical trials in cancer	BRAF|PIK3CA|KRAS	759.1881495906648	67.30724048508111
279.47691152968423	0.3740417706489154	0.022	48	8	CHOL	LY3009120	Clinical trials	TP53|KRAS|NRAS	269.59292168874913	-166.56647026337544
1408.036455086908	-9.910192784889176	0.8620000000000001	48	8	CHOL	DOCETAXEL	Approved in cancer	PIK3CA|TP53|KRAS	1361.939265042874	-55.03888131306523
1386.8970665241434	4.918081474204513	0.8420000000000001	48	8	CHOL	BORTEZOMIB	Approved in cancer	PIK3CA|TP53|KRAS	1273.9117781580806	-172.9891687635874
1597.8832225410647	-5.829434201337023	0.999	48	8	CHOL	COPANLISIB	Approved in cancer	PIK3R1|PTEN|KRAS	1622.0576664803025	26.004927312782883
1371.6246722092737	4.414265770097472	0.8310000000000001	48	8	CHOL	CAPECITABINE	Approved in cancer	PIK3CA|PTEN|KRAS	1317.40496631451	184.95819552957943
1357.029432044352	7.903768818072564	0.8220000000000001	48	8	CHOL	FLOXURIDINE	Approved in cancer	PIK3CA|IDH1	1279.3833534585556	-168.62575656181687
1244.9554401590954	0.4349214691707175	0.7370000000000001	48	8	CHOL	PONATINIB	Approved in other pathologies and in clinical trials in cancer	FGFR2|PIK3CA|KRAS	1146.0278501044472	-19.42680700711702
919.0176946357648	5.66882519306904	0.492	48	8	CHOL	IPATASERTIB	Clinical trials in cancer	PIK3CA|PTEN|KRAS	818.9047364819194	66.21710573155593
1057.6107051270642	-9.694278353807022	0.596	48	8	CHOL	PF-04691502	Clinical trials in cancer	PIK3R1|PTEN|KRAS	960.0668840701935	121.88164131077707
1050.3596797484315	-7.200114173844639	0.595	48	8	CHOL	APITOLISIB	Clinical trials in cancer	PIK3R1|PTEN|KRAS	1000.3834674381555	73.21703584827864
874.3214978590477	-8.792823522775251	0.462	48	8	CHOL	AZD8055	Clinical trials in cancer	PIK3CA|PTEN|KRAS	831.6298575919388	-29.05685677941284
876.7414463322542	-1.5165364596285258	0.462	48	8	CHOL	ONATASERTIB	Clinical trials in cancer	PIK3CA|PTEN|KRAS	822.0945246898721	64.80122935165357
869.2308937309385	-3.0550892643856287	0.462	48	8	CHOL	OSI-027	Clinical trials in cancer	PIK3CA|PTEN|KRAS	819.5793309262194	27.82494744710928
880.2794050264322	5.284377072548551	0.463	48	8	CHOL	VOXTALISIB	Clinical trials in cancer	PIK3R1|PTEN|KRAS	892.7006453487407	-113.78448220044693
860.1571103370684	-3.3759146701290774	0.452	48	8	CHOL	FIMEPINOSTAT	Clinical trials in cancer	PIK3CA|PTEN|KRAS	820.973274129919	72.10105849179891
838.2712169274718	1.0296570474598639	0.434	48	8	CHOL	PANULISIB	Clinical trials in cancer	PIK3R1|PTEN|KRAS	771.799090801956	126.70814503897901
819.8225944572489	-7.186573414824949	0.422	48	8	CHOL	AZD8835	Clinical trials in cancer	PIK3CA|PTEN|KRAS	767.183502244036	-15.096280190589681
862.2286760541939	4.006960073466189	0.453	48	8	CHOL	RIGOSERTIB	Clinical trials in cancer	PIK3CA|PTEN|KRAS	809.0632263172952	30.50651629850978
820.9025380179107	0.40241764988792283	0.422	48	8	CHOL	DEMCIZUMAB	Clinical trials in cancer	PIK3CA|TP53|KRAS	811.0498552752487	-41.221317153879
831.2393385945895	4.087582996781094	0.432	48	8	CHOL	LINSITINIB	Clinical trials in cancer	PIK3CA|PTEN|KRAS	756.8046972803221	-82.87397571332863
513.4815470170811	0.4319093699756422	0.195	48	8	CHOL	TASELISIB	Clinical trials	PIK3R1|PTEN|KRAS	453.25096363991054	-34.34587876852339
256.4866466594411	-12.766271296495887	0.0004	48	8	CHOL	1056901-62-2	Experimental	PIK3CA|PTEN|KRAS	266.93596878898194	112.11155338065828
243.54147568624327	-9.756683027757049	0.0004	48	8	CHOL	PKI-402	Experimental	PIK3CA|PTEN|KRAS	275.541816491218	-115.2589512471464
1410.093209341946	15.492002738313232	0.8620000000000001	48	8	CHOL	METHOTREXATE	Approved in cancer	IDH1|TP53	1360.8947362443948	-15.40811643781737
1357.662840490232	0.2607609646730964	0.8220000000000001	48	8	CHOL	DAUNORUBICIN HYDROCHLORIDE	Approved in cancer	IDH1|TP53	1332.9912556991871	52.03501989746255
1363.9643750739476	4.628556070748459	0.8220000000000001	48	8	CHOL	DOXORUBICIN HYDROCHLORIDE	Approved in cancer	IDH1|TP53	1233.609082704619	-7.774684728381914
1358.2988460709337	-7.379924454089803	0.8220000000000001	48	8	CHOL	MITOXANTRONE HYDROCHLORIDE	Approved in cancer	IDH1|TP53	1305.0013016114972	76.90249234569228
1103.0905101936041	4.261442331763391	0.632	48	8	CHOL	THIORIDAZINE HYDROCHLORIDE	Approved in other pathologies and in clinical trials in cancer	IDH1|TP53	1057.280789671333	159.17546784692257
1103.0895631773756	-3.4065576097572148	0.632	48	8	CHOL	MERCAPTOPURINE	Approved in other pathologies and in clinical trials in cancer	IDH1|TP53	1062.3380529824922	88.01469564403055
1089.696784423315	0.4157181540912802	0.622	48	8	CHOL	AZACITIDINE	Approved in other pathologies and in clinical trials in cancer	IDH1|TP53	1086.347934317855	-23.271339862497882
819.826420738171	7.994531689777233	0.422	48	8	CHOL	FENRETINIDE	Clinical trials in cancer	IDH1|TP53	736.5966382842976	-79.94929293926276
644.1985556063522	-3.402339739939208	0.292	48	8	CHOL	CHLORPROMAZINE	Approved in other pathologies	IDH1|TP53	598.0343699302039	-65.73462620843243
644.1985387822976	4.265660260042324	0.292	48	8	CHOL	AZATHIOPRINE	Approved in other pathologies	IDH1|TP53	609.32002573365	7.521652761914396
603.7447791269096	0.43204194132781026	0.262	48	8	CHOL	PIMOZIDE	Approved in other pathologies	IDH1|TP53	561.7195932084876	-27.06672421041185
590.2870145593749	0.43326224440522765	0.252	48	8	CHOL	SERTRALINE	Approved in other pathologies	IDH1|TP53	542.0115459671822	-19.974054548428057
563.3868171667833	8.08241127280732	0.2319999999999999	48	8	CHOL	PAROXETINE HYDROCHLORIDE	Approved in other pathologies	IDH1|TP53	504.68667599127843	4.121669786256092
563.3885665014232	-7.229865934915551	0.2319999999999999	48	8	CHOL	PROCHLORPERAZINE	Approved in other pathologies	IDH1|TP53	490.03344065415934	57.38158914153837
562.9855753247645	0.4275371569362676	0.2319999999999999	48	8	CHOL	SERTRALINE HYDROCHLORIDE	Approved in other pathologies	IDH1|TP53	528.0420150056596	-4.304088711735943
550.0238423422825	4.269158408076095	0.2219999999999999	48	8	CHOL	HEXACHLOROPHENE	Approved in other pathologies	IDH1|TP53	489.44955274622254	-87.48939109133075
550.0220171987426	-3.398841374712532	0.2219999999999999	48	8	CHOL	TRIAMTERENE	Approved in other pathologies	IDH1|TP53	474.0807804810073	-16.0512499455522
292.9510971049677	0.41425820914497535	0.032	48	8	CHOL	TETRANDRINE	Clinical trials	IDH1|TP53	267.427692892167	-143.3206904446984
246.03735081648176	12.76513592217816	0.0004	48	8	CHOL	ASTEMIZOLE	Experimental	IDH1|TP53	194.23662259612706	77.82653410615336
259.9536395490247	2.1722017994464125	0.0004	48	8	CHOL	1,10-PHENANTHROLINE	Experimental	IDH1|TP53	195.45251734606	-72.6075126711357
245.28625897236205	-2.299609668063624	0.0004	48	8	CHOL	148672-13-3	Experimental	IDH1|TP53	165.50704837035033	-95.09945760491854
251.0736426598882	18.541368070109343	0.0004	48	8	CHOL	2,6-DIMETHOXY-1,4-BENZOQUINONE	Experimental	IDH1|TP53	257.89953596160206	-4.302892951520988
258.2233388548848	-5.303014109267906	0.0004	48	8	CHOL	2-(PYRIDIN-2-YLAMINO)QUINOLIN-8-OL	Experimental	IDH1|TP53	247.54898684975726	132.21480298041593
239.70208098503343	2.95538250702441	0.0004	48	8	CHOL	2-CHLOROADENOSINE	Experimental	IDH1|TP53	141.45540447928914	-92.86401990033978
250.88294521168544	-7.53299735110221	0.0004	48	8	CHOL	3-METHYLTOXOFLAVIN	Experimental	IDH1|TP53	149.48704941958238	-41.456018177639834
252.62685308910665	-0.0699824700106717	0.0004	48	8	CHOL	ALEXIDINE DIHYDROCHLORIDE	Experimental	IDH1|TP53	105.20263050521017	-24.74975899593042
247.03661332467198	5.178583352174996	0.0004	48	8	CHOL	BENZETHONIUM CHLORIDE	Experimental	IDH1|TP53	270.8494578618178	-87.15319308896619
1455.987613538269	68.68070555610012	0.892	383	322	COAD	FLUOROURACIL	Approved in same tumor type	PTEN|TP53|ATM	1420.0700548503419	-232.53641039237655
1002.7870792721775	14.17509338181165	0.554	383	321	COAD	SAPANISERTIB	Clinical trials in cancer	APC|PTEN|TP53	949.3531554111705	-199.65490989699492
1320.6440644802997	0.42940119026138746	0.793	383	310	COAD	DASATINIB	Approved in other pathologies and in clinical trials in cancer	APC|SMAD3|TP53	1180.8558809893038	52.63947426546403
1584.5835152724997	11.519358897954561	0.997	383	297	COAD	REGORAFENIB	Approved in same tumor type	KRAS|APC|NRAS	1674.8907744911664	-25.201496957614182
1605.096363352608	-34.776645824196976	1	383	295	COAD	ALPELISIB	Approved in cancer	PTEN|TP53|ESR1	1599.6075382437868	192.11517435437509
1543.2947655813593	22.983473629778985	0.957	383	295	COAD	BINIMETINIB	Approved in cancer	NF1|PTEN|ATM	1577.2378075402635	-214.52231585784992
990.8354305812451	44.99754627472012	0.546	383	293	COAD	MIRDAMETINIB	Clinical trials in cancer	NRAS|PTEN|TP53	919.2322161789489	177.22898413383996
1070.0596290806593	47.88563302085976	0.597	383	292	COAD	GEDATOLISIB	Clinical trials in cancer	NRAS|PTEN|TP53	1016.4873887471091	-207.66667600187074
973.6835469653622	-1.3844507386895373	0.546	383	292	COAD	PIMASERTIB	Clinical trials in cancer	NRAS|NF1|TP53	927.6682687756962	94.20205959772886
1616.257581442829	13.369000196804961	1	383	291	COAD	DABRAFENIB	Approved in cancer	KRAS|NRAS|TP53	1651.1933853899523	-56.77815696026158
1528.408927124853	-4.830751354494993	0.94	383	290	COAD	TRASTUZUMAB	Approved in cancer	APC|PTEN|ESR1	1553.8095173869442	-154.6687813945456
1187.086932026497	-17.08692775948964	0.694	383	289	COAD	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	NRAS|NF1|TP53	1163.3421040488174	11.328948081085287
1546.4454130465422	-30.25042324935518	0.95	383	288	COAD	TRAMETINIB	Approved in cancer	NRAS|NF1|TP53	1544.6182094154453	145.58756745494924
1479.4438198168566	-39.886965799887435	0.892	383	288	COAD	IRINOTECAN	Approved in same tumor type	TP53|TGFBR2|ATM	1475.5163435039626	-58.280875312165264
1273.3224655242188	0.43915258815925995	0.7580000000000001	383	284	COAD	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	KRAS|APC|TP53	1152.8054007654305	-83.9607995903542
1457.6287544841064	-61.660706072626965	0.892	383	283	COAD	VENETOCLAX	Approved in cancer	KRAS|PTEN|TP53	1402.15719923916	-275.33331541431664
1443.3624647887866	38.64429544939787	0.893	383	283	COAD	DOXORUBICIN	Approved in cancer	GATA3|TP53|ATM	1522.5805748599537	-84.2808259884584
1421.7718059172425	-20.42826654568438	0.892	383	282	COAD	BEVACIZUMAB	Approved in same tumor type	PIK3CA|KRAS|TP53	1388.8760739545112	-230.0963835309356
919.2369361545083	2.620598361034297	0.492	383	281	COAD	NAVITOCLAX	Clinical trials in cancer	KRAS|PTEN|TP53	877.2526671861924	199.94324754414453
1429.6448670723535	-49.74063672702732	0.893	383	280	COAD	CARBOPLATIN	Approved in cancer	BRCA2|PTEN|TP53	1462.7375944204023	-206.69197464681068
1039.4776586732723	-42.94445392909273	0.592	383	279	COAD	NVP-CGM097	Clinical trials in cancer	PIK3CA|KRAS|TP53	991.2206086713526	235.35112507342444
299.3957385884034	-1.2083407237565211	0.034	383	277	COAD	LY3009120	Clinical trials	KRAS|NRAS|TP53	356.57410594711644	51.586250310870554
1477.0434620855149	-9.63983767577767	0.893	383	274	COAD	PACLITAXEL	Approved in cancer	PTEN|TP53|ATM	1479.6304054114491	219.22021583968967
644.3358595942245	0.430312729616503	0.292	383	274	COAD	GEMCITABINE	Approved in other pathologies	NRAS|PTEN|TP53	598.4784144167083	70.64564965470049
1599.2195734874258	38.47249472157648	0.999	383	271	COAD	ENCORAFENIB	Approved in same tumor type	KRAS|PTEN|TP53	1603.9029962527738	-136.11088005787457
1394.1520406769891	21.73523976875407	0.8530000000000001	383	269	COAD	PEMBROLIZUMAB	Approved in same tumor type	NRAS|MSH2|TP53	1277.8799067848272	-221.63802800748817
1461.8215313545131	15.391909935823179	0.893	383	267	COAD	CISPLATIN	Approved in cancer	TP53|ATM|ESR1	1472.0135461285108	264.0592479637314
239.38481210197443	-22.611527890581414	0.0004	383	266	COAD	PF-477736	Experimental	BRAF|KRAS|TP53	129.4999349412329	57.17189580232068
997.8600197536599	-42.10793902822857	0.552	383	264	COAD	DS-7423	Clinical trials in cancer	KRAS|PTEN|TP53	932.8455891829274	235.96002226594737
1067.7475248518294	-50.868112670214856	0.596	383	264	COAD	CAPIVASERTIB	Clinical trials in cancer	KRAS|PTEN|TP53	1008.4933657985721	154.22199440565282
1472.6681261101935	41.921668795313764	0.893	383	263	COAD	VANDETANIB	Approved in cancer	APC|PTEN|ATM	1479.0304126563653	-32.483695714124195
233.4417353122604	5.388810598721932	0.0004	383	263	COAD	ABT-737	Experimental	KRAS|PTEN|TP53	85.20721539111196	29.366406969460684
1579.5120660865352	-18.916783892187766	0.994	383	262	COAD	BORTEZOMIB	Approved in cancer	PSMB8|KRAS|TP53	1564.5217250950268	-6.849207680596521
831.6102905585416	1.3153482138408208	0.432	383	260	COAD	DEMCIZUMAB	Clinical trials in cancer	PIK3CA|KRAS|TP53	778.3096988962656	186.64137949069607
1378.6573891391147	-2.075362446615202	0.8420000000000001	383	256	COAD	OLAPARIB	Approved in cancer	TP53|ATM|ESR1	1266.0388128411146	-42.39916236224471
1448.4937797097189	-9.416188296072079	0.892	383	254	COAD	ABEMACICLIB	Approved in cancer	NRAS|TP53|ESR1	1384.4200333017611	111.9137661652066
847.2410567469346	24.292907099609437	0.442	383	253	COAD	ADAVOSERTIB	Clinical trials in cancer	KRAS|NRAS|TP53	798.4524140728071	-93.2223005359104
1018.5391487650704	-23.4889712000886	0.5630000000000001	383	250	COAD	BERZOSERTIB	Clinical trials in cancer	BRCA2|TP53|ATM	935.3448025856774	-226.7942672133516
1432.2931671715228	12.256482762023523	0.892	383	246	COAD	PAZOPANIB	Approved in cancer	KRAS|BRCA2|TP53	1446.0752554218886	-277.87745090416576
1557.2855763727412	-2.7001460896296123	0.96	383	246	COAD	CRIZOTINIB	Approved in cancer	SMAD4|KRAS|TP53	1568.7728055423484	71.2585733369234
1523.484670466222	43.87416146483912	0.94	383	237	COAD	EVEROLIMUS	Approved in cancer	PTEN|ATM|ESR1	1538.896749250125	62.04281196754275
1488.421169674649	20.221046481352545	0.892	383	232	COAD	PALBOCICLIB	Approved in cancer	NRAS|PTEN|ESR1	1442.4434646865386	63.823450385524694
1515.048305664673	19.951922019211906	0.94	383	230	COAD	COBIMETINIB	Approved in cancer	KRAS|NRAS|NF1	1550.8288529272663	189.85975343357006
1624.2035186158193	-13.865925113605499	1	383	228	COAD	SORAFENIB	Approved in cancer	KRAS|NRAS|PTEN	1618.3879371048815	-90.91532094838934
956.2468986224077	-23.433940843343947	0.536	383	227	COAD	TAK-733	Clinical trials in cancer	MAP2K1|KRAS|NRAS	952.4311582361756	148.4458242815207
256.4035592493308	18.28018991785666	0.0004	383	222	COAD	1173900-33-8	Experimental	PTEN|TP53|ATM	281.94641675776563	43.73051721184484
1452.3618496283343	-34.89540777742252	0.892	383	221	COAD	DOCETAXEL	Approved in cancer	KRAS|TP53|ESR1	1424.833232704123	300.02722668767456
1195.2048652228314	9.218546457275352	0.692	383	219	COAD	SULINDAC	Approved in other pathologies and in clinical trials in cancer	FMO3|PIK3CA|APC	1136.0037536060158	-166.79252043163416
1519.2207540343154	-33.43447483225114	0.94	383	218	COAD	TEMSIROLIMUS	Approved in cancer	PIK3CA|KRAS|PTEN	1506.3649500702825	186.66868338796712
1403.6854782784	-40.43052689921984	0.8620000000000001	383	216	COAD	TOPOTECAN	Approved in cancer	PIK3CA|PTEN|TP53	1375.2775685390168	-181.96463887925663
1083.1622698417448	3.774587042075666	0.597	383	215	COAD	PILARALISIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	1021.1444138614368	-127.53099697413887
1061.4066363857369	-4.890492687623606	0.593	383	215	COAD	IZORLISIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	1022.4587223162473	-79.03667267172327
1501.6361018715797	-0.08388968961452292	0.93	383	213	COAD	NERATINIB	Approved in cancer	PIK3CA|KRAS|ESR1	1511.3017716274805	-259.45253379553174
871.6360839352178	-19.10545603945718	0.461	383	213	COAD	CAMPTOTHECIN	Clinical trials in cancer	BRAF|PIK3CA|KRAS	858.6061779365482	155.78610731619534
255.45699196048236	41.760170311701245	0.0004	383	209	COAD	DEL-22379	Experimental	MAP2K1|KRAS|NRAS	161.1081384208295	-125.31715936464931
1029.2072053546854	25.38479619822462	0.594	383	208	COAD	LIFIRAFENIB	Clinical trials in cancer	BRAF|KRAS|NRAS	996.8475907327819	194.7749456852161
1417.744537895378	32.031210949579844	0.882	383	205	COAD	FOLINIC ACID	Approved in same tumor type	BRAF|APC|GATA3	1523.4754688928704	104.80972867995172
1043.4020624778855	51.2162255321995	0.597	383	203	COAD	PICTILISIB	Clinical trials in cancer	MPL|KRAS|PTEN	989.5347447798792	-160.20383847919786
1573.5614649791562	36.27545767652771	0.992	383	203	COAD	TAMOXIFEN	Approved in cancer	PIK3CA|TP53|ESR1	1649.8819988054056	-17.120075766699017
848.9778385852952	-18.534846641053804	0.442	383	202	COAD	TANESPIMYCIN	Clinical trials in cancer	MTOR|PIK3CA|TP53	800.8425387265632	-69.22849503491604
1026.9007048625122	-0.4542324268238076	0.593	383	201	COAD	RESVERATROL	Clinical trials in cancer	TP53|ITGB3|ESR1	980.1819227912829	182.57438479750766
360.74631582052734	0.42922503717167615	0.082	383	201	COAD	EMODIN	Clinical trials	AR|PIK3CA|TP53	369.05478776699647	16.200928904794864
1499.268132268804	-22.473014636644876	0.927	383	199	COAD	RALOXIFENE	Approved in cancer	PIK3CA|TP53|ESR1	1516.9254775667496	-11.84219362588314
1143.6320221795913	0.49629995721457476	0.6619999999999999	383	198	COAD	METFORMIN	Approved in other pathologies and in clinical trials in cancer	KRAS|PTEN|ATM	1116.0631049446197	147.5445140641055
1429.052547317608	60.4482272759069	0.892	383	198	COAD	DUVELISIB	Approved in cancer	PIK3CA|TP53	1327.8230430069939	-195.84625064526364
434.5289775381493	10.58710652004774	0.136	383	197	COAD	REFAMETINIB	Clinical trials	MAP2K1|KRAS|PTEN	406.53773191856953	51.65962420714558
1059.850446060024	-27.23148048378758	0.595	383	195	COAD	212631-79-3	Clinical trials in cancer	BRAF|MAP2K1|KRAS	1029.9044116478558	41.19320524070349
1395.9987274548623	-19.382942606812776	0.8420000000000001	383	194	COAD	PANOBINOSTAT	Approved in cancer	BRAF|KMT2A|KRAS	1351.4511680563346	4.250936080735386
912.5139110422055	-22.290439457988953	0.492	383	194	COAD	SARACATINIB	Clinical trials in cancer	BRAF|IDH1|KRAS	876.1913897351847	175.21410977706387
428.72856929689135	-10.030507023588854	0.133	383	194	COAD	RO4987655	Clinical trials	BRAF|MAP2K1|KRAS	404.11413805696475	-12.910595416769809
1369.068128943065	20.400179835547902	0.8320000000000001	383	193	COAD	ATEZOLIZUMAB	Approved in cancer	ALK|BRAF|KRAS	1226.6007244349796	194.84565119432244
1045.4002567014757	10.528095707078194	0.595	383	193	COAD	APITOLISIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	949.2422022650074	-135.9088278170533
1580.181907008368	-43.60106941446492	0.993	383	192	COAD	INFIGRATINIB	Approved in cancer	PIK3CA|KRAS|PTEN	1642.6475307872768	-112.49794401088477
1601.8981072628114	-8.541899535326792	0.999	383	192	COAD	COPANLISIB	Approved in cancer	PIK3CA|KRAS|PTEN	1650.7000193555214	55.88716450905426
1041.9858341606196	-15.812665573840547	0.596	383	192	COAD	PF-04691502	Clinical trials in cancer	PIK3CA|KRAS|PTEN	1049.7153753398525	-48.790940550001125
995.874639715937	-15.365136909997233	0.552	383	192	COAD	VOXTALISIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	941.3727155629092	4.2912367376697205
909.9672609905816	26.587392145656793	0.491	383	192	COAD	ULIXERTINIB	Clinical trials in cancer	BRAF|KRAS	756.2358028448741	36.159778494734326
856.2168558108466	1.7851351378537856	0.444	383	192	COAD	PANULISIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	759.7115348228235	-43.669356979886004
237.00369691808424	29.892588334650412	0.0004	383	192	COAD	TW-37	Experimental	BRAF|KRAS	193.65526158234653	-2.9911239441161968
1405.5158958314164	-0.5565772303644962	0.8520000000000001	383	191	COAD	CAPECITABINE	Approved in same tumor type	KRAS|CDH1|PTEN	1365.5121581352776	-239.6382565081763
955.1207965032568	17.132506774832393	0.535	383	191	COAD	AZD8055	Clinical trials in cancer	PIK3CA|KRAS|PTEN	960.273047492875	31.958860106072677
947.4861501408061	-2.364989820696678	0.534	383	191	COAD	ONATASERTIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	919.2070186594655	32.68246490373076
877.2120576954914	2.2685307861594595	0.462	383	191	COAD	FIMEPINOSTAT	Clinical trials in cancer	PIK3CA|KRAS|PTEN	868.4602823010753	-182.94397580881008
274.8221432736536	5.2426647723477515	0.0004	383	191	COAD	1056901-62-2	Experimental	PIK3CA|KRAS|PTEN	223.0729182594449	-108.91547390200748
256.163084110691	-4.276397422787511	0.0004	383	191	COAD	A-443654	Experimental	PIK3CA|KRAS|SMAD3	238.8350466357185	-225.77674934914631
874.1967463484111	22.945760098899655	0.463	383	190	COAD	RIGOSERTIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	828.4907483413787	-139.32757251077925
895.7042836487446	-7.452800639465181	0.482	383	190	COAD	LINSITINIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	788.649335617795	106.95166148461203
827.962593531524	-22.910595168207436	0.433	383	190	COAD	AZD8835	Clinical trials in cancer	PIK3CA|KRAS|PTEN	653.0774504001658	63.46547034932311
254.86705649451946	-41.99879216163873	0.0004	383	190	COAD	PKI-402	Experimental	PIK3CA|KRAS|PTEN	112.428870267226	96.26057672326942
513.3233086881438	0.4327640106581043	0.195	383	189	COAD	TASELISIB	Clinical trials	PIK3CA|KRAS|PTEN	437.0128985630915	24.108678468985886
1050.2574841818519	30.921283526430585	0.596	383	189	COAD	SONOLISIB	Clinical trials in cancer	PIK3R1|PIK3CA|KRAS	1044.9319707258583	191.7893400477338
1083.9047516594028	25.80723187870211	0.599	383	188	COAD	IPATASERTIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	1023.7795252373619	172.30704816052793
1179.1580916826438	24.64337082975561	0.692	383	188	COAD	PONATINIB	Approved in other pathologies and in clinical trials in cancer	ERBB2|PIK3CA|KRAS	1154.3228825888325	-59.2518878145483
1065.3480177988554	16.779933078924955	0.595	383	188	COAD	SERABELISIB	Clinical trials in cancer	MTOR|PIK3CA|KRAS	944.2884132409393	46.91875029217999
974.5004211121278	24.657087860006243	0.538	383	188	COAD	RIDAFOROLIMUS	Clinical trials in cancer	MTOR|PIK3CA|KRAS	913.2632720359958	-219.4641564924397
1173.4278374354317	4.873058685986365	0.692	383	187	COAD	MIDOSTAURIN	Approved in other pathologies and in clinical trials in cancer	PIK3CA|KRAS	1146.7671193378537	26.949688628924974
264.0428407820651	-23.4569927156044	0.0004	383	187	COAD	DEGUELIN	Experimental	PIK3CA|KRAS	257.998434838027	-35.92290421114774
978.5902596318473	-26.92184357953485	0.541	383	187	COAD	VANTICTUMAB	Clinical trials in cancer	FZD6|CTNNB1|APC	928.6578654083285	-6.809544309466901
1078.6730552922343	-18.29240943020369	0.596	383	185	COAD	BUPARLISIB	Clinical trials in cancer	KRAS|NRAS|PTEN	982.9423428972527	-99.29572364033118
1376.406541015007	-25.84894254495282	0.8420000000000001	383	182	COAD	VINORELBINE	Approved in cancer	SMARCA4|APC|BRCA2	1207.9299425694094	90.96525386642622
1529.417385987009	-1.0652066797614168	0.949	47	9	DLBC	ENCORAFENIB	Approved in cancer	KRAS|PTEN|TP53	1567.9660362911245	-92.92630100753122
1576.8485783249412	0.6776716614942586	0.984	47	9	DLBC	ALPELISIB	Approved in cancer	KRAS|PTEN|TP53	1599.9485432936242	-21.837714574709025
987.8790734503096	4.240658644643958	0.546	47	9	DLBC	MIRDAMETINIB	Clinical trials in cancer	KRAS|PTEN|TP53	931.3797496359595	40.20014271519648
1531.4281904518218	7.201972661984399	0.95	47	8	DLBC	DABRAFENIB	Approved in cancer	MAP2K1|KRAS|TP53	1525.474277338079	64.75522473158975
1537.1178024231765	1.8569249601930835	0.95	47	8	DLBC	TRAMETINIB	Approved in cancer	MAP2K1|KRAS|TP53	1468.8405210315248	74.43418879932574
1375.8045525888397	-3.5560403804094847	0.8320000000000001	47	8	DLBC	FLUOROURACIL	Approved in cancer	KRAS|PTEN|TP53	1290.845441391676	7.587519947823267
1173.4086778195197	0.4319244221987333	0.6839999999999999	47	8	DLBC	DASATINIB	Approved in other pathologies and in clinical trials in cancer	MAP2K1|KRAS|TP53	1127.8378183598043	25.46832494230958
1037.7711286758185	-5.493678855391266	0.584	47	8	DLBC	GEDATOLISIB	Clinical trials in cancer	KRAS|PTEN|TP53	970.2630474118544	-11.76868910904139
988.4128089926877	-3.9775183081177943	0.546	47	8	DLBC	PIMASERTIB	Clinical trials in cancer	MAP2K1|KRAS|TP53	895.8824224488036	-5.875996218589421
822.7229124577087	-3.1544341911834692	0.423	47	8	DLBC	SAPANISERTIB	Clinical trials in cancer	KRAS|PTEN|TP53	714.4935088499366	-23.324080531687002
247.54815042780223	-2.779057753270962	0.0004	47	8	DLBC	1173900-33-8	Experimental	BRAF|PTEN|TP53	242.469635767448	-15.520161916886167
1376.4488065796772	3.7980971658297165	0.8320000000000001	47	7	DLBC	VENETOCLAX	Approved in cancer	KRAS|PTEN|TP53	1292.4968938183777	-229.96893770160477
1385.5451146566836	5.156338621410697	0.8420000000000001	47	7	DLBC	CISPLATIN	Approved in cancer	KRAS|PTEN|TP53	1477.1933523215703	-172.8755314170691
1362.1463175545618	4.748776688386727	0.8220000000000001	47	7	DLBC	VORINOSTAT	Approved in cancer	BRAF|PTEN|TP53	1299.5061960706973	-234.1608172837718
1355.339985849442	3.2973896468456587	0.8220000000000001	47	7	DLBC	TOPOTECAN	Approved in cancer	BRAF|PTEN|TP53	1159.8054968840102	-98.75808831585422
1106.0087388537472	3.0924271274847115	0.634	47	7	DLBC	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	KRAS|PTEN|TP53	1111.480830831391	-19.348574656123787
873.4964306358905	0.42213347555920677	0.462	47	7	DLBC	NAVITOCLAX	Clinical trials in cancer	KRAS|PTEN|TP53	833.0379385128481	80.53662843633714
822.5085670921625	4.223970358739706	0.423	47	7	DLBC	DS-7423	Clinical trials in cancer	KRAS|PTEN|TP53	773.5149896130143	60.35252748807949
563.2772050669253	0.431593363368421	0.2319999999999999	47	7	DLBC	GEMCITABINE	Approved in other pathologies	KRAS|PTEN|TP53	507.7978994248662	26.522147452725733
1531.0854768006532	-8.693001577379931	0.95	47	7	DLBC	VEMURAFENIB	Approved in cancer	BRAF|MAP2K1|TP53	1549.2641344845392	-7.906594991362596
1371.5880767017777	-9.090896818844868	0.8320000000000001	47	6	DLBC	BEVACIZUMAB	Approved in cancer	BRAF|KRAS|TP53	1306.3805128020633	138.09158786403214
1524.9070091924211	4.779351303453694	0.947	47	6	DLBC	BINIMETINIB	Approved in cancer	MAP2K1|KRAS|PTEN	1505.8268800073238	-14.46612876717964
1391.0885557741942	1.6959792266606826	0.8430000000000001	47	6	DLBC	PACLITAXEL	Approved in cancer	KRAS|PTEN|TP53	1400.2588884556772	118.0707384343865
1364.8576507903672	-1.1873937210088172	0.8230000000000001	47	6	DLBC	PEMBROLIZUMAB	Approved in cancer	BRAF|KRAS|TP53	1219.0010372805764	-44.76175295992141
1370.552280833098	1.0057719509939318	0.8320000000000001	47	6	DLBC	DOXORUBICIN	Approved in cancer	BRAF|KRAS|TP53	1265.5797180998024	39.67875325117794
1362.2091167446583	11.275895129700189	0.8220000000000001	47	6	DLBC	IRINOTECAN	Approved in cancer	BRAF|KRAS|TP53	1278.7987637855526	-17.383069378817737
1354.7883334642893	-7.521237066649235	0.8210000000000001	47	6	DLBC	CARBOPLATIN	Approved in cancer	KRAS|PTEN|TP53	1271.0489668619196	1.5871492655667225
1372.832509423764	9.239950935248231	0.8320000000000001	47	6	DLBC	OLAPARIB	Approved in cancer	KRAS|PTEN|TP53	1342.054620335509	-90.92902708073032
1360.5701413154002	-5.538872009764077	0.8220000000000001	47	6	DLBC	CAPMATINIB	Approved in cancer	BRAF|TP53	1311.5047219555186	-69.78798116442901
1319.7790016095137	0.410111888658804	0.792	47	6	DLBC	FOSTAMATINIB	Approved in other pathologies and in clinical trials in cancer	PIK3CD|BRAF|IKBKB	1332.3759235931147	-41.62944026478618
1104.041196053533	-3.136200275830163	0.633	47	6	DLBC	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	PIK3CA|KRAS|TP53	1035.2648675193168	-72.67969591183429
941.3088010464212	0.43036328478453356	0.512	47	6	DLBC	NVP-CGM097	Clinical trials in cancer	BRAF|KRAS|TP53	936.9778537705898	-102.52692791661732
832.7533035619673	3.8607698353199282	0.432	47	6	DLBC	CAPIVASERTIB	Clinical trials in cancer	KRAS|PTEN|TP53	757.3617040972027	70.15918079207881
811.0756841696157	0.9179579169070848	0.414	47	6	DLBC	E6201	Clinical trials in cancer	BRAF|MAP2K1|PTEN	760.2740904747284	16.52593315474715
806.6808628150985	5.1612996445666965	0.412	47	6	DLBC	GANETESPIB	Clinical trials in cancer	BRAF|TP53	668.5316902729181	-82.95272697588558
447.7460090500561	1.902010716673061	0.146	47	6	DLBC	REFAMETINIB	Clinical trials	MAP2K1|KRAS|PTEN	408.649146874752	-0.05252065952200269
499.79428095950954	0.430041159691001	0.185	47	6	DLBC	OMIPALISIB	Clinical trials	BRAF|MAP2K1|PTEN	442.24847478456496	0.22256369637725015
282.76107658015167	-1.8442273592419838	0.024	47	6	DLBC	LY3009120	Clinical trials	BRAF|KRAS|TP53	280.2416008528153	30.18089236002578
278.6360824871956	2.6604466281932844	0.022	47	6	DLBC	PF-04217903	Clinical trials	BRAF|TP53	166.80172112307855	-15.37596199833456
248.10768852785824	4.157879393816188	0.0008	47	6	DLBC	918505-84-7	Experimental	BRAF|MAP2K1|PTEN	156.14213369402268	-138.00834042017942
253.93093803474596	6.0218286990970284	0.0004	47	6	DLBC	ABT-737	Experimental	KRAS|PTEN|TP53	162.1564661493014	-112.66596178262202
251.9706258818542	-8.152002870284349	0.0004	47	6	DLBC	PF-477736	Experimental	BRAF|KRAS|TP53	154.29032092637684	-33.91286853559018
1535.4914021456277	-4.46558417966861	0.95	47	5	DLBC	COBIMETINIB	Approved in cancer	BRAF|MAP2K1|KRAS	1552.7166135315274	-84.06349383292489
1381.5806888804004	0.509134853308268	0.8420000000000001	47	5	DLBC	DOCETAXEL	Approved in cancer	PIK3CA|KRAS|TP53	1301.2052639805459	-48.93051751876649
1368.0854923066192	6.120936457520116	0.8320000000000001	47	5	DLBC	BORTEZOMIB	Approved in cancer	PIK3CA|KRAS|TP53	1282.9754226198434	-15.78578670332547
1582.0331488707338	-3.9635221255076374	0.986	47	5	DLBC	IDELALISIB	Approved in cancer	PIK3CA|BRAF|PTEN	1607.1596728186548	-73.55316196542546
1040.0047320905792	9.45708547994144	0.585	47	5	DLBC	DACTOLISIB	Clinical trials in cancer	BRAF|KRAS|PTEN	1006.5501458597892	130.13756446827176
1027.0116292236398	0.5172397659559635	0.5750000000000001	47	5	DLBC	212631-79-3	Clinical trials in cancer	BRAF|MAP2K1|KRAS	976.5864493157153	-16.239419633588966
1037.6987893352566	4.737607922852561	0.584	47	5	DLBC	PICTILISIB	Clinical trials in cancer	BRAF|KRAS|PTEN	957.3981406483074	-31.287955433963333
1042.9415185930566	5.097309313694723	0.585	47	5	DLBC	PILARALISIB	Clinical trials in cancer	BRAF|KRAS|PTEN	929.1231512859883	110.80741132719368
1040.6375380705872	0.3765565849775214	0.584	47	5	DLBC	BUPARLISIB	Clinical trials in cancer	BRAF|KRAS|PTEN	997.1001392123043	53.516434083657856
982.8440431333808	-0.5634487711925829	0.546	47	5	DLBC	TAK-733	Clinical trials in cancer	BRAF|MAP2K1|KRAS	913.6225888404116	-75.20191763891908
1032.5225132410724	3.821989277631559	0.582	47	5	DLBC	GSK2636771	Clinical trials in cancer	PIK3CA|BRAF|PTEN	927.2428952414847	43.15994490166753
1031.9263659724995	-2.573495314323253	0.582	47	5	DLBC	IZORLISIB	Clinical trials in cancer	BRAF|KRAS|PTEN	996.8288511812574	-11.639268516139737
808.4683531016859	-4.130474288419748	0.412	47	5	DLBC	DEMCIZUMAB	Clinical trials in cancer	PIK3CA|KRAS|TP53	721.6672420107207	79.57712958430409
442.30004199815124	0.2794241746868522	0.143	47	5	DLBC	RO4987655	Clinical trials	BRAF|MAP2K1|KRAS	404.439614662997	3.3022615528463177
257.08214872885907	0.22745508639508216	0.0008	47	5	DLBC	SAR-260301	Experimental	PIK3CA|BRAF|PTEN	216.57391722683107	-32.30213484679766
249.56084892898943	9.651029218247118	0.0004	47	5	DLBC	DEL-22379	Experimental	BRAF|MAP2K1|KRAS	101.11645399539496	29.996417334489877
1251.8706786817247	0.4296377292581326	0.7420000000000001	47	5	DLBC	ASPIRIN	Approved in other pathologies and in clinical trials in cancer	FAS|IKBKB|TP53	1171.052375356589	-33.32060135177741
1578.7452080627427	7.3714201125918635	0.984	47	5	DLBC	DUVELISIB	Approved in cancer	PIK3CD|PIK3CA|TP53	1576.5151479795868	3.4889635271963186
1383.4874118277596	-4.39157361312985	0.8420000000000001	47	5	DLBC	ERLOTINIB	Approved in cancer	BRAF|TP53	1405.1296798187602	-158.22762479349868
1359.2299164525905	-11.059304354503666	0.8220000000000001	47	5	DLBC	PANITUMUMAB	Approved in cancer	MAP2K1|TP53	1267.1505872172384	8.208810707415608
1545.4671925626749	0.360421048636681	0.96	47	4	DLBC	SORAFENIB	Approved in cancer	BRAF|KRAS|PTEN	1510.060428001495	-2.158892200213387
1386.5919368770349	-8.091709416323539	0.8420000000000001	47	4	DLBC	PALBOCICLIB	Approved in cancer	BRAF|KRAS|PTEN	1388.4409968563193	-45.985448742955725
1388.6503434807446	-4.200917148396087	0.8420000000000001	47	4	DLBC	ABEMACICLIB	Approved in cancer	KRAS|TP53	1340.0505438956009	7.441074504064602
1378.084995191565	9.235902224107889	0.8320000000000001	47	4	DLBC	TRASTUZUMAB	Approved in cancer	BRAF|KRAS|PTEN	1311.6306195660009	-36.1451819053282
1369.7254776388459	-4.1810926502337225	0.8320000000000001	47	4	DLBC	PAZOPANIB	Approved in cancer	KRAS|TP53	1280.0560102799168	-148.49989033108506
1441.6219675306354	0.4235887423946849	0.883	47	4	DLBC	VANDETANIB	Approved in cancer	MAP2K1|KRAS|PTEN	1478.6443955917496	201.6098247869736
1583.381346138027	0.6745016045097145	0.986	47	4	DLBC	COPANLISIB	Approved in cancer	PIK3CA|KRAS|PTEN	1605.7094479615625	36.35158273317771
1574.8810635942677	-5.550056182828115	0.982	47	4	DLBC	INFIGRATINIB	Approved in cancer	PIK3CA|KRAS|PTEN	1565.6183241267274	-23.110795289398368
1364.011263864454	-10.399435620081618	0.8230000000000001	47	4	DLBC	EVEROLIMUS	Approved in cancer	BRAF|KRAS|PTEN	1406.7296798262446	41.436753239171935
1365.7623884479342	-6.358547285623615	0.8230000000000001	47	4	DLBC	TEMSIROLIMUS	Approved in cancer	BRAF|KRAS|PTEN	1261.7862314401075	52.399504107852806
1355.7545535275392	-2.360927169875538	0.8220000000000001	47	4	DLBC	OXALIPLATIN	Approved in cancer	BRAF|KRAS|PTEN	1280.3975275989844	160.1569635243833
1347.4124437045361	2.559590266083859	0.812	47	4	DLBC	CRIZOTINIB	Approved in cancer	KRAS|TP53	1214.7378633119392	-82.28665405802317
1357.803018172289	8.405135187415908	0.8220000000000001	47	4	DLBC	NIVOLUMAB	Approved in cancer	BRAF|PTEN	1272.3405726563622	-30.510355392680424
832.7580504135675	-4.727519946776738	0.432	47	4	DLBC	VORUCICLIB	Clinical trials in cancer	PIM1|BRAF	750.6206404114954	-79.10422743292004
834.9579067391844	-0.910876479099727	0.432	47	4	DLBC	UPROSERTIB	Clinical trials in cancer	PIK3CA|BRAF|PTEN	759.626836930814	46.535937249505906
830.5539074173531	-0.9133205068598045	0.432	47	4	DLBC	RIGOSERTIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	806.0390339244077	26.39408990285156
1035.8167980558835	0.2889229199049339	0.583	47	4	DLBC	PF-04691502	Clinical trials in cancer	PIK3CA|KRAS|PTEN	960.9341670166037	19.584803789644866
1043.537906384128	-3.482740887474108	0.584	47	4	DLBC	APITOLISIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	952.8436221342979	54.19066093313202
803.647051619076	-3.814739247046873	0.412	47	4	DLBC	ADAVOSERTIB	Clinical trials in cancer	KRAS|TP53	721.6936611737957	-150.373046099082
819.1169277638897	8.781548631839854	0.422	47	4	DLBC	AZD8835	Clinical trials in cancer	PIK3CA|KRAS|PTEN	792.7982193012517	-39.48663582952781
816.8773511046684	4.992418550397645	0.422	47	4	DLBC	BERZOSERTIB	Clinical trials in cancer	KRAS|TP53	797.1823109160404	-106.51729184855209
818.0217941245626	0.7425149579847812	0.422	47	4	DLBC	FIMEPINOSTAT	Clinical trials in cancer	PIK3CA|KRAS|PTEN	787.5922403701563	-101.84182999465854
816.6201442773234	-3.4312705210761294	0.422	47	4	DLBC	PANULISIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	750.9643800184688	98.58374080863081
818.3951078579003	-7.461744474297234	0.422	47	4	DLBC	VOXTALISIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	761.0146993299961	-82.36904776541817
445.84657493713246	-2.999448209634238	0.145	47	4	DLBC	TASELISIB	Clinical trials	PIK3CA|KRAS|PTEN	402.9277351085993	-0.8754890220087646
252.31575562209255	1.0232788111690354	0.0004	47	4	DLBC	NVP-AEW541	Experimental	PIK3CA|BRAF|PTEN	185.79040799754515	-67.84391203566256
253.64631083638955	-3.174915875013994	0.0004	47	4	DLBC	TRACAZOLATE	Experimental	CREBBP|TP53	197.7906479294616	-74.5438411513447
1357.164694319189	12.762629712632787	0.8220000000000001	47	4	DLBC	CICLOPHOSPHAMIDE	Approved in cancer	FAS|TP53	1324.4693961915777	-28.565585463441124
1089.6708894668936	0.42105521485549957	0.622	47	4	DLBC	DAUNORUBICIN	Approved in other pathologies and in clinical trials in cancer	FAS|TP53	1015.7423703146413	71.63446635496837
266.0871047623686	-2.08538017019805	0.012	47	4	DLBC	MPA	Clinical trials	FAS|TP53	272.10081537969296	49.5401455201044
268.03884034910084	1.8641688848983335	0.012	47	4	DLBC	VESNARINONE	Clinical trials	FAS|TP53	271.54462819842854	35.120827105417135
1399.0123921979348	0.28363862922728345	0.8520000000000001	47	4	DLBC	TAMOXIFEN	Approved in cancer	PIK3CA|TP53	1290.2129803955097	-119.09003714102442
1347.4416613665123	-1.8443128128024284	0.812	47	4	DLBC	RALOXIFENE	Approved in cancer	PIK3CA|TP53	1307.5820691317094	66.91681807344378
1386.3096909086976	-0.47042636158798246	0.8420000000000001	47	4	DLBC	GEFITINIB	Approved in cancer	PIM1|BRAF|IKBKB	1391.391157596207	-102.7700808780608
860.0235177345877	0.4111720265936185	0.452	47	4	DLBC	RESVERATROL	Clinical trials in cancer	PIK3CA|TP53	793.1570019945431	-79.08237983055237
805.9055915175445	-0.03397034049774561	0.412	47	4	DLBC	TANESPIMYCIN	Clinical trials in cancer	PIK3CA|TP53	794.2100062505265	-31.70202992885143
263.64398762534296	1.580469157455724	0.012	47	4	DLBC	EMODIN	Clinical trials	PIK3CA|TP53	237.61891246033326	-14.470590239619469
1359.6768301586708	-0.3581885657246744	0.8220000000000001	47	4	DLBC	MITOXANTRONE	Approved in cancer	PIM1|TP53	1412.1304401234518	150.79338117286545
1403.4901362489243	49.65533529322818	0.8530000000000001	182	114	ESCA	DOXORUBICIN	Approved in cancer	KRAS|TP53|KMT2A	1415.4824466764408	36.54171396125423
1447.3977926322707	-28.552396136918645	0.892	182	112	ESCA	BORTEZOMIB	Approved in cancer	KRAS|TP53|RB1	1465.6468637905512	-260.7410528048687
1404.4464761475565	23.857534909320435	0.8520000000000001	182	112	ESCA	FLUOROURACIL	Approved in cancer	PIK3CA|KRAS|TP53	1384.5162058467274	317.98249227023797
856.6402375812692	-8.668707486722354	0.452	182	112	ESCA	SAPANISERTIB	Clinical trials in cancer	TP53|SMAD4|RB1	818.6804674003124	-8.75127930237909
1385.0444382162566	-15.463026889084148	0.8420000000000001	182	111	ESCA	IRINOTECAN	Approved in cancer	TP53|BRCA2|SMAD4	1279.9518563096246	-83.52011645662544
1186.4069438320125	9.86608632484652	0.692	182	111	ESCA	DASATINIB	Approved in other pathologies and in clinical trials in cancer	ASXL1|KRAS|TP53	1157.4075512470802	139.7503761407212
1586.2726089086964	0.4334853155268945	0.99	182	110	ESCA	ALPELISIB	Approved in cancer	PIK3CA|KRAS|TP53	1618.2000435313864	79.31519583427331
1406.0719226049957	-1.4862285081275957	0.8520000000000001	182	110	ESCA	BEVACIZUMAB	Approved in cancer	PIK3CA|KRAS|TP53	1356.7948315574256	-43.69701691608782
1493.2009930529684	-10.325364476650748	0.92	182	110	ESCA	DABRAFENIB	Approved in cancer	PIK3CA|KRAS|TP53	1356.9744215652943	32.63707601015537
1447.0446658553135	-2.930453654280285	0.884	182	110	ESCA	TRAMETINIB	Approved in cancer	TP53|NF1|RB1	1479.2634232087198	138.74523624415406
1427.0743491328003	12.37707000901898	0.8620000000000001	182	110	ESCA	VENETOCLAX	Approved in cancer	ASXL1|KRAS|TP53	1370.8307938523749	-317.0163178523277
1040.9714951519056	-11.185468862427115	0.587	182	110	ESCA	GEDATOLISIB	Clinical trials in cancer	PIK3CA|KRAS|TP53	960.8280165923572	-226.65749227568634
1050.6670788060655	12.048700664482652	0.592	182	110	ESCA	RESVERATROL	Clinical trials in cancer	CSNK2A1|PIK3CA|TP53	1027.3585384318076	115.96996211228264
922.7569039995221	1.581278625579614	0.492	182	110	ESCA	NAVITOCLAX	Clinical trials in cancer	PIK3CA|KRAS|TP53	853.9509901578857	71.07731059251256
995.1814901089199	0.4285065673903432	0.552	182	110	ESCA	NVP-CGM097	Clinical trials in cancer	PIK3CA|KRAS|TP53	929.7715385993085	150.83808404136164
901.0339482827673	-11.139949653244713	0.482	182	110	ESCA	MIRDAMETINIB	Clinical trials in cancer	PIK3CA|KRAS|TP53	862.5905016981286	107.08975045394027
901.6604610164578	15.322101775703459	0.483	182	110	ESCA	PIMASERTIB	Clinical trials in cancer	KRAS|TP53|NF1	883.1180044224388	-104.48558368917243
414.53637163641224	0.42083320464476515	0.122	182	110	ESCA	EMODIN	Clinical trials	CSNK2A1|PIK3CA|TP53	389.2842720675369	4.942889448207836
1405.8540419649617	-29.61363059581703	0.8520000000000001	182	109	ESCA	CARBOPLATIN	Approved in cancer	TP53|BRCA2|SMAD4	1295.9689964930162	-268.0880773053351
1468.7224270898403	9.620403402474636	0.893	182	109	ESCA	PACLITAXEL	Approved in cancer	TP53|BRCA2|SMAD4	1502.6852244961312	109.85145590600837
1382.1355497789143	35.70404645771674	0.8420000000000001	182	109	ESCA	TOPOTECAN	Approved in cancer	PIK3CA|TP53|RB1	1334.829251715493	135.0659005833395
878.2993584602766	-21.702175187501553	0.462	182	109	ESCA	CAPIVASERTIB	Clinical trials in cancer	PIK3CA|KRAS|TP53	856.8556878515498	132.68384767220078
860.5377371539307	16.314593515714904	0.452	182	109	ESCA	DS-7423	Clinical trials in cancer	PIK3CA|KRAS|TP53	816.858125691302	-228.66845757298506
812.7508808067475	13.35556249164648	0.422	182	109	ESCA	DEMCIZUMAB	Clinical trials in cancer	PIK3CA|KRAS|TP53	821.91600392576	100.77154717309708
249.6111764543312	82.99131237153114	0.0004	182	109	ESCA	1173900-33-8	Experimental	BRAF|PIK3CA|TP53	234.39269714756955	-57.31601989966791
221.92066789787089	0.5666986730506665	0.0004	182	109	ESCA	ABT-737	Experimental	PIK3CA|KRAS|TP53	196.03956261296153	-46.665978491341235
1468.746685957043	-15.21838369769921	0.892	182	108	ESCA	DUVELISIB	Approved in cancer	PIK3CA|TP53	1383.2051814195654	-5.6212114862878195
1448.8625180163656	24.540558400779986	0.892	182	108	ESCA	TAMOXIFEN	Approved in cancer	ERBB2|PIK3CA|TP53	1415.3357532657687	278.16686515866945
1383.7575854582979	9.5781437159024	0.8420000000000001	182	108	ESCA	RALOXIFENE	Approved in cancer	PIK3CA|TP53	1294.3767731960284	-203.44649267161776
1493.045805176274	14.63585909085782	0.92	182	108	ESCA	VEMURAFENIB	Approved in cancer	BRAF|PIK3CA|TP53	1527.89922344192	-240.6470406227051
1131.4720234692006	0.4207991260646793	0.653	182	108	ESCA	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	KRAS|TP53|RB1	1113.667606352898	-72.41640013105302
836.6763657008996	6.6486546438223115	0.432	182	108	ESCA	TANESPIMYCIN	Clinical trials in cancer	PIK3CA|TP53	721.1733983827662	-10.323159817461885
1170.9037237538923	-9.690296347042931	0.6839999999999999	182	107	ESCA	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	KRAS|TP53|NF1	1139.0623010688432	-40.226570311417674
207.78866836160591	-61.743590043890435	0.0004	182	107	ESCA	93718-83-3	Experimental	SMAD3|TP53|KMT2A	241.61633515454423	-121.74996931125372
1383.8457033708655	-40.60471447727733	0.8420000000000001	182	106	ESCA	VORINOSTAT	Approved in cancer	BRAF|TP53|RB1	1380.731511519801	212.51471023878952
1426.0966435504447	-15.809669570798093	0.8630000000000001	182	105	ESCA	CISPLATIN	Approved in cancer	TP53|BRCA2|SMAD4	1465.78186860683	-180.11947287030586
1425.528519727053	36.956108780951894	0.8620000000000001	182	105	ESCA	METHOTREXATE	Approved in cancer	NFE2L2|TP53|RB1	1376.6416667693834	-122.13020749702767
1103.1671043433275	-23.52729937922689	0.632	182	105	ESCA	AZACITIDINE	Approved in other pathologies and in clinical trials in cancer	SMAD3|ASXL1|TP53	1059.0044635319882	29.037103087469973
1103.16444950414	24.39698766961868	0.632	182	105	ESCA	MERCAPTOPURINE	Approved in other pathologies and in clinical trials in cancer	NFE2L2|TP53|RB1	1073.2604182471002	142.04887824328915
220.57693598611039	-41.20122770784411	0.0004	182	105	ESCA	CHEMBL2002487	Experimental	NFE2L2|GNAS|TP53	200.4388125618724	145.76257258882356
257.09663176435396	-21.375067397323733	0.0004	182	105	ESCA	TRACAZOLATE	Experimental	CREBBP|TP53|KMT2A	108.99697433818545	18.01728536117531
1514.0915260565864	2.4961207003562436	0.929	182	104	ESCA	ENCORAFENIB	Approved in cancer	BRAF|KRAS|TP53	1456.7034524466226	111.75964527029197
1343.095602274098	-39.67545496386222	0.8220000000000001	182	104	ESCA	METHYLPREDNISOLONE	Approved in cancer	NFE2L2|TP53	1238.0699719041534	135.1679420023666
1363.643544731364	-27.55053084911961	0.8320000000000001	182	104	ESCA	DAUNORUBICIN HYDROCHLORIDE	Approved in cancer	TP53|KMT2A	1268.7013959585468	201.60689683366923
1363.4168617937173	-3.6885883268185182	0.8320000000000001	182	104	ESCA	DOXORUBICIN HYDROCHLORIDE	Approved in cancer	NFE2L2|SMAD3|TP53	1236.4218768370142	-149.45845672825857
1342.8662910747976	-15.817233507721141	0.8220000000000001	182	104	ESCA	MECHLORETHAMINE HYDROCHLORIDE	Approved in cancer	NFE2L2|TP53	1282.144214377793	269.26123031952415
1342.6201280018515	8.029854584578544	0.8220000000000001	182	104	ESCA	MELPHALAN	Approved in cancer	NFE2L2|TP53	1181.110661284782	-229.0830251585822
1362.459295122732	21.27810666516379	0.8320000000000001	182	104	ESCA	PEMBROLIZUMAB	Approved in same tumor type	BRAF|KRAS|TP53	1231.3476446774887	-262.0045566374733
1103.2188502391996	0.43104941217049486	0.632	182	104	ESCA	CLADRIBINE	Approved in other pathologies and in clinical trials in cancer	NFE2L2|TP53	1076.9804927219002	40.57525641738121
880.714855503013	2.5837256978911967	0.472	182	104	ESCA	GENISTEIN	Clinical trials in cancer	NFE2L2|SMAD3|TP53	846.6774033658787	242.17982297286062
819.1678379018401	-10.196138912893218	0.422	182	104	ESCA	CARBENDAZIM	Clinical trials in cancer	NFE2L2|TP53	792.9605644884741	59.532344609463195
606.4559428836334	-3.4060970966102104	0.262	182	104	ESCA	AZATHIOPRINE	Approved in other pathologies	NFE2L2|TP53	573.2184978929391	-16.289989938673756
589.0167136506184	12.875010921356619	0.252	182	104	ESCA	GEMCITABINE	Approved in other pathologies	KRAS|TP53|SMAD4	568.3929334883536	-103.5783864142393
583.6445199237315	-10.366785077287716	0.242	182	104	ESCA	DOPAMINE	Approved in other pathologies	NFE2L2|TP53	564.4126926747836	-72.32195981232165
561.2023624459539	-18.456928281557282	0.2319999999999999	182	104	ESCA	HEXACHLOROPHENE	Approved in other pathologies	NFE2L2|SMAD3|TP53	514.4087282414051	-47.65988996490597
542.9748543693531	-3.066942087322559	0.2219999999999999	182	104	ESCA	NITAZOXANIDE	Approved in other pathologies	NFE2L2|TP53	481.72084399026267	24.048814529293423
547.1940144535201	20.41635616045653	0.2219999999999999	182	104	ESCA	PROCHLORPERAZINE EDISYLATE	Approved in other pathologies	NFE2L2|TP53	467.85974838021247	-29.153245456823953
565.420693113444	5.024900055715278	0.2319999999999999	182	104	ESCA	TRIAMTERENE	Approved in other pathologies	NFE2L2|TP53	521.5742486737547	8.629150607646466
317.5450761270137	-3.1019690095173758	0.022	182	104	ESCA	LY3009120	Clinical trials	BRAF|KRAS|TP53	315.628830940961	65.16762290104319
200.23216955121248	43.40716433271831	0.0004	182	104	ESCA	1,10-PHENANTHROLINE	Experimental	NFE2L2|TP53	291.43008999490866	-114.7849138216644
303.37177485485404	-64.32563286718938	0.0004	182	104	ESCA	2,3,4,6-TETRACHLOROPHENOL	Experimental	NFE2L2|TP53	230.2954125591594	206.89580896889282
273.85184042405405	81.47365796204025	0.0004	182	104	ESCA	2-AMINOANTHRACENE	Experimental	NFE2L2|TP53	89.21664518739465	-153.21048853395942
219.73256468055175	-82.64083851453798	0.0004	182	104	ESCA	3-METHYLTOXOFLAVIN	Experimental	NFE2L2|SMAD3|TP53	295.9092928440132	-71.75465514083429
295.4543001207745	39.05070742803724	0.0004	182	104	ESCA	7,12-DIMETHYLBENZ[A]ANTHRACENE	Experimental	NFE2L2|TP53	152.42114069321445	68.13905225983297
268.30513378206604	-42.43112941706059	0.0004	182	104	ESCA	ANTIMYCIN A	Experimental	NFE2L2|TP53	350.74108986488454	-73.11292869224279
187.42611947846274	22.483866754015338	0.0004	182	104	ESCA	BENZETHONIUM CHLORIDE	Experimental	NFE2L2|TP53	141.86872250467596	-137.30656305791024
260.68945385745894	61.26297613414954	0.0004	182	104	ESCA	BENZO[B]FLUORANTHENE	Experimental	NFE2L2|TP53	203.488071746167	-118.9095068514918
225.27543800056054	83.92272669241896	0.0004	182	104	ESCA	BENZO[K]FLUORANTHENE	Experimental	NFE2L2|TP53	293.62043402553877	-168.29152649689456
297.6966622215824	79.9851839117897	0.0004	182	104	ESCA	CADMIUM DICHLORIDE	Experimental	NFE2L2|TP53	133.57481589257299	-24.595278069107223
263.59042720147426	102.93974466394076	0.0004	182	104	ESCA	CHLORANIL	Experimental	NFE2L2|TP53	230.01870381041564	34.65313238732426
211.21907046073085	22.166104570496003	0.0004	182	104	ESCA	DAIDZEIN	Experimental	NFE2L2|TP53	211.09954445782566	-172.27667046650308
235.03826038143467	21.01188020291329	0.0004	182	104	ESCA	DIBENZ[A,H]ANTHRACENE	Experimental	NFE2L2|TP53	46.097896050957814	40.935104594493055
306.45917997624247	17.964092442317394	0.0004	182	104	ESCA	DICHLOROPHEN	Experimental	NFE2L2|TP53	108.22880076691857	181.6480492135226
237.70990672545665	104.23860431299875	0.0004	182	104	ESCA	DINOSEB	Experimental	NFE2L2|TP53	163.34392002355744	-83.28922686189289
231.24469217435504	-103.55103416027058	0.0004	182	104	ESCA	ELLIPTICINE	Experimental	NFE2L2|TP53	300.4637991617154	163.35423800204893
209.2430315308352	-20.06371055390835	0.0004	182	104	ESCA	FENTICLOR	Experimental	NFE2L2|SMAD3|TP53	128.4610084353257	31.487539813405334
258.83809310110007	19.998948511332458	0.0004	182	104	ESCA	GALLIC ACID	Experimental	NFE2L2|TP53	314.3982986232592	144.03440825703439
224.07189033725965	42.14369515821048	0.0004	182	104	ESCA	GLUTARAL	Experimental	NFE2L2|TP53	129.84842422456774	172.58720403474092
267.3985829578388	-83.86904353032038	0.0004	182	104	ESCA	GNF-PF-308	Experimental	NFE2L2|TP53	276.8654317858529	-210.81003086717556
292.1259928189511	-43.32285984896703	0.0004	182	104	ESCA	GNF-PF-3343	Experimental	NFE2L2|TP53	171.68142412766932	37.09539345693622
247.8857492380687	41.13502226145246	0.0004	182	104	ESCA	GNF-PF-3837	Experimental	NFE2L2|SMAD3|TP53	176.4177295574765	-199.1748594176978
243.54725794594896	-83.16798273722134	0.0004	182	104	ESCA	GNF-PF-4029	Experimental	TP53|KMT2A	165.4615592408715	232.84646329714394
284.49331929421913	60.17426606015417	0.0004	182	104	ESCA	HOMIDIUM BROMIDE	Experimental	NFE2L2|TP53	48.154094214881354	-6.31214643005157
304.8175914498154	-23.213044994142138	0.0004	182	104	ESCA	IOXYNIL	Experimental	NFE2L2|TP53	260.9095276235753	-155.49236394357234
236.96327517763999	62.28715730618728	0.0004	182	104	ESCA	KINETIN RIBOSIDE	Experimental	NFE2L2|TP53	216.9434153587648	-237.7769862907814
244.51126554068023	-41.77735154004938	0.0004	182	104	ESCA	KRESOXIM-METHYL	Experimental	NFE2L2|TP53	76.9379095088034	3.9584167848197467
255.07541719554308	-104.22776073408947	0.0004	182	104	ESCA	MALONOBEN	Experimental	NFE2L2|TP53	258.20630989220587	-81.61335799376513
293.7411844785704	-2.1490994136458426	0.0004	182	104	ESCA	MERCURIC CHLORIDE	Experimental	NFE2L2|TP53	232.42909427930317	-198.22127203696672
280.9334934131398	-22.27889029312496	0.0004	182	104	ESCA	MLS000541562	Experimental	NFE2L2|TP53	245.27621884655196	164.84331290587613
246.09682647572745	-0.12553133354464308	0.0004	182	104	ESCA	PENTACHLOROPHENOL	Experimental	NFE2L2|TP53	189.78406546882746	229.84206686084008
255.78674617443033	-62.73143100809152	0.0004	182	104	ESCA	PF-477736	Experimental	BRAF|KRAS|TP53	253.36988570931007	-208.85102276851796
279.5968376298914	-63.48370612805505	0.0004	182	104	ESCA	PHENYLMERCURIC ACETATE	Experimental	NFE2L2|TP53	123.19968084030248	-212.56354082078656
231.9958718694185	-62.189163356653154	0.0004	182	104	ESCA	PROPACHLOR	Experimental	NFE2L2|TP53	111.39435794500804	74.38017181339035
233.193787562194	-20.827381608107004	0.0004	182	104	ESCA	PROPARGITE	Experimental	NFE2L2|TP53	165.64369281139022	-178.64273022608057
282.6711988874074	18.949717835122158	0.0004	182	104	ESCA	PYRACLOSTROBIN	Experimental	NFE2L2|TP53	98.46634832410065	-131.62420570895773
197.60397741285368	0.875917911001693	0.0004	182	104	ESCA	ROTENONE	Experimental	NFE2L2|TP53	79.49224144346373	144.3132166199564
271.65833673705714	40.09494383463371	0.0004	182	104	ESCA	RUFOCROMOMYCIN	Experimental	NFE2L2|SMAD3|TP53	79.78030456278464	-56.949276193605215
269.9149595716231	-1.1795210048122726	0.0004	182	104	ESCA	SMR000060445	Experimental	NFE2L2|TP53	198.99322834793603	-192.35064732947333
213.13270595383338	63.38838596727808	0.0004	182	104	ESCA	SMR000065948	Experimental	TP53|KMT2A	222.76374551592616	61.08489485251965
196.6653635448306	-40.33465039173788	0.0004	182	104	ESCA	TEROXIRONE	Experimental	NFE2L2|TP53	312.12280932413927	-148.7635076184885
1157.1779717479494	0.43490392637340847	0.6719999999999999	365	151	GBM	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	PTEN|TP53|NF1	1140.1642039231542	215.91720376886786
1419.1402581000434	-7.19394026042599	0.8620000000000001	365	146	GBM	VENETOCLAX	Approved in cancer	KRAS|PTEN|TP53	1351.0980320694157	-161.12287809654157
1586.2065593684329	0.43888350284512967	0.99	365	144	GBM	ALPELISIB	Approved in cancer	NRAS|PTEN|TP53	1606.6066651577607	47.43874911475987
1403.0385048345722	14.805010722334998	0.8530000000000001	365	144	GBM	CISPLATIN	Approved in cancer	BRCA2|PTEN|TP53	1367.32644021156	-223.33002088806433
1378.6419774375763	16.620761191446547	0.8420000000000001	365	144	GBM	OLAPARIB	Approved in cancer	BRCA2|PTEN|TP53	1342.7797589415973	96.00425955342905
946.2041283539052	-7.16067041879586	0.514	365	144	GBM	SAPANISERTIB	Clinical trials in cancer	PTEN|TP53|RB1	864.3905104710943	-117.60199270083034
576.5132894312353	4.1805382899682115	0.242	365	144	GBM	GEMCITABINE	Approved in other pathologies	NRAS|PTEN|TP53	546.7013255510271	67.77364248114714
1042.4398311549785	0.43496072804879304	0.587	365	143	GBM	GEDATOLISIB	Clinical trials in cancer	NRAS|PTEN|TP53	1002.5646542405674	-43.76060004831203
941.9010869613911	8.835424065613068	0.512	365	140	GBM	DS-7423	Clinical trials in cancer	KRAS|PTEN|TP53	898.8736818360923	219.80341405821707
1400.9859068206213	-26.214255975293014	0.8520000000000001	365	138	GBM	FLUOROURACIL	Approved in cancer	KRAS|PTEN|TP53	1438.309923991762	81.4717491894474
1403.539268618747	-1.6372327517286465	0.8520000000000001	365	138	GBM	TOPOTECAN	Approved in cancer	PTEN|TP53|RB1	1248.7213206401186	-43.27672116353929
262.1719970981228	-18.742658227944617	0.0004	365	138	GBM	1173900-33-8	Experimental	PIK3CA|PTEN|TP53	208.30252179028784	130.14153836461787
1455.9944254786676	11.458785671231084	0.893	365	137	GBM	PACLITAXEL	Approved in cancer	BRCA2|PTEN|TP53	1497.922638551705	135.7699105595263
1418.4744027836653	9.294581100140562	0.8620000000000001	365	137	GBM	CARBOPLATIN	Approved in cancer	BRCA2|PTEN|TP53	1297.9672679673622	-136.5568997831471
914.0709270817019	-13.071284904613066	0.492	365	136	GBM	MIRDAMETINIB	Clinical trials in cancer	NRAS|PTEN|TP53	861.9426042789773	87.85814192969013
914.8285854805422	2.8110918052750833	0.492	365	136	GBM	NAVITOCLAX	Clinical trials in cancer	KRAS|PTEN|TP53	918.9705929511401	-17.238100506677625
1519.103467226618	-4.732132626190634	0.94	365	135	GBM	VEMURAFENIB	Approved in cancer	NRAS|PTEN|TP53	1529.8208824442947	251.391804648865
846.659505288429	0.40293316125811884	0.442	365	135	GBM	CAPIVASERTIB	Clinical trials in cancer	KRAS|PTEN|TP53	706.9866245354169	-121.57248731943687
241.29788981102806	33.76920089820413	0.0004	365	134	GBM	ABT-737	Experimental	KRAS|PTEN|TP53	139.86013706657286	111.83377669424618
1383.750840432968	-16.25913793148061	0.8420000000000001	365	130	GBM	TEMOZOLOMIDE	Approved in same tumor type	IDH1|PTEN|TP53	1379.480510603935	-250.1990550129977
1377.2205187254835	0.7246225362183907	0.8420000000000001	365	129	GBM	VORINOSTAT	Approved in cancer	PTEN|TP53|RB1	1316.1835533443048	24.790590659261056
1532.3665541727541	2.8975294081247682	0.949	365	126	GBM	ENCORAFENIB	Approved in cancer	KRAS|PTEN|TP53	1455.8563296647885	49.10165675948542
1504.1528088146276	-6.232856254018941	0.93	365	121	GBM	ERLOTINIB	Approved in cancer	BRAF|PTEN|TP53	1520.5786438052617	61.00187475900188
819.7768578798542	9.525463974302227	0.422	365	121	GBM	ONC201	Clinical trials in cancer	PTEN|TP53	760.9418590177557	205.47705351170072
1453.8276327667172	-12.241430043137399	0.892	365	120	GBM	TRAMETINIB	Approved in cancer	TP53|NF1|RB1	1339.137571788231	118.70391001417818
1490.21948400453	-4.507406711067205	0.92	365	117	GBM	PANITUMUMAB	Approved in cancer	EGFR|PTEN|TP53	1527.7399396652183	-139.8797283833726
913.9526690515952	17.26455038148356	0.492	365	110	GBM	PIMASERTIB	Clinical trials in cancer	NRAS|TP53|NF1	857.3064575757196	29.790210920595428
1390.264779271088	7.905838992453226	0.8420000000000001	365	103	GBM	BEVACIZUMAB	Approved in same tumor type	PIK3CA|KRAS|TP53	1189.6374572941795	80.133830619413
1184.16373964323	0.43407656337046774	0.692	365	103	GBM	DASATINIB	Approved in other pathologies and in clinical trials in cancer	FGFR3|KRAS|TP53	1148.06631547482	126.89627039971589
1219.2784145054256	0.4344611659514328	0.7180000000000001	365	101	GBM	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	KRAS|TP53|RB1	1161.0271938120313	-66.8242545036314
1448.4712308371363	-0.3320297329457844	0.892	365	100	GBM	BORTEZOMIB	Approved in cancer	KRAS|TP53|RB1	1432.7514003455005	275.67502673519624
1498.3141889327846	5.4481293257156835	0.929	365	99	GBM	TAMOXIFEN	Approved in cancer	IDH1|PIK3CA|TP53	1507.4838601327383	147.28996922227066
1389.7904930524132	-4.137059505793161	0.8420000000000001	365	99	GBM	METHOTREXATE	Approved in cancer	IDH1|TP53|RB1	1260.8442397735723	-26.755486600480452
1102.9788146013339	0.8951773192192434	0.632	365	97	GBM	MERCAPTOPURINE	Approved in other pathologies and in clinical trials in cancer	IDH1|TP53|RB1	1043.7051514114023	-64.10781060490902
1520.6550733058668	8.785220656279108	0.94	365	95	GBM	DABRAFENIB	Approved in cancer	KRAS|NRAS|TP53	1471.6925726322308	-142.43004418714688
1509.8826442633383	5.1916836086156195	0.93	365	94	GBM	EVEROLIMUS	Approved in same tumor type	BRCA2|PTEN|RB1	1487.004689568204	45.016197335707375
1391.3465816884036	22.464362579270272	0.8420000000000001	365	93	GBM	IRINOTECAN	Approved in cancer	KRAS|BRCA2|TP53	1278.5453820935954	-66.66309446038294
1396.5931603262723	-13.355708604655234	0.8530000000000001	365	92	GBM	DOXORUBICIN	Approved in cancer	PIK3CA|KRAS|TP53	1307.9832349080207	270.8391585516756
981.5922956568879	0.4398892393426195	0.542	365	92	GBM	NVP-CGM097	Clinical trials in cancer	PIK3CA|KRAS|TP53	892.2443759414359	102.07639667646436
1103.1953511022602	-10.457670359011587	0.632	365	92	GBM	METFORMIN	Approved in other pathologies and in clinical trials in cancer	PIK3CA|KRAS|PTEN	1063.2153049993285	155.04733455744474
933.3856391555539	-1.8429706013389762	0.512	365	91	GBM	BERZOSERTIB	Clinical trials in cancer	KRAS|BRCA2|TP53	894.6526287013503	-142.60235703754466
825.2336556860032	-1.7908524410291307	0.422	365	90	GBM	DEMCIZUMAB	Clinical trials in cancer	PIK3CA|KRAS|TP53	674.6247040078885	-66.21614797837056
814.3675017829543	-1.8135705638900674	0.422	365	90	GBM	FENRETINIDE	Clinical trials in cancer	ESR1|IDH1|TP53	743.9920360401195	98.23083004749094
819.8174760624534	-11.211670177786914	0.422	365	90	GBM	TANESPIMYCIN	Clinical trials in cancer	MTOR|PIK3CA|TP53	782.4692915317141	151.0700797926579
1487.1902553041234	7.399882365288391	0.917	365	89	GBM	RALOXIFENE	Approved in cancer	ESR1|PIK3CA|TP53	1499.433303494165	84.17493346281788
956.4659605905515	2.0144770467040303	0.523	365	89	GBM	RESVERATROL	Clinical trials in cancer	ESR1|PIK3CA|TP53	897.2752325821065	-30.882405761714722
563.2334790517773	-10.062340288062956	0.2319999999999999	365	89	GBM	PIMOZIDE	Approved in other pathologies	MTOR|IDH1|TP53	521.7502241504673	-8.859933330679098
266.04955450030604	12.474372303659976	0.0004	365	89	GBM	1,10-PHENANTHROLINE	Experimental	MTOR|IDH1|TP53	197.74109963627853	127.43264790490377
244.45872345368664	-5.436762996985408	0.0004	365	89	GBM	148672-13-3	Experimental	MTOR|IDH1|TP53	131.58929224755488	-93.47233299353078
256.48555210242927	-40.11417162768569	0.0004	365	89	GBM	MALONOBEN	Experimental	MTOR|IDH1|TP53	160.2105649794208	-194.48140434154286
264.95801879265946	31.89634005360864	0.0004	365	89	GBM	N-OLEOYLDOPAMINE	Experimental	MTOR|IDH1|TP53	203.42418580773378	-16.522137061238737
1459.7286426051567	-1.3349675599801571	0.892	365	88	GBM	DUVELISIB	Approved in cancer	PIK3CA|TP53	1343.9426741481734	39.116669487400515
1407.4011094094415	-14.457857622779784	0.8520000000000001	365	88	GBM	DOCETAXEL	Approved in cancer	PIK3CA|KRAS|TP53	1412.406353761106	220.3871295428183
1360.0696657743815	-11.007298441855795	0.8220000000000001	365	88	GBM	DAUNORUBICIN HYDROCHLORIDE	Approved in cancer	ESR1|IDH1|TP53	1436.8164507686708	-106.1159200271088
1363.9297847853134	-1.08740098098599	0.8220000000000001	365	88	GBM	DOXORUBICIN HYDROCHLORIDE	Approved in cancer	ESR1|IDH1|TP53	1198.8314935653666	52.31597638243869
672.5128063274833	0.4298470038905009	0.313	365	88	GBM	HEXACHLOROPHENE	Approved in other pathologies	ESR1|IDH1|TP53	612.6906438732283	-20.630009606737815
549.742355772278	-10.061972270603434	0.2219999999999999	365	88	GBM	TRIAMTERENE	Approved in other pathologies	ESR1|IDH1|TP53	509.34886848438833	-3.4122058171136302
280.90002631343344	6.978014646302	0.022	365	88	GBM	EMODIN	Clinical trials	PIK3CA|TP53	161.26967448581456	-67.82372932800205
269.9055806968444	22.41723299191051	0.0004	365	88	GBM	BENZETHONIUM CHLORIDE	Experimental	ESR1|IDH1|TP53	95.31560690414717	-111.02633664054281
263.4744722358302	-32.03065509334405	0.0004	365	88	GBM	DICHLOROPHEN	Experimental	ESR1|IDH1|TP53	209.08483526371793	-205.75779767877512
260.507547484162	3.3606173282619523	0.0004	365	88	GBM	GNF-PF-4029	Experimental	IDH1|MEN1|TP53	340.67894433274614	-86.99071950157439
254.27190528928892	31.652247518976964	0.0004	365	88	GBM	PROPACHLOR	Experimental	ESR1|IDH1|TP53	173.08289809760421	180.89139339775318
1357.0214632314749	6.947490551379161	0.8220000000000001	365	87	GBM	LORLATINIB	Approved in cancer	TP53|RB1	1187.8416718778344	3.8356192714419706
1367.3680409731362	8.929534888353857	0.8320000000000001	365	87	GBM	MITOXANTRONE HYDROCHLORIDE	Approved in cancer	IDH1|TP53	1340.9329053074578	-230.6583986851951
1091.181013333218	0.44431921858745227	0.623	365	87	GBM	AZACITIDINE	Approved in other pathologies and in clinical trials in cancer	IDH1|TP53	1030.8914918374976	-29.382333625178177
1103.2064142798527	11.973608856214042	0.632	365	87	GBM	THIORIDAZINE HYDROCHLORIDE	Approved in other pathologies and in clinical trials in cancer	IDH1|TP53	1061.627133259834	-85.36124365294003
1028.8358311561938	0.43477887542303506	0.5770000000000001	365	87	GBM	PICTILISIB	Clinical trials in cancer	KRAS|PTEN|RB1	995.7134203506129	-75.63602908697021
901.8709287667654	0.19302930749364577	0.483	365	87	GBM	SELICICLIB	Clinical trials in cancer	TP53|RB1	843.6769727048033	25.06509238811998
589.9229302523172	0.3816188566007668	0.252	365	87	GBM	AZATHIOPRINE	Approved in other pathologies	IDH1|TP53	558.8590785640731	-19.426344272989013
576.5158602513093	-9.47746146808015	0.242	365	87	GBM	CHLORPROMAZINE	Approved in other pathologies	IDH1|TP53	547.5977491252133	-41.747452534499274
563.1936571247795	11.112766548177774	0.2319999999999999	365	87	GBM	PAROXETINE HYDROCHLORIDE	Approved in other pathologies	IDH1|TP53	491.8801279432806	-28.951958293388657
563.0972459210564	0.5772076698010267	0.2319999999999999	365	87	GBM	PROCHLORPERAZINE	Approved in other pathologies	IDH1|TP53	524.5584176264667	-35.20906844626566
549.7293532981704	11.029526764103707	0.2219999999999999	365	87	GBM	SERTRALINE	Approved in other pathologies	IDH1|TP53	462.68107652318616	-12.934453416327443
550.3079579938767	0.5094263555511418	0.2219999999999999	365	87	GBM	SERTRALINE HYDROCHLORIDE	Approved in other pathologies	IDH1|TP53	483.8440825278803	-23.24466989112821
279.5912851064982	-3.5305206163146465	0.022	365	87	GBM	TETRANDRINE	Clinical trials	IDH1|TP53	169.73469747456787	7.482514088483526
248.80223360132845	22.60796084437652	0.0004	365	87	GBM	2,6-DIMETHOXY-1,4-BENZOQUINONE	Experimental	IDH1|TP53	269.7558205072694	120.60289303344967
251.60032786284697	41.875590949149256	0.0004	365	87	GBM	2-(PYRIDIN-2-YLAMINO)QUINOLIN-8-OL	Experimental	IDH1|TP53	241.66044879115594	44.284843274693515
259.3338011099082	22.36650999145533	0.0004	365	87	GBM	2-CHLOROADENOSINE	Experimental	IDH1|TP53	223.36978698860025	88.56711779758979
253.29600353220314	-28.684958380637568	0.0004	365	87	GBM	3-METHYLTOXOFLAVIN	Experimental	IDH1|TP53	265.57953360944225	-22.711199706024985
233.84233465465914	-5.035235463321754	0.0004	365	87	GBM	ALEXIDINE DIHYDROCHLORIDE	Experimental	IDH1|TP53	153.08947744310882	-186.85175518065077
255.42757412645477	12.606746060431533	0.0004	365	87	GBM	ASTEMIZOLE	Experimental	IDH1|TP53	93.00538738888598	45.04029857609723
238.3802891990104	21.032132167013174	0.0004	365	87	GBM	BROXYQUINOLINE	Experimental	IDH1|TP53	258.17252965436563	53.386643578801
265.59232390708263	-5.89358726225484	0.0004	365	87	GBM	CHEMBL2002487	Experimental	IDH1|TP53	178.8345265909654	122.45222237221208
233.3808050155094	-23.394594955372725	0.0004	365	87	GBM	CHEMBL405317	Experimental	IDH1|TP53	191.85065130871783	-89.177337705209
245.86821417279162	-40.052480365152434	0.0004	365	87	GBM	CLOFOCTOL	Experimental	IDH1|TP53	206.1389614882692	-25.311063501682042
227.86973978621765	21.341486454862746	0.0004	365	87	GBM	DIIODOHYDROXYQUINOLINE	Experimental	IDH1|TP53	127.51440033500266	-38.631006289903155
249.954251209557	3.5676030518837933	0.0004	365	87	GBM	ELLIPTICINE	Experimental	IDH1|TP53	176.09996278011192	168.89836230954108
238.40026511809754	-32.62474623115173	0.0004	365	87	GBM	FENTICLOR	Experimental	IDH1|TP53	282.8239849856105	-19.131920454594137
228.45585908013868	-14.07721521533216	0.0004	365	87	GBM	KINETIN RIBOSIDE	Experimental	IDH1|TP53	168.3302594521207	66.98434633903298
238.96576636707266	-14.461400852542823	0.0004	365	87	GBM	MANGOSTIN	Experimental	IDH1|TP53	202.96751753963073	34.29330643010968
271.06771866044755	3.0988525235551947	0.0004	365	87	GBM	MICHLER'S KETONE	Experimental	IDH1|TP53	234.670912215049	-135.27527664247606
244.91474604201474	12.839640154181893	0.0004	365	87	GBM	MLS000073613	Experimental	IDH1|TP53	226.79451568784907	-72.52549600997452
249.51325216559403	-14.752190096429246	0.0004	365	87	GBM	PIPERLONGUMINE	Experimental	IDH1|TP53	144.19815501337285	78.07214383373923
244.0052259400732	-23.733779183509057	0.0004	365	87	GBM	RUFOCROMOMYCIN	Experimental	IDH1|TP53	215.80868223654022	-199.48242967569556
239.40492280170787	3.848632861408305	0.0004	365	87	GBM	SMR000031817	Experimental	IDH1|TP53	180.30821815977703	62.700624912806035
273.8780407833551	-12.384756981697876	0.0004	365	87	GBM	SMR000080328	Experimental	IDH1|TP53	145.58177839616508	-18.14160651026677
232.80933790071225	12.06480749956242	0.0004	365	87	GBM	THIOMERSAL	Experimental	IDH1|TP53	245.18372180859296	-69.56640982482604
255.07573631944013	-5.763261539866846	0.0004	365	87	GBM	TOXOFLAVIN	Experimental	IDH1|TP53	215.27338234441842	35.79152751055727
1400.5011658170135	28.10724353069125	0.8520000000000001	365	85	GBM	PALBOCICLIB	Approved in cancer	NRAS|PTEN|RB1	1273.536654551973	-124.33207002804403
1353.7047412671575	-2.8186447706991657	0.8220000000000001	365	83	GBM	ABEMACICLIB	Approved in cancer	KRAS|NRAS|TP53	1264.8362600841722	-233.6926256253596
1518.7063739180587	22.027548553666094	0.94	505	283	HNSC	TRAMETINIB	Approved in cancer	NF1|RB1|TP53	1542.9017977703497	-196.66932816564588
630.7963605077613	0.4315945334822118	0.282	505	271	HNSC	GEMCITABINE	Approved in other pathologies	HRAS|SMAD4|TP53	591.242969804029	-30.249961685934323
1600.551361371383	-6.447734627490377	1	505	269	HNSC	ALPELISIB	Approved in cancer	PTEN|HRAS|TP53	1622.5481336881037	177.97116434882116
1168.4803137414988	0.4357204875565799	0.6819999999999999	505	268	HNSC	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	HRAS|NF1|TP53	1140.1319355393725	-119.08258562933327
957.7994911848706	-16.989120163750215	0.524	505	268	HNSC	SAPANISERTIB	Clinical trials in cancer	SMAD4|RB1|TP53	903.6043162868231	201.64166917685583
1503.6828699620796	4.954541029148061	0.93	505	266	HNSC	VEMURAFENIB	Approved in cancer	PTEN|HRAS|TP53	1436.8373551763557	-157.91818732494596
1457.8599679433767	-26.307747645256228	0.893	505	265	HNSC	PACLITAXEL	Approved in cancer	BRCA2|SMAD4|TP53	1489.6214401617578	-77.42634447992553
1439.747594394703	28.86980948846275	0.883	505	265	HNSC	CARBOPLATIN	Approved in cancer	BRCA2|SMAD4|TP53	1505.1628594173314	-238.36648165480116
1190.510309271352	0.44975453982360136	0.695	505	263	HNSC	DASATINIB	Approved in other pathologies and in clinical trials in cancer	ASXL1|HRAS|TP53	1155.1295583389606	-166.41946279737178
1518.5047159241262	-20.1466914981051	0.94	505	260	HNSC	DABRAFENIB	Approved in cancer	PIK3CA|HRAS|TP53	1575.0164633702423	-169.3771120130818
1525.0427972572822	0.4358242479454475	0.942	505	260	HNSC	BEVACIZUMAB	Approved in cancer	PIK3CA|HRAS|TP53	1514.0848811361532	242.2858507685304
1233.7461374940935	-6.46182360345756	0.7280000000000001	505	257	HNSC	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	HRAS|RB1|TP53	1158.00077436758	-123.22086728815997
1403.9949248833357	28.504160291451228	0.8510000000000001	505	253	HNSC	IRINOTECAN	Approved in cancer	BRCA2|SMAD4|TP53	1300.2105526892947	-38.9819304404092
939.7065667131077	-5.268040156688414	0.516	505	251	HNSC	CAPIVASERTIB	Clinical trials in cancer	PIK3CA|PTEN|TP53	892.8008315583679	52.63875518922646
1405.7812367436607	-12.735407644096568	0.8520000000000001	505	250	HNSC	TOPOTECAN	Approved in cancer	PTEN|RB1|TP53	1321.0814595712732	278.8706427563183
1056.148690659366	0.41406094260020154	0.597	505	250	HNSC	GEDATOLISIB	Clinical trials in cancer	PIK3CA|PTEN|TP53	1054.469524076485	60.956683816035536
1421.4713337155351	39.88094805895966	0.8620000000000001	505	249	HNSC	VENETOCLAX	Approved in cancer	ASXL1|PTEN|TP53	1335.72828483261	165.29741376858578
1422.596683324339	-24.822851136696528	0.8620000000000001	505	249	HNSC	FLUOROURACIL	Approved in cancer	PIK3CA|PTEN|TP53	1356.9900977209736	-273.087766389644
976.0467654171437	-5.669072694072213	0.536	505	249	HNSC	MIRDAMETINIB	Clinical trials in cancer	PIK3CA|PTEN|TP53	916.2147215931257	217.93597062425158
1471.797132360346	-10.142417349438261	0.893	505	249	HNSC	BORTEZOMIB	Approved in cancer	PIK3CA|RB1|TP53	1495.2530222648122	168.47845280932307
914.4514057163342	0.4219470216458774	0.492	505	248	HNSC	NAVITOCLAX	Clinical trials in cancer	PIK3CA|PTEN|TP53	871.471905226436	-234.07778704932372
250.77399680245895	32.725446568826584	0.0004	505	248	HNSC	1173900-33-8	Experimental	PIK3CA|PTEN|TP53	109.03481603701529	-112.28402631661994
958.0278605143691	4.405559454171765	0.522	505	247	HNSC	DS-7423	Clinical trials in cancer	PIK3CA|PTEN|TP53	895.5885263010264	183.77978484673292
267.7438921506669	21.044018647050876	0.0004	505	247	HNSC	ABT-737	Experimental	PIK3CA|PTEN|TP53	118.60402995549741	-94.9668278452044
1440.3160373075534	-14.480486697663167	0.883	505	244	HNSC	CISPLATIN	Approved in cancer	BRCA2|SMAD4|TP53	1361.130117949676	95.65353453512341
1438.3005844989452	7.19069677555288	0.883	505	244	HNSC	DOXORUBICIN	Approved in cancer	BRAF|PIK3CA|TP53	1423.3378813046336	231.97320727604466
975.6047430927738	14.853847569851865	0.536	505	244	HNSC	PIMASERTIB	Clinical trials in cancer	PIK3CA|NF1|TP53	920.2725870843426	117.40884691799778
1475.1346153255988	10.069355700677107	0.892	505	243	HNSC	TAMOXIFEN	Approved in cancer	RRAS2|PIK3CA|TP53	1475.5435710478255	-81.84684526641063
994.1016882625262	4.010648935558919	0.552	505	243	HNSC	NVP-CGM097	Clinical trials in cancer	BRAF|PIK3CA|TP53	922.3147270982512	-67.54055461700773
940.7496394294466	15.266698721463342	0.513	505	243	HNSC	RESVERATROL	Clinical trials in cancer	AKT1|PIK3CA|TP53	876.599760015088	135.1427736505537
1387.6533372278325	-39.46578480054848	0.8420000000000001	505	242	HNSC	OLAPARIB	Approved in cancer	PTEN|BRCA2|TP53	1333.134787152915	-135.44073658780297
1459.7048274838398	35.65979984492631	0.892	505	242	HNSC	DUVELISIB	Approved in cancer	PIK3CA|TP53	1437.9601513810744	-30.19473404994548
1359.6437121880965	1.6845804306051662	0.8320000000000001	505	242	HNSC	RALOXIFENE	Approved in cancer	PIK3CA|TP53	1208.7098527164012	175.16095076746814
818.0603732276041	17.738546858541667	0.422	505	242	HNSC	DEMCIZUMAB	Clinical trials in cancer	PIK3CA|TP53	809.504754077562	-187.8814576328835
834.8617780909038	-9.418419261836789	0.432	505	242	HNSC	TANESPIMYCIN	Clinical trials in cancer	MTOR|PIK3CA|TP53	727.7519152001437	-191.45991559201087
1456.139124391239	16.106240152098394	0.891	505	235	HNSC	DOCETAXEL	Approved in cancer	PIK3CA|HRAS|TP53	1460.6748901952662	25.396112236527898
1409.51186362364	6.533644416635667	0.8620000000000001	505	221	HNSC	PANITUMUMAB	Approved in cancer	PTEN|HRAS|TP53	1489.373145447469	127.47328526766586
234.36299117062316	22.138889306008934	0.0004	505	220	HNSC	167869-21-8	Experimental	HRAS|TP53	229.73424250459354	4.5906304682829955
250.16987287219607	12.90389474185443	0.0004	505	217	HNSC	PF-477736	Experimental	BRAF|CDKN2A|TP53	67.18018843385602	-14.438183503944146
1421.7100504426714	20.180696868533772	0.8620000000000001	505	216	HNSC	CRIZOTINIB	Approved in cancer	CDKN2A|SMAD4|TP53	1318.4934030804066	-7.663739125584669
1423.5919832769725	-5.094855804824277	0.8720000000000001	505	215	HNSC	ABEMACICLIB	Approved in cancer	CDKN2A|TP53	1461.9769035337888	148.00591116571178
1388.8923793148206	-3.7077953820080722	0.8420000000000001	505	211	HNSC	VORINOSTAT	Approved in cancer	PTEN|RB1|TP53	1422.5180025539212	-170.86531242940788
1499.8731587567866	-14.405878885057149	0.929	505	207	HNSC	ENCORAFENIB	Approved in cancer	BRAF|PTEN|TP53	1529.9802787446538	181.93948656412175
1592.7990289459394	11.82802106045358	0.996	505	207	HNSC	PAZOPANIB	Approved in cancer	FGFR3|BRCA2|TP53	1636.6065119933814	-94.64116961663763
818.1963943438337	-17.994899185542067	0.422	505	206	HNSC	ONC201	Clinical trials in cancer	AKT1|PTEN|TP53	728.1520320280097	-128.87347273087275
1439.5682038335888	-33.33213982243245	0.882	505	205	HNSC	ERLOTINIB	Approved in cancer	APC|PTEN|TP53	1329.1739269344553	-183.2951184970759
1454.5504217865362	-2.2491349714651108	0.892	505	205	HNSC	METHOTREXATE	Approved in cancer	NALCN|RB1|TP53	1487.8304412537868	199.14242562315656
1417.1719914155995	-43.011720822776084	0.8620000000000001	505	205	HNSC	CICLOPHOSPHAMIDE	Approved in cancer	CTNNB1|BRCA2|TP53	1407.05567778417	1.4048812682802634
1368.5711997305903	23.470195162478262	0.8320000000000001	505	204	HNSC	LORLATINIB	Approved in cancer	RB1|TP53	1344.946163980667	-59.791744133068036
1225.9243495680485	11.136193263222907	0.7240000000000001	505	204	HNSC	MERCAPTOPURINE	Approved in other pathologies and in clinical trials in cancer	NOTCH1|RB1|TP53	1149.4344957996136	110.70017827914808
875.1680322878555	0.4422694078832876	0.463	505	204	HNSC	SELICICLIB	Clinical trials in cancer	RB1|TP53	795.9997212105471	224.80110439293003
233.31568504382741	-12.533522133428534	0.0004	505	203	HNSC	PLUMBAGIN	Experimental	EP300|TP53	180.00312770767684	192.3641560447101
261.7119404666211	-31.190978385397813	0.0004	505	203	HNSC	TRACAZOLATE	Experimental	CREBBP|TP53	322.38343851266677	28.653460747383633
1385.0098805728828	27.950136992952622	0.8420000000000001	505	202	HNSC	CAPMATINIB	Approved in cancer	BRAF|TP53	1250.3504471599476	-177.02133044606688
1404.4555439342007	-31.5523191426812	0.8520000000000001	505	202	HNSC	ETOPOSIDE	Approved in cancer	BRCA2|TP53	1226.4478815844016	117.01510315964163
1103.4107180456115	-20.229395646562523	0.632	505	202	HNSC	CHLORAMBUCIL	Approved in other pathologies and in clinical trials in cancer	BRCA2|TP53	1093.5345624570666	38.532367392298596
957.6062881737198	23.185459300746203	0.522	505	202	HNSC	BERZOSERTIB	Clinical trials in cancer	MTOR|BRCA2|TP53	926.8557486864415	-49.40739407172299
818.3731008097018	-0.8378091405519115	0.422	505	202	HNSC	GANETESPIB	Clinical trials in cancer	BRAF|TP53	697.2514619504626	-1.5597277803613565
291.8814243908072	-2.399374473177687	0.032	505	202	HNSC	LY3009120	Clinical trials	BRAF|TP53	349.45091987455555	-95.81973314904171
305.7929683745709	7.371446576638391	0.042	505	202	HNSC	PF-04217903	Clinical trials	BRAF|TP53	365.9700221633534	-38.22434300439622
234.7566766783781	4.438893908039773	0.0004	505	202	HNSC	SMR000031817	Experimental	CTNNB1|TP53	59.97365024698445	-61.1177161063744
1373.2822823062563	-27.753069734169003	0.8320000000000001	505	201	HNSC	TEMOZOLOMIDE	Approved in cancer	NOTCH1|PTEN|TP53	1217.8717747725027	-99.50539947245943
1393.0690439527032	13.046451530381404	0.8420000000000001	505	201	HNSC	DAUNORUBICIN HYDROCHLORIDE	Approved in cancer	WRN|TP53	1277.1743578274197	-199.1478730427782
1388.7849413294002	-20.972790805675004	0.8420000000000001	505	201	HNSC	DOXORUBICIN HYDROCHLORIDE	Approved in cancer	WRN|TP53	1243.1401885076812	-0.48313733456751606
1391.8266095506679	43.465544496435285	0.8420000000000001	505	201	HNSC	MITOXANTRONE HYDROCHLORIDE	Approved in cancer	WRN|TP53	1349.9103747419178	175.10288194172983
1132.4665293128305	-17.46207279695679	0.652	505	201	HNSC	AZACITIDINE	Approved in other pathologies and in clinical trials in cancer	CD247|ASXL1|TP53	1115.8139411065251	-198.7043641071723
1211.2347892646687	0.4968872877464605	0.7120000000000001	505	201	HNSC	HALOPERIDOL	Approved in other pathologies and in clinical trials in cancer	MTOR|GRIN2B|TP53	1161.3827751958493	-10.212496124100682
1011.3531777465264	-2.8995729550944134	0.562	505	201	HNSC	2-PHENYLETHYL ISOTHIOCYANATE	Clinical trials in cancer	MTOR|ACTA2|TP53	954.490400536016	15.910421377425422
939.5864102890284	-24.159771466013808	0.512	505	201	HNSC	GENISTEIN	Clinical trials in cancer	AKT1|TP53	915.2103405171677	-158.39896252461267
849.6921398305659	1.7146025124578728	0.442	505	201	HNSC	ADAVOSERTIB	Clinical trials in cancer	STK11|TP53	747.6103422795627	-114.02720775394748
834.4803314295752	9.123197869636243	0.432	505	201	HNSC	NORDIHYDROGUAIARETIC ACID	Clinical trials in cancer	WRN|TP53	768.4534787388418	-172.37771394872155
698.337810567499	0.43166206530500517	0.3320000000000001	505	201	HNSC	AZATHIOPRINE	Approved in other pathologies	RAC1|TP53	620.8278602709161	64.8836106354178
605.2052965877615	0.4316142623360122	0.263	505	201	HNSC	TRIFLUOPERAZINE	Approved in other pathologies	AKT1|TP53	565.0009568079895	32.37587303480021
247.73425179108148	-21.488812903854978	0.0004	505	201	HNSC	2,6-DIMETHOXY-1,4-BENZOQUINONE	Experimental	WRN|TP53	234.47855535063945	148.84539048590534
249.08104934106686	-4.628711481466837	0.0004	505	201	HNSC	93718-83-3	Experimental	MTOR|WRN|TP53	218.24554031904665	-47.1977163597671
246.2772412295274	-38.33297223284802	0.0004	505	201	HNSC	ALEXIDINE DIHYDROCHLORIDE	Experimental	WRN|TP53	115.08045991489394	-18.113513170592938
263.01491816232465	-14.248044399840296	0.0004	505	201	HNSC	HOMIDIUM BROMIDE	Experimental	WRN|TP53	193.54381188044212	95.90209002004264
264.3808940636675	2.616726863726882	0.0004	505	201	HNSC	THUNBERGINOL B	Experimental	WRN|TP53	190.61048038850527	31.863793426314913
1356.7305945066723	35.63074630632087	0.8320000000000001	505	200	HNSC	IBRUTINIB	Approved in cancer	ERBB4|TP53	1214.084206878022	-51.792046068937424
1373.0289654723267	39.86733731008022	0.8320000000000001	505	200	HNSC	PEMBROLIZUMAB	Approved in cancer	BRAF|TP53	1234.7988373224875	-41.956736236356335
1352.3109946266077	18.677926186362924	0.8320000000000001	505	200	HNSC	IFOSFAMIDE	Approved in cancer	TP53	1230.9829212980635	18.044878588880238
1357.4012999126885	-33.49779288524908	0.8320000000000001	505	200	HNSC	MECHLORETHAMINE HYDROCHLORIDE	Approved in cancer	TP53	1358.7769381470232	251.7417524495782
1357.4510658481702	-16.69031602531203	0.8320000000000001	505	200	HNSC	MELPHALAN	Approved in cancer	TP53	1273.6700064555066	-10.141550016092822
1369.9347194849684	-44.72536792008455	0.8320000000000001	505	200	HNSC	METHYLPREDNISOLONE	Approved in cancer	TP53	1295.6033034043403	-110.80502278057554
1373.230762103459	-10.859931484862301	0.8320000000000001	505	200	HNSC	RITUXIMAB	Approved in cancer	TP53	1360.4536716336847	65.50127058787186
1376.7819466585706	8.61194347071094	0.8320000000000001	505	200	HNSC	TAMOXIFEN CITRATE	Approved in cancer	TP53	1230.4766433952223	-110.31289321854557
1341.5913229896382	-11.137807091177393	0.8220000000000001	505	200	HNSC	TRABECTEDIN	Approved in cancer	TP53	1330.3986766932082	-64.0284497251871
1341.5914798399215	5.702192484448432	0.8220000000000001	505	200	HNSC	TRIFLURIDINE	Approved in cancer	TP53	1166.8100254841852	-26.38884853098733
1319.567054724333	0.40105257379190107	0.792	505	200	HNSC	ASPIRIN	Approved in other pathologies and in clinical trials in cancer	TP53	1282.429890042922	-39.65424638071096
1101.8332366321642	-3.3899341524669353	0.632	505	200	HNSC	CLADRIBINE	Approved in other pathologies and in clinical trials in cancer	TP53	1087.8444714627362	-163.6568060364674
1129.8464764542753	16.148584463655652	0.652	505	200	HNSC	DAUNORUBICIN	Approved in other pathologies and in clinical trials in cancer	TP53	1113.117312146023	133.8704673906858
1117.1547731660264	-10.359903233767625	0.642	505	200	HNSC	ENALAPRIL	Approved in other pathologies and in clinical trials in cancer	TP53	1009.5416485819292	181.23151002725535
1115.638659017392	6.413844127013817	0.642	505	200	HNSC	FENOFIBRATE	Approved in other pathologies and in clinical trials in cancer	TP53	1129.2068490163474	30.022655991137384
1130.9168611720374	-0.6575949293433041	0.652	505	200	HNSC	FLUPHENAZINE	Approved in other pathologies and in clinical trials in cancer	TP53	1099.293597349304	-58.3036241601489
1086.5453525104133	3.6847637048876436	0.622	505	200	HNSC	HYDRALAZINE HYDROCHLORIDE	Approved in other pathologies and in clinical trials in cancer	TP53	1088.446190407065	-134.5610078680974
1147.4438789763392	2.5740118665059413	0.6619999999999999	505	200	HNSC	LOPERAMIDE	Approved in other pathologies and in clinical trials in cancer	MTOR|TP53	1150.4638356717005	-6.759555317297213
1088.0707812268424	-13.084097365858753	0.622	505	200	HNSC	METHYLENE BLUE CATION	Approved in other pathologies and in clinical trials in cancer	TP53	1079.6965367242965	-116.58051001266193
1100.3082497933526	13.371304869646849	0.632	505	200	HNSC	THIAMAZOLE	Approved in other pathologies and in clinical trials in cancer	TP53	1098.2739649917426	-233.00231947001234
1107.1321631483315	28.76675245650867	0.632	505	200	HNSC	THIORIDAZINE HYDROCHLORIDE	Approved in other pathologies and in clinical trials in cancer	TP53	1039.345492872158	51.63663164647397
1355.1245417740006	10.803292484006619	0.8220000000000001	66	10	KICH	ABEMACICLIB	Approved in cancer	NRAS|TP53	1283.004240523541	-271.570266434917
1389.2646162057322	0.26780496310544777	0.8430000000000001	66	10	KICH	CISPLATIN	Approved in cancer	NRAS|TP53	1327.1463518196765	7.613518701053607
1451.3031802076866	7.1925840782207615	0.892	66	10	KICH	ALPELISIB	Approved in cancer	NRAS|TP53	1273.0609627068927	5.884294045723124
1377.4843751262197	8.828110498113688	0.8320000000000001	66	10	KICH	CARBOPLATIN	Approved in cancer	NRAS|TP53	1371.3109304261004	3.321724733229928
1440.2260898568131	3.4491966883665555	0.882	66	10	KICH	DABRAFENIB	Approved in cancer	NRAS|TP53	1352.972080478779	-29.084341208626995
1376.6961695497764	-4.657796776074292	0.8320000000000001	66	10	KICH	DOXORUBICIN HYDROCHLORIDE	Approved in same tumor type	FANCD2|TP53	1181.0875395168255	32.94517435902412
1342.9408255688957	5.062918477288747	0.812	66	10	KICH	PEMBROLIZUMAB	Approved in same tumor type	NRAS|TP53	1239.7674311362557	-112.3417228011331
1451.2919181180584	-6.320612900050918	0.892	66	10	KICH	TRAMETINIB	Approved in cancer	NRAS|TP53	1447.4740958456466	17.88418506182498
1426.654343821347	-2.62503569992586	0.8720000000000001	66	10	KICH	VEMURAFENIB	Approved in cancer	NRAS|TP53	1445.464866608592	-154.7259541498498
1157.1579842946014	0.43220359300974565	0.6719999999999999	66	10	KICH	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	NRAS|TP53	1039.8420851796814	33.81768832220254
807.4904798842309	-9.125572055364103	0.412	66	10	KICH	ADAVOSERTIB	Clinical trials in cancer	NRAS|TP53	692.3493032652755	72.04244680820679
917.3748364119082	0.44558996171389254	0.492	66	10	KICH	GEDATOLISIB	Clinical trials in cancer	NRAS|TP53	907.5205477908013	40.99123784836118
887.5148090966916	-3.282599923616175	0.472	66	10	KICH	MIRDAMETINIB	Clinical trials in cancer	NRAS|TP53	872.8348098503284	63.5909511514387
890.0656207261278	3.302892729255433	0.472	66	10	KICH	PIMASERTIB	Clinical trials in cancer	NRAS|TP53	891.2132066644912	-3.9875944878873213
549.9250272687559	0.43250338256973464	0.2219999999999999	66	10	KICH	GEMCITABINE	Approved in other pathologies	NRAS|TP53	482.90351803742544	-30.118574912180947
779.8054576442279	3.9644594851205	0.392	66	10	KICH	ZINC	Approved in other pathologies	KRT5|TP53	660.3259019923114	56.196581240077734
779.8066702468086	-3.0955404107431264	0.392	66	10	KICH	ZINC ACETATE	Approved in other pathologies	KRT5|TP53	659.4028531865147	125.7464413798528
266.321896420797	-3.0975616651742826	0.012	66	10	KICH	INOSITOL	Clinical trials	NRAS|TP53	183.51522422432848	-40.450305755224434
266.32189651954974	3.9624383348257197	0.012	66	10	KICH	LY3009120	Clinical trials	NRAS|TP53	267.84941063894155	49.659518559875636
1440.2453025020393	-3.3087760012988383	0.882	66	9	KICH	BORTEZOMIB	Approved in cancer	TP53	1432.395432907754	51.035758266818874
1451.4680760877432	0.43652100891557666	0.892	66	9	KICH	ENCORAFENIB	Approved in cancer	TP53	1337.4551600907905	-106.29457783337978
1365.1573851412677	-3.526035016584899	0.8220000000000001	66	9	KICH	DAUNORUBICIN HYDROCHLORIDE	Approved in cancer	TP53	1277.3012443500247	-28.332148501100676
1426.6596064229545	4.132962251022633	0.8720000000000001	66	9	KICH	METHOTREXATE	Approved in cancer	TP53	1343.080134572051	106.50735358641441
1389.720038099435	7.010150265756437	0.8430000000000001	66	9	KICH	DOXORUBICIN	Approved in same tumor type	TP53	1378.7051423002051	-75.98349372631183
1414.8757782562009	-2.5937323539739054	0.8630000000000001	66	9	KICH	PACLITAXEL	Approved in cancer	TP53	1379.1617783344275	163.55249311920977
1376.9165244994451	2.0932956453015663	0.8320000000000001	66	9	KICH	BEVACIZUMAB	Approved in same tumor type	TP53	1368.3232723639885	-57.77360084259537
1358.7788518732239	-12.718873298459187	0.8220000000000001	66	9	KICH	CAPMATINIB	Approved in cancer	TP53	1314.3211757025401	95.6332116535566
1383.8146379756092	4.40543938681779	0.8420000000000001	66	9	KICH	CICLOPHOSPHAMIDE	Approved in cancer	TP53	1355.684301091084	-167.68059998061628
1353.490863555027	-9.023364250343263	0.8220000000000001	66	9	KICH	CRIZOTINIB	Approved in cancer	TP53	1309.8337814986044	-42.10174902735781
1457.0583345497225	-2.796489731703673	0.892	66	9	KICH	DUVELISIB	Approved in cancer	TP53	1325.5705883161115	-54.268979170604695
1371.5306634462222	5.643888270072267	0.8320000000000001	66	9	KICH	ERLOTINIB	Approved in cancer	TP53	1288.8617876550331	86.18664758760627
1399.3769678528963	3.6930742412815505	0.8520000000000001	66	9	KICH	ETOPOSIDE	Approved in cancer	TP53	1357.4410641436357	55.454439288840945
1399.388901177825	-2.7629147298784176	0.8520000000000001	66	9	KICH	FLUOROURACIL	Approved in cancer	TP53	1449.666848095896	-105.06886630869388
1370.4503159643662	-7.2162163166846085	0.8320000000000001	66	9	KICH	IBRUTINIB	Approved in cancer	TP53	1267.549860379659	131.2128262512279
1361.3124515104623	13.50888504460815	0.8220000000000001	66	9	KICH	IFOSFAMIDE	Approved in cancer	TP53	1234.109149969275	125.20701331531876
1354.013020618411	-2.5870281472489864	0.8220000000000001	66	9	KICH	IRINOTECAN	Approved in cancer	TP53	1382.581461096119	-130.67921421798462
1364.6096387001805	-9.95822202563042	0.8220000000000001	66	9	KICH	LORLATINIB	Approved in cancer	TP53	1183.4702305322426	-52.08328858071485
1344.3203101027993	11.678020988455842	0.812	66	9	KICH	MECHLORETHAMINE HYDROCHLORIDE	Approved in cancer	TP53	1286.2205583715554	-94.78217387637446
1348.190181896679	-5.352868618125143	0.812	66	9	KICH	MELPHALAN	Approved in cancer	TP53	1198.8547088273185	-13.658600138116412
1359.8526263772421	0.15551968487889667	0.8220000000000001	66	9	KICH	METHYLPREDNISOLONE	Approved in cancer	TP53	1281.3198239192586	62.16730129366971
1371.142322060279	-0.8000144538091547	0.8320000000000001	66	9	KICH	MITOXANTRONE	Approved in cancer	TP53	1291.8192473640065	81.53484591100874
1347.6654907440168	-11.78365798682077	0.812	66	9	KICH	MITOXANTRONE HYDROCHLORIDE	Approved in cancer	TP53	1414.1323504568486	-7.5237814864058805
1359.3177195128853	-6.266517457347021	0.8220000000000001	66	9	KICH	OLAPARIB	Approved in cancer	TP53	1217.78984941161	184.78353502100703
1354.5618842316812	3.8475851058815067	0.8220000000000001	66	9	KICH	PANITUMUMAB	Approved in cancer	TP53	1278.522989606251	-72.00492946703307
1412.720908404811	3.4920274115418124	0.8620000000000001	66	9	KICH	PAZOPANIB	Approved in same tumor type	TP53	1379.7318371208673	-135.44565366505614
1366.2420327952493	9.338127858609681	0.8220000000000001	66	9	KICH	RALOXIFENE	Approved in cancer	TP53	1291.6485851311988	-123.42382954492712
1342.3525206124277	-8.119977800619637	0.812	66	9	KICH	RITUXIMAB	Approved in cancer	TP53	1200.7794952965037	-207.30981710830758
1457.0641183245455	3.6595076775203665	0.892	66	9	KICH	TAMOXIFEN	Approved in cancer	TP53	1439.76140784681	-145.7227565677032
1360.3965460106308	6.589062204876399	0.8220000000000001	66	9	KICH	TAMOXIFEN CITRATE	Approved in cancer	TP53	1358.0781427563245	-53.87462748939868
1349.2435434126915	7.50918378875852	0.812	66	9	KICH	TEMOZOLOMIDE	Approved in cancer	TP53	1301.0231656100013	-50.44777908653984
1365.694560419956	2.8997561327776396	0.8220000000000001	66	9	KICH	TOPOTECAN	Approved in cancer	TP53	1380.644905445316	5.601889357758921
1348.704112152322	1.076934647456767	0.812	66	9	KICH	TRABECTEDIN	Approved in cancer	TP53	1229.1644268729428	-162.72885599233706
1342.8691344946667	-1.6858486786637457	0.812	66	9	KICH	TRIFLURIDINE	Approved in cancer	TP53	1184.1573124281663	-119.91030172608941
1387.6881193091363	-6.305247255030764	0.8420000000000001	66	9	KICH	VENETOCLAX	Approved in cancer	TP53	1470.9156805785874	21.03471846705088
1382.89275958514	-1.98269463944888	0.8420000000000001	66	9	KICH	VORINOSTAT	Approved in cancer	TP53	1365.6931014309282	38.60221349365753
1319.9459731198278	0.4070452212204714	0.792	66	9	KICH	ASPIRIN	Approved in other pathologies and in clinical trials in cancer	TP53	1358.2125167290121	19.040129764110162
1104.2832418872745	8.90391097092646	0.632	66	9	KICH	CLADRIBINE	Approved in other pathologies and in clinical trials in cancer	TP53	1028.0983738117634	30.582751727875632
1100.702325566443	-1.6913755460739708	0.632	66	9	KICH	MERCAPTOPURINE	Approved in other pathologies and in clinical trials in cancer	TP53	1057.4375137866475	-81.95421022461849
1171.9884484357462	0.4321284238918963	0.6829999999999999	66	9	KICH	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	TP53	1120.883933046041	99.37645744519449
1116.206179704741	-2.8294252980589363	0.642	66	9	KICH	AZACITIDINE	Approved in other pathologies and in clinical trials in cancer	TP53	1081.4016047563655	-35.92481212266142
1074.1213146939872	2.566683110401243	0.612	66	9	KICH	CHLORAMBUCIL	Approved in other pathologies and in clinical trials in cancer	TP53	1044.928561495295	58.31008934593703
1184.063492320408	0.4320597682894345	0.692	66	9	KICH	DASATINIB	Approved in other pathologies and in clinical trials in cancer	TP53	1135.021622901183	-130.45797777642608
1099.4364237355176	4.638087207435433	0.632	66	9	KICH	DAUNORUBICIN	Approved in other pathologies and in clinical trials in cancer	TP53	1013.5601493228513	112.8352708501896
1089.824909126865	0.5067710293552068	0.622	66	9	KICH	ENALAPRIL	Approved in other pathologies and in clinical trials in cancer	TP53	1007.8312707298586	-102.99643395809177
1078.9901664163476	-1.6770550092018652	0.612	66	9	KICH	FENOFIBRATE	Approved in other pathologies and in clinical trials in cancer	TP53	1024.0492056109392	160.1149064755117
1105.5525600904052	2.5749972975720254	0.632	66	9	KICH	FLUPHENAZINE	Approved in other pathologies and in clinical trials in cancer	TP53	1090.0726328083142	43.61510120929873
1106.8228778390649	-3.753664673156038	0.632	66	9	KICH	HALOPERIDOL	Approved in other pathologies and in clinical trials in cancer	TP53	1051.989054868523	-37.629615740601
1075.3696955544704	8.899830816164183	0.612	66	9	KICH	HYDRALAZINE HYDROCHLORIDE	Approved in other pathologies and in clinical trials in cancer	TP53	992.5957315134256	120.75601125781355
1116.2409668987284	3.6264809784551915	0.642	66	9	KICH	LOPERAMIDE	Approved in other pathologies and in clinical trials in cancer	TP53	1045.5873388194495	30.875357783085036
1072.8808983615343	-3.7666885904174308	0.612	66	9	KICH	METHYLENE BLUE CATION	Approved in other pathologies and in clinical trials in cancer	TP53	1017.4856324481783	89.6563090204724
1080.233271091056	4.654177862946909	0.612	66	9	KICH	THIAMAZOLE	Approved in other pathologies and in clinical trials in cancer	TP53	1069.0843312003362	130.1470644891391
1077.7452059155864	-8.011502840722216	0.612	66	9	KICH	THIORIDAZINE HYDROCHLORIDE	Approved in other pathologies and in clinical trials in cancer	TP53	1012.9978199900651	71.53050057441507
1101.9768159806151	-8.019297154109012	0.632	66	9	KICH	WARFARIN	Approved in other pathologies and in clinical trials in cancer	VWF|TP53	1083.2447820275509	-32.83700581439521
877.2390203593168	0.23142721023995705	0.463	66	9	KICH	SELICICLIB	Clinical trials in cancer	TP53	813.0742053805209	-64.70775753194648
981.7331679090928	-2.7952411078833563	0.542	66	9	KICH	KEVETRIN	Clinical trials in cancer	TP53	866.341984783326	66.05306823250976
981.7331534259437	3.6607588921004037	0.542	66	9	KICH	NVP-CGM097	Clinical trials in cancer	TP53	940.1781532984925	105.89597502700803
913.7037807591944	-5.229838174790814	0.492	66	9	KICH	NAVITOCLAX	Clinical trials in cancer	TP53	871.1515388422836	127.00947118616722
812.0332302876307	3.283766102025254	0.412	66	9	KICH	1026680-07-8	Clinical trials in cancer	TP53	758.0527158863771	118.39925389153888
874.114598515547	5.882070273417071	0.462	66	9	KICH	2-PHENYLETHYL ISOTHIOCYANATE	Clinical trials in cancer	TP53	841.0893257735564	131.83127004995958
816.424456955172	-3.5243202132616887	0.422	66	9	KICH	ALVESPIMYCIN	Clinical trials in cancer	TP53	803.6933181073429	-17.735992633503685
801.6530268654737	7.309891233125427	0.412	66	9	KICH	AVASTIN	Clinical trials in cancer	TP53	731.1094057255636	-83.03707953256179
820.7360034755864	-8.328565971902435	0.422	66	9	KICH	AZD6738	Clinical trials in cancer	TP53	711.1252997931489	-75.69162241369914
870.7823945748543	0.35330134986861594	0.462	66	9	KICH	BERZOSERTIB	Clinical trials in cancer	TP53	871.3072178880752	-96.55193140265807
883.4175091838463	2.0937873332946424	0.472	66	9	KICH	CAPIVASERTIB	Clinical trials in cancer	TP53	871.1789801416686	-108.39388367847974
799.2969418562745	1.2439318437034501	0.412	66	9	KICH	CARBENDAZIM	Clinical trials in cancer	TP53	712.2619290487743	52.41172723848601
803.3656721372612	-3.7741087529220465	0.412	66	9	KICH	DEMCIZUMAB	Clinical trials in cancer	TP53	730.4562704775718	8.92958809137292
860.4989315903118	0.40397902888631165	0.452	66	9	KICH	DS-7423	Clinical trials in cancer	TP53	788.8594478415641	-63.67789980695723
822.7485288430726	-2.1963569802997824	0.422	66	9	KICH	FENRETINIDE	Clinical trials in cancer	TP53	755.5346589228976	-80.14444553968367
818.4317947404437	2.6056599773000073	0.422	66	9	KICH	GANETESPIB	Clinical trials in cancer	TP53	759.2237987465791	23.51213529857597
910.61451950081	0.43843615430103	0.492	66	9	KICH	GENISTEIN	Clinical trials in cancer	TP53	878.960663298925	-91.20999147614071
820.24432945912	8.80516381313413	0.422	66	9	KICH	NORDIHYDROGUAIARETIC ACID	Clinical trials in cancer	TP53	788.2664073019939	-103.63992971796746
808.0277000446354	8.34388600904498	0.412	66	9	KICH	ONC201	Clinical trials in cancer	TP53	734.9272145986414	-13.454368505173221
809.7433606946248	-2.754745169112482	0.412	66	9	KICH	QUINACRINE DIHYDROCHLORIDE	Clinical trials in cancer	TP53	708.9818299009451	50.70479203222976
913.6923010552014	6.11357462868267	0.492	66	9	KICH	RESVERATROL	Clinical trials in cancer	TP53	827.1522987009093	31.522031786509388
873.9046657422116	-5.297482556581656	0.462	66	9	KICH	SAPANISERTIB	Clinical trials in cancer	TP53	841.180444592064	77.37656739469736
824.7050627277039	4.138066781116635	0.422	66	9	KICH	TANESPIMYCIN	Clinical trials in cancer	TP53	774.2248697359413	-45.3789522752985
805.6739969326329	2.2572618599133136	0.412	66	9	KICH	TIRAPAZAMINE	Clinical trials in cancer	TP53	697.7724338258098	20.908608296562193
752.7023185345541	-2.792751915344354	0.372	66	9	KICH	ZINC CHLORIDE	Approved in other pathologies	TP53	631.9280616379629	60.651944254459664
752.7025388633081	3.6632480808959826	0.372	66	9	KICH	ZINC SULFATE	Approved in other pathologies	TP53	643.4793753530025	-26.763299030355597
578.2226631207442	0.432540334344651	0.243	66	9	KICH	TRIFLUOPERAZINE	Approved in other pathologies	TP53	506.05338428405696	-36.92225775989982
1518.7519379414923	0.5741674945728334	0.94	370	63	KIRC	EVEROLIMUS	Approved in same tumor type	PTEN|VHL|KRAS	1546.7563070822628	-137.68073296243554
1014.1145865866789	3.40029839251892	0.5660000000000001	370	62	KIRC	GEDATOLISIB	Clinical trials in cancer	VHL|KRAS|TP53	926.4773807821477	-58.93380220106427
1373.67993397434	-3.0641798225122727	0.8320000000000001	370	61	KIRC	OLAPARIB	Approved in cancer	VHL|KRAS|TP53	1288.0961329338477	-123.00141186538612
1009.7749166748621	-2.7019478378844894	0.5640000000000001	370	58	KIRC	APITOLISIB	Clinical trials in cancer	PTEN|VHL|KRAS	1009.3119064352935	-76.92561143970215
1373.4944516633923	4.314804084981745	0.8320000000000001	370	57	KIRC	BEVACIZUMAB	Approved in same tumor type	VHL|KRAS|TP53	1379.6273132121823	99.09539489483961
1390.2098924129798	2.718431335237483	0.8440000000000001	370	56	KIRC	TRAMETINIB	Approved in cancer	PIK3CA|VHL|KRAS	1333.338431645137	147.30014575862606
1441.780532532519	0.5637380040761855	0.883	370	52	KIRC	REGORAFENIB	Approved in cancer	PIK3CA|VHL|KRAS	1427.012039553658	-151.93089486281426
1384.9972971799398	-1.5400818482021066	0.8420000000000001	370	50	KIRC	SUNITINIB	Approved in same tumor type	VHL|KRAS	1363.2369767014948	-111.58328202926901
900.8329553412996	0.4358262297098463	0.482	370	50	KIRC	SARACATINIB	Clinical trials in cancer	VHL|KRAS	826.6413059771425	0.7300762419527018
1089.5732259318872	0.49730890814259965	0.622	370	49	KIRC	NICOTINE	Approved in other pathologies and in clinical trials in cancer	VHL	1022.1352723104784	50.97931600383643
833.0733380373454	0.5107418842017921	0.432	370	49	KIRC	CEDIRANIB	Clinical trials in cancer	FGFR3|VHL	735.2760329008457	-84.61083277090033
806.845736555347	0.48054308262103973	0.412	370	49	KIRC	TELAGLENASTAT	Clinical trials in cancer	VHL	706.2926898877654	-10.295729245427708
576.8126588391192	0.35552718858292565	0.242	370	49	KIRC	IBUPROFEN	Approved in other pathologies	VHL	529.1693864184842	-9.68611297258002
1534.7762954122738	-0.33687808092108185	0.952	370	18	KIRC	ALPELISIB	Approved in cancer	PTEN|KRAS|TP53	1485.775208199351	-44.19939602776293
968.4458759818199	-0.972254710311006	0.532	370	17	KIRC	DS-7423	Clinical trials in cancer	PTEN|KRAS|TP53	935.795719725468	-46.324355814429765
972.7042167626862	1.2743730283339403	0.534	370	17	KIRC	SAPANISERTIB	Clinical trials in cancer	PTEN|KRAS|TP53	891.8309383679118	63.06547655410853
1441.7551026890696	-4.056192008712117	0.883	370	15	KIRC	PACLITAXEL	Approved in cancer	PTEN|KRAS|TP53	1365.959859845762	39.125815050345096
1386.7019969704995	-5.718582569702534	0.8430000000000001	370	15	KIRC	CISPLATIN	Approved in cancer	PIK3CA|PTEN|KRAS	1406.3401179604327	42.37966230159472
1246.2893907968187	0.4314853115883466	0.7380000000000001	370	15	KIRC	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	PIK3CA|KRAS|TP53	1185.7194862303709	33.520914697909205
819.9777237042686	-1.4613493408399734	0.422	370	15	KIRC	TANESPIMYCIN	Clinical trials in cancer	MTOR|PIK3CA|TP53	795.0273897226983	-31.87479874765657
1388.667871716599	-4.073834996501404	0.8420000000000001	370	14	KIRC	CARBOPLATIN	Approved in cancer	PTEN|KRAS|TP53	1273.2906326305003	-55.79717530474748
1399.5930761546963	-0.5355066924314826	0.8520000000000001	370	14	KIRC	FLUOROURACIL	Approved in cancer	PTEN|KRAS|TP53	1398.1931571100422	-0.06010150214973464
1089.5728782390133	-3.906691078132326	0.622	370	14	KIRC	METFORMIN	Approved in other pathologies and in clinical trials in cancer	PIK3CA|PTEN|KRAS	1038.5163270749613	36.82222790990127
966.0221336264652	0.15510654001755597	0.532	370	14	KIRC	BERZOSERTIB	Clinical trials in cancer	MTOR|KRAS|TP53	909.3848058872962	38.0212593859965
1534.7698688320215	2.3371141963800994	0.952	370	13	KIRC	INFIGRATINIB	Approved in cancer	PIK3CA|PTEN|KRAS	1550.9213593960708	-5.240985960808871
944.428464413353	0.4419179949650811	0.514	370	13	KIRC	CAPIVASERTIB	Clinical trials in cancer	PTEN|KRAS|TP53	925.9736674098201	39.94413410516631
247.73768664445842	1.6949030912263936	0.0004	370	13	KIRC	1173900-33-8	Experimental	PIK3CA|PTEN|TP53	217.17774836231501	-99.85389983084097
1504.005205105639	0.5033355329272808	0.929	370	12	KIRC	COPANLISIB	Approved in cancer	PIK3CA|PTEN|KRAS	1462.3431799315015	176.62214563319066
1518.7499284905177	5.628167095097808	0.94	370	12	KIRC	TEMSIROLIMUS	Approved in same tumor type	PIK3CA|PTEN|KRAS	1394.776475686479	101.73294496944192
1130.1271160088097	-0.7233562355716572	0.652	370	12	KIRC	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	PTEN|KRAS|TP53	1072.9044880063368	5.9073419369257465
998.7546168904424	-0.3655174127675025	0.555	370	12	KIRC	PF-04691502	Clinical trials in cancer	PIK3CA|PTEN|KRAS	969.8132721697963	103.90240377171313
972.9983834164527	-1.2755648132299484	0.535	370	12	KIRC	AZD8055	Clinical trials in cancer	PIK3CA|PTEN|KRAS	875.8281965671688	106.26246899456953
971.0776337644674	-2.7106096444770458	0.534	370	12	KIRC	ONATASERTIB	Clinical trials in cancer	PIK3CA|PTEN|KRAS	903.637227831486	44.023002759227325
971.4098492856613	3.4897284822938843	0.534	370	12	KIRC	OSI-027	Clinical trials in cancer	PIK3CA|PTEN|KRAS	923.2758564262738	-57.145659710505356
820.0436264556653	2.566996897998507	0.422	370	12	KIRC	PANULISIB	Clinical trials in cancer	PIK3CA|PTEN|KRAS	719.5449384439726	2.9846555840471183
969.113353857041	3.5483831145552927	0.533	370	12	KIRC	VISTUSERTIB	Clinical trials in cancer	PIK3CA|PTEN|KRAS	904.78422481531	13.229129812199773
967.9737172651558	1.551998994211658	0.532	370	12	KIRC	VOXTALISIB	Clinical trials in cancer	PIK3CA|PTEN|KRAS	917.9635501723425	80.69254569194442
333.53362028039004	0.4354317517661741	0.062	370	12	KIRC	OMIPALISIB	Clinical trials	MTOR|PIK3CA|PTEN	284.97479762524245	32.530369433367525
1130.127535301447	1.5726437261430135	0.652	370	12	KIRC	HALOPERIDOL	Approved in other pathologies and in clinical trials in cancer	MTOR|TP53	1090.0265794903344	-61.034819408566904
1143.4416049031224	0.427956984747226	0.6619999999999999	370	12	KIRC	LOPERAMIDE	Approved in other pathologies and in clinical trials in cancer	MTOR|TP53	1148.383917415627	2.402065897694939
887.3119366151623	0.43689324583564826	0.472	370	12	KIRC	2-PHENYLETHYL ISOTHIOCYANATE	Clinical trials in cancer	MTOR|TP53	882.0688387179667	-87.16085803988234
833.1184302680199	4.806505226232275	0.432	370	12	KIRC	FENRETINIDE	Clinical trials in cancer	MTOR|TP53	745.8809698702257	-121.38653884440208
590.1110460762022	0.3542650607416533	0.252	370	12	KIRC	PERPHENAZINE	Approved in other pathologies	MTOR|TP53	552.4034285407746	-38.05457254576669
576.8036881184388	-3.940463445272144	0.242	370	12	KIRC	PIMOZIDE	Approved in other pathologies	MTOR|TP53	550.2148682009572	31.05547406648239
252.79644835879404	5.038274915484976	0.0004	370	12	KIRC	(R,S)-INDATRALINE	Experimental	MTOR|TP53	260.9359984377004	-26.454768652074904
248.61363769977467	5.645865864389208	0.0004	370	12	KIRC	1,10-PHENANTHROLINE	Experimental	MTOR|TP53	110.63533815523812	-86.17741615444604
251.18788413921447	-0.35174337273045353	0.0004	370	12	KIRC	148672-13-3	Experimental	MTOR|TP53	249.92551770532089	77.69280842836298
249.27370384520725	3.447087993937089	0.0004	370	12	KIRC	93718-83-3	Experimental	MTOR|TP53	183.23251803938422	-67.96298327029658
253.45940625605277	-4.279447722128708	0.0004	370	12	KIRC	CHEMBL591618	Experimental	MTOR|TP53	199.28687943999404	-14.798645199262808
246.59839131095475	-0.34584831734838417	0.0004	370	12	KIRC	GNF-PF-308	Experimental	MTOR|TP53	157.40104865240752	-114.06892361427529
248.87875895980105	-4.321812444199054	0.0004	370	12	KIRC	GNF-PF-3964	Experimental	MTOR|TP53	122.0139610357044	-24.387173454905962
254.808483879096	0.9228034753523957	0.0004	370	12	KIRC	GOSSYPOL	Experimental	MTOR|TP53	223.91320402921494	24.357055025862337
250.0374912122225	-2.330691415888708	0.0004	370	12	KIRC	MALONOBEN	Experimental	MTOR|TP53	226.01728648593968	-48.53741554453177
253.83195015634283	2.99496730564519	0.0004	370	12	KIRC	N-OLEOYLDOPAMINE	Experimental	MTOR|TP53	194.63478998023277	24.265223898567257
254.5668734322903	-2.2756724770269443	0.0004	370	12	KIRC	ROTENONE	Experimental	MTOR|TP53	208.25315363942528	-46.40511323393409
247.74559151946357	-2.3261731827278425	0.0004	370	12	KIRC	TCMDC-124166	Experimental	MTOR|TP53	246.05539858810164	-21.082344797041458
251.1731045121155	-4.3236321759610234	0.0004	370	12	KIRC	TCMDC-125575	Experimental	MTOR|TP53	189.8400895578584	117.68480433295673
248.89765001668712	-0.34012755945349227	0.0004	370	12	KIRC	TCMDC-125578	Experimental	MTOR|TP53	196.34929270145358	-12.768066533154837
247.0497493451802	3.941082261198261	0.0004	370	12	KIRC	TCMDC-125580	Experimental	MTOR|TP53	189.01439843594545	-58.02625285834556
251.53571012412738	3.1193854483203154	0.0004	370	12	KIRC	VANOXERINE	Experimental	MTOR|TP53	210.22499881165896	102.93233511403616
1377.8418496421684	2.447526523482537	0.8320000000000001	370	12	KIRC	IRINOTECAN	Approved in cancer	PIK3CA|KRAS|TP53	1381.7751392282828	9.139774183002714
1399.622492019305	1.8143091954433999	0.8520000000000001	370	11	KIRC	VANDETANIB	Approved in cancer	MTOR|PTEN|KRAS	1279.5142198172252	-32.14617733852171
1383.6214101133178	2.530138264164833	0.8420000000000001	370	11	KIRC	VENETOCLAX	Approved in cancer	PTEN|KRAS|TP53	1366.411940367968	-111.79570856613529
1360.3894997311324	0.4081801684018842	0.8220000000000001	370	11	KIRC	TOPOTECAN	Approved in cancer	PIK3CA|PTEN|TP53	1370.0481891372933	-39.17860747235477
1000.6808323858621	0.7809783863260975	0.557	370	11	KIRC	DACTOLISIB	Clinical trials in cancer	MTOR|PIK3CA|PTEN	933.7899427127384	-43.85727602378881
860.3418010915805	1.228671950731325	0.452	370	11	KIRC	MIRDAMETINIB	Clinical trials in cancer	PTEN|KRAS|TP53	882.2924697194766	-91.14986117698926
873.7552905608748	0.43477341066142117	0.462	370	11	KIRC	NAVITOCLAX	Clinical trials in cancer	PTEN|KRAS|TP53	865.7881408354909	-18.198524037723047
996.5846467871543	0.1932686584538601	0.553	370	11	KIRC	SAMOTOLISIB	Clinical trials in cancer	MTOR|PIK3CA|PTEN	916.6483497941193	-11.588707789052904
970.9037477957197	-0.4794183077512457	0.533	370	11	KIRC	BGT-226 FREE BASE	Clinical trials in cancer	MTOR|PIK3CA|PTEN	919.8213534274329	-27.765896873526685
818.8550907244303	0.6651512888198283	0.422	370	11	KIRC	PKI-179	Clinical trials in cancer	MTOR|PIK3CA|PTEN	778.5985847750578	-115.70709450546076
970.2140279746161	1.5970283078187322	0.533	370	11	KIRC	VS-5584	Clinical trials in cancer	MTOR|PIK3CA|PTEN	922.0641884996435	78.89826436126134
252.2721262287267	-2.3760210339459036	0.0004	370	11	KIRC	ABT-737	Experimental	PTEN|KRAS|TP53	226.4237967693263	-67.30972622453032
1389.2862107559297	-1.806643599996221	0.8430000000000001	370	11	KIRC	DOXORUBICIN	Approved in same tumor type	PIK3CA|KRAS|TP53	1347.0235796819181	-52.87396376572718
1413.2590591447374	-0.646535747012706	0.8620000000000001	370	11	KIRC	DOCETAXEL	Approved in cancer	PIK3CA|KRAS|TP53	1377.4123319940993	5.117990631134319
1377.8578662638756	-0.6210102415280971	0.8320000000000001	370	10	KIRC	VEMURAFENIB	Approved in cancer	PIK3CA|PTEN|TP53	1384.5915549654649	63.89553233834664
549.8574862276622	0.41264172240423136	0.2219999999999999	370	10	KIRC	GEMCITABINE	Approved in other pathologies	PIK3CA|PTEN|KRAS	516.0949759912992	-3.1848030981139743
1319.37818901041	0.4271398633386809	0.792	370	10	KIRC	FOSTAMATINIB	Approved in other pathologies and in clinical trials in cancer	FGFR3|MTOR|BMPR2	1210.3434108004142	-104.6882920295951
974.9038320841248	0.1828829880091689	0.538	370	10	KIRC	RIDAFOROLIMUS	Clinical trials in cancer	MTOR|PIK3CA|KRAS	924.0168394658126	23.16307984877534
822.2021532635409	2.2042708245602682	0.423	370	10	KIRC	CAMPTOTHECIN	Clinical trials in cancer	MTOR|PIK3CA|KRAS	738.6836555895686	-10.908988641352295
959.8579884607617	0.46408933757018644	0.525	370	10	KIRC	SERABELISIB	Clinical trials in cancer	MTOR|PIK3CA|KRAS	925.3106210764488	-56.74168283978868
1413.955461143623	1.3717318636100515	0.8620000000000001	370	10	KIRC	BORTEZOMIB	Approved in cancer	PIK3CA|KRAS|TP53	1429.4846449189465	-34.6518381051541
1184.0861764902288	0.429963440280801	0.692	370	10	KIRC	DASATINIB	Approved in other pathologies and in clinical trials in cancer	PIK3CA|KRAS|TP53	1152.8041004714769	-35.40522660064636
1385.7005759277636	2.5890408261982145	0.8420000000000001	370	9	KIRC	ERLOTINIB	Approved in cancer	MAP3K1|PTEN|TP53	1342.702922414564	109.23625463222072
998.0648309198331	1.6541601015898948	0.554	370	9	KIRC	XL-765	Clinical trials in cancer	MTOR|PIK3CA	937.718341707592	-6.631545505383087
996.1810014157164	2.2351372814144668	0.553	370	9	KIRC	SF1126	Clinical trials in cancer	MTOR|PIK3CA	949.8927004948556	-77.19186811829191
994.8660839200923	-0.9781650174832066	0.552	370	9	KIRC	BIMIRALISIB	Clinical trials in cancer	MTOR|PIK3CA	971.0867564108571	30.25424232438246
253.29314896601758	-0.5698528523022048	0.0008	370	9	KIRC	PI-103	Experimental	MTOR|PIK3CA	227.0895170206148	13.453641923700076
250.1438579914107	1.4993377098426492	0.0004	370	9	KIRC	154447-36-6	Experimental	MTOR|PIK3CA	154.29981902184187	-134.5470913248658
251.59158665501585	6.800935841630576	0.0004	370	9	KIRC	PWT-33579	Experimental	MTOR|PIK3CA	295.07564909360497	-21.60055572207571
252.57469693978797	1.2666140497319702	0.0004	370	9	KIRC	PWT-33587	Experimental	MTOR|PIK3CA	208.04958800278712	-46.475690474418485
250.66944704777086	5.057823043102246	0.0008	370	9	KIRC	WORTMANNIN	Experimental	MTOR|PIK3CA	209.1956140288335	-44.95357157502599
1370.7142965198177	0.6902088307902261	0.8320000000000001	370	9	KIRC	CICLOPHOSPHAMIDE	Approved in cancer	ATM|MUTYH|TP53	1410.5657485180038	-66.63967009867635
1411.9667992817338	0.984562652235411	0.8620000000000001	370	9	KIRC	DABRAFENIB	Approved in cancer	PIK3CA|KRAS|TP53	1315.5036404937462	113.86363836934805
1453.6845303181988	-0.6414596380773787	0.892	370	9	KIRC	DUVELISIB	Approved in cancer	PIK3CA|TP53	1379.0370230567833	6.5930275720452585
1376.4469723759978	0.8329685721650719	0.8320000000000001	370	9	KIRC	RALOXIFENE	Approved in cancer	PIK3CA|TP53	1345.3848617986305	-41.93701340887847
1453.6983549932665	1.3304919024933497	0.892	370	9	KIRC	TAMOXIFEN	Approved in cancer	PIK3CA|TP53	1285.8901853839084	56.88858762951085
994.658372462308	0.9828653112285792	0.552	370	9	KIRC	NVP-CGM097	Clinical trials in cancer	PIK3CA|KRAS|TP53	969.2293854500117	38.326887610523244
820.9335206092184	0.6246356806170468	0.422	370	9	KIRC	DEMCIZUMAB	Clinical trials in cancer	PIK3CA|KRAS|TP53	752.855578548367	1.7930366608782435
860.3426917800302	-0.8513278585653268	0.452	370	9	KIRC	PIMASERTIB	Clinical trials in cancer	PIK3CA|KRAS|TP53	759.7431364392475	25.918696992903136
914.3507073391092	0.43619932810977957	0.492	370	9	KIRC	RESVERATROL	Clinical trials in cancer	PIK3CA|TP53	863.7951413572224	63.762939004455944
1385.4394570070554	1.8124435827625973	0.8420000000000001	278	22	KIRP	TRAMETINIB	Approved in cancer	KRAS|CDKN2A|STAG2	1343.9377820159373	-42.71289645918921
1103.129830218617	0.4328689478367096	0.632	278	21	KIRP	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	BRAF|NF1|KRAS	1037.0644601771573	34.26949130849593
1373.2089327256629	2.5298850522257226	0.8320000000000001	278	18	KIRP	BEVACIZUMAB	Approved in same tumor type	BRAF|VHL|KRAS	1360.8867530324176	84.78821523049879
1132.7478241319561	0.43257599448983797	0.654	278	18	KIRP	DASATINIB	Approved in other pathologies and in clinical trials in cancer	FGFR3|BRAF|KRAS	1073.2750895883305	4.730463930103525
1559.2299257431966	0.43359329937024427	0.97	278	17	KIRP	ALPELISIB	Approved in cancer	FGFR3|BRAF|KRAS	1561.7126539756136	8.21729807020185
1373.9253295533895	-0.9139839949472446	0.8320000000000001	278	17	KIRP	FLUOROURACIL	Approved in cancer	PIK3CA|BRAF|KRAS	1373.0138374998132	-12.647030573195593
1014.9765762399264	0.8550633315219613	0.5670000000000001	278	17	KIRP	GEDATOLISIB	Clinical trials in cancer	BRAF|VHL|KRAS	960.9486466774675	22.233429703770383
944.6959755037104	0.45768611210542076	0.514	278	17	KIRP	SAPANISERTIB	Clinical trials in cancer	BRAF|KRAS|CDKN2A	914.3748023016892	83.96501254106204
1360.1027997475148	-3.523324092416942	0.8220000000000001	278	16	KIRP	PALBOCICLIB	Approved in cancer	BRAF|KRAS|CDKN2A	1327.4753024559488	127.68565403798044
947.9202164054808	1.4526592107710883	0.518	278	16	KIRP	DACTOLISIB	Clinical trials in cancer	FGFR3|BRAF|KRAS	870.0450297893373	93.66770827358448
1360.548400684719	2.1329615037047347	0.8220000000000001	278	16	KIRP	OLAPARIB	Approved in cancer	VHL|KRAS|STAG2	1282.9542792519528	39.00120036639771
1413.1798918412483	0.41999107042178707	0.8620000000000001	278	16	KIRP	PACLITAXEL	Approved in cancer	PIK3CA|KRAS|CDKN2A	1372.2262797609535	-12.822828507361407
1385.2982304390978	-1.9195548425254572	0.8420000000000001	278	16	KIRP	CARBOPLATIN	Approved in cancer	PIK3CA|KRAS|CDKN2A	1374.049880349224	2.7451793803167845
1491.6737969299854	-1.9680701490984518	0.92	278	15	KIRP	EVEROLIMUS	Approved in same tumor type	BRAF|VHL|KRAS	1469.0726271770186	-43.26119881650715
1001.6853008514013	-0.3574047123054527	0.557	278	15	KIRP	PILARALISIB	Clinical trials in cancer	PIK3CA|BRAF|KRAS	921.1597777297053	-27.786751377149443
1219.383065454892	0.4320263394313315	0.7180000000000001	278	15	KIRP	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	TP53|PIK3CA|KRAS	1171.3215383857223	23.15105094471997
1363.004811584864	-2.2680662252701893	0.8230000000000001	278	14	KIRP	DOXORUBICIN	Approved in same tumor type	PIK3CA|BRAF|KRAS	1413.869292579842	-5.784788297623777
833.3102481572811	2.806931976791418	0.432	278	14	KIRP	MIRDAMETINIB	Clinical trials in cancer	PIK3CA|BRAF|KRAS	720.7031749747246	-132.08145414391322
831.6123907068287	0.313818279708471	0.432	278	14	KIRP	PIMASERTIB	Clinical trials in cancer	BRAF|NF1|KRAS	731.2890560932741	-16.070010896052963
817.6622578649713	1.709695556926789	0.421	278	14	KIRP	CAMPTOTHECIN	Clinical trials in cancer	BRAF|KRAS|STAG2	798.2215309257953	-21.035655645982672
1562.766903418534	0.4335140730924252	0.973	278	14	KIRP	PAZOPANIB	Approved in same tumor type	TP53|FGFR3|KRAS	1551.1129080839664	-9.343109230727237
1388.1451328861979	-0.5481517447448709	0.8430000000000001	278	14	KIRP	BORTEZOMIB	Approved in cancer	PIK3CA|FGFR3|KRAS	1344.3677987468454	35.238480222522384
1255.872385741644	0.43152242795233064	0.7450000000000001	278	14	KIRP	PONATINIB	Approved in other pathologies and in clinical trials in cancer	PIK3CA|FGFR3|KRAS	1166.8943161961306	-3.9332321809542066
1493.889133179421	0.08098422090878898	0.92	278	13	KIRP	DABRAFENIB	Approved in cancer	BRAF|KRAS|STAG2	1488.3977460228798	106.52693080589944
1504.4748864513906	1.2486549080878717	0.93	278	13	KIRP	SORAFENIB	Approved in same tumor type	FGFR3|BRAF|KRAS	1512.1246263473572	34.037622334149205
1369.991995628671	2.2438839103147927	0.8320000000000001	278	13	KIRP	VENETOCLAX	Approved in cancer	PIK3CA|BRAF|KRAS	1299.1685127751516	-47.25233812325274
1357.4704395882409	2.3850332057042465	0.8220000000000001	278	13	KIRP	IRINOTECAN	Approved in cancer	PIK3CA|BRAF|KRAS	1275.4447402323397	-34.49899310229915
846.2698274289138	-0.13187802567156837	0.442	278	13	KIRP	NAVITOCLAX	Clinical trials in cancer	PIK3CA|BRAF|KRAS	795.4417731776956	-60.41156452101323
940.8026405326034	3.58131237298241	0.512	278	13	KIRP	NVP-CGM097	Clinical trials in cancer	PIK3CA|BRAF|KRAS	865.4841901613562	31.448794582342913
1493.2432787858831	2.881450405939262	0.92	278	13	KIRP	CRIZOTINIB	Approved in cancer	TP53|KRAS|CDKN2A	1469.845251446116	-16.562759979395565
939.7526070575738	-0.5156774853750221	0.512	278	13	KIRP	DS-7423	Clinical trials in cancer	TP53|PIK3CA|KRAS	893.9727751016462	-50.12519787392711
833.4214982626714	-2.0096623535445985	0.432	278	13	KIRP	CAPIVASERTIB	Clinical trials in cancer	PIK3CA|FGFR3|KRAS	795.4075263089317	-79.62776909026583
1491.2270785010778	0.9406889993481968	0.92	278	12	KIRP	TEMSIROLIMUS	Approved in same tumor type	PIK3CA|BRAF|KRAS	1375.9130133630676	3.802601091681879
549.8184991973835	0.43250597387799417	0.2219999999999999	278	12	KIRP	GEMCITABINE	Approved in other pathologies	BRAF|KRAS|CDKN2A	490.1978716887585	-23.505433828309492
1369.2538494108187	-0.4567439967191831	0.8320000000000001	278	12	KIRP	CISPLATIN	Approved in cancer	PIK3CA|KRAS|STAG2	1360.521773960714	-16.206192702510634
818.70266553675	-0.9676872702708863	0.422	278	12	KIRP	TANESPIMYCIN	Clinical trials in cancer	MTOR|TP53|PIK3CA	759.6288710703797	-32.899042402232595
1549.6160266088432	0.4339818049361952	0.963	278	12	KIRP	INFIGRATINIB	Approved in cancer	PIK3CA|FGFR3|KRAS	1563.3056844060193	8.185664075447136
1359.0081913722756	4.72290353382823	0.8220000000000001	278	12	KIRP	CAPECITABINE	Approved in cancer	MET|PIK3CA|KRAS	1291.8537298184074	-41.906859469092154
1365.189948609653	-0.5155472549452895	0.8240000000000001	278	11	KIRP	COBIMETINIB	Approved in cancer	BRAF|NF1|KRAS	1372.833136191086	2.780671485522845
1501.0037626922378	0.4063518621231026	0.927	278	11	KIRP	REGORAFENIB	Approved in cancer	BRAF|VHL|KRAS	1469.8196696641046	21.795982540881965
987.3087760797744	0.4486380387534723	0.546	278	11	KIRP	BUPARLISIB	Clinical trials in cancer	FGFR3|BRAF|KRAS	931.1653253387067	6.490279973073342
1001.9307492417753	2.5045268467241044	0.557	278	11	KIRP	PICTILISIB	Clinical trials in cancer	PIK3CA|BRAF|KRAS	945.8851908263691	56.54019748916255
249.24873592430234	1.609967334956366	0.0004	278	11	KIRP	PF-477736	Experimental	BRAF|KRAS|CDKN2A	222.42987257298194	-54.92121985105969
821.346425354471	-1.2323830669738527	0.422	278	11	KIRP	DEMCIZUMAB	Clinical trials in cancer	TP53|PIK3CA|KRAS	740.088862350941	-9.455642634314955
251.83462219312162	1.5444877120708327	0.0004	278	11	KIRP	ABT-737	Experimental	TP53|PIK3CA|KRAS	172.40346997350545	-73.12810981114724
1089.69917325999	0.432987130748387	0.622	278	11	KIRP	METFORMIN	Approved in other pathologies and in clinical trials in cancer	MTOR|PIK3CA|KRAS	1024.029703165018	-12.876084622720413
946.803555769919	-1.6965948895426664	0.515	278	11	KIRP	AZD8055	Clinical trials in cancer	MTOR|PIK3CA|KRAS	920.5611283193883	-26.737786324591468
940.6114004849396	-3.1065459895444576	0.512	278	11	KIRP	VOXTALISIB	Clinical trials in cancer	MTOR|PIK3CA|KRAS	908.7885923436403	1.1565952388580456
1011.9656615702525	0.6707878456099365	0.5650000000000001	278	11	KIRP	APITOLISIB	Clinical trials in cancer	PIK3CA|VHL|KRAS	973.1159714583151	3.5173876975816256
1488.8833385396003	2.032519960812124	0.919	278	10	KIRP	ENCORAFENIB	Approved in cancer	TP53|BRAF|KRAS	1414.5520948482617	21.71285007393101
1362.8784619601724	0.4613273520762391	0.8220000000000001	278	10	KIRP	PEMBROLIZUMAB	Approved in same tumor type	TP53|BRAF|KRAS	1347.1358854663079	-50.85884292123683
1360.7558290921888	-0.7323202617420179	0.8220000000000001	278	10	KIRP	NERATINIB	Approved in cancer	PIK3CA|BRAF|KRAS	1299.8805742472048	-47.99434295671048
1373.062098108799	-3.7303191617447737	0.8320000000000001	278	10	KIRP	OXALIPLATIN	Approved in cancer	MET|BRAF|KRAS	1289.8344364891022	32.01100980104701
1361.590869001259	4.805560573370968	0.8220000000000001	278	10	KIRP	TRASTUZUMAB	Approved in cancer	PIK3CA|BRAF|KRAS	1288.3670697571872	-99.1880023685599
1319.69123782591	0.4314621097851159	0.792	278	10	KIRP	FOSTAMATINIB	Approved in other pathologies and in clinical trials in cancer	MTOR|FGFR3|BRAF	1197.6549756718691	47.90327190894624
820.3097619327979	1.0552686223151397	0.422	278	10	KIRP	TAK-733	Clinical trials in cancer	PIK3CA|BRAF|KRAS	725.5147411973228	-47.4686510005792
997.0141665508932	0.9372157312715217	0.553	278	10	KIRP	IZORLISIB	Clinical trials in cancer	PIK3CA|BRAF|KRAS	911.1915546178441	-51.38820922382695
268.8211115608008	0.41637152021286283	0.014	278	10	KIRP	LY3009120	Clinical trials	TP53|BRAF|KRAS	208.3463151140004	-47.88282528712847
1371.2357914106226	-2.1122326857137637	0.8320000000000001	278	10	KIRP	DOCETAXEL	Approved in cancer	TP53|PIK3CA|KRAS	1342.4074894349396	-67.9410160252068
941.8324681678279	1.1349467514172886	0.512	278	10	KIRP	BERZOSERTIB	Clinical trials in cancer	MTOR|TP53|KRAS	848.4789260788397	106.16249835054907
1544.5274754583495	0.43420110205707374	0.959	278	10	KIRP	COPANLISIB	Approved in cancer	MTOR|PIK3CA|KRAS	1503.2760232732805	21.901677775553196
1013.2182359009711	-1.506642186795574	0.5660000000000001	278	10	KIRP	PF-04691502	Clinical trials in cancer	MTOR|PIK3CA|KRAS	961.8570004878368	12.255558369309654
998.8971541340583	-0.6149347047719118	0.555	278	10	KIRP	SERABELISIB	Clinical trials in cancer	MTOR|PIK3CA|KRAS	982.5874164301554	93.18511847902852
945.6706668360504	3.2340279432856107	0.514	278	10	KIRP	ONATASERTIB	Clinical trials in cancer	MTOR|PIK3CA|KRAS	924.8795849803937	40.791975609570216
944.4184088793988	-2.475027640764864	0.514	278	10	KIRP	OSI-027	Clinical trials in cancer	MTOR|PIK3CA|KRAS	930.3121104071507	2.1713237792408506
810.2878326682098	-0.20682122799121316	0.414	278	10	KIRP	PANULISIB	Clinical trials in cancer	MTOR|PIK3CA|KRAS	728.2330213510145	1.0168630656798712
949.2413425114604	-1.0977232266191947	0.518	278	10	KIRP	RIDAFOROLIMUS	Clinical trials in cancer	MTOR|PIK3CA|KRAS	849.1236989206197	104.71420777552049
942.3053859452923	-1.2548907495422839	0.513	278	10	KIRP	VISTUSERTIB	Clinical trials in cancer	MTOR|PIK3CA|KRAS	910.5528440062112	-51.56473301070349
1489.28304116669	-0.6510070719370162	0.919	278	9	KIRP	CAPMATINIB	Approved in cancer	MET|TP53|BRAF	1427.7414792522195	-24.475985082476313
806.3704393958654	2.0350582973906626	0.412	278	9	KIRP	GANETESPIB	Clinical trials in cancer	MET|TP53|BRAF	735.9834535287787	-17.260947526555327
279.4875879751745	1.5734825560447803	0.022	278	9	KIRP	RO4987655	Clinical trials	FGFR3|BRAF|KRAS	233.58392815294195	12.769193710609727
405.3365247909243	0.4322321008900758	0.115	278	9	KIRP	PF-04217903	Clinical trials	MET|TP53|BRAF	388.5096346584379	-8.60961666038341
1357.8284499201243	-1.8903116425823043	0.8220000000000001	278	9	KIRP	ABEMACICLIB	Approved in cancer	TP53|KRAS|CDKN2A	1225.6337608688189	-47.48414067901595
806.3131171545296	-0.2617513540739651	0.412	278	9	KIRP	ADAVOSERTIB	Clinical trials in cancer	STK11|TP53|KRAS	753.8208490469893	-35.60729499469977
252.68889330811956	-0.7412673723111993	0.0004	278	9	KIRP	PKI-402	Experimental	STK11|PIK3CA|KRAS	164.8790382254164	-64.38346820488069
1504.5850533250004	-1.3329955833534086	0.93	278	9	KIRP	CABOZANTINIB	Approved in same tumor type	MET|KRAS	1458.175321578535	3.330542634556849
943.3152596417257	2.9747018320085203	0.513	278	9	KIRP	SAR125844	Clinical trials in cancer	MET|KRAS	931.6728247499226	8.346123193893675
279.4870159439064	-0.7225173726965579	0.022	278	9	KIRP	BMS-754807	Clinical trials	MET|KRAS	195.57136553513604	-104.39701619595363
251.21821242772606	-2.5062227229846883	0.0004	278	9	KIRP	A-443654	Experimental	NFE2L2|PIK3CA|KRAS	163.3733120072785	-97.78281314792217
1490.7716545619971	3.338612832796912	0.92	278	8	KIRP	VEMURAFENIB	Approved in cancer	PIK3CA|BRAF|STAG2	1471.7580316115684	-17.717777314408465
1363.2087697872537	2.7311703301593298	0.8230000000000001	278	8	KIRP	BINIMETINIB	Approved in cancer	BRAF|NF1|KRAS	1285.7612265143414	54.480333783679754
1358.6526347554875	0.177929357864258	0.8220000000000001	278	8	KIRP	TOPOTECAN	Approved in cancer	PIK3CA|BRAF|STAG2	1319.1271792421996	-66.85701377940394
846.2815541068895	2.380094602567766	0.442	278	8	KIRP	212631-79-3	Clinical trials in cancer	STK11|BRAF|KRAS	761.7061830078814	63.05766909238275
834.1967162332251	0.37972691949514115	0.432	278	8	KIRP	SARACATINIB	Clinical trials in cancer	BRAF|VHL|KRAS	782.312564639351	65.32353854501144
250.49104558105626	-0.40246453657633197	0.0004	278	8	KIRP	1173900-33-8	Experimental	TP53|PIK3CA|BRAF	247.56489981980263	-76.3266041949967
1116.5854706452753	0.43267369472434325	0.642	278	8	KIRP	MIDOSTAURIN	Approved in other pathologies and in clinical trials in cancer	PIK3CA|KRAS	1067.3738507183375	18.418708263775954
819.7208576720444	3.2737773945100628	0.422	278	8	KIRP	IPATASERTIB	Clinical trials in cancer	PIK3CA|KRAS	783.6619217536548	-37.91089636762388
999.7864106604964	1.5018644897645004	0.556	278	8	KIRP	SONOLISIB	Clinical trials in cancer	PIK3CA|KRAS	958.9973921372592	21.244969705070844
808.274958851369	-1.3121938330532998	0.413	278	8	KIRP	AZD8835	Clinical trials in cancer	PIK3CA|KRAS	750.6858029921118	99.52290514662769
810.0080737657255	2.0730265505915213	0.414	278	8	KIRP	FIMEPINOSTAT	Clinical trials in cancer	PIK3CA|KRAS	737.0127374569599	11.332987717045853
808.2451733729266	0.8388117384342024	0.412	278	8	KIRP	LINSITINIB	Clinical trials in cancer	PIK3CA|KRAS	750.843638888255	-38.547621018765284
822.5892334736076	0.7852745040996183	0.423	278	8	KIRP	RIGOSERTIB	Clinical trials in cancer	PIK3CA|KRAS	801.4950347316054	-106.11914362131738
459.3346101416795	0.43237637465045964	0.155	278	8	KIRP	TASELISIB	Clinical trials	PIK3CA|KRAS	411.4415489099256	3.142903362723416
250.5936342794818	3.5593749237840484	0.0004	278	8	KIRP	1056901-62-2	Experimental	PIK3CA|KRAS	264.6431479528751	-28.084370563825843
249.05023497474008	-2.0009540721230223	0.0004	278	8	KIRP	DEGUELIN	Experimental	PIK3CA|KRAS	218.87184026465368	-55.14415406262968
1347.4905954371468	1.4365458536788935	0.812	278	7	KIRP	ATEZOLIZUMAB	Approved in cancer	BRAF|KRAS	1342.1102583237719	106.80829445683037
1356.586223061444	-0.05943646781094003	0.8220000000000001	278	7	KIRP	IMATINIB	Approved in cancer	MET|BRAF|CDKN2A	1310.722077274188	-5.14851640412914
1347.492022704615	-0.5714536390767364	0.812	278	7	KIRP	PANOBINOSTAT	Approved in cancer	BRAF|KRAS	1320.789445445403	-67.07431747198824
1371.4931509431644	0.31798298693067295	0.8320000000000001	278	7	KIRP	VORINOSTAT	Approved in cancer	TP53|SMARCB1|BRAF	1289.5600575333976	32.10076501521317
944.2237235026315	4.925547139344161	0.514	278	7	KIRP	LIFIRAFENIB	Clinical trials in cancer	BRAF|KRAS	894.694022765224	-6.8809899121177125
1373.3429953286736	-2.077092994212734	0.8330000000000001	124	27	LAML	VENETOCLAX	Approved in same tumor type	TP53|KRAS|FLT3	1336.5662823999319	-96.35991846348364
1222.3714387627722	-0.3682435065518348	0.7200000000000001	124	21	LAML	DASATINIB	Approved in other pathologies and in clinical trials in cancer	TP53|KRAS|KIT	1138.774649685779	-11.31345640677904
1358.2950023970577	9.644489167874184	0.8220000000000001	124	17	LAML	CRIZOTINIB	Approved in cancer	NPM1|TP53|KRAS	1265.7095869622667	121.40871647344113
1359.4302251010113	-4.042765120266296	0.8220000000000001	124	15	LAML	VORINOSTAT	Approved in same tumor type	TUBA1A|NPM1|TP53	1361.9251035213008	42.01110004760292
1349.9965680719004	0.9756511828163639	0.812	124	15	LAML	BORTEZOMIB	Approved in same tumor type	TP53|KRAS|FLT3	1255.3060799604564	-47.00473167397203
1345.3854103301462	-8.239987092330495	0.812	124	15	LAML	BEVACIZUMAB	Approved in cancer	TP53|KRAS|KIT	1352.5215720196773	-54.91625287728121
1350.5855756530761	7.59071715788096	0.8130000000000001	124	15	LAML	CISPLATIN	Approved in cancer	TP53|KRAS|NRAS	1316.8988504018241	-69.43686810631914
535.8703512083993	6.017184037387835	0.212	124	15	LAML	GEMCITABINE	Approved in other pathologies	TP53|KRAS|NRAS	470.92514518750625	-11.949730336112395
1235.47792037429	0.45951560677337966	0.7300000000000001	124	14	LAML	MIDOSTAURIN	Approved in other pathologies and in clinical trials in cancer	KRAS|KIT|FLT3	1149.1026592228684	-69.68971919648257
1104.8990013774778	-1.995921584257502	0.633	124	14	LAML	AZACITIDINE	Approved in other pathologies and in clinical trials in cancer	IDH1|TP53|FLT3	1034.199732407984	-75.98101102163122
1342.077196262688	-3.6266505528888047	0.812	124	14	LAML	OLAPARIB	Approved in cancer	IDH1|TP53|KRAS	1301.6501823278247	-62.619976180187535
832.5009995639601	-6.643320957672529	0.432	124	14	LAML	BERZOSERTIB	Clinical trials in cancer	IDH1|TP53|KRAS	783.6677825180766	-86.77251674718518
1345.1643231309845	9.28807451301941	0.812	124	14	LAML	LORLATINIB	Approved in cancer	NPM1|TP53	1310.3148981797685	-4.712776072735437
1354.0698919807764	-2.7350548660861023	0.8220000000000001	124	13	LAML	METHOTREXATE	Approved in same tumor type	IDH1|TP53|FLT3	1309.5403319561708	80.67438386754156
1370.0464961317775	4.605387703468637	0.8320000000000001	124	13	LAML	TRAMETINIB	Approved in cancer	KRAS|KIT|NRAS	1285.0829335782137	12.61722366155351
1350.6636880485144	-6.6462001358395355	0.8130000000000001	124	13	LAML	PEMBROLIZUMAB	Approved in same tumor type	KRAS|KIT|NRAS	1313.468530958306	174.6567972936025
829.5766247765233	2.302233228190204	0.432	124	13	LAML	MIRDAMETINIB	Clinical trials in cancer	KRAS|KIT|NRAS	799.1407623605583	-108.26977279563692
1366.6857811246355	0.8761977379979555	0.8230000000000001	124	12	LAML	PACLITAXEL	Approved in same tumor type	TUBA1A|TP53|KRAS	1364.7187629063305	-54.08645922029447
829.1129345964868	-2.708096339806417	0.432	124	12	LAML	SARACATINIB	Clinical trials in cancer	IDH2|IDH1|KRAS	769.5574427297341	-43.34683762083648
1079.1740938001144	-0.04222313557946222	0.613	124	12	LAML	DAUNORUBICIN	Approved in other pathologies and in clinical trials in cancer	THRB|TP53|FLT3	1031.1888230323204	-133.5072703281407
1375.062066508902	5.007621702981879	0.8320000000000001	124	12	LAML	ALPELISIB	Approved in cancer	TP53|KRAS|NRAS	1380.6199022032508	-20.979395269355706
1355.1965449330698	4.888172574052959	0.8220000000000001	124	12	LAML	DABRAFENIB	Approved in cancer	TP53|KRAS|NRAS	1223.740361356865	21.64694281675989
1363.2151190987286	-7.831776853882417	0.8220000000000001	124	12	LAML	ABEMACICLIB	Approved in cancer	TP53|KRAS|NRAS	1252.7660504001187	-36.54100323955825
1341.9901460751562	4.359881367408889	0.812	124	12	LAML	CARBOPLATIN	Approved in cancer	TP53|KRAS|NRAS	1196.4329343352533	-66.46578940844616
1486.3580602546983	0.43451660127570335	0.916	124	12	LAML	PAZOPANIB	Approved in cancer	TP53|KRAS|KIT	1437.7946395456074	-147.79741469655204
1101.3259185024167	1.7750715511818953	0.632	124	12	LAML	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	TP53|KRAS|NRAS	1013.7903255062213	-56.85313461642836
830.9722078922941	7.1358445726502	0.432	124	12	LAML	GEDATOLISIB	Clinical trials in cancer	TP53|KRAS|NRAS	785.6410117381607	-107.19611679978594
836.895224275291	-3.8759675045817517	0.432	124	12	LAML	PIMASERTIB	Clinical trials in cancer	TP53|KRAS|NRAS	750.2568670846239	-34.942069143857225
806.1268607187386	-1.9742581263880083	0.412	124	12	LAML	ADAVOSERTIB	Clinical trials in cancer	TP53|KRAS|NRAS	796.1800638152556	-42.76753946643694
264.2587994579576	2.458670475504647	0.012	124	12	LAML	LY3009120	Clinical trials	TP53|KRAS|NRAS	156.3469299280559	-92.2287622669007
1359.1061760977495	-10.123604288383603	0.8220000000000001	124	11	LAML	ENTRECTINIB	Approved in cancer	NPM1|KIT|FLT3	1306.7166867963304	-42.34783254099577
960.0148465104376	0.4340033668144372	0.526	124	11	LAML	ENMD-2076	Clinical trials in cancer	NPM1|KIT|FLT3	924.6109076045457	-39.87380261112335
1355.4678825950946	-7.39466232894506	0.8220000000000001	124	11	LAML	DAUNORUBICIN HYDROCHLORIDE	Approved in same tumor type	THRB|IDH1|TP53	1247.8142514525762	-147.12583558774975
1357.446681168313	0.7474276659126247	0.8220000000000001	124	11	LAML	DOXORUBICIN HYDROCHLORIDE	Approved in same tumor type	THRB|IDH1|TP53	1311.8349147070476	-38.9828174320414
538.7299666880365	1.683037738153871	0.212	124	11	LAML	HEXACHLOROPHENE	Approved in other pathologies	THRB|IDH1|TP53	490.8616483784317	14.208938909557304
534.2190211941967	1.0930725197332265	0.212	124	11	LAML	TRIAMTERENE	Approved in other pathologies	THRB|IDH1|TP53	470.9123514673925	32.85454405283579
1372.3794122290371	8.878986580470809	0.8320000000000001	124	11	LAML	ENCORAFENIB	Approved in cancer	TP53|KRAS	1315.9535780673862	196.60648996027658
1361.990917030307	0.4789252538551523	0.8220000000000001	124	11	LAML	DOCETAXEL	Approved in cancer	TP53|KRAS	1289.9951686471366	-102.68815436112777
1364.5665938795219	-3.323011493043623	0.8230000000000001	124	11	LAML	DOXORUBICIN	Approved in same tumor type	TP53|KRAS	1237.3618089778467	71.60154481655292
1347.1022781372114	-3.3352813301651167	0.812	124	11	LAML	FLUOROURACIL	Approved in cancer	TP53|KRAS	1293.5342618078298	-35.5175190958675
1344.8137081904138	0.588871190860516	0.812	124	11	LAML	IRINOTECAN	Approved in cancer	TP53|KRAS	1334.870204580322	148.28334491786308
1105.8898925115575	2.938790264475955	0.633	124	11	LAML	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	TP53|KRAS	1045.253485271934	-57.835137988603876
835.5904928305235	8.073378817014884	0.432	124	11	LAML	CAPIVASERTIB	Clinical trials in cancer	TP53|KRAS	705.1213278142507	112.2283307664162
834.2292370220958	3.7377298976954876	0.432	124	11	LAML	NAVITOCLAX	Clinical trials in cancer	TP53|KRAS	720.0026829432244	-24.258977721914732
804.8266299792098	2.5542454647892043	0.412	124	11	LAML	DEMCIZUMAB	Clinical trials in cancer	TP53|KRAS	691.2349618138298	-12.879767259403053
837.6771109963603	0.7688000673449267	0.432	124	11	LAML	DS-7423	Clinical trials in cancer	TP53|KRAS	713.5999575118807	-120.60095611836161
941.1939729785536	0.4342413705805086	0.512	124	11	LAML	NVP-CGM097	Clinical trials in cancer	TP53|KRAS	868.249433840862	128.59014590824154
833.3846936933151	-0.7343491921393479	0.432	124	11	LAML	SAPANISERTIB	Clinical trials in cancer	TP53|KRAS	738.4859672202498	-63.02157740892791
249.95558775402898	-6.857902129529606	0.0004	124	11	LAML	ABT-737	Experimental	TP53|KRAS	173.3382840041441	-73.81342493674795
247.46363895927138	10.129015549918051	0.0004	124	11	LAML	PF-477736	Experimental	TP53|KRAS	158.70748476688044	56.99904476756353
1218.4418625236258	4.165897049356829	0.7180000000000001	124	10	LAML	ENASIDENIB	Approved in other pathologies and in clinical trials in cancer	IDH2|FLT3	1157.0413369144358	-3.3046217342843534
1502.4600315005625	0.43411014115400803	0.928	124	10	LAML	SORAFENIB	Approved in cancer	KIT|NRAS|FLT3	1504.9530769558398	-14.617142895396853
1359.7258600395992	4.491882891917044	0.8220000000000001	124	10	LAML	CERITINIB	Approved in cancer	NPM1|FLT3	1325.2939675796101	-16.730871718099365
245.99883553213002	-5.098371999342248	0.0004	124	10	LAML	1197958-12-5	Experimental	NPM1|FLT3	180.22813679922052	27.83816111681716
1363.9503071919128	4.494258022660318	0.8220000000000001	124	10	LAML	TAMOXIFEN	Approved in cancer	IDH1|TP53	1344.163491161407	-42.17642519387434
1363.564263712322	8.700580179519278	0.8220000000000001	124	10	LAML	MITOXANTRONE HYDROCHLORIDE	Approved in same tumor type	IDH1|TP53	1287.895334006237	-80.90191989692018
1346.5365397108014	4.622337138573698	0.812	124	10	LAML	TEMOZOLOMIDE	Approved in cancer	IDH1|TP53	1255.0412477475036	200.93481852682226
1075.6891253024248	2.8814349242144317	0.612	124	10	LAML	MERCAPTOPURINE	Approved in other pathologies and in clinical trials in cancer	IDH1|TP53	1005.4469194550755	138.64120039099953
1074.7873837220877	-1.2451905870914572	0.612	124	10	LAML	THIORIDAZINE HYDROCHLORIDE	Approved in other pathologies and in clinical trials in cancer	IDH1|TP53	1053.2859960062153	17.699597141089896
809.0804808920745	1.4857191858157819	0.412	124	10	LAML	FENRETINIDE	Clinical trials in cancer	IDH1|TP53	814.4634240793431	92.46849997200758
549.3320669687216	-2.1588375712958907	0.2219999999999999	124	10	LAML	CHLORPROMAZINE	Approved in other pathologies	IDH1|TP53	478.38974003596303	11.51479471828452
546.9352712473378	1.32091090292775	0.2219999999999999	124	10	LAML	PIMOZIDE	Approved in other pathologies	IDH1|TP53	498.2577932442203	-33.45572278253499
551.1458361563398	1.6575399927777994	0.2219999999999999	124	10	LAML	AZATHIOPRINE	Approved in other pathologies	IDH1|TP53	515.0917007392668	-7.944330398021748
541.1627657002575	-1.9700753338226775	0.212	124	10	LAML	PAROXETINE HYDROCHLORIDE	Approved in other pathologies	IDH1|TP53	469.3715008651718	-15.781289779818024
532.7972923823627	-3.059289310773977	0.212	124	10	LAML	PROCHLORPERAZINE	Approved in other pathologies	IDH1|TP53	490.4166541801808	-20.475979522205336
535.5141933147665	-6.298167641397612	0.212	124	10	LAML	SERTRALINE	Approved in other pathologies	IDH1|TP53	476.63157103076196	-20.392233149209062
536.9593063598418	-2.329058891614835	0.212	124	10	LAML	SERTRALINE HYDROCHLORIDE	Approved in other pathologies	IDH1|TP53	478.4062403207566	-18.40622284489484
264.26119546684396	-2.0895457080648896	0.012	124	10	LAML	TETRANDRINE	Clinical trials	IDH1|TP53	209.33918770028293	138.1929417248656
241.52349835594146	0.6886914855974453	0.0004	124	10	LAML	1,10-PHENANTHROLINE	Experimental	IDH1|TP53	179.90147139513397	0.021600443709132833
258.74676466642904	9.44073230073704	0.0004	124	10	LAML	148672-13-3	Experimental	IDH1|TP53	206.6378639546923	-48.32896867392182
257.2612442388873	-5.6491340018407925	0.0004	124	10	LAML	2,6-DIMETHOXY-1,4-BENZOQUINONE	Experimental	IDH1|TP53	239.48314028903005	-0.7864982982315212
242.08166066311497	-3.4927125078879726	0.0004	124	10	LAML	2-(PYRIDIN-2-YLAMINO)QUINOLIN-8-OL	Experimental	IDH1|TP53	165.89439036716885	-72.30725433360251
251.4760708779366	-15.301744644014633	0.0004	124	10	LAML	2-CHLOROADENOSINE	Experimental	IDH1|TP53	148.1133956058155	-26.129092001594927
249.3515738720279	-2.5269163333536824	0.0004	124	10	LAML	3-METHYLTOXOFLAVIN	Experimental	IDH1|TP53	251.64027628512824	-72.1115273936048
247.44881454967697	-13.650513838836986	0.0004	124	10	LAML	ALEXIDINE DIHYDROCHLORIDE	Experimental	IDH1|TP53	243.38518077076859	-10.946498871634759
244.85734616110057	3.2433682020583205	0.0004	124	10	LAML	ASTEMIZOLE	Experimental	IDH1|TP53	90.36866636104715	-77.35974302116882
256.6161343816696	-1.4939827420933511	0.0004	124	10	LAML	BENZETHONIUM CHLORIDE	Experimental	IDH1|TP53	277.91714084374524	-118.64360139852175
254.03908710601826	-8.376721515613923	0.0004	124	10	LAML	BROXYQUINOLINE	Experimental	IDH1|TP53	191.66381999963207	-94.27176148324817
254.38447647818415	15.218986466482647	0.0004	124	10	LAML	CHEMBL2002487	Experimental	IDH1|TP53	196.11126770104073	88.76946437524276
251.49882797346626	8.438410869379226	0.0004	124	10	LAML	CHEMBL405317	Experimental	IDH1|TP53	182.86708876393197	-46.94348653954722
252.09080457481178	4.25259374946981	0.0004	124	10	LAML	CLOFOCTOL	Experimental	IDH1|TP53	226.59641942638427	13.854423743851243
247.16375565185132	14.499307140855933	0.0004	124	10	LAML	DICHLOROPHEN	Experimental	IDH1|TP53	236.97941628019328	50.23490279867599
243.32053467329612	11.54106513196524	0.0004	124	10	LAML	DIIODOHYDROXYQUINOLINE	Experimental	IDH1|TP53	227.746032629845	-47.310293096292725
254.8455952458093	11.021998426221614	0.0004	124	10	LAML	ELLIPTICINE	Experimental	IDH1|TP53	243.244975001566	-11.19196643164804
244.05755527949557	7.381861613016923	0.0004	124	10	LAML	FENTICLOR	Experimental	IDH1|TP53	221.92398140654484	-56.603114999261464
254.8063761006801	-12.539480501400902	0.0004	124	10	LAML	GNF-PF-4029	Experimental	IDH1|TP53	181.69382239508647	28.977578095996364
250.8279645945234	-11.122273175874966	0.0004	124	10	LAML	KINETIN RIBOSIDE	Experimental	IDH1|TP53	216.27269745272787	51.651315339965976
259.9344360825261	1.0895816416551156	0.0004	124	10	LAML	MALONOBEN	Experimental	IDH1|TP53	206.95937447684418	-44.28479966567849
259.3357441124681	5.2710694066499855	0.0004	124	10	LAML	MANGOSTIN	Experimental	IDH1|TP53	198.12070292855455	-11.730538767429238
258.0177687122601	-9.800665481094313	0.0004	124	10	LAML	MICHLER'S KETONE	Experimental	IDH1|TP53	199.74286457520483	-31.679898993019492
242.68654891150734	-7.717669424192593	0.0004	124	10	LAML	MLS000073613	Experimental	IDH1|TP53	197.1669135960511	-107.51913240379423
246.50002432427993	-9.534144249933178	0.0004	124	10	LAML	N-OLEOYLDOPAMINE	Experimental	IDH1|TP53	234.27514132632177	67.29735077814979
250.97883051945192	12.712476312935081	0.0004	124	10	LAML	PIPERLONGUMINE	Experimental	IDH1|TP53	193.6907743861725	19.88422667234093
245.44052988080878	-0.9254363184508065	0.0004	124	10	LAML	PROPACHLOR	Experimental	IDH1|TP53	121.26765609270504	-26.254941684858892
256.00474065603686	2.6702851150058677	0.0004	124	10	LAML	RUFOCROMOMYCIN	Experimental	IDH1|TP53	182.61505365082706	118.53675959143959
253.3151336193205	-4.102597623601753	0.0004	124	10	LAML	SMR000031817	Experimental	IDH1|TP53	213.97100302681213	68.18667480867964
255.41152318050553	6.85045816946797	0.0004	124	10	LAML	SMR000080328	Experimental	IDH1|TP53	208.44613320524604	-49.93949207161893
248.77612584742678	1.6520767802122407	0.0004	124	10	LAML	THIOMERSAL	Experimental	IDH1|TP53	115.7339075008091	61.948430356971755
248.18858250622736	5.830759129639716	0.0004	124	10	LAML	TOXOFLAVIN	Experimental	IDH1|TP53	218.12243020549076	-98.18109108625323
252.68796818150028	0.07025353661305189	0.0004	124	10	LAML	DEGUELIN	Experimental	NPM1|KRAS	145.0007443616526	57.25815240161808
1412.350495039271	-61.97217313718288	0.8430000000000001	506	421	LGG	VENETOCLAX	Approved in cancer	PIK3CA|PTEN|TP53	1318.9415291983173	306.1087989883967
1157.0580846772423	0.8739533662734971	0.6719999999999999	506	413	LGG	DASATINIB	Approved in other pathologies and in clinical trials in cancer	FGFR1|PIK3CA|TP53	1140.0520586309985	190.63140231768438
1393.1492328806028	78.7475167016417	0.8420000000000001	506	406	LGG	OLAPARIB	Approved in cancer	PIK3CA|PTEN|TP53	1319.6232683864218	-304.4670910497213
1431.6334184432055	1.3219875972611987	0.8530000000000001	506	403	LGG	CISPLATIN	Approved in cancer	NRAS|PTEN|TP53	1427.7180310187655	-133.00212680203913
1408.5716658059544	24.643783777722774	0.8420000000000001	506	402	LGG	BEVACIZUMAB	Approved in same tumor type	KRAS|PIK3CA|TP53	1428.8769618295269	176.96221607511444
611.7401500741963	-30.41278168514748	0.252	506	401	LGG	GEMCITABINE	Approved in other pathologies	NRAS|PTEN|TP53	568.54219307268	78.31686328940845
874.5272042010824	0.4311256161873871	0.462	506	401	LGG	SARACATINIB	Clinical trials in cancer	IDH2|IDH1|KRAS	851.4808768949878	181.58498501094908
1511.8758600813776	-7.724636931625469	0.932	506	400	LGG	TAMOXIFEN	Approved in cancer	IDH1|PIK3CA|TP53	1526.959042406115	204.44027892580453
1422.4326590337503	-30.12340897435419	0.8420000000000001	506	400	LGG	TEMOZOLOMIDE	Approved in same tumor type	IDH1|PTEN|TP53	1232.262550548294	-212.72086583949198
253.42419245482793	109.83065546370801	0.0008	506	399	LGG	ISOCITRIC ACID	Experimental	IDH2|IDH1	272.41040592782446	162.16157664736153
259.5010782355858	-86.1717744385855	0.0004	506	399	LGG	ALKYLATING CHEMOTHERAPY	Experimental	IDH2|IDH1	194.41978122116913	-220.53290154646936
1116.9975560664147	56.17484561464906	0.632	506	398	LGG	METFORMIN	Approved in other pathologies and in clinical trials in cancer	KRAS|PIK3CA|PTEN	1097.8489798809555	212.25352225903703
1400.0687501813889	-6.651776546196743	0.8420000000000001	506	396	LGG	METHOTREXATE	Approved in cancer	IDH1|RB1|TP53	1345.6529089576554	287.1971272240082
1134.953915992843	-27.20817288441026	0.642	506	396	LGG	MERCAPTOPURINE	Approved in other pathologies and in clinical trials in cancer	IDH1|RB1|TP53	1067.9746144485198	198.40033940013785
1118.9562735498262	0.7835181273521812	0.633	506	395	LGG	AZACITIDINE	Approved in other pathologies and in clinical trials in cancer	IDH1|TP53|DNMT3A	1052.638919792314	-152.43635278686202
1380.0942645488778	-69.67812111616084	0.8320000000000001	506	394	LGG	DAUNORUBICIN HYDROCHLORIDE	Approved in cancer	AR|IDH1|TP53	1202.368430919565	258.4501663220352
1368.8538273918914	-14.336119995053707	0.8320000000000001	506	394	LGG	DOXORUBICIN HYDROCHLORIDE	Approved in cancer	AR|IDH1|TP53	1219.5189196175093	152.8676849423054
1385.2059995972327	47.11450948576555	0.8320000000000001	506	394	LGG	MITOXANTRONE HYDROCHLORIDE	Approved in cancer	AR|IDH1|TP53	1179.7850957772962	-74.34937430168901
1118.1445999360412	-54.69762292682955	0.632	506	394	LGG	THIORIDAZINE HYDROCHLORIDE	Approved in other pathologies and in clinical trials in cancer	IDH1|TP53	1071.3756813222099	230.0634620269904
968.2391190699989	0.43235790109659433	0.532	506	394	LGG	BERZOSERTIB	Clinical trials in cancer	IDH1|KRAS|TP53	899.9814657445087	-64.36324672985532
842.1132602860882	0.43072109953095605	0.432	506	394	LGG	FENRETINIDE	Clinical trials in cancer	MTOR|IDH1|TP53	737.2173735655282	-225.61506207332897
599.4340900075797	54.25314153879381	0.242	506	394	LGG	AZATHIOPRINE	Approved in other pathologies	HBB|IDH1|TP53	546.5335176482763	-2.9682471888792463
614.3532802746506	25.52253061473968	0.252	506	394	LGG	CHLORPROMAZINE	Approved in other pathologies	IDH1|TP53	568.1212655103268	-44.703244055176526
593.4820494443086	-57.36038764539444	0.2319999999999999	506	394	LGG	HEXACHLOROPHENE	Approved in other pathologies	AR|IDH1|TP53	517.1721356023622	89.88207974048402
561.4267009769964	-55.06534995676492	0.2319999999999999	506	394	LGG	PAROXETINE HYDROCHLORIDE	Approved in other pathologies	IDH1|TP53	533.8397059882806	36.34474268288204
597.0083133838139	-1.5377402671225013	0.242	506	394	LGG	PIMOZIDE	Approved in other pathologies	MTOR|IDH1|TP53	549.184217889383	108.66735473899922
582.2907961377139	27.099533204566285	0.2319999999999999	506	394	LGG	PROCHLORPERAZINE	Approved in other pathologies	IDH1|TP53	504.90496541564835	-75.07520602899588
579.409117564888	-28.496273268209706	0.2319999999999999	506	394	LGG	SERTRALINE	Approved in other pathologies	IDH1|TP53	509.4690588700183	-106.87424321120679
567.3119349094593	55.478071850368934	0.2319999999999999	506	394	LGG	SERTRALINE HYDROCHLORIDE	Approved in other pathologies	AR|IDH1|TP53	539.7483072781753	-59.49717036073005
564.935070169325	0.15801778173482717	0.2319999999999999	506	394	LGG	TRIAMTERENE	Approved in other pathologies	AR|IDH1|TP53	483.4420328870632	75.79979571194195
313.3629089867195	-3.9139942707495834	0.022	506	394	LGG	TETRANDRINE	Clinical trials	IDH1|TP53	294.9754078192778	190.4801807421402
269.54351585709077	-116.85713466933753	0.0004	506	394	LGG	1,10-PHENANTHROLINE	Experimental	MTOR|IDH1|TP53	86.77549608842371	-30.276741266165658
219.1600907536787	55.280601118544524	0.0004	506	394	LGG	148672-13-3	Experimental	MTOR|IDH1|TP53	143.4689733012284	215.5262958074897
234.1169060728937	26.967288998280992	0.0004	506	394	LGG	2,6-DIMETHOXY-1,4-BENZOQUINONE	Experimental	IDH1|TP53	238.2033430178385	-171.27226752897792
204.2199608371547	83.65278445502418	0.0004	506	394	LGG	2-(PYRIDIN-2-YLAMINO)QUINOLIN-8-OL	Experimental	IDH1|TP53	253.15566391456653	222.82801156113555
231.94101724733963	-28.319340093663982	0.0004	506	394	LGG	2-CHLOROADENOSINE	Experimental	IDH1|TP53	161.99467060045845	-222.87467841314592
291.76135150902115	-87.83699755786473	0.0004	506	394	LGG	3-METHYLTOXOFLAVIN	Experimental	NFE2L2|IDH1|TP53	202.0503349222224	204.88209981620042
281.28265882450654	-2.810464597467899	0.0004	506	394	LGG	ALEXIDINE DIHYDROCHLORIDE	Experimental	AR|IDH1|TP53	285.0526132084742	-141.77329013022575
285.6645359145282	108.30786542826331	0.0004	506	394	LGG	ASTEMIZOLE	Experimental	AR|IDH1|TP53	105.61518172973052	153.76069320311734
221.1662035325769	110.9370813029791	0.0004	506	394	LGG	BENZETHONIUM CHLORIDE	Experimental	AR|IDH1|TP53	179.18551481200163	-105.63874015552635
238.0986450982124	-110.3655337888775	0.0004	506	394	LGG	BROXYQUINOLINE	Experimental	IDH1|TP53	112.22489668481218	-186.86064676972651
187.03477771252514	56.59029430009139	0.0004	506	394	LGG	CHEMBL2002487	Experimental	NFE2L2|IDH1|TP53	317.01609961142645	5.297192033881117
206.14545903895453	-106.70008166030057	0.0004	506	394	LGG	CHEMBL405317	Experimental	IDH1|TP53	223.21998298138843	180.48481430254748
195.52452015207245	-23.951575754336744	0.0004	506	394	LGG	CLOFOCTOL	Experimental	IDH1|TP53	165.45994382240133	-47.96611753321113
266.2420902965323	25.61667064585012	0.0004	506	394	LGG	DICHLOROPHEN	Experimental	AR|IDH1|TP53	201.374387641792	-146.05343625371552
278.4628687130874	-58.61805416570678	0.0004	506	394	LGG	DIIODOHYDROXYQUINOLINE	Experimental	IDH1|TP53	168.55941003081782	-150.93579388352188
225.2441933181033	-80.93402125447669	0.0004	506	394	LGG	ELLIPTICINE	Experimental	HBB|IDH1|TP53	218.80730516637482	232.07485560771744
268.44472298877093	81.20188987224128	0.0004	506	394	LGG	FENTICLOR	Experimental	AR|IDH1|TP53	267.2310959382204	-184.51445901018153
236.31317603005812	82.43333873735406	0.0004	506	394	LGG	GNF-PF-4029	Experimental	IDH1|TP53	65.09023198801896	-85.12959815542246
201.91206661283132	28.232894932993617	0.0004	506	394	LGG	KINETIN RIBOSIDE	Experimental	NFE2L2|IDH1|TP53	252.12764044073413	11.72317501428958
310.4965141356761	-60.01385460226105	0.0004	506	394	LGG	MALONOBEN	Experimental	MTOR|IDH1|TP53	139.24938411870306	-110.1176038039645
191.64139149421348	-78.03163936335466	0.0004	506	394	LGG	MANGOSTIN	Experimental	IDH1|TP53	120.23902668978444	-155.95410115506712
300.549459997605	79.83971598464143	0.0004	506	394	LGG	MICHLER'S KETONE	Experimental	AR|IDH1|TP53	71.80664060316556	107.16976236045917
315.4420621952972	51.31281943511681	0.0004	506	394	LGG	MLS000073613	Experimental	IDH1|TP53	75.82962139772978	-115.41730038799876
246.43453201923452	-56.779730556149275	0.0004	506	394	LGG	N-OLEOYLDOPAMINE	Experimental	MTOR|IDH1|TP53	305.0539029165493	117.80339097078695
251.2370693122751	53.987750246577235	0.0004	506	394	LGG	PIPERLONGUMINE	Experimental	IDH1|TP53	69.64149132641057	55.58691874414555
217.016756530854	-0.133086049496427	0.0004	506	394	LGG	PROPACHLOR	Experimental	AR|IDH1|TP53	156.97970377236112	165.05936704787024
210.7423897663905	-52.17345450484024	0.0004	506	394	LGG	RUFOCROMOMYCIN	Experimental	NFE2L2|IDH1|TP53	175.47193279008002	82.60037759655478
296.103978823122	-31.286198293078712	0.0004	506	394	LGG	SMR000031817	Experimental	IDH1|TP53	260.6838071294217	95.57915450965959
264.00643351489504	-29.90397248288437	0.0004	506	394	LGG	SMR000080328	Experimental	IDH1|TP53	252.974089698258	190.70861917154207
249.11874094705493	-1.4109819104808423	0.0004	506	394	LGG	THIOMERSAL	Experimental	AR|IDH1|TP53	323.1397265573422	-76.96312617391271
283.3570484734696	52.673391108875336	0.0004	506	394	LGG	TOXOFLAVIN	Experimental	NFE2L2|IDH1|TP53	272.0393668929339	-56.852175607796966
1362.090130031078	69.27806278327202	0.8220000000000001	506	391	LGG	RUCAPARIB	Approved in cancer	IDH1|PTEN	1295.8735868363835	-156.8117195896614
1354.4285151172644	38.311013745815984	0.8220000000000001	506	391	LGG	FLOXURIDINE	Approved in cancer	IDH1|PIK3CA	1191.9906392051462	213.58052576701255
1323.6029366738164	30.005681537920225	0.8220000000000001	506	391	LGG	NIRAPARIB	Approved in cancer	IDH1|PTEN	1187.098807288784	182.90413485550584
1329.6476554254666	-53.030571322396696	0.8220000000000001	506	391	LGG	TALAZOPARIB	Approved in cancer	IDH1|PTEN	1264.9591381806615	162.83183844776852
298.20172645859793	24.293322605660308	0.0004	506	391	LGG	A-443654	Experimental	IDH1|KRAS|PIK3CA	55.88492006745426	-37.032664956480744
1416.1899620117943	55.96312497769094	0.8520000000000001	506	389	LGG	VANDETANIB	Approved in cancer	KRAS|FGFR1|PTEN	1377.847168540291	290.69304316348604
1227.3631166319688	0.43597653196289343	0.7240000000000001	506	385	LGG	DECITABINE	Approved in other pathologies and in clinical trials in cancer	IDH1|DNMT3A	1154.2480061725064	69.88199910858319
671.0434820299823	0.4358048847256555	0.312	506	385	LGG	MICONAZOLE	Approved in other pathologies	CACNA1C|IDH1	610.962608136003	43.22162343213927
1484.77372160673	9.266720698094133	0.918	506	384	LGG	IVOSIDENIB	Approved in cancer	IDH1	1547.1376267445432	16.59304226565598
1346.1057076760749	7.771073714748553	0.8220000000000001	506	384	LGG	EPIRUBICIN HYDROCHLORIDE	Approved in cancer	NFE2L2|IDH1	1184.180335881852	-202.07482216407675
1331.7058866166676	60.538332832767935	0.8220000000000001	506	384	LGG	ESTRADIOL VALERATE	Approved in cancer	AR|IDH1	1315.9658186383	237.86230874512523
1390.6672909011088	-37.32895795617259	0.8320000000000001	506	384	LGG	IMATINIB MESYLATE	Approved in cancer	IDH1	1256.0805545555922	272.59695837354377
1315.870114184492	-0.6240153224482867	0.8220000000000001	506	384	LGG	LOMUSTINE	Approved in same tumor type	IDH1	1183.2096471853506	115.31779566776714
1349.3798816151966	-77.73188268367646	0.8220000000000001	506	384	LGG	RALOXIFENE HYDROCHLORIDE	Approved in cancer	AR|IDH1	1225.4321819563952	279.56442802388403
1360.248801146274	-44.91504730223056	0.8320000000000001	506	384	LGG	TIOGUANINE	Approved in cancer	HBB|AR|IDH1	1259.8752410731267	102.4579646127188
1338.2126474657903	-22.60794828542413	0.8220000000000001	506	384	LGG	TOPOTECAN HYDROCHLORIDE	Approved in cancer	HBB|AR|IDH1	1239.710752551958	56.23617016106917
1377.1155601611713	16.27491768287271	0.8320000000000001	506	384	LGG	VINBLASTINE SULFATE	Approved in cancer	AR|IDH1	1426.9922213706354	208.6097197936797
1055.772723342044	-0.20059646340095583	0.622	506	384	LGG	6-MERCAPTOPURINE MONOHYDRATE	Approved in other pathologies and in clinical trials in cancer	IDH1	1065.291492065904	-28.48987913124043
1070.9631476206173	27.17644726587838	0.622	506	384	LGG	DIGOXIN	Approved in other pathologies and in clinical trials in cancer	NFE2L2|AR|IDH1	1037.2461686703064	-230.6485803152029
1133.6515598026745	28.960949546528184	0.642	506	384	LGG	ETACRYNIC ACID	Approved in other pathologies and in clinical trials in cancer	NFE2L2|AR|IDH1	1087.7621734270974	-77.40961354326966
1085.1094675270667	55.1733041287153	0.622	506	384	LGG	FLUPHENAZINE DIHYDROCHLORIDE	Approved in other pathologies and in clinical trials in cancer	IDH1	1038.881379662603	-9.26473911282514
1071.7593179419537	-27.120306630433703	0.622	506	384	LGG	IDARUBICIN HYDROCHLORIDE	Approved in other pathologies and in clinical trials in cancer	AR|IDH1	1050.9977883093145	124.83695077039971
1086.3961565915188	-54.86349354727177	0.622	506	384	LGG	LOPERAMIDE HYDROCHLORIDE	Approved in other pathologies and in clinical trials in cancer	IDH1	1010.6988533583209	-4.107778879051267
1102.314964138574	27.8579956852829	0.632	506	384	LGG	LOVASTATIN	Approved in other pathologies and in clinical trials in cancer	IDH1	1085.6581834077226	-5.944159374086723
1087.156382215711	0.2810809397724654	0.622	506	384	LGG	PYRIMETHAMINE	Approved in other pathologies and in clinical trials in cancer	AR|IDH1	1068.9744609198938	-194.8557724282614
1103.122101761699	-26.730858037869808	0.632	506	384	LGG	SIMVASTATIN	Approved in other pathologies and in clinical trials in cancer	NFE2L2|AR|IDH1	1079.1368874846269	116.09137285658664
814.497537382894	16.108961014057627	0.422	506	384	LGG	5-FLUOROURIDINE	Clinical trials in cancer	NFE2L2|HBB|IDH1	674.7563774205885	76.404494312856
814.497265022803	-15.247038984759513	0.422	506	384	LGG	CINOBUFOTALIN	Clinical trials in cancer	NFE2L2|IDH1	686.6032391706416	184.04191087520655
516.2709997536795	-24.110968312637198	0.2219999999999999	506	384	LGG	AMCINONIDE	Approved in other pathologies	AR|IDH1	473.1972264621761	-76.71259518831398
552.0886458149507	83.3662672598735	0.2219999999999999	506	384	LGG	AZELASTINE HYDROCHLORIDE	Approved in other pathologies	IDH1	477.79590981327937	-107.60769917957674
519.0686179675085	30.126270124978817	0.2219999999999999	506	384	LGG	CHLORHEXIDINE	Approved in other pathologies	AR|IDH1	442.8288865004438	-18.097247014045365
535.5881234135529	56.74577988894927	0.2219999999999999	506	384	LGG	CHLORPROMAZINE HYDROCHLORIDE	Approved in other pathologies	AR|IDH1	460.56120458073116	97.7466593715854
550.4159647418209	28.446013196065394	0.2219999999999999	506	384	LGG	CICLOPIROX OLAMINE	Approved in other pathologies	AR|IDH1	445.4348026385105	-62.21233309423444
502.0060154667981	3.8151881709620454	0.2219999999999999	506	384	LGG	FLUVASTATIN	Approved in other pathologies	IDH1	490.5400185392752	106.85031060929413
547.5701994483927	-26.47456557262055	0.2219999999999999	506	384	LGG	GALANTHAMINE HYDROBROMIDE	Approved in other pathologies	IDH1	502.6714095795201	43.011878111401984
529.8109654425566	-52.35209924812827	0.2219999999999999	506	384	LGG	MEFLOQUINE HYDROCHLORIDE	Approved in other pathologies	AR|IDH1	458.3148412950676	9.41247352788858
533.3196664219324	2.1860781449652507	0.2219999999999999	506	384	LGG	METHYLTHIONINIUM CHLORIDE	Approved in other pathologies	NFE2L2|AR|IDH1	487.0765378657657	-48.739265678138
542.911497103988	-80.84025121480607	0.2219999999999999	506	384	LGG	MICONAZOLE NITRATE	Approved in other pathologies	IDH1	487.07336047460115	-2.949267722231042
1518.6446263076941	0.43516041456882704	0.94	367	111	LIHC	TRAMETINIB	Approved in cancer	NF1|RB1|STK11	1549.439873099963	-1.815461343564806
1397.8139251024888	-7.489067101203034	0.8510000000000001	367	93	LIHC	CICLOPHOSPHAMIDE	Approved in cancer	BRCA2|CTNNB1|TP53	1360.5036410076807	301.70859224003436
243.34661388988798	-17.820578837307238	0.0004	367	93	LIHC	SMR000031817	Experimental	CTNNB1|IDH1|TP53	155.48096834698276	-65.70399382238321
1453.865268486587	-2.6814228314126183	0.892	367	75	LIHC	CISPLATIN	Approved in cancer	NRAS|TP53|STK11	1489.8457294781074	-19.94902082222987
1368.960421121209	-0.864216821135642	0.8320000000000001	367	72	LIHC	CARBOPLATIN	Approved in cancer	KRAS|NRAS|TP53	1320.2077646801729	-173.1343077086596
1330.485899494541	0.42622675424567547	0.8	367	72	LIHC	DASATINIB	Approved in other pathologies and in clinical trials in cancer	KRAS|APC|TP53	1393.6132504342524	-16.054588554850653
957.5169259385432	0.4055073360312349	0.524	367	72	LIHC	SAPANISERTIB	Clinical trials in cancer	TP53|RB1|STK11	903.3582312400519	-80.58781268934278
1130.1197914646552	0.43218420647832545	0.652	367	71	LIHC	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	TP53|NF1|STK11	1108.4612452418528	-52.663466139330836
1405.5134963870437	-1.2943583488775232	0.8530000000000001	367	70	LIHC	PACLITAXEL	Approved in cancer	SMAD4|KRAS|TP53	1340.2827173760897	-14.962167034309005
974.275260065152	4.5789764788173954	0.536	367	70	LIHC	MIRDAMETINIB	Clinical trials in cancer	NRAS|TP53|STK11	920.7912477715983	-147.40995008281962
562.9679248612024	-3.407559133402515	0.2319999999999999	367	70	LIHC	GEMCITABINE	Approved in other pathologies	KRAS|NRAS|TP53	510.77873391650115	109.15508181345075
1586.223142131079	0.43371767269729844	0.99	367	69	LIHC	ALPELISIB	Approved in cancer	KRAS|NRAS|TP53	1572.3199368234004	-147.69015903212804
1042.4338127850583	0.43113482786861823	0.587	367	69	LIHC	GEDATOLISIB	Clinical trials in cancer	NRAS|TP53|STK11	1035.045953753353	-71.32591729692456
1397.7835576679345	2.288040583199887	0.8520000000000001	367	68	LIHC	BORTEZOMIB	Approved in cancer	KRAS|TP53|RB1	1261.5342162005059	-217.98210981706535
1388.5820695899222	-10.68896540997062	0.8420000000000001	367	68	LIHC	VENETOCLAX	Approved in cancer	PTEN|KRAS|TP53	1325.6325624187748	-99.32366901359494
1389.7541925540474	14.113369568140769	0.8420000000000001	367	67	LIHC	BEVACIZUMAB	Approved in same tumor type	PIK3CA|KRAS|TP53	1342.8114847786471	105.20196782891003
1218.469890668046	0.7276015781520186	0.7180000000000001	367	67	LIHC	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	APC|TP53|RB1	1138.309421625992	76.40731009756922
974.3173078783578	-3.8879465541903926	0.536	367	67	LIHC	PIMASERTIB	Clinical trials in cancer	NRAS|TP53|NF1	932.4700900886871	-71.06866427589458
1368.85421720238	7.651724012399228	0.8320000000000001	367	66	LIHC	OLAPARIB	Approved in cancer	PTEN|KRAS|TP53	1275.97675086736	137.80352374396836
1382.3350096573845	-5.225035084038865	0.8410000000000001	367	66	LIHC	FLUOROURACIL	Approved in cancer	KRAS|APC|TP53	1250.745688235185	-144.42493061310748
1397.40444634819	10.642034027373569	0.8520000000000001	367	66	LIHC	DOXORUBICIN	Approved in cancer	KRAS|TP53|KMT2A	1387.5567164023	-114.26981808735565
941.0468318346161	4.069138546451029	0.512	367	66	LIHC	DS-7423	Clinical trials in cancer	PTEN|KRAS|TP53	874.4017707077242	-61.82171211363415
1480.9536769843546	0.44428545986124846	0.912	367	65	LIHC	DABRAFENIB	Approved in cancer	KRAS|NRAS|TP53	1411.3686357773638	166.8273460433581
1373.6993791425145	-13.842969979822811	0.8320000000000001	367	65	LIHC	IRINOTECAN	Approved in cancer	SMAD4|KRAS|TP53	1334.3532047433955	240.56697487118373
859.8796868722146	-2.968455907891922	0.452	367	65	LIHC	CAPIVASERTIB	Clinical trials in cancer	PTEN|KRAS|TP53	805.0780156324184	-82.00087296588552
1372.7489069906749	14.740479303299509	0.8320000000000001	367	64	LIHC	TOPOTECAN	Approved in cancer	PTEN|TP53|RB1	1183.4787991742228	-55.75368109567218
887.1439390504519	0.4382542714170654	0.472	367	64	LIHC	NAVITOCLAX	Clinical trials in cancer	PTEN|KRAS|TP53	859.5020765198575	199.11418362889668
244.9183299920909	2.1513164926544732	0.0004	367	64	LIHC	ABT-737	Experimental	PTEN|KRAS|TP53	191.05080924279602	188.94228313246379
1404.501376905852	6.888026115520887	0.8530000000000001	367	63	LIHC	VEMURAFENIB	Approved in cancer	PTEN|NRAS|TP53	1498.8041035515962	-16.999775690887276
1594.3611421301334	0.43359362493313824	0.996	367	62	LIHC	PAZOPANIB	Approved in cancer	BRCA2|KRAS|TP53	1590.9607424436658	-73.05944359713358
1356.4278585885775	8.238082726172905	0.8220000000000001	367	62	LIHC	PEMBROLIZUMAB	Approved in same tumor type	KRAS|NRAS|TP53	1299.4282572928676	-19.787324548967433
981.3453886570398	0.4228103723715151	0.542	367	62	LIHC	NVP-CGM097	Clinical trials in cancer	PIK3CA|KRAS|TP53	899.7985389880083	-82.84946379565577
943.0251471727365	-3.655558497637344	0.513	367	62	LIHC	BERZOSERTIB	Clinical trials in cancer	IDH1|KRAS|TP53	881.74700531312	-138.36216024958705
817.2330414163341	0.5567596832872255	0.422	367	62	LIHC	DEMCIZUMAB	Clinical trials in cancer	PIK3CA|KRAS|TP53	783.7238571304124	4.452741984960824
240.84505815668783	16.643760590290327	0.0004	367	62	LIHC	1173900-33-8	Experimental	PIK3CA|PTEN|TP53	188.0416729831694	106.311508368163
1377.0421333244285	0.672178254536334	0.8320000000000001	367	61	LIHC	VORINOSTAT	Approved in cancer	PTEN|TP53|RB1	1304.862943048393	66.81186888162006
832.9733842473989	0.4479095973340179	0.432	367	61	LIHC	ADAVOSERTIB	Clinical trials in cancer	NRAS|TP53|STK11	727.9925264609218	52.59540025835
248.30295402731758	14.773812848301077	0.0004	367	61	LIHC	93718-83-3	Experimental	MTOR|TP53|KMT2A	87.65223378983383	46.85763083554983
1494.0535320828023	0.43724476147673386	0.922	367	60	LIHC	ENCORAFENIB	Approved in cancer	PTEN|KRAS|TP53	1447.5145752427245	-51.33287809401841
1544.3383090801633	0.43417555970717103	0.959	367	60	LIHC	TAMOXIFEN	Approved in cancer	IDH1|PIK3CA|TP53	1477.1016045745093	-71.96721139950414
1390.8793972228964	6.271680202868112	0.8420000000000001	367	60	LIHC	ERLOTINIB	Approved in cancer	PTEN|APC|TP53	1298.4042778388916	-29.290166905098772
1384.427446318772	2.3586916804053715	0.8420000000000001	367	60	LIHC	METHOTREXATE	Approved in cancer	IDH1|TP53|RB1	1364.0724824284275	-14.054157720105394
1089.827634687782	0.43057723777710066	0.622	367	60	LIHC	MERCAPTOPURINE	Approved in other pathologies and in clinical trials in cancer	IDH1|TP53|RB1	1000.0668816870801	58.38019146528376
279.0688015158814	3.833044368634063	0.022	367	60	LIHC	LY3009120	Clinical trials	KRAS|NRAS|TP53	278.75953605238885	-122.94320883656036
1389.7850299895078	-2.8621345330319343	0.8420000000000001	367	59	LIHC	ABEMACICLIB	Approved in cancer	KRAS|NRAS|TP53	1309.779816495316	-287.8479457610009
1406.937895161482	-9.191740988031285	0.8520000000000001	367	59	LIHC	DOCETAXEL	Approved in cancer	PIK3CA|KRAS|TP53	1392.9654186426935	-14.494835313045257
967.5698884604712	0.15899737907395206	0.533	367	59	LIHC	RESVERATROL	Clinical trials in cancer	ESR1|PIK3CA|TP53	905.8340706612154	-3.1647406955200097
861.8450026390061	4.536482328815993	0.453	367	59	LIHC	SELICICLIB	Clinical trials in cancer	TP53|RB1|DYRK1A	724.9544585685411	5.838005240644293
817.9805976942297	-7.001012886940089	0.422	367	59	LIHC	TANESPIMYCIN	Clinical trials in cancer	MTOR|PIK3CA|TP53	712.0830038512487	-2.445449374045296
292.5547615964408	-2.9156343181093973	0.032	367	59	LIHC	EMODIN	Clinical trials	NFE2L2|PIK3CA|TP53	305.2820050182358	73.71927124228534
257.2965755516471	-12.814549269168936	0.0004	367	59	LIHC	CHEMBL2002487	Experimental	GNAS|IDH1|TP53	254.73485133283748	-143.71906175804895
1453.8646173595157	5.566577142886217	0.892	367	58	LIHC	DUVELISIB	Approved in cancer	PIK3CA|TP53	1533.8008819178674	5.8767274540291226
1355.5432393491428	-7.6353688127007615	0.8220000000000001	367	58	LIHC	CRIZOTINIB	Approved in cancer	SMAD4|KRAS|TP53	1310.308160147522	-162.76578351926838
1376.593846960231	8.13928784822636	0.8320000000000001	367	58	LIHC	DAUNORUBICIN HYDROCHLORIDE	Approved in cancer	IDH1|TP53|KMT2A	1341.497521218637	-66.01601151458344
1501.4835320233487	0.4363048258337585	0.927	367	58	LIHC	RALOXIFENE	Approved in cancer	ESR1|PIK3CA|TP53	1490.6259332037828	114.351943217584
699.5740292096591	0.4336780464953165	0.3330000000000001	367	58	LIHC	HEXACHLOROPHENE	Approved in other pathologies	PAX8|IDH1|TP53	635.6955943933397	-2.4674192740175727
1362.3104100569058	3.609435975008523	0.8220000000000001	367	57	LIHC	DOXORUBICIN HYDROCHLORIDE	Approved in cancer	PAX8|IDH1|TP53	1270.4399819201697	237.1613630380633
1355.6896988329854	0.7446539568804269	0.8220000000000001	367	57	LIHC	LORLATINIB	Approved in cancer	TP53|RB1	1362.759035480648	-175.87688963214637
549.9604316814766	-5.603991487017282	0.2219999999999999	367	57	LIHC	TRIAMTERENE	Approved in other pathologies	JAK2|IDH1|TP53	529.0840769192907	-43.03228347113097
262.2948043536397	10.530399971808095	0.0004	367	57	LIHC	1,10-PHENANTHROLINE	Experimental	MTOR|IDH1|TP53	197.8853423676539	85.2105283382902
255.3867463033785	12.624332212416022	0.0004	367	57	LIHC	3-METHYLTOXOFLAVIN	Experimental	GALK1|IDH1|TP53	194.2592103872978	-128.49379703764257
250.20237872145563	7.588593283786253	0.0004	367	57	LIHC	GNF-PF-4029	Experimental	IDH1|TP53|KMT2A	190.201415466096	71.7566354215015
243.12302745488304	9.503478024878092	0.0004	367	57	LIHC	KINETIN RIBOSIDE	Experimental	PAX8|IDH1|TP53	185.06151002242396	-141.33772299680982
262.2390183495386	-7.436851556340287	0.0004	367	57	LIHC	MALONOBEN	Experimental	MTOR|IDH1|TP53	151.2126549610776	-85.92542331569987
238.82387963322054	-2.36279676538976	0.0004	367	57	LIHC	PF-477736	Experimental	KRAS|TP53	241.99996806729905	93.55064027245959
259.55090480215404	-19.771177352856625	0.0004	367	57	LIHC	RUFOCROMOMYCIN	Experimental	ATM|IDH1|TP53	190.45440538390014	-121.19908442305584
252.48956210173787	-18.313471624108246	0.0004	367	57	LIHC	TOXOFLAVIN	Experimental	GALK1|IDH1|TP53	175.70368066631752	-87.67464968682945
1374.7704719443748	-6.328728520694881	0.8320000000000001	367	56	LIHC	MITOXANTRONE HYDROCHLORIDE	Approved in cancer	PAX8|IDH1|TP53	1349.1794459370842	99.62797327184995
1361.45311499457	-3.5003427197129895	0.8220000000000001	367	56	LIHC	TEMOZOLOMIDE	Approved in cancer	IDH1|PTEN|TP53	1326.5397007497959	124.08190730734532
1103.149128010226	3.8965604448738134	0.632	367	56	LIHC	AZACITIDINE	Approved in other pathologies and in clinical trials in cancer	NFE2L2|IDH1|TP53	1077.286683293368	182.53940825549915
817.6670056961814	7.974657552656026	0.422	367	56	LIHC	FENRETINIDE	Clinical trials in cancer	MTOR|IDH1|TP53	714.8462897675699	99.73635556916764
576.3424891929159	4.032086493416017	0.242	367	56	LIHC	AZATHIOPRINE	Approved in other pathologies	NFE2L2|IDH1|TP53	519.655139765131	-60.29441398871137
576.3777690270272	-3.071825902813657	0.242	367	56	LIHC	PIMOZIDE	Approved in other pathologies	MTOR|IDH1|TP53	523.3222379690973	-70.65838093865753
252.2792775316263	0.5327607987997283	0.0004	367	56	LIHC	148672-13-3	Experimental	MTOR|IDH1|TP53	201.79557737236422	-35.459411569508404
249.30647944641868	-24.72478573810335	0.0004	367	56	LIHC	BENZETHONIUM CHLORIDE	Experimental	ESR1|IDH1|TP53	220.59134840494266	-163.10861908524157
259.23829389580976	-0.9574914000397143	0.0004	367	56	LIHC	DICHLOROPHEN	Experimental	ESR1|IDH1|TP53	210.9876644424304	36.690124258421434
251.55110855006293	26.317639223083148	0.0004	367	56	LIHC	DIIODOHYDROXYQUINOLINE	Experimental	PAX8|IDH1|TP53	243.5400228809445	37.61881238508661
249.99887955934804	-11.567843363079731	0.0004	367	56	LIHC	ELLIPTICINE	Experimental	NFE2L2|IDH1|TP53	250.27817604434057	-25.87610374003262
260.6388701032528	17.486249289996806	0.0004	367	56	LIHC	FENTICLOR	Experimental	NFE2L2|IDH1|TP53	280.54940838180266	-41.76864122444937
253.8575572654998	19.602994264238475	0.0004	367	56	LIHC	N-OLEOYLDOPAMINE	Experimental	MTOR|IDH1|TP53	162.11781647881094	93.65042787077977
247.64939744947873	-4.84371293327294	0.0004	367	56	LIHC	PIPERLONGUMINE	Experimental	PAX8|IDH1|TP53	168.10876683422705	179.8982817581412
241.81020951799883	-8.85898513894054	0.0004	367	56	LIHC	PROPACHLOR	Experimental	ESR1|IDH1|TP53	139.29424063245875	71.42710724686395
237.81840767180896	4.707473168744912	0.0004	367	56	LIHC	TRACAZOLATE	Experimental	CREBBP|TP53|KMT2A	246.22501891895791	-154.78110318671338
1383.6071177717417	9.571417787613797	0.8420000000000001	367	55	LIHC	ETOPOSIDE	Approved in cancer	ATM|BRCA2|TP53	1434.8912479593653	-117.3487767395602
1368.1451090751127	-8.738513885382929	0.8320000000000001	367	55	LIHC	PANITUMUMAB	Approved in cancer	MAP2K1|PTEN|TP53	1306.8106580678225	32.97770586723479
1226.0852593200766	0.000511285657779581	0.7220000000000001	367	55	LIHC	LOPERAMIDE	Approved in other pathologies and in clinical trials in cancer	CACNA1A|MTOR|TP53	1164.484411081797	55.16528193482853
1103.1495126970117	-3.1534395446308565	0.632	367	55	LIHC	THIORIDAZINE HYDROCHLORIDE	Approved in other pathologies and in clinical trials in cancer	IDH1|TP53	1052.5499162486465	-22.341301123262866
823.8208422958553	-2.7682582044983235	0.422	367	55	LIHC	AZD6738	Clinical trials in cancer	ATM|BRCA2|TP53	797.078079346008	-58.668907426971884
823.6359585302023	4.225298400920138	0.422	367	55	LIHC	ONC201	Clinical trials in cancer	PTEN|TP53	704.8005165359068	-1.1097486313216791
566.7081425332245	3.4530038755236205	0.2319999999999999	367	55	LIHC	CHLORPROMAZINE	Approved in other pathologies	IDH1|TP53	502.6823756406667	-37.83301608010842
546.4545148936268	0.5760268624977414	0.2219999999999999	367	55	LIHC	PAROXETINE HYDROCHLORIDE	Approved in other pathologies	IDH1|TP53	496.0920959917718	61.002196000800154
559.7165445419193	3.697824266601714	0.2319999999999999	367	55	LIHC	PROCHLORPERAZINE	Approved in other pathologies	IDH1|TP53	497.7811966773269	89.09406346894161
553.4517272172595	0.5841630461841021	0.2219999999999999	367	55	LIHC	SERTRALINE	Approved in other pathologies	IDH1|TP53	468.2981956821985	-7.200375303705044
549.9479852114919	6.6395579924914045	0.2219999999999999	367	55	LIHC	SERTRALINE HYDROCHLORIDE	Approved in other pathologies	IDH1|TP53	485.20705847570196	37.65036843431096
292.5615668020555	4.298362472101729	0.032	367	55	LIHC	INOSITOL	Clinical trials	NRAS|TP53	207.78448939040615	-42.650614005069286
279.0819798057459	-3.434943683961535	0.022	367	55	LIHC	TETRANDRINE	Clinical trials	IDH1|TP53	217.7040155886748	-37.37563520466966
264.44029571517433	3.777220868815675	0.0004	367	55	LIHC	2,6-DIMETHOXY-1,4-BENZOQUINONE	Experimental	IDH1|TP53	338.98575823692227	-68.31662266234225
254.56015480189882	-6.174514774994009	0.0004	367	55	LIHC	2-(PYRIDIN-2-YLAMINO)QUINOLIN-8-OL	Experimental	IDH1|TP53	210.4820030932721	62.381570165542854
257.05032874716346	5.73859905909751	0.0004	367	55	LIHC	2-CHLOROADENOSINE	Experimental	IDH1|TP53	193.22961157506688	81.64247468497666
246.17385673391064	21.754140578349222	0.0004	367	55	LIHC	ALEXIDINE DIHYDROCHLORIDE	Experimental	IDH1|TP53	84.45919718625089	-10.720747161239842
1530.970899194996	-10.465798893842162	0.95	497	288	LUAD	TRAMETINIB	Approved in same tumor type	NF1|RB1|STK11	1585.7348741947487	88.88763772508497
1186.8777794385455	11.738442891382533	0.694	497	282	LUAD	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	TP53|NF1|STK11	1145.4497354652522	95.31995957662474
1065.06874917703	-10.129759016101389	0.597	497	277	LUAD	GEDATOLISIB	Clinical trials in cancer	PTEN|TP53|STK11	988.0621763770496	-138.01160377351925
1032.650980356908	-1.5925611015101993	0.586	497	274	LUAD	PIMASERTIB	Clinical trials in cancer	NRAS|TP53|NF1	960.2657168731038	71.0740377595036
1186.878815978695	-11.595557085594947	0.694	497	273	LUAD	DASATINIB	Approved in other pathologies and in clinical trials in cancer	KRAS|HRAS|TP53	1148.1704455269683	161.0072797076333
1459.5211719984263	-38.827690290298534	0.892	497	270	LUAD	FLUOROURACIL	Approved in cancer	PTEN|TP53|ATM	1477.0056257032181	-129.68832660836898
1612.3916490072488	-6.1839098955720715	1	497	269	LUAD	DABRAFENIB	Approved in same tumor type	NRAS|HRAS|TP53	1609.4128027856245	-30.05191138958557
1421.9180100049066	19.479947905292335	0.8720000000000001	497	268	LUAD	IRINOTECAN	Approved in cancer	BRCA2|SMAD4|ATM	1410.8291948155654	80.83387354118992
1463.5578759732134	16.85684460973016	0.892	497	266	LUAD	BEVACIZUMAB	Approved in same tumor type	KRAS|HRAS|TP53	1437.6781617866645	-71.17052430483491
1601.5409014779593	-26.139538757890307	0.999	497	261	LUAD	ENCORAFENIB	Approved in cancer	KRAS|PTEN|TP53	1663.3508589210219	-0.7503457283675061
1467.645920396731	38.63170431764681	0.893	497	260	LUAD	PACLITAXEL	Approved in same tumor type	BRCA2|SMAD4|ATM	1413.4274883959747	-108.50462837980498
254.3073603726823	-21.770315551767567	0.0004	497	258	LUAD	PF-477736	Experimental	CDKN2A|KRAS|TP53	120.8499867799272	-129.04434631686001
1442.329359683999	11.090469314998472	0.892	497	256	LUAD	CARBOPLATIN	Approved in cancer	TP53|BRCA2|SMAD4	1507.6964586436522	51.40014706110739
1396.8359472307418	-4.0338326895395085	0.8520000000000001	497	255	LUAD	PEMBROLIZUMAB	Approved in same tumor type	KRAS|NRAS|TP53	1253.6621948404193	40.048814056466796
1447.0426586726896	32.02533920863908	0.893	497	253	LUAD	CISPLATIN	Approved in cancer	SMAD4|ATM|STK11	1493.6773575826062	17.703925410766686
968.1099854500095	8.881484941503317	0.534	497	253	LUAD	SAPANISERTIB	Clinical trials in cancer	SMAD4|RB1|STK11	901.329423709375	-202.44405401799466
1031.8383699143349	20.522188145340095	0.586	497	251	LUAD	MIRDAMETINIB	Clinical trials in cancer	PTEN|TP53|STK11	979.2316529711848	-240.50671636173377
1603.4558799018753	30.816660242198054	1	497	245	LUAD	ALPELISIB	Approved in cancer	PTEN|HRAS|TP53	1609.39820656591	-111.12905313309867
603.764310451362	0.43278223416231754	0.262	497	245	LUAD	GEMCITABINE	Approved in other pathologies	BRCA1|TP53|SMAD4	580.2150813232693	4.2229362289436665
1505.5884263719474	-12.770510518941649	0.93	497	244	LUAD	CRIZOTINIB	Approved in same tumor type	KRAS|TP53|SMAD4	1517.6963195270375	-109.5708010807923
1473.0745556399866	-2.386198660830104	0.892	497	243	LUAD	DOXORUBICIN	Approved in same tumor type	BRCA1|TP53|ATM	1469.2432034848741	-282.8379083524792
1459.2309248040017	-17.356545765787075	0.892	497	239	LUAD	VENETOCLAX	Approved in cancer	KRAS|PTEN|TP53	1294.2000597119384	16.39328134567822
914.2146080919234	3.426100327288907	0.492	497	237	LUAD	NAVITOCLAX	Clinical trials in cancer	KRAS|PTEN|TP53	882.0675700889485	224.22475494960537
1008.8236276919154	0.4121626682762951	0.562	497	236	LUAD	NVP-CGM097	Clinical trials in cancer	PIK3CA|KRAS|TP53	932.8119642899312	-128.11329567641155
1246.3309623793834	0.43424690599655946	0.7380000000000001	497	233	LUAD	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	TP53|RB1|STK11	1159.6044292232168	119.23522246057968
293.10642057404976	0.4741031596265941	0.032	497	231	LUAD	LY3009120	Clinical trials	KRAS|NRAS|TP53	337.0817362823029	65.96919417692177
1442.1120004712634	-27.159465385403934	0.892	497	226	LUAD	BORTEZOMIB	Approved in cancer	KRAS|TP53|RB1	1483.1440830157983	-14.282911534353303
860.2537657967906	-6.13772142222092	0.452	497	225	LUAD	ADAVOSERTIB	Clinical trials in cancer	BRCA1|TP53|STK11	733.3718852929314	76.83130471492603
987.0163137149441	1.776903282900065	0.542	497	224	LUAD	DS-7423	Clinical trials in cancer	KRAS|PTEN|TP53	948.462103328126	85.15970457390807
914.2815223821497	-16.08203941832707	0.492	497	223	LUAD	CAPIVASERTIB	Clinical trials in cancer	KRAS|PTEN|TP53	861.6394787563604	-104.03065434880966
254.9885675644475	10.411289978004817	0.0004	497	223	LUAD	ABT-737	Experimental	KRAS|PTEN|TP53	117.76576150039533	-58.92826961844358
832.8242697948882	9.63174883540239	0.432	497	222	LUAD	DEMCIZUMAB	Clinical trials in cancer	PIK3CA|KRAS|TP53	803.489891111258	109.81980053263737
1053.9401599034748	-27.888045551383982	0.593	497	219	LUAD	BERZOSERTIB	Clinical trials in cancer	TP53|BRCA2|ATM	1006.8176021579503	-132.42510834505993
1476.2034065473176	-26.657082563578115	0.892	497	218	LUAD	ABEMACICLIB	Approved in cancer	KRAS|NRAS|TP53	1422.5304067789796	124.63983254640334
1515.432037822709	4.073865351045299	0.936	497	216	LUAD	PAZOPANIB	Approved in cancer	BRCA1|TP53|BRCA2	1528.812825284501	230.20527279037884
1426.0752600476872	-0.5647785486355303	0.885	497	216	LUAD	OLAPARIB	Approved in cancer	TP53|BRCA2|ATM	1442.265458030211	288.5704789222299
1442.323536805419	-8.624630588266768	0.892	497	210	LUAD	DOCETAXEL	Approved in same tumor type	KRAS|HRAS|TP53	1389.9567707880392	-192.1871664391148
1532.2240967729197	10.9192235279167	0.95	497	210	LUAD	EVEROLIMUS	Approved in same tumor type	ATM|RB1|STK11	1533.7878259154313	-101.60618538375932
1497.9772876147981	4.1862944673316065	0.93	497	193	LUAD	TEMSIROLIMUS	Approved in cancer	PIK3CA|KRAS|PTEN	1542.2491724508461	241.65069694560623
1609.0049935753498	13.070735390829498	1	497	192	LUAD	SORAFENIB	Approved in cancer	NRAS|PTEN|SMARCA4	1594.7604878988955	-100.04546519720253
1582.7645263132215	11.091011045072037	0.997	497	187	LUAD	REGORAFENIB	Approved in cancer	FGFR2|KRAS|NRAS	1624.2751253375861	-145.16817969846628
1548.602769332162	15.061265822468641	0.962	497	185	LUAD	TRASTUZUMAB	Approved in cancer	PIK3CA|KRAS|PTEN	1511.3924342299856	224.03171985736282
1557.587542245209	2.1103898414261266	0.967	497	182	LUAD	NERATINIB	Approved in cancer	BRAF|PIK3CA|KRAS	1572.7505417797606	-187.3378468890735
1037.275256623498	-24.61757018342911	0.594	497	178	LUAD	LIFIRAFENIB	Clinical trials in cancer	BRAF|KRAS|NRAS	959.6438231972985	-179.12296038679472
914.2964561259962	21.0412251161479	0.492	497	176	LUAD	SARACATINIB	Clinical trials in cancer	BRAF|IDH1|KRAS	892.2650558481853	168.99737510218262
1373.8255770005478	-4.496478829671332	0.8320000000000001	497	175	LUAD	ATEZOLIZUMAB	Approved in same tumor type	EGFR|BRAF|KRAS	1438.0687557637937	110.8125049142127
1584.6470322919815	-19.064132412999385	0.997	497	169	LUAD	BINIMETINIB	Approved in cancer	HRAS|NF1|ATM	1653.778787927259	-34.4678964456194
1596.6657818915721	3.724084653657684	1	497	168	LUAD	COBIMETINIB	Approved in cancer	KRAS|NRAS|NF1	1629.7993902828623	62.99422157692544
1572.4253560468787	-0.10088225486168767	0.98	497	167	LUAD	VANDETANIB	Approved in cancer	KRAS|PTEN|ATM	1559.258891284033	-88.13968117663991
1326.1525893092844	0.43411338264260735	0.797	497	165	LUAD	PONATINIB	Approved in other pathologies and in clinical trials in cancer	PIK3CA|FGFR2|KRAS	1252.809522323327	143.45213099879538
1071.4923572652424	7.525537138538141	0.597	497	165	LUAD	PILARALISIB	Clinical trials in cancer	KRAS|PTEN|STK11	976.218496622015	106.33929355845589
874.3661018595889	12.22734223763581	0.462	497	164	LUAD	LINSITINIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	824.2989869542001	-24.165473301427937
1058.001731298737	19.272605558850756	0.596	497	164	LUAD	BUPARLISIB	Clinical trials in cancer	NRAS|PTEN|HRAS	1082.728917058333	84.70824416979389
1046.6036143210729	10.961135530337458	0.595	497	162	LUAD	212631-79-3	Clinical trials in cancer	KRAS|HRAS|STK11	968.6025897372439	-2.301936939828437
1455.9320892206613	-0.3618939605160847	0.892	497	161	LUAD	PALBOCICLIB	Approved in cancer	NRAS|PTEN|RB1	1339.6035301667298	38.41520026329647
1046.5755725772563	-13.544672122584387	0.586	497	157	LUAD	TAK-733	Clinical trials in cancer	MAP2K1|KRAS|NRAS	986.7015821523462	86.0241833800639
848.383988117333	5.078560157332106	0.442	497	156	LUAD	GANETESPIB	Clinical trials in cancer	EGFR|BRAF|TP53	710.0847542210828	-84.09619345499615
1519.1388348959551	19.616099457497143	0.938	497	156	LUAD	SUNITINIB	Approved in cancer	EGFR|FGFR2|KRAS	1505.815552122479	-82.19425167760177
1489.1686279753383	-8.002605952757847	0.92	497	156	LUAD	CABOZANTINIB	Approved in cancer	EGFR|KRAS|HRAS	1481.7508903835628	-183.13588254170165
827.1526011082758	-5.513417581588982	0.432	497	155	LUAD	POZIOTINIB	Clinical trials in cancer	ERBB2|EGFR|KRAS	736.3061510303692	-71.64501214453169
1429.2216909751817	-17.175770700333857	0.882	497	154	LUAD	CAPMATINIB	Approved in same tumor type	EGFR|BRAF|TP53	1342.7305408793313	-74.72827838485365
1552.177047545752	-11.36842857248081	0.966	497	154	LUAD	ERDAFITINIB	Approved in cancer	EGFR|FGFR2|KRAS	1558.5770213115957	-54.033948162390416
1505.9524755879527	16.837160111088167	0.933	497	154	LUAD	RAMUCIRUMAB	Approved in same tumor type	ERBB2|EGFR|KRAS	1473.4933628725332	-224.59422241078676
374.235846722744	0.4387454246898983	0.092	497	154	LUAD	BMS-754807	Clinical trials	EGFR|KRAS|PTEN	367.67475319029427	33.98503755654289
1071.583633334333	21.322513751097915	0.597	497	153	LUAD	PICTILISIB	Clinical trials in cancer	PTEN|RB1|STK11	984.8764743882656	-174.87681183231945
260.3104063431195	25.633025477673954	0.0004	497	153	LUAD	GA201	Experimental	EGFR|KRAS	251.03146457129486	-48.08022013602289
1047.3784765229184	27.933548717888783	0.593	497	152	LUAD	IZORLISIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	1057.2848714817148	-12.652444889765945
860.8295181829538	10.023291927485957	0.452	497	152	LUAD	CAMPTOTHECIN	Clinical trials in cancer	BRAF|PIK3CA|KRAS	846.3820875340137	10.562551112719518
1130.1016497808776	0.4519398865068922	0.652	497	151	LUAD	METFORMIN	Approved in other pathologies and in clinical trials in cancer	HRAS|ATM|STK11	1081.2644596809705	56.710878456358245
1595.000661046623	-9.94504380161527	1	497	149	LUAD	VEMURAFENIB	Approved in cancer	PTEN|HRAS|TP53	1603.3404500818099	83.83231744995663
1411.472695157941	5.097056904821102	0.8620000000000001	497	149	LUAD	ETOPOSIDE	Approved in same tumor type	TP53|BRCA2|ATM	1481.0903890431432	-92.0249307072962
502.05799957572344	-5.2604094556430425	0.186	497	149	LUAD	REFAMETINIB	Clinical trials	MAP2K1|KRAS|PTEN	422.2099718693984	-26.31298924978654
241.60372702570442	1.7037036357147883	0.0004	497	149	LUAD	DEL-22379	Experimental	MAP2K1|KRAS|NRAS	193.05147389799	-64.16526369941901
973.8579177172306	-7.267459838914618	0.535	497	148	LUAD	AZD8055	Clinical trials in cancer	PTEN|HRAS|STK11	893.1117729204044	-187.3200015904044
264.5145019883567	-2.31108467224027	0.0004	497	147	LUAD	1173900-33-8	Experimental	PTEN|TP53|ATM	231.75409516883485	-95.38052389611687
496.26053989772237	6.276886816965714	0.183	497	147	LUAD	RO4987655	Clinical trials	FGFR2|MAP2K1|KRAS	436.5584002516634	7.549980041502948
984.7989201489867	-13.960353886967766	0.542	497	146	LUAD	VOXTALISIB	Clinical trials in cancer	KRAS|PTEN|STK11	941.0321173733867	-42.92108392108034
247.3951330896222	24.285135414547142	0.0004	497	145	LUAD	PKI-402	Experimental	KRAS|PTEN|STK11	154.4361022899409	-8.904354360948389
1371.7384017382578	9.141280852269233	0.8320000000000001	497	143	LUAD	PANOBINOSTAT	Approved in cancer	KMT2A|BRAF|KRAS	1443.0112808315232	-201.32981607592455
875.2351142837293	-1.094613884084879	0.462	497	143	LUAD	ULIXERTINIB	Clinical trials in cancer	BRAF|KRAS	815.4388478338822	-96.8127363564144
239.73658734583177	14.29239920393826	0.0004	497	143	LUAD	TW-37	Experimental	BRAF|KRAS	140.71581813738388	11.758748806744535
252.2882745464076	-4.927148234297334	0.0004	497	139	LUAD	PLUMBAGIN	Experimental	ERBB2|EGFR|TP53	252.87385629897403	116.00888679620573
1402.6043996799506	-19.826520817182654	0.8520000000000001	497	138	LUAD	TOPOTECAN	Approved in same tumor type	PTEN|TP53|RB1	1290.788485033407	110.67636818162975
576.8198229165441	0.4330566268755547	0.242	497	138	LUAD	RIBAVIRIN	Approved in other pathologies	EGFR|TP53	515.1164961772427	24.777518850231132
835.4744505865808	-15.017791284047888	0.432	497	134	LUAD	PHENFORMIN	Clinical trials in cancer	KRAS|STK11	746.9782559026867	-51.136562593497246
1543.9324943255233	1.9102557883041698	0.96	497	133	LUAD	ERLOTINIB	Approved in same tumor type	AR|PTEN|TP53	1538.5874980013184	-144.38667862633054
1393.0335124540063	12.138954411327177	0.8520000000000001	497	133	LUAD	VORINOSTAT	Approved in cancer	PTEN|TP53|RB1	1448.1008978011089	182.37448853476144
1383.3204982340724	5.621325073530556	0.8420000000000001	497	133	LUAD	TEMOZOLOMIDE	Approved in cancer	PTEN|BRCA1|TP53	1198.4883555507895	-78.30497873335158
1595.4314585039272	16.766632393832623	0.999	497	133	LUAD	COPANLISIB	Approved in cancer	PIK3CA|KRAS|PTEN	1605.5421671187003	-95.52933485661944
839.6594116926739	-4.044749930870154	0.434	497	133	LUAD	PANULISIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	779.8573710454245	169.58461971338573
241.81068300340058	-10.653010832831171	0.0004	497	133	LUAD	A-443654	Experimental	PIK3CA|SMAD3|KRAS	174.68500154715724	-28.118991818683867
1412.9652253308614	-7.841613676310885	0.8620000000000001	497	132	LUAD	CICLOPHOSPHAMIDE	Approved in cancer	TP53|BRCA2|ATM	1397.919180709667	282.1950055834731
1585.1889943590375	-2.5141582254291563	1	497	132	LUAD	INFIGRATINIB	Approved in cancer	FGFR2|KRAS|PTEN	1642.6894778604951	43.587794620343516
1404.3128149888935	15.104957645339539	0.8520000000000001	497	132	LUAD	CAPECITABINE	Approved in cancer	PIK3CA|KRAS|PTEN	1295.4411014771501	134.87816490063938
1058.6178881584299	6.384369420578338	0.596	497	132	LUAD	PF-04691502	Clinical trials in cancer	PIK3CA|KRAS|PTEN	1070.7062737631709	-8.461546935648755
1049.9895310393217	-1.4046503771656944	0.595	497	132	LUAD	APITOLISIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	1028.6277259579392	130.77976478986523
961.6324606725784	-6.290812991479612	0.534	497	132	LUAD	ONATASERTIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	903.7161041459879	169.59897378058065
877.1931277765789	-13.000686624667395	0.464	497	132	LUAD	FIMEPINOSTAT	Clinical trials in cancer	PIK3CA|KRAS|PTEN	831.794558862225	187.62080838945633
887.2079717269529	0.40291676438786794	0.472	497	132	LUAD	RIGOSERTIB	Clinical trials in cancer	KRAS|PTEN|HRAS	834.6744078092607	-116.64968769349782
231.46390966015105	-5.2684795694902675	0.0004	497	132	LUAD	1056901-62-2	Experimental	PIK3CA|KRAS|PTEN	267.6558229008434	77.17466530428112
1474.2180470906546	11.618079122709673	0.893	478	254	LUSC	PACLITAXEL	Approved in same tumor type	BRCA1|ATM|TP53	1502.6336138698528	-67.22468056830954
1429.97678404328	21.82116722641632	0.8720000000000001	478	253	LUSC	CARBOPLATIN	Approved in cancer	BRCA2|BRCA1|TP53	1477.1156557364284	160.2496333357688
1009.6138796540124	-13.440406826877705	0.5640000000000001	478	253	LUSC	SAPANISERTIB	Clinical trials in cancer	SMAD4|RB1|TP53	933.2523274920997	-84.20024520159063
1187.5104283263495	0.47946660976805333	0.693	478	246	LUSC	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	HRAS|NF1|TP53	1136.226771081443	-98.70623806042374
1446.5735875776431	35.91327049574258	0.892	478	244	LUSC	TRAMETINIB	Approved in same tumor type	NF1|RB1|TP53	1476.6126061864838	110.96375930277014
1601.681649608386	3.150408536699956	1	478	242	LUSC	ALPELISIB	Approved in cancer	PTEN|HRAS|TP53	1610.4191027019015	-187.29907110469946
1445.3993797910682	-17.721626479181197	0.882	478	241	LUSC	FLUOROURACIL	Approved in cancer	PTEN|ATM|TP53	1373.3000292091215	32.251782962240526
1055.8888139557525	0.45545374256838045	0.597	478	239	LUSC	GEDATOLISIB	Clinical trials in cancer	NRAS|PTEN|TP53	984.6896495526197	37.807745667010096
906.6826634326951	-7.414690057505453	0.492	478	238	LUSC	MIRDAMETINIB	Clinical trials in cancer	NRAS|PTEN|TP53	896.114347302899	-156.22320512549692
991.6360875070498	-1.566869507753239	0.554	478	238	LUSC	CAPIVASERTIB	Clinical trials in cancer	KRAS|PTEN|TP53	952.4662683783454	-163.41385423075306
1533.4644361893984	-3.1121079019441993	0.95	478	237	LUSC	VEMURAFENIB	Approved in cancer	PTEN|HRAS|TP53	1566.6248346547736	208.88764909715684
1438.749231256999	2.199504737487956	0.882	478	237	LUSC	VENETOCLAX	Approved in cancer	KRAS|PTEN|TP53	1448.910827880303	270.7841691498626
919.4620157658919	25.436697116618376	0.492	478	237	LUSC	NAVITOCLAX	Clinical trials in cancer	KRAS|PTEN|TP53	804.6101688958961	-50.52402701222215
255.6004595662484	57.05674668164963	0.0004	478	237	LUSC	1173900-33-8	Experimental	PTEN|ATM|TP53	95.6884249071425	60.26130585473268
1408.5206176421539	22.066928727640004	0.8620000000000001	478	236	LUSC	TOPOTECAN	Approved in same tumor type	PTEN|RB1|TP53	1320.463665626261	-39.35321284740979
1027.6963207828726	-1.8863266893106072	0.5720000000000001	478	236	LUSC	DS-7423	Clinical trials in cancer	KRAS|PTEN|TP53	942.45485697722	185.76838804283744
228.44563261826355	-20.57064902010967	0.0004	478	236	LUSC	ABT-737	Experimental	KRAS|PTEN|TP53	277.4919585153742	7.028265385296379
1466.0663056889698	-20.67049050477908	0.892	478	234	LUSC	BORTEZOMIB	Approved in cancer	KRAS|RB1|TP53	1380.7649027017499	-85.76383087218007
1489.445618438241	-5.450870069662329	0.922	478	232	LUSC	CISPLATIN	Approved in cancer	BRCA1|ATM|TP53	1466.9538757106125	239.53034919428472
1418.7418692742071	39.90984150302825	0.8620000000000001	478	232	LUSC	IRINOTECAN	Approved in cancer	BRCA1|ATM|TP53	1358.9530706803382	-208.6829551545179
628.312518472531	-0.3073725470921147	0.282	478	232	LUSC	GEMCITABINE	Approved in other pathologies	SMAD4|BRCA1|TP53	590.1381396442096	93.990410160826
1412.1273704334599	-30.83449810544448	0.8620000000000001	478	231	LUSC	BEVACIZUMAB	Approved in same tumor type	KRAS|HRAS|TP53	1403.0727920056968	296.41993826948345
1418.3412002835164	4.109021506987659	0.8650000000000001	478	230	LUSC	OLAPARIB	Approved in cancer	BRCA1|ATM|TP53	1458.7787010225138	-73.88490300105288
1557.6658261239793	-5.7603114222230545	0.97	478	229	LUSC	DABRAFENIB	Approved in same tumor type	NRAS|HRAS|TP53	1589.4402961920193	-116.8246347896011
903.2896699459131	12.835748680825162	0.492	478	229	LUSC	PIMASERTIB	Clinical trials in cancer	NRAS|NF1|TP53	835.2067378781525	223.96060307661628
1453.529404843377	-36.66613501756132	0.893	478	228	LUSC	DOXORUBICIN	Approved in same tumor type	BRCA1|ATM|TP53	1429.9520545502087	79.18009256357794
1330.2230622682914	0.42867850299373345	0.8	478	228	LUSC	DASATINIB	Approved in other pathologies and in clinical trials in cancer	KRAS|HRAS|TP53	1240.673580701983	166.4583536555973
1389.5799046969848	29.409873140381848	0.8520000000000001	478	226	LUSC	VORINOSTAT	Approved in cancer	PTEN|RB1|TP53	1302.1087376036517	-7.826897081551351
913.6830635728229	-26.453883660995984	0.492	478	223	LUSC	RESVERATROL	Clinical trials in cancer	PIK3CA|BRCA1|TP53	881.2141028102159	97.81438170294928
1009.7910564157874	7.480024809029999	0.562	478	223	LUSC	NVP-CGM097	Clinical trials in cancer	PIK3CA|KRAS|TP53	951.8833246266819	-84.85360192729662
319.9550358385281	0.4211759104842656	0.052	478	223	LUSC	EMODIN	Clinical trials	PIK3CA|BRCA1|TP53	324.81745756187877	-131.11463918203324
1458.4696189816286	-2.0947842421684584	0.892	478	222	LUSC	TAMOXIFEN	Approved in cancer	PIK3CA|BRCA1|TP53	1377.248403041984	-65.57501721285185
816.6462438167632	-6.25310415679499	0.422	478	222	LUSC	DEMCIZUMAB	Clinical trials in cancer	PIK3CA|KRAS|TP53	686.6255444073787	-182.77758647636756
1582.8755185801542	-4.576726239539312	0.989	478	220	LUSC	ENCORAFENIB	Approved in cancer	KRAS|PTEN|TP53	1598.8907106616932	-82.66615710124417
1452.825859305767	16.519986078123566	0.892	478	219	LUSC	DUVELISIB	Approved in cancer	PIK3CA|TP53	1418.45274719778	-73.17162561253025
1391.5917077381116	-23.499454027298583	0.8520000000000001	478	219	LUSC	RALOXIFENE	Approved in cancer	PIK3CA|TP53	1362.1033701384706	316.8919374879921
849.9130616412762	12.835844455976314	0.442	478	219	LUSC	TANESPIMYCIN	Clinical trials in cancer	MTOR|PIK3CA|TP53	801.7143035519657	184.16723306213294
1406.8616911398126	-11.868770568971911	0.8620000000000001	478	216	LUSC	CRIZOTINIB	Approved in same tumor type	CDKN2A|SMAD4|TP53	1241.8749625574276	149.73357336761427
226.07992756746384	17.212644269196034	0.0004	478	216	LUSC	PF-477736	Experimental	KRAS|CDKN2A|TP53	223.1925440720085	-86.85715569706034
1425.7205757457355	-14.020618344797526	0.8720000000000001	478	214	LUSC	ABEMACICLIB	Approved in cancer	CDKN2A|NRAS|TP53	1484.0101342515154	182.52125664105762
833.1867728651331	3.5792365620313547	0.432	478	214	LUSC	ONC201	Clinical trials in cancer	PTEN|TP53	670.5027303513975	101.5455459406449
1465.9233750792944	30.38897509302518	0.892	478	213	LUSC	METHOTREXATE	Approved in same tumor type	NOTCH1|RB1|TP53	1451.3498478099461	251.20404144771737
1569.872912408278	9.438628081314505	0.977	478	213	LUSC	PAZOPANIB	Approved in cancer	BRCA2|BRCA1|TP53	1588.2745174896606	170.17166988460178
1232.804076214993	0.43156390288228863	0.7280000000000001	478	213	LUSC	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	HRAS|RB1|TP53	1171.2950047189256	-55.753458276987516
1118.7727959520098	7.634346130251714	0.642	478	213	LUSC	MERCAPTOPURINE	Approved in other pathologies and in clinical trials in cancer	NOTCH1|RB1|TP53	1123.2074727997888	209.6730718491571
1025.9688481719913	17.741994302477565	0.5730000000000001	478	211	LUSC	BERZOSERTIB	Clinical trials in cancer	BRCA1|ATM|TP53	951.5849747211817	102.94806419830655
921.3404097671553	5.824003198343831	0.493	478	210	LUSC	SELICICLIB	Clinical trials in cancer	DYRK1A|RB1|TP53	842.9019543030545	57.80229043038537
1370.9683818483254	-17.556881144412642	0.8320000000000001	478	209	LUSC	LORLATINIB	Approved in same tumor type	RB1|TP53	1241.1564840747571	-163.91249738013735
1508.8915061843759	-5.967274579494045	0.93	478	209	LUSC	PANITUMUMAB	Approved in cancer	PTEN|HRAS|TP53	1503.1603315789816	-197.45858411395955
1431.481881960015	-31.755380885068462	0.8720000000000001	478	208	LUSC	CICLOPHOSPHAMIDE	Approved in cancer	BRCA1|ATM|TP53	1509.3415519347716	92.51745799980665
849.184360515964	-6.017646013247457	0.442	478	208	LUSC	ADAVOSERTIB	Clinical trials in cancer	NRAS|BRCA1|TP53	768.3265708430592	-57.87928699576713
1518.6234765811655	9.656247240238315	0.94	478	207	LUSC	ERLOTINIB	Approved in same tumor type	APC|PTEN|TP53	1539.2311678764386	39.18507774027523
1421.9694474415655	-47.46366167995376	0.8720000000000001	478	207	LUSC	ETOPOSIDE	Approved in same tumor type	BRCA2|ATM|TP53	1430.2143987320642	-207.9324311047151
1101.1877598091398	-6.88209942764783	0.632	478	205	LUSC	CHLORAMBUCIL	Approved in other pathologies and in clinical trials in cancer	BRCA2|BRCA1|TP53	1085.639004381316	-179.20272726928022
290.15248120142934	3.057451042662308	0.024	478	205	LUSC	LY3009120	Clinical trials	KRAS|NRAS|TP53	326.8453483087615	106.72849864997886
1382.4141998089815	11.78282431898424	0.8420000000000001	478	205	LUSC	TEMOZOLOMIDE	Approved in cancer	PTEN|BRCA1|TP53	1431.8006762411483	-110.31385643798733
1399.2181225028442	5.042995706239935	0.8520000000000001	478	204	LUSC	DOXORUBICIN HYDROCHLORIDE	Approved in same tumor type	BLM|BRCA1|TP53	1494.2771789813166	-45.76504980747404
227.82922320567604	-1.2268316465621183	0.0004	478	204	LUSC	167869-21-8	Experimental	HRAS|TP53	120.52353314045872	-0.07297552221010051
244.0586171180466	-9.073587814353658	0.0004	478	204	LUSC	RUFOCROMOMYCIN	Experimental	BLM|ATM|TP53	185.49762926760775	177.19110572810212
684.7420374595629	0.4333523122355416	0.322	478	203	LUSC	DOPAMINE	Approved in other pathologies	NFE2L2|SOD1|TP53	622.7348183632898	-67.08767389548338
576.941106841286	-2.1409542755845337	0.242	478	203	LUSC	TRIAMTERENE	Approved in other pathologies	JAK2|NFE2L2|TP53	506.38398593529433	67.37138020579337
252.06923300518199	-63.612033008210574	0.0004	478	203	LUSC	1,10-PHENANTHROLINE	Experimental	MTOR|NFE2L2|TP53	252.94855010417152	-100.37489052655151
235.24136609600404	-57.25386213892851	0.0004	478	203	LUSC	93718-83-3	Experimental	NFE2L2|BLM|TP53	132.62145072823176	192.88832922982846
236.84594201155667	62.05574056859194	0.0004	478	203	LUSC	GNF-PF-308	Experimental	MTOR|NFE2L2|TP53	220.4391939766711	138.60495092700899
225.2352787418477	35.6799477751743	0.0004	478	203	LUSC	MALONOBEN	Experimental	MTOR|NFE2L2|TP53	186.72200524269857	159.73344554162935
232.40976098704442	-39.46923317465007	0.0004	478	203	LUSC	ROTENONE	Experimental	MTOR|NFE2L2|TP53	238.47575450533867	-79.18936800921094
260.28173807498337	-16.89510356105575	0.0004	478	203	LUSC	VANOXERINE	Experimental	MTOR|NFE2L2|TP53	306.0379514483169	-128.97429984847253
1385.0677561939979	-6.06230763650052	0.8420000000000001	478	202	LUSC	CAPMATINIB	Approved in same tumor type	EGFR|BRAF|TP53	1314.7992112547008	-277.1112315315095
1365.5548032952772	18.131124759874695	0.8320000000000001	478	202	LUSC	MECHLORETHAMINE HYDROCHLORIDE	Approved in cancer	NFE2L2|TP53	1344.1908116487189	311.82307657200465
1368.3921579060823	0.45338075941313605	0.8320000000000001	478	202	LUSC	MELPHALAN	Approved in cancer	NFE2L2|TP53	1316.6322503712406	262.6049486559052
1500.5173020040193	10.188636366635478	0.926	478	202	LUSC	METHYLPREDNISOLONE	Approved in cancer	NFE2L2|NR3C1|TP53	1547.6509359202928	-15.79424825225351
1100.7467996493156	11.141980794036783	0.632	478	202	LUSC	CLADRIBINE	Approved in other pathologies and in clinical trials in cancer	NFE2L2|TP53	1087.329544884497	155.1208304121629
1118.8017570842096	-10.729686903611906	0.642	478	202	LUSC	AZACITIDINE	Approved in other pathologies and in clinical trials in cancer	NFE2L2|NR3C1|TP53	1055.9495723513028	148.4546085970154
1167.7667850479672	0.36078175029132353	0.6819999999999999	478	202	LUSC	HALOPERIDOL	Approved in other pathologies and in clinical trials in cancer	EPM2A|GRIN2A|TP53	1122.5560300732823	-111.3649219850878
925.5698992999168	-11.916798990173845	0.492	478	202	LUSC	GENISTEIN	Clinical trials in cancer	NFE2L2|CFTR|TP53	867.9943432050551	-39.85305797648337
817.0808740537888	12.483701391860023	0.422	478	202	LUSC	CARBENDAZIM	Clinical trials in cancer	NFE2L2|TP53	735.2091814265871	158.79060820547966
833.310717683472	-14.826458602111302	0.432	478	202	LUSC	GANETESPIB	Clinical trials in cancer	EGFR|BRAF|TP53	740.4385394481334	35.13955133499243
647.3956953248398	1.4066756500643294	0.292	478	202	LUSC	AZATHIOPRINE	Approved in other pathologies	NFE2L2|TP53	607.6464391448612	-73.01860406843927
779.3517129495345	15.94135041154334	0.392	478	202	LUSC	ZINC	Approved in other pathologies	TTR|SOD1|TP53	674.8223691134863	25.357072246991436
779.3537038324804	-15.078275348621702	0.392	478	202	LUSC	ZINC ACETATE	Approved in other pathologies	TTR|SOD1|TP53	651.2551733193	81.48749531447271
788.3047132156667	0.4329145446099858	0.392	478	202	LUSC	ZINC CHLORIDE	Approved in other pathologies	TTR|SOD1|TP53	631.4818354342425	-53.511695390442924
770.4007132523932	0.4317677882634712	0.392	478	202	LUSC	ZINC SULFATE	Approved in other pathologies	TTR|SOD1|TP53	636.4873818678768	72.17126712222543
593.663800371585	4.361409463944852	0.252	478	202	LUSC	HEXACHLOROPHENE	Approved in other pathologies	NFE2L2|TP53	553.5209948324477	21.08754916451116
562.6005302482235	8.649036517163609	0.2319999999999999	478	202	LUSC	NITAZOXANIDE	Approved in other pathologies	NFE2L2|TP53	533.7418725686001	-112.86807031153903
560.4103637326853	-9.12049883461603	0.2319999999999999	478	202	LUSC	PROCHLORPERAZINE EDISYLATE	Approved in other pathologies	NFE2L2|TP53	524.6547057778087	113.66550202560768
257.89453799410927	18.78096508203606	0.0004	478	202	LUSC	2,3,4,6-TETRACHLOROPHENOL	Experimental	NFE2L2|TP53	239.99648406528027	116.2134262566712
249.12820493481146	-45.92684594765376	0.0004	478	202	LUSC	2-AMINOANTHRACENE	Experimental	NFE2L2|TP53	217.56015686092417	155.931401058505
241.89341577359525	26.716635502837306	0.0004	478	202	LUSC	3-METHYLTOXOFLAVIN	Experimental	NFE2L2|BLM|TP53	273.18086158896995	-11.132321227100192
273.92232117627975	10.85366214791381	0.0004	478	202	LUSC	7,12-DIMETHYLBENZ[A]ANTHRACENE	Experimental	NFE2L2|TP53	97.1042664188146	107.2674643619223
277.8200199611325	-24.639000074410546	0.0004	478	202	LUSC	ANTIMYCIN A	Experimental	NFE2L2|TP53	180.98392547298278	-129.51542172536466
265.9260257483261	-52.22376424552894	0.0004	478	202	LUSC	BENZETHONIUM CHLORIDE	Experimental	NFE2L2|TP53	226.39640174293783	-147.2620914148336
240.80474479619485	44.5990221793997	0.0004	478	202	LUSC	BENZO[B]FLUORANTHENE	Experimental	NFE2L2|TP53	72.15868637051123	80.42299210408908
271.81173665622373	46.51578898900442	0.0004	478	202	LUSC	BENZO[K]FLUORANTHENE	Experimental	NFE2L2|NR3C1|TP53	261.4587702975432	-115.78715701612238
246.26710850058626	-28.062524528123646	0.0004	478	202	LUSC	CADMIUM DICHLORIDE	Experimental	NFE2L2|TP53	203.10218373659796	165.7099982427165
275.1764140775398	-6.944075880111768	0.0004	478	202	LUSC	CHEMBL2002487	Experimental	NFE2L2|TP53	145.3286890684704	-157.0679154322022
242.97464809622457	8.870832288554737	0.0004	478	202	LUSC	CHLORANIL	Experimental	NFE2L2|TP53	89.56213904142857	172.48743111852633
272.8368474653179	28.63260888794113	0.0004	478	202	LUSC	DAIDZEIN	Experimental	NFE2L2|TP53	243.75209777099275	-142.64688006565473
259.020811991147	0.9289282706750441	0.0004	478	202	LUSC	DIBENZ[A,H]ANTHRACENE	Experimental	NFE2L2|TP53	278.41256245075056	-79.92033774220035
262.94816573434673	-34.56914563433793	0.0004	478	202	LUSC	DICHLOROPHEN	Experimental	NFE2L2|TP53	113.28355003669279	-77.16175923982665
256.818671155597	36.63081138432531	0.0004	478	202	LUSC	DINOSEB	Experimental	NFE2L2|TP53	307.4400037058897	84.07393902945608
1385.56436488457	2.722482466687694	0.8420000000000001	78	7	MESO	TAMOXIFEN	Approved in cancer	TP53	1280.728420236733	-165.87872240629022
1412.680887941828	-1.8595009511395233	0.8620000000000001	78	7	MESO	ALPELISIB	Approved in cancer	TP53|KRAS	1381.4087275537363	10.090629340387721
1370.581474817311	0.4611295301213545	0.8320000000000001	78	7	MESO	DABRAFENIB	Approved in cancer	TP53|KRAS	1411.1623074352672	8.673648567899704
1370.4656187053633	-4.124462018175393	0.8320000000000001	78	7	MESO	TRAMETINIB	Approved in cancer	TP53|KRAS	1325.0813595150214	-15.818344809886554
1412.6798270828035	2.728498926212069	0.8620000000000001	78	7	MESO	ENCORAFENIB	Approved in cancer	TP53|KRAS	1307.780282119129	63.80170189497585
1370.695659340727	5.0463015988495385	0.8320000000000001	78	7	MESO	ABEMACICLIB	Approved in cancer	TP53|KRAS	1364.6277935595365	-55.8728697648108
1385.5690918891073	-1.865515098201314	0.8420000000000001	78	7	MESO	DUVELISIB	Approved in cancer	TP53	1323.4576967958467	224.19347083213165
1357.1597824964772	10.485836902406191	0.8220000000000001	78	7	MESO	METHOTREXATE	Approved in cancer	TP53	1239.151158503215	41.933081579399754
1398.4812195503039	-1.9065604665989326	0.8520000000000001	78	7	MESO	BORTEZOMIB	Approved in cancer	TP53|KRAS	1378.0946271602425	-15.836845574166176
1361.5178673094556	-0.8307114580661903	0.8230000000000001	78	7	MESO	CISPLATIN	Approved in cancer	TP53|KRAS	1324.8759654956737	-28.605848961314365
1366.032639100769	-0.022038576020150913	0.8230000000000001	78	7	MESO	DOXORUBICIN	Approved in cancer	TP53|KRAS	1203.2683932379014	-13.861074046792623
1402.3768443849501	0.5187066659687218	0.8530000000000001	78	7	MESO	PACLITAXEL	Approved in cancer	TP53|KRAS	1453.9462413458411	68.59970349761434
1362.9223871050683	-8.64921981068764	0.8230000000000001	78	7	MESO	PEMBROLIZUMAB	Approved in cancer	TP53|KRAS	1234.168992434818	70.6044353658358
1374.4955312169095	-1.9320985178136993	0.8320000000000001	78	7	MESO	BEVACIZUMAB	Approved in cancer	TP53|KRAS	1416.3608462274199	167.79805006342372
1354.053241580229	1.8536379515578574	0.8220000000000001	78	7	MESO	CARBOPLATIN	Approved in cancer	TP53|KRAS	1324.2734527912037	-55.36054014342773
1364.6265533513047	7.803099617750888	0.8220000000000001	78	7	MESO	CRIZOTINIB	Approved in cancer	TP53|KRAS	1238.2045718522622	40.66553549765851
1355.6032421615023	6.171542979945343	0.8220000000000001	78	7	MESO	FLUOROURACIL	Approved in cancer	TP53|KRAS	1299.4505551235018	-22.472144908310014
1374.6104713379812	2.654461496478831	0.8320000000000001	78	7	MESO	IRINOTECAN	Approved in cancer	TP53|KRAS	1276.668910752363	-30.929812604194893
1363.0837313814104	3.47954540723768	0.8220000000000001	78	7	MESO	OLAPARIB	Approved in cancer	TP53|KRAS	1245.0975795192685	40.9137422355773
1360.1161700704315	6.984226392729852	0.8220000000000001	78	7	MESO	PAZOPANIB	Approved in cancer	TP53|KRAS	1243.9017514459815	-141.59711688872875
1398.3298679377845	2.680124171838969	0.8520000000000001	78	7	MESO	VENETOCLAX	Approved in cancer	TP53|KRAS	1258.9399812959764	-32.59293885656777
1355.44404968234	-5.954772148773742	0.8220000000000001	78	7	MESO	ETOPOSIDE	Approved in cancer	TP53	1218.757569514261	169.28274739427405
1357.0078320740747	-1.6421737215716234	0.8220000000000001	78	7	MESO	TOPOTECAN	Approved in cancer	TP53	1297.336910650864	6.161026202096366
1343.7244806452952	-6.038332582312307	0.812	78	7	MESO	CAPMATINIB	Approved in cancer	TP53	1253.5419295188174	-37.96201061461622
1344.9612930538924	10.388472487801835	0.812	78	7	MESO	CICLOPHOSPHAMIDE	Approved in cancer	TP53	1170.4180082360976	-88.12182326822519
1364.4786680823597	-4.3308773732674695	0.8220000000000001	78	7	MESO	DAUNORUBICIN HYDROCHLORIDE	Approved in cancer	TP53	1289.4182981679567	29.808393088347145
1346.6853839981727	-9.544154864045424	0.812	78	7	MESO	DOXORUBICIN HYDROCHLORIDE	Approved in cancer	TP53	1222.69104492527	-46.88767995690381
1340.7653297541688	-0.9974673269543359	0.812	78	7	MESO	IFOSFAMIDE	Approved in cancer	TP53	1236.0276053417324	-6.813831794598173
1343.6715964942923	2.551062664496129	0.812	78	7	MESO	LORLATINIB	Approved in cancer	TP53	1305.2289631144745	22.561381448953426
1358.405944232632	-9.45855328403141	0.8220000000000001	78	7	MESO	MECHLORETHAMINE HYDROCHLORIDE	Approved in cancer	TP53	1265.8846032420172	116.57190206938748
1351.3904234412728	-8.560530183173057	0.812	78	7	MESO	MELPHALAN	Approved in cancer	TP53	1280.2113009444317	40.071181179680565
1351.1607092351696	-1.693782189647692	0.812	78	7	MESO	METHYLPREDNISOLONE	Approved in cancer	TP53	1223.5350776368996	14.354053844292508
1359.9648645669452	-5.143520101145128	0.8220000000000001	78	7	MESO	MITOXANTRONE	Approved in cancer	TP53	1314.2459907945974	91.21213678604954
1351.1087880990292	5.350837024593261	0.812	78	7	MESO	MITOXANTRONE HYDROCHLORIDE	Approved in cancer	TP53	1254.573404329999	50.33484525364918
1358.5653667519487	2.669974506637402	0.8220000000000001	78	7	MESO	RALOXIFENE	Approved in cancer	TP53	1382.4373897266837	-75.69210836192522
1345.2869861343813	-1.7306991720550116	0.812	78	7	MESO	RITUXIMAB	Approved in cancer	TP53	1250.463689459122	66.42775858927465
1342.0528129031807	6.840315900026667	0.812	78	7	MESO	TAMOXIFEN CITRATE	Approved in cancer	TP53	1259.4856080537754	85.57262866870491
1349.4876496221889	9.643904915748976	0.812	78	7	MESO	TEMOZOLOMIDE	Approved in cancer	TP53	1259.3881305154623	78.5596468471507
1348.2439900144807	-5.236846243059972	0.812	78	7	MESO	TRABECTEDIN	Approved in cancer	TP53	1244.9514532111436	42.86851052426084
1346.5779772410942	6.098678766767506	0.812	78	7	MESO	TRIFLURIDINE	Approved in cancer	TP53	1225.8641133478063	136.79478164983527
1348.201927088765	1.8076962722181236	0.812	78	7	MESO	VORINOSTAT	Approved in cancer	TP53	1323.3684903936169	-50.59106561476352
1143.4547386833199	0.4329290476606218	0.6619999999999999	78	7	MESO	DASATINIB	Approved in other pathologies and in clinical trials in cancer	TP53|KRAS	1077.6819309403631	-20.93480519031624
1101.857012439054	2.7740507298111936	0.632	78	7	MESO	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	TP53|KRAS	1047.135751894645	139.85481789020054
1279.0208428650574	0.4323714377532326	0.762	78	7	MESO	ASPIRIN	Approved in other pathologies and in clinical trials in cancer	TP53	1171.6696677715931	67.69079774024954
1101.6900103088083	-1.8120913021322167	0.632	78	7	MESO	FLUPHENAZINE	Approved in other pathologies and in clinical trials in cancer	TP53	1056.0537371103705	-170.40784516195782
1076.0521506560601	1.5007045530623202	0.612	78	7	MESO	CLADRIBINE	Approved in other pathologies and in clinical trials in cancer	TP53	1029.0715010809963	-20.78055691603808
1105.744344548636	0.33549289181920017	0.633	78	7	MESO	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	TP53|KRAS	1080.5503174565756	97.78037627632585
1091.195317445131	-1.07793433208289	0.622	78	7	MESO	AZACITIDINE	Approved in other pathologies and in clinical trials in cancer	TP53	1057.3469612096983	-42.631790282547
1078.5626097615846	-2.340394364131811	0.612	78	7	MESO	CHLORAMBUCIL	Approved in other pathologies and in clinical trials in cancer	TP53	1048.7345715173192	29.37033408502566
1087.7495022448657	1.9541436728953556	0.622	78	7	MESO	DAUNORUBICIN	Approved in other pathologies and in clinical trials in cancer	TP53	1046.5335056136792	5.200007118297577
1088.6556624031018	6.451095837321134	0.622	78	7	MESO	ENALAPRIL	Approved in other pathologies and in clinical trials in cancer	TP53	1006.9131812178615	-18.175978821000513
1092.0982771611475	3.418251029631193	0.622	78	7	MESO	FENOFIBRATE	Approved in other pathologies and in clinical trials in cancer	TP53	1055.6090760227898	-135.93646005131555
1116.1443190556038	0.4325356244135321	0.642	78	7	MESO	HALOPERIDOL	Approved in other pathologies and in clinical trials in cancer	TP53	1056.752707532772	-135.78584980124157
1078.130358325848	5.592052348718454	0.612	78	7	MESO	HYDRALAZINE HYDROCHLORIDE	Approved in other pathologies and in clinical trials in cancer	TP53	1017.8882842439743	-66.51806815148757
1090.2862672053416	-5.573778792961434	0.622	78	7	MESO	LOPERAMIDE	Approved in other pathologies and in clinical trials in cancer	TP53	1046.8856684288849	10.167899745025295
1080.633974719019	1.7488340233713302	0.612	78	7	MESO	MERCAPTOPURINE	Approved in other pathologies and in clinical trials in cancer	TP53	1045.8822271156791	6.583751136083691
1076.4892725034097	-6.432319116546381	0.612	78	7	MESO	METHYLENE BLUE CATION	Approved in other pathologies and in clinical trials in cancer	TP53	1041.7479293044719	111.30576178466447
1073.550096059654	5.3426680492488	0.612	78	7	MESO	THIAMAZOLE	Approved in other pathologies and in clinical trials in cancer	TP53	1055.2483216521407	49.41161012448654
1073.9806024581333	-2.5909237218177736	0.612	78	7	MESO	THIORIDAZINE HYDROCHLORIDE	Approved in other pathologies and in clinical trials in cancer	TP53	1058.9289253289148	-169.814954686174
1086.8442087309659	-2.5403026584080806	0.622	78	7	MESO	WARFARIN	Approved in other pathologies and in clinical trials in cancer	TP53	1069.0581476868997	-5.034669302430586
873.5267596408179	0.43211940024866635	0.462	78	7	MESO	GEDATOLISIB	Clinical trials in cancer	TP53|KRAS	852.3980847402609	-111.5406152474752
834.7563875898268	-1.8038099055834778	0.433	78	7	MESO	SELICICLIB	Clinical trials in cancer	TP53	811.4066638220124	82.6136109362011
830.8726768523669	-4.252746141877282	0.432	78	7	MESO	CAPIVASERTIB	Clinical trials in cancer	TP53|KRAS	760.1559729838453	-51.97194567892976
834.3843438146547	7.36261810096056	0.432	78	7	MESO	MIRDAMETINIB	Clinical trials in cancer	TP53|KRAS	815.6043656125648	89.0090867968836
834.5716069921189	2.7778612666336358	0.432	78	7	MESO	PIMASERTIB	Clinical trials in cancer	TP53|KRAS	805.6385051187608	60.70134185816582
887.0285448480608	0.4322353428533461	0.472	78	7	MESO	RESVERATROL	Clinical trials in cancer	TP53	805.4273872123634	122.05222525983561
845.9899661383239	0.4198698617541652	0.442	78	7	MESO	GENISTEIN	Clinical trials in cancer	TP53	782.3067979821568	24.778030751142126
900.5228724315542	0.4323080421593204	0.482	78	7	MESO	NAVITOCLAX	Clinical trials in cancer	TP53|KRAS	859.7804280106076	-35.74415293806416
954.6736723111985	5.0189259519465	0.522	78	7	MESO	NVP-CGM097	Clinical trials in cancer	TP53|KRAS	896.9315929709519	-101.30621291418828
954.7222346673744	0.43293689429617643	0.522	78	7	MESO	EPRENETAPOPT	Clinical trials in cancer	TP53	867.2590991904333	-31.85528139560941
954.6734853332764	-4.154804107811884	0.522	78	7	MESO	KEVETRIN	Clinical trials in cancer	TP53	929.0318665146065	39.767967515896856
819.5247548698277	-3.528266586826362	0.422	78	7	MESO	ADAVOSERTIB	Clinical trials in cancer	TP53|KRAS	759.8887718563533	-54.29717478320829
830.506741827737	4.910668908725825	0.432	78	7	MESO	BERZOSERTIB	Clinical trials in cancer	TP53|KRAS	777.532053002572	13.384585089442169
821.8687881908048	0.416518246659507	0.422	78	7	MESO	DEMCIZUMAB	Clinical trials in cancer	TP53|KRAS	733.7778435470059	-18.089583389075017
834.9320788293201	-6.386993623971307	0.432	78	7	MESO	DS-7423	Clinical trials in cancer	TP53|KRAS	750.8969818977049	-36.2871617037828
830.6912568820384	0.3263807204434386	0.432	78	7	MESO	SAPANISERTIB	Clinical trials in cancer	TP53|KRAS	807.4760438375702	-14.608142316981656
802.0979783561253	-3.9867877603136037	0.412	78	7	MESO	1026680-07-8	Clinical trials in cancer	TP53	754.8246675844534	-51.840357398221016
819.6227134144999	4.418599506564732	0.422	78	7	MESO	2-PHENYLETHYL ISOTHIOCYANATE	Clinical trials in cancer	TP53	808.3868847600528	102.51450942367586
806.5000938617076	-2.7022437176099743	0.412	78	7	MESO	ALVESPIMYCIN	Clinical trials in cancer	TP53	693.2129895008406	96.85629950519836
803.187121213457	0.4679705621978769	0.412	78	7	MESO	AVASTIN	Clinical trials in cancer	TP53	706.375518744243	-2.5241317213262278
808.6819308681339	6.213194147679758	0.412	78	7	MESO	AZD6738	Clinical trials in cancer	TP53	750.8200909640701	-43.6608281113387
805.4153546107161	-7.155432955038464	0.412	78	7	MESO	CARBENDAZIM	Clinical trials in cancer	TP53	750.9455288511148	100.56571000343644
809.8185801721415	-5.871151889633609	0.412	78	7	MESO	FENRETINIDE	Clinical trials in cancer	TP53	734.602365650945	-80.92926553574416
810.9055536369548	-1.4180704357783043	0.412	78	7	MESO	GANETESPIB	Clinical trials in cancer	TP53	781.6248256088238	28.45544567888092
817.2799420636921	0.47383507789299983	0.422	78	7	MESO	NORDIHYDROGUAIARETIC ACID	Clinical trials in cancer	TP53	769.8480047877023	-50.8709680674518
807.5895447257137	1.753976505702468	0.412	78	7	MESO	ONC201	Clinical trials in cancer	TP53	693.3868843500547	-9.182775838766162
811.992120617054	3.041449923854117	0.412	78	7	MESO	QUINACRINE DIHYDROCHLORIDE	Clinical trials in cancer	TP53	700.7890120373498	101.28787631233445
805.3664865199339	9.380549735417588	0.412	78	7	MESO	TANESPIMYCIN	Clinical trials in cancer	TP53	750.2413241225663	1.9444321125590989
804.2759349059489	4.924044249788722	0.412	78	7	MESO	TIRAPAZAMINE	Clinical trials in cancer	TP53	768.3838170786855	-45.06681455167117
563.1272833145633	2.7236212330106753	0.2319999999999999	78	7	MESO	AZATHIOPRINE	Approved in other pathologies	TP53	516.257469460399	32.73309405860789
549.1244863026719	2.7725481880461302	0.2219999999999999	78	7	MESO	GEMCITABINE	Approved in other pathologies	TP53|KRAS	507.85152108165863	7.000705478324107
563.1260974014774	-1.864378613721044	0.2319999999999999	78	7	MESO	AMOXAPINE	Approved in other pathologies	TP53	487.4937615747786	50.33712041655315
725.4063925691398	2.7263482707336095	0.352	78	7	MESO	ZINC	Approved in other pathologies	TP53	644.6954989197834	16.751372783052886
725.4063960529911	-1.8616517292650485	0.352	78	7	MESO	ZINC ACETATE	Approved in other pathologies	TP53	642.7788079141019	12.527284675356299
712.1602546303058	-1.8616344078294276	0.342	78	7	MESO	ZINC CHLORIDE	Approved in other pathologies	TP53	647.1090764016042	-30.561638518737084
712.1602522156616	2.726365592169941	0.342	78	7	MESO	ZINC SULFATE	Approved in other pathologies	TP53	642.920265091313	-31.681244343367325
553.0165240478236	0.3415553948772754	0.2229999999999999	78	7	MESO	TRIFLUOPERAZINE	Approved in other pathologies	TP53	476.39593133996897	11.394340599917058
536.683501189531	2.727639841210447	0.212	78	7	MESO	(S)-FLUOXETINE	Approved in other pathologies	TP53	457.4460924887434	-8.549552330120292
548.9663881577662	-1.813936027162697	0.2219999999999999	78	7	MESO	CHLORPROMAZINE	Approved in other pathologies	TP53	517.3074396229435	33.2007635848646
536.6829438972924	-1.8603601249431279	0.212	78	7	MESO	CLEMASTINE	Approved in other pathologies	TP53	468.44593443741576	24.3012239212986
1379.888278212426	-30.63361194650426	0.8340000000000001	406	249	OV	CARBOPLATIN	Approved in cancer	BRCA2|BRCA1|TP53	1281.796057241593	-307.8547151464267
1428.8587448011426	26.360281880488373	0.8530000000000001	406	248	OV	PACLITAXEL	Approved in cancer	BRCA1|ATM|TP53	1216.2908141308721	-137.68008699646865
1387.4656605251905	-54.86822661038988	0.8430000000000001	406	248	OV	CISPLATIN	Approved in cancer	BRCA1|ATM|TP53	1335.7280105270816	-2.9785547964388286
1412.709895210776	6.838703573966825	0.8420000000000001	406	248	OV	IRINOTECAN	Approved in cancer	BRCA1|ATM|TP53	1201.4240008384168	-177.24349355897064
1465.5014408977497	-8.036236455821012	0.892	406	247	OV	DOXORUBICIN	Approved in cancer	BRCA1|ATM|TP53	1411.5073839548409	-186.22877289228924
1420.3097009961193	-17.293920558203638	0.8520000000000001	406	246	OV	PAZOPANIB	Approved in cancer	BRCA2|BRCA1|TP53	1323.6689830721377	-230.83621042423778
1134.2271429356692	14.810057312414642	0.652	406	246	OV	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	NRAS|NF1|TP53	1106.1921541946367	-127.25531941594377
875.042556133528	33.64809799564304	0.452	406	246	OV	SAPANISERTIB	Clinical trials in cancer	KRAS|RB1|TP53	807.7300750823559	12.942274010202567
1363.7729752759408	16.360801249526276	0.8350000000000001	406	245	OV	OLAPARIB	Approved in cancer	BRCA1|ATM|TP53	1246.4984031181766	-78.59525459149557
948.7870701323054	-0.06221020805028843	0.523	406	245	OV	BERZOSERTIB	Clinical trials in cancer	BRCA1|ATM|TP53	890.5586702035728	-222.11750540232603
1444.8951014286913	-22.493422533298514	0.882	406	244	OV	BORTEZOMIB	Approved in cancer	KRAS|RB1|TP53	1503.2964635377205	-27.112026931077366
851.3271394442146	-1.1116172598962635	0.442	406	244	OV	PIMASERTIB	Clinical trials in cancer	NRAS|NF1|TP53	778.9004064478211	88.44632125521298
847.0081545989638	-50.798972565662694	0.442	406	244	OV	ADAVOSERTIB	Clinical trials in cancer	NRAS|BRCA1|TP53	785.2100614648531	-224.9151293424672
576.8360153714102	0.43253362566525766	0.242	406	244	OV	GEMCITABINE	Approved in other pathologies	NRAS|BRCA1|TP53	558.0215484252624	51.4601106421305
1532.0821634697556	0.4505432410926744	0.95	406	243	OV	ALPELISIB	Approved in cancer	KRAS|NRAS|TP53	1571.3492028283747	231.45962699712823
1355.3057996671785	-25.440080041241686	0.8320000000000001	406	243	OV	CICLOPHOSPHAMIDE	Approved in cancer	BRCA1|ATM|TP53	1275.538152693149	291.6901107203431
1362.8410279465797	-49.13374425898871	0.8320000000000001	406	243	OV	FLUOROURACIL	Approved in cancer	KRAS|ATM|TP53	1281.709748700576	247.34866405495535
1345.7053518884868	-67.27060232751006	0.8230000000000001	406	243	OV	PEMBROLIZUMAB	Approved in cancer	NRAS|MSH2|TP53	1375.6159832585463	136.44215946387789
1150.6968718825005	-31.369389825637853	0.6629999999999999	406	243	OV	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	KRAS|RB1|TP53	1134.5742340247275	-190.7221080523811
991.810130893622	0.3537725114632906	0.547	406	243	OV	GEDATOLISIB	Clinical trials in cancer	KRAS|NRAS|TP53	934.0669968466212	-174.25258523814355
854.4027353609428	47.905315913766856	0.442	406	243	OV	MIRDAMETINIB	Clinical trials in cancer	KRAS|NRAS|TP53	794.216692972666	33.29972313718142
1412.1459247444548	-59.7579542662515	0.8520000000000001	406	242	OV	DABRAFENIB	Approved in cancer	KRAS|NRAS|TP53	1366.8250481307432	-26.154742962589978
1437.1351045005047	1.2040378168781842	0.8720000000000001	406	242	OV	TAMOXIFEN	Approved in cancer	PIK3CA|BRCA1|TP53	1455.1582811300557	166.45198404184578
1394.8029319523343	-78.91516128846081	0.8420000000000001	406	242	OV	VENETOCLAX	Approved in cancer	PIK3CA|KRAS|TP53	1335.9079207302611	-280.4519969675823
1404.0189785915832	30.422296377786495	0.8420000000000001	406	242	OV	TOPOTECAN	Approved in cancer	PIK3CA|RB1|TP53	1315.0253080341024	-138.81918481101388
848.9092760700833	-25.898482602489764	0.442	406	242	OV	CAPIVASERTIB	Clinical trials in cancer	PIK3CA|KRAS|TP53	751.7754527483969	-161.77964548221362
893.891904687496	-6.619260620348342	0.472	406	242	OV	NAVITOCLAX	Clinical trials in cancer	PIK3CA|KRAS|TP53	880.9237013034889	153.85912803762324
874.2664430917613	8.629076095179357	0.452	406	242	OV	DS-7423	Clinical trials in cancer	PIK3CA|KRAS|TP53	797.5909687303084	204.49125035661564
259.3607354975268	0.539573956343645	0.0004	406	242	OV	ABT-737	Experimental	PIK3CA|KRAS|TP53	182.32570123259936	14.00597224400994
1388.1376670705276	11.412201441655554	0.8420000000000001	406	241	OV	BEVACIZUMAB	Approved in cancer	PIK3CA|KRAS|TP53	1443.0089255315881	-92.91960119560964
1083.206879567062	-38.93634835804539	0.622	406	241	OV	CHLORAMBUCIL	Approved in other pathologies and in clinical trials in cancer	BRCA2|BRCA1|TP53	1086.9638764584413	-215.90136110387368
902.8334293596281	16.499373763547055	0.482	406	241	OV	RESVERATROL	Clinical trials in cancer	PIK3CA|BRCA1|TP53	847.7046817307252	-148.46566942278585
970.234333613322	12.669363391705986	0.532	406	241	OV	NVP-CGM097	Clinical trials in cancer	PIK3CA|KRAS|TP53	905.4596494454917	152.13684120430054
807.0777662005482	-22.214627245768867	0.422	406	241	OV	DEMCIZUMAB	Clinical trials in cancer	PIK3CA|KRAS|TP53	673.8783000218802	-162.367214553154
301.41432933387546	0.19768052431419392	0.032	406	241	OV	EMODIN	Clinical trials	PIK3CA|BRCA1|TP53	317.7564995035625	-49.72441146116071
1457.2882133685182	15.557461407571196	0.892	406	240	OV	ENCORAFENIB	Approved in cancer	PTEN|KRAS|TP53	1440.0273962079948	-253.02786840451668
1505.992091342647	12.340456212580392	0.93	406	240	OV	CRIZOTINIB	Approved in cancer	ALK|KRAS|TP53	1515.7396547224503	-46.962711842159706
1370.048439552947	-72.86609442080413	0.8320000000000001	406	240	OV	ABEMACICLIB	Approved in cancer	KRAS|NRAS|TP53	1299.2115071036367	284.2877058273221
1404.1756961978022	-36.312940704840656	0.8420000000000001	406	240	OV	DOXORUBICIN HYDROCHLORIDE	Approved in cancer	YWHAG|BRCA1|TP53	1259.6732095905204	-1.835802912977016
1395.4709122473707	53.641205156084396	0.8420000000000001	406	240	OV	DAUNORUBICIN HYDROCHLORIDE	Approved in cancer	YWHAG|BRCA1|TP53	1395.7227479624999	44.1736623214872
1315.7661170781123	25.76409049141023	0.8230000000000001	406	240	OV	TEMOZOLOMIDE	Approved in cancer	MSH6|BRCA1|TP53	1200.065289160324	134.77114572057422
1268.6923822532258	0.4513754539802335	0.7550000000000001	406	240	OV	DASATINIB	Approved in other pathologies and in clinical trials in cancer	PIK3CA|KRAS|TP53	1154.410938005729	43.69914065825438
280.51274278845403	13.348310244248097	0.022	406	240	OV	LY3009120	Clinical trials	KRAS|NRAS|TP53	347.6420139873679	100.58390336042004
1428.3367954016344	-40.9177751752575	0.8520000000000001	406	239	OV	METHOTREXATE	Approved in cancer	NTRK1|RB1|TP53	1388.401327441392	-158.54878270418342
1500.1387831389088	-11.548913788992365	0.927	406	239	OV	LORLATINIB	Approved in cancer	ALK|RB1|TP53	1548.394933169193	222.2263420155315
1371.8271043471914	-7.073335047453497	0.8320000000000001	406	239	OV	VORINOSTAT	Approved in cancer	PTEN|RB1|TP53	1252.134786185843	-274.25635741324015
258.67519150192896	-48.676500749950435	0.0004	406	239	OV	MLS000104825	Experimental	BRCA1|TP53	138.87633157408308	-177.2894120117504
259.0085621976571	-24.126317677657653	0.0004	406	239	OV	ONONIN	Experimental	BRCA1|TP53	215.0573890693919	-10.095869322921487
237.57998258836437	-36.12067447089453	0.0004	406	239	OV	PF-477736	Experimental	KRAS|TP53	294.77520285273937	-40.47562559447357
258.34784430483614	49.74999272499872	0.0004	406	239	OV	QUINALIZARIN	Experimental	BRCA1|TP53	289.7040916632417	94.74170841630769
258.9791694156819	25.205240000637104	0.0004	406	239	OV	TCMDC-125575	Experimental	BRCA1|TP53	235.82347187877056	81.16669521331778
1419.628573910001	49.48277846834287	0.8520000000000001	406	238	OV	TRAMETINIB	Approved in cancer	NF1|RB1|TP53	1378.9110078388876	-205.88387866609835
1411.2071382244922	72.43455671751482	0.8520000000000001	406	238	OV	VEMURAFENIB	Approved in cancer	PIK3CA|NRAS|TP53	1359.374190883795	-295.13202876038287
1107.211022700969	-44.248093508902514	0.632	406	238	OV	MERCAPTOPURINE	Approved in other pathologies and in clinical trials in cancer	RB1|TP53	1114.2474710274491	188.7215600653696
869.2044048065184	-39.878316206617626	0.443	406	238	OV	SELICICLIB	Clinical trials in cancer	RB1|TP53	769.4278774136184	111.05957267228598
237.92878986960594	-11.640066092200982	0.0004	406	238	OV	1173900-33-8	Experimental	PIK3CA|ATM|TP53	92.00751015219477	87.10215542198688
1450.2399133311521	39.017544074042064	0.882	406	237	OV	DUVELISIB	Approved in cancer	PIK3CA|TP53	1389.7087978153488	88.65012801569873
1396.1360593072754	-11.801260247891975	0.8420000000000001	406	237	OV	RALOXIFENE	Approved in cancer	PIK3CA|TP53	1211.7204012461707	17.954059785976625
1386.7391286868726	76.61920568267982	0.8320000000000001	406	237	OV	ETOPOSIDE	Approved in cancer	BRCA2|ATM|TP53	1256.019885909399	-297.9342853077704
830.8761650312395	12.636328922679354	0.432	406	237	OV	TANESPIMYCIN	Clinical trials in cancer	PIK3CA|TP53	696.2889414545562	58.500289724851086
1293.1403741519352	0.47127822486802984	0.772	406	236	OV	ASPIRIN	Approved in other pathologies and in clinical trials in cancer	NTRK1|TP53	1170.5643096224785	159.08921850700722
826.879398496057	-36.61539977453657	0.432	406	236	OV	AZD6738	Clinical trials in cancer	BRCA2|ATM|TP53	764.6499893686564	-238.10167491606592
812.5100963751961	50.4708271562703	0.422	406	236	OV	GANETESPIB	Clinical trials in cancer	ALK|TP53	709.7261887709033	202.46870954702825
810.7669457889378	26.28492606245669	0.422	406	236	OV	ONC201	Clinical trials in cancer	PTEN|TP53	713.9713777543459	178.8802673541923
414.75629728042895	0.43250876075364886	0.122	406	236	OV	CINNARIZINE	Clinical trials	CACNA1S|TP53	398.21508991697834	-34.77432398263633
280.3046485775935	-12.235113963705714	0.022	406	236	OV	INOSITOL	Clinical trials	NRAS|TP53	317.15044630611743	-171.9823186707774
238.02756162387882	12.695823295750529	0.0004	406	236	OV	93718-83-3	Experimental	GNAS|TP53	258.45703616333225	39.603747054512326
237.57726095536935	36.943642393179545	0.0004	406	236	OV	CHEMBL2002487	Experimental	GNAS|TP53	188.14998161291325	-171.10476884288474
1323.9785577951031	2.795157878051384	0.8220000000000001	406	235	OV	CAPMATINIB	Approved in cancer	TP53	1235.3677950487859	-239.4463760619083
1371.480343894912	57.84085913597892	0.8320000000000001	406	235	OV	MITOXANTRONE HYDROCHLORIDE	Approved in cancer	TP53	1298.8910408139027	-74.47948266127943
1347.6318317899834	-2.1453912321042026	0.8220000000000001	406	235	OV	IFOSFAMIDE	Approved in cancer	TP53	1166.5952072016603	227.0574407211124
1338.8998997017384	-43.686880479564394	0.8220000000000001	406	235	OV	MECHLORETHAMINE HYDROCHLORIDE	Approved in cancer	TP53	1313.337910798665	210.7114798736792
1355.7456285324024	39.52006907623871	0.8320000000000001	406	235	OV	MELPHALAN	Approved in cancer	TP53	1213.2205642885704	-245.9682743047009
1339.7333240040336	21.106810726170522	0.8220000000000001	406	235	OV	METHYLPREDNISOLONE	Approved in cancer	TP53	1215.2486932864392	54.64299100246694
1347.716979285802	62.31736683876525	0.8220000000000001	406	235	OV	RITUXIMAB	Approved in cancer	TP53	1220.6866785404136	-15.761196365392863
1379.8987358587603	34.88607591637975	0.8320000000000001	406	235	OV	TAMOXIFEN CITRATE	Approved in cancer	TP53	1235.5219014829831	254.5400256019749
1331.3055373987659	-20.228152078771615	0.8220000000000001	406	235	OV	TRABECTEDIN	Approved in cancer	TP53	1275.3902839847974	-284.21243937614156
1331.995294601569	43.98303482726098	0.8220000000000001	406	235	OV	TRIFLURIDINE	Approved in cancer	TP53	1223.2486788327124	75.30954217777293
1104.8320627636476	43.31598460451107	0.632	406	235	OV	CLADRIBINE	Approved in other pathologies and in clinical trials in cancer	TP53	1053.1233223745849	97.20481427872039
1076.89529131954	-15.341365579417982	0.622	406	235	OV	THIORIDAZINE HYDROCHLORIDE	Approved in other pathologies and in clinical trials in cancer	TP53	1043.160483010869	-204.01838248961752
1100.3803760030016	-20.93222975294063	0.632	406	235	OV	AZACITIDINE	Approved in other pathologies and in clinical trials in cancer	TP53	1062.5465008762872	-220.92841693061627
1116.9967555920039	-3.3906879444622007	0.642	406	235	OV	DAUNORUBICIN	Approved in other pathologies and in clinical trials in cancer	TP53	1079.1354735536584	21.7443426706877
1069.999640439174	7.79683929098934	0.622	406	235	OV	ENALAPRIL	Approved in other pathologies and in clinical trials in cancer	TP53	1045.6907361577141	241.17111915092534
1110.0964962138178	19.753404982301163	0.632	406	235	OV	FENOFIBRATE	Approved in other pathologies and in clinical trials in cancer	TP53	1112.4145915301642	40.068039936509365
1140.4793854566924	-9.048473903237635	0.652	406	235	OV	FLUPHENAZINE	Approved in other pathologies and in clinical trials in cancer	TP53	1095.5679585172352	137.8326502174665
1157.8644636104345	7.690355490975037	0.6619999999999999	406	235	OV	HALOPERIDOL	Approved in other pathologies and in clinical trials in cancer	LDLR|TP53	1127.3169692521499	164.93917792476776
1086.5903621208709	25.32637002157668	0.622	406	235	OV	HYDRALAZINE HYDROCHLORIDE	Approved in other pathologies and in clinical trials in cancer	TP53	1078.8663729314437	-238.73220463794706
1152.6122448386495	31.264351687733523	0.6619999999999999	406	235	OV	LOPERAMIDE	Approved in other pathologies and in clinical trials in cancer	TP53	1103.7606135899237	164.82267104109093
1081.3340452595935	48.89707746580439	0.622	406	235	OV	METHYLENE BLUE CATION	Approved in other pathologies and in clinical trials in cancer	TP53	1021.8018696560957	-181.3715941069263
1093.4939759078661	2.1969709871447094	0.632	406	235	OV	THIAMAZOLE	Approved in other pathologies and in clinical trials in cancer	TP53	1070.9936015841286	-130.06180715379807
1123.8536779436977	-26.55628179533656	0.642	406	235	OV	WARFARIN	Approved in other pathologies and in clinical trials in cancer	TP53	1089.9833251609864	184.72998545378374
852.5833931510639	23.414524686700105	0.442	406	235	OV	GENISTEIN	Clinical trials in cancer	TP53	763.2069798799173	-214.33254008640864
970.469962737019	-11.777501088551247	0.532	406	235	OV	KEVETRIN	Clinical trials in cancer	TP53	905.2646078773001	108.21169578349793
829.0730324067781	-11.536864741358016	0.432	406	235	OV	FENRETINIDE	Clinical trials in cancer	TP53	688.3784508104959	-117.16407278516223
832.5086187720322	36.8429473612305	0.432	406	235	OV	NORDIHYDROGUAIARETIC ACID	Clinical trials in cancer	TP53	659.5450633151164	-142.94136901761084
809.007497538007	2.1450856794833157	0.422	406	235	OV	1026680-07-8	Clinical trials in cancer	TP53	697.7077571638383	-164.3785246314933
871.1281029786837	-15.654580218580918	0.442	406	235	OV	2-PHENYLETHYL ISOTHIOCYANATE	Clinical trials in cancer	TP53	764.2800733928852	-189.72869716411915
804.8084060517824	-46.54556060260282	0.422	406	235	OV	ALVESPIMYCIN	Clinical trials in cancer	TP53	692.8406114498018	-48.93387323503532
787.1382119144812	-8.122290628122329	0.412	406	235	OV	AVASTIN	Clinical trials in cancer	TP53	654.0404010186571	138.52954022257308
788.8990690867274	15.965434077390626	0.412	406	235	OV	CARBENDAZIM	Clinical trials in cancer	TP53	652.5572173785504	113.94571531772647
1420.6294372858868	-35.56586560005397	0.8530000000000001	171	104	PAAD	PACLITAXEL	Approved in same tumor type	CDKN2A|TP53|BRCA2	1512.7045461434536	-133.65960356347983
1395.3382520866992	-75.49029421775109	0.8420000000000001	171	104	PAAD	IRINOTECAN	Approved in same tumor type	KRAS|TP53|BRCA2	1273.3433223250397	-261.2453468533364
1427.8151585485093	49.55573883149722	0.8540000000000001	171	103	PAAD	TRAMETINIB	Approved in cancer	CDKN2A|TP53|STK11	1346.0336830994581	-315.9597749344301
1378.5712875297243	54.77376398279904	0.8430000000000001	171	103	PAAD	ABEMACICLIB	Approved in cancer	KRAS|CDKN2A|TP53	1285.469791772675	-182.09812903641003
1375.7741913506375	12.709364811421267	0.8430000000000001	171	103	PAAD	DOXORUBICIN	Approved in cancer	ATM|KRAS|TP53	1260.4885056320118	-129.1640439754022
1376.4571642171559	-55.98384191594694	0.8420000000000001	171	103	PAAD	CARBOPLATIN	Approved in cancer	CDKN2A|TP53|BRCA2	1258.7368055363759	245.1859883765946
1400.8239437488471	11.961102558348756	0.8420000000000001	171	103	PAAD	CRIZOTINIB	Approved in cancer	KRAS|CDKN2A|TP53	1313.4451969752413	-253.35253108117817
1423.9770418604128	-60.538265671195575	0.8520000000000001	171	103	PAAD	FLUOROURACIL	Approved in same tumor type	APC|KRAS|TP53	1384.0327139250346	-296.17677141362225
983.2144810067786	12.771694152493922	0.543	171	103	PAAD	BERZOSERTIB	Clinical trials in cancer	KRAS|TP53|BRCA2	906.5280806382123	-110.74539195171954
889.2525802315673	10.784220996078432	0.462	171	103	PAAD	SAPANISERTIB	Clinical trials in cancer	CDKN2A|TP53|STK11	840.9303730722929	116.68355222182947
250.68385873832236	12.803224284301194	0.0004	171	103	PAAD	PF-477736	Experimental	KRAS|CDKN2A|TP53	59.96924936134306	21.151743402838832
1412.3210347378185	-10.217988425032047	0.8520000000000001	171	102	PAAD	ENCORAFENIB	Approved in cancer	KRAS|TP53	1304.0309700868127	110.39536586670187
1400.8971818453995	-51.07675984711031	0.8420000000000001	171	102	PAAD	VENETOCLAX	Approved in cancer	KRAS|TP53	1339.3057957361016	-212.39096037498788
1445.459260762376	-38.845197540836466	0.8620000000000001	171	102	PAAD	BORTEZOMIB	Approved in cancer	KRAS|TP53	1401.8677527222121	-209.69252218233265
1438.3771841703337	26.940374462535402	0.8720000000000001	171	102	PAAD	ALPELISIB	Approved in cancer	ERBB2|KRAS|TP53	1364.7682378985821	188.0253624345258
1390.5427130916555	76.64992413989944	0.8420000000000001	171	102	PAAD	DABRAFENIB	Approved in cancer	KRAS|TP53	1365.3577644583138	-99.49520581302335
1345.7062794269507	30.78002735229279	0.8230000000000001	171	102	PAAD	PEMBROLIZUMAB	Approved in cancer	KRAS|TP53	1290.074395371165	208.26895100787692
1376.2105358174713	-31.012067077844108	0.8420000000000001	171	102	PAAD	BEVACIZUMAB	Approved in cancer	ERBB2|KRAS|TP53	1290.1996340382423	311.77347499226113
1402.8842619843192	49.25762764993482	0.8420000000000001	171	102	PAAD	PAZOPANIB	Approved in cancer	KRAS|TP53|BRCA2	1283.138230064306	98.99333408468556
1157.1148257672808	0.42379028327732726	0.6719999999999999	171	102	PAAD	DASATINIB	Approved in other pathologies and in clinical trials in cancer	APC|KRAS|TP53	1121.3427635793917	-148.529841558704
1119.2813421711392	13.568893110345698	0.644	171	102	PAAD	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	KRAS|TP53|STK11	1099.0303333524516	-149.16272854328514
869.5431040624413	-59.37563731528773	0.452	171	102	PAAD	NAVITOCLAX	Clinical trials in cancer	KRAS|TP53	803.4570184868419	-208.28388840415738
909.7502629557728	-3.455374684542477	0.472	171	102	PAAD	GEDATOLISIB	Clinical trials in cancer	KRAS|TP53|STK11	855.2398653177885	214.61284026183267
848.856375060061	2.3980517604217937	0.442	171	102	PAAD	CAPIVASERTIB	Clinical trials in cancer	KRAS|TP53	774.995318293314	-26.984333136884857
876.1758724627291	-31.598858418632318	0.452	171	102	PAAD	MIRDAMETINIB	Clinical trials in cancer	KRAS|TP53|STK11	850.9154532565617	-197.41824773061396
873.0861211228428	39.40827384592603	0.453	171	102	PAAD	PIMASERTIB	Clinical trials in cancer	KRAS|TP53	827.0308026662659	-204.20288650991245
981.2728663695891	-12.128721679388292	0.542	171	102	PAAD	NVP-CGM097	Clinical trials in cancer	KRAS|TP53	932.3891765998899	-28.406152474678322
834.338868909349	63.51952897645381	0.432	171	102	PAAD	ADAVOSERTIB	Clinical trials in cancer	KRAS|TP53|STK11	695.6642405688185	-94.18127399711705
823.0472412691149	0.6474620307363637	0.432	171	102	PAAD	DEMCIZUMAB	Clinical trials in cancer	KRAS|TP53	660.8203631034362	-26.859369868642943
853.0890581329066	-40.79205691231667	0.442	171	102	PAAD	DS-7423	Clinical trials in cancer	KRAS|TP53	813.8695305075073	-165.80897514810536
293.28352633899544	0.43212539799887395	0.032	171	102	PAAD	LY3009120	Clinical trials	KRAS|TP53	327.84861558095116	85.55605094083046
250.68376327047807	-12.172775715516337	0.0004	171	102	PAAD	ABT-737	Experimental	KRAS|TP53	137.28442121596262	-48.212411853387124
1387.6409059052626	-8.959877175371304	0.8430000000000001	171	101	PAAD	CISPLATIN	Approved in cancer	TP53|BRCA2|STK11	1431.353012626037	257.39957218272633
1414.629292226241	70.97833468233571	0.8450000000000001	171	101	PAAD	OLAPARIB	Approved in same tumor type	KRAS|TP53|BRCA2	1326.1670991201581	88.94794138568489
578.2711988319738	0.4322991207103257	0.243	171	101	PAAD	GEMCITABINE	Approved in other pathologies	KRAS|CDKN2A|TP53	527.3864274979269	63.68077285932557
1131.6625553871495	-7.719265047200793	0.652	171	100	PAAD	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	KRAS|TP53|STK11	1111.5477110440975	-217.3084262716602
1436.0400716844374	-16.23710068627426	0.8620000000000001	171	99	PAAD	DOCETAXEL	Approved in cancer	ERBB2|KRAS|TP53	1276.2200724651173	48.88740261390714
1415.4893347800717	29.894284787314433	0.8430000000000001	171	87	PAAD	PALBOCICLIB	Approved in cancer	ERBB2|KRAS|CDKN2A	1297.1717808490048	-289.8010561622039
1367.6319944943682	75.0793599480084	0.8330000000000001	171	86	PAAD	TEMSIROLIMUS	Approved in cancer	ERBB2|CTNNB1|KRAS	1264.121715274924	-183.05181522405215
1368.3105098238814	34.32081001085146	0.8430000000000001	171	85	PAAD	BINIMETINIB	Approved in cancer	ATM|APC|KRAS	1376.3082352260033	-274.70833529785335
1372.5123011652188	-78.81508736669123	0.8330000000000001	171	85	PAAD	EVEROLIMUS	Approved in same tumor type	KRAS|BRCA2|STK11	1238.48853235489	205.85930297094097
1365.0896049513633	-7.5647986663089455	0.8320000000000001	171	85	PAAD	VANDETANIB	Approved in cancer	ATM|APC|KRAS	1240.510739621101	118.57594475037007
1105.3849253015467	-4.594948542015686	0.632	171	85	PAAD	METFORMIN	Approved in other pathologies and in clinical trials in cancer	ATM|KRAS|STK11	1069.5670629437727	57.35244876618262
1388.838998961788	31.385852961522232	0.8440000000000001	171	84	PAAD	COBIMETINIB	Approved in cancer	KRAS	1401.1585024624164	-131.88230062248672
1398.8909207018737	-28.560976403495175	0.8420000000000001	171	84	PAAD	SORAFENIB	Approved in cancer	ERBB2|KRAS	1295.05114081632	167.23872740406318
1443.6565533367907	4.832068275196718	0.8620000000000001	171	84	PAAD	COPANLISIB	Approved in cancer	ERBB2|KRAS	1408.099214823011	191.53761390702016
1356.0884894269054	-45.6695198011837	0.8330000000000001	171	84	PAAD	REGORAFENIB	Approved in cancer	APC|KRAS	1226.792718419952	178.96852133091636
1518.8145914530048	0.4350007461476082	0.934	171	84	PAAD	SOTORASIB	Approved in cancer	KRAS	1549.6157725867752	-245.95505761274853
1423.556057678915	9.555411880686961	0.8620000000000001	171	84	PAAD	INFIGRATINIB	Approved in cancer	KRAS	1400.5562385024323	-251.2500439056737
1322.9828591255139	30.23122868218141	0.812	171	84	PAAD	ATEZOLIZUMAB	Approved in cancer	KRAS	1161.2261273688323	178.77180422526737
1356.0536677501725	51.02788285130123	0.8320000000000001	171	84	PAAD	CABOZANTINIB	Approved in cancer	KRAS	1251.6427785609537	-252.69316328058375
1336.7163813798184	-35.97508265595968	0.8220000000000001	171	84	PAAD	CAPECITABINE	Approved in cancer	ERBB2|KRAS	1250.717678977622	-56.0145808431579
1318.7524945668358	-25.90263630958364	0.812	171	84	PAAD	CETUXIMAB + CHEMOTHERAPY	Approved in cancer	KRAS	1184.7785968614453	238.8960529149287
1332.7517206266912	12.08001218019703	0.812	171	84	PAAD	CHEMOTHERAPY + PANITUMUMAB	Approved in cancer	KRAS	1254.2044439445285	-227.24851273540392
1353.2254115743388	9.40830743589899	0.8320000000000001	171	84	PAAD	ERDAFITINIB	Approved in cancer	KRAS	1220.0051348688867	239.3170513913381
1337.8123485428084	-56.5372871849773	0.8220000000000001	171	84	PAAD	IXABEPILONE	Approved in cancer	ERBB2|KRAS	1255.109370918877	127.37559820522046
1500.932773124027	-9.894478424587902	0.93	171	84	PAAD	NERATINIB	Approved in cancer	ERBB2|KRAS	1519.6702276167905	74.1223022436991
1335.3922103403206	51.0250423279538	0.8220000000000001	171	84	PAAD	PANOBINOSTAT	Approved in cancer	KRAS	1253.8075814814263	298.1536180635602
1347.42456401375	69.79248708923473	0.8320000000000001	171	84	PAAD	PEMETREXED	Approved in cancer	KRAS	1346.5486742937487	-145.82985223643038
1356.0267796936653	-66.26222412343773	0.8320000000000001	171	84	PAAD	RAMUCIRUMAB	Approved in cancer	ERBB2|KRAS	1245.7065911664315	-191.3728874029594
1342.4622900650795	-8.195233016335692	0.8220000000000001	171	84	PAAD	ROMIDEPSIN	Approved in cancer	ERBB2|KRAS	1232.1720984084056	-283.75587540344327
1354.2559206479234	-25.133842870465315	0.8320000000000001	171	84	PAAD	SUNITINIB	Approved in cancer	ERBB2|KRAS	1279.9440682815418	182.35360767916603
1322.0027353829892	-5.537840659079421	0.812	171	84	PAAD	TAZEMETOSTAT	Approved in cancer	KRAS	1177.962477990168	76.31480537507616
1500.9264505247975	10.75352060739425	0.93	171	84	PAAD	TRASTUZUMAB	Approved in cancer	ERBB2|APC|KRAS	1538.2390159030579	-175.02003211024856
1157.1867179118485	23.17274329106874	0.6719999999999999	171	84	PAAD	PONATINIB	Approved in other pathologies and in clinical trials in cancer	ERBB2|KRAS	1115.7420739544782	-93.69475510977074
1089.8912720760457	9.236342515204996	0.622	171	84	PAAD	NILOTINIB	Approved in other pathologies and in clinical trials in cancer	KRAS	1071.3565037543087	-169.34291074235807
1085.618427133953	-10.964714390332688	0.622	171	84	PAAD	LONAFARNIB	Approved in other pathologies and in clinical trials in cancer	KRAS	1077.0430487655897	-149.52117243432832
1157.1931674787209	-22.32514433999586	0.6719999999999999	171	84	PAAD	MIDOSTAURIN	Approved in other pathologies and in clinical trials in cancer	KRAS	1108.0839161732656	-9.605230619592419
853.7022537534424	51.58292417714162	0.442	171	84	PAAD	DINACICLIB	Clinical trials in cancer	KRAS	878.1028645254016	6.65566687123993
833.8986114967075	40.81050149026612	0.432	171	84	PAAD	VOLASERTIB	Clinical trials in cancer	KRAS	788.4897775345513	14.330990885102437
837.0869348696833	-17.086804692299722	0.442	171	84	PAAD	RIGOSERTIB	Clinical trials in cancer	KRAS	776.1128848124861	210.70983393590126
825.9351828129691	-56.78094061023599	0.432	171	84	PAAD	IPATASERTIB	Clinical trials in cancer	ERBB2|KRAS	758.2680381522674	221.76190869689293
894.8694977029808	32.93712644244678	0.462	171	84	PAAD	PILARALISIB	Clinical trials in cancer	ERBB2|KRAS|STK11	828.3811091348456	-182.40437339741538
891.1101600564465	53.2362910105264	0.462	171	84	PAAD	PF-04691502	Clinical trials in cancer	KRAS	813.5777024797665	147.46887999411933
898.9034288371209	-30.921210568967552	0.462	171	84	PAAD	SONOLISIB	Clinical trials in cancer	KRAS	857.3004054530243	15.800202317510013
852.0377269086068	31.071118511848596	0.442	171	84	PAAD	TAK-733	Clinical trials in cancer	KRAS	781.8989297756699	-202.174960490444
870.9941211685059	-2.8851283722918595	0.462	171	84	PAAD	212631-79-3	Clinical trials in cancer	ERBB2|KRAS|STK11	836.1175221131936	203.17277875718963
910.4247972704666	19.35915682110769	0.472	171	84	PAAD	APITOLISIB	Clinical trials in cancer	KRAS	831.5391631669958	70.62533034597044
889.0428443052122	-12.820277755554656	0.462	171	84	PAAD	SERABELISIB	Clinical trials in cancer	KRAS	848.0808162597235	-63.087114672814806
812.7975921526894	70.83098829325567	0.422	171	84	PAAD	LIFIRAFENIB	Clinical trials in cancer	ERBB2|KRAS	648.8767167087669	-88.91238720151762
834.6210763951273	20.07508895996068	0.432	171	84	PAAD	ULIXERTINIB	Clinical trials in cancer	KRAS	681.4692555905543	-32.14632277595476
857.6135531085214	-18.560019282078883	0.442	171	84	PAAD	GDC-0623	Clinical trials in cancer	KRAS	789.7491871305	-116.5478124823071
890.073309496368	-49.57435998094937	0.462	171	84	PAAD	IZORLISIB	Clinical trials in cancer	ERBB2|KRAS	836.9775558866594	-2.056188736149579
867.4058548552439	17.37470666905793	0.452	171	84	PAAD	SARACATINIB	Clinical trials in cancer	KRAS	810.1960835171386	71.63353087510777
801.771390682725	-7.197182556498774	0.422	171	84	PAAD	AZD8055	Clinical trials in cancer	ERBB2|KRAS|STK11	739.3895603216239	0.6694971714283326
796.5367449771737	58.08826315181079	0.422	171	84	PAAD	AZD8835	Clinical trials in cancer	KRAS	671.3227780940603	125.08574440807001
816.474332926051	29.784322800386434	0.422	171	84	PAAD	CAMPTOTHECIN	Clinical trials in cancer	KRAS	760.0265407370301	130.4695316935098
790.833741877441	-46.94481782541638	0.412	171	84	PAAD	DANUSERTIB	Clinical trials in cancer	KRAS	657.906769395197	31.838850675604107
845.8075760613453	-62.31554842313321	0.432	171	84	PAAD	FIMEPINOSTAT	Clinical trials in cancer	ERBB2|KRAS	720.4832005705678	113.81361713177756
815.6956711398667	50.400418083678375	0.422	171	84	PAAD	LINSITINIB	Clinical trials in cancer	KRAS	687.7516757284102	12.59247212749753
797.3025620162007	37.47791629299613	0.422	171	84	PAAD	ONATASERTIB	Clinical trials in cancer	KRAS	744.93215698401	-201.17396967357152
810.9980540586874	-42.56157008309793	0.422	171	84	PAAD	OSI-027	Clinical trials in cancer	KRAS	646.720084297609	-43.3937100001456
806.1213639979828	-62.56811034099756	0.422	171	84	PAAD	PANULISIB	Clinical trials in cancer	KRAS	661.0674667173087	-72.80954835741632
816.9331163100359	-21.262489806407814	0.422	171	84	PAAD	PHENFORMIN	Clinical trials in cancer	KRAS|STK11	674.1925538733587	147.7614903592031
804.1576390339844	13.257604188876428	0.425	171	84	PAAD	POZIOTINIB	Clinical trials in cancer	ERBB2|KRAS	773.694129669751	-125.81529259135417
780.6190172436761	-14.992715358096632	0.412	171	84	PAAD	RALIMETINIB	Clinical trials in cancer	KRAS	640.7770279955266	-69.96422791379554
797.1994134324834	-27.28283879003041	0.422	171	84	PAAD	RIDAFOROLIMUS	Clinical trials in cancer	KRAS	666.931740420252	-122.15879679202038
780.6727887655801	25.254980772567166	0.412	171	84	PAAD	RILOTUMUMAB	Clinical trials in cancer	KRAS	713.0589266082352	-205.06428538860797
830.753171972594	-36.671320597868515	0.432	171	84	PAAD	SALIRASIB	Clinical trials in cancer	KRAS	799.0677467627172	-135.31148764099623
785.1957560906177	5.108452181690296	0.422	171	84	PAAD	SAR125844	Clinical trials in cancer	KRAS	680.3823227542539	-77.59220365785525
1362.987441702465	3.651603169304792	0.8220000000000001	178	26	PCPG	TRAMETINIB	Approved in same tumor type	FGFR1|HRAS|NF1	1212.2957045658638	-184.62998233780556
1346.7617811072216	3.294398386665023	0.812	178	25	PCPG	EVEROLIMUS	Approved in same tumor type	VHL|RET|HRAS	1263.304449872373	56.89992910647163
1089.203023186585	0.8293626271811831	0.622	178	25	PCPG	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	FGFR1|HRAS|NF1	1076.5321988248957	7.147166901942029
1357.4016221383577	6.995637091578459	0.8220000000000001	178	23	PCPG	BINIMETINIB	Approved in same tumor type	BRAF|HRAS|NF1	1270.1734454299847	5.284744457065841
1492.093442995889	3.5085162474897515	0.92	178	23	PCPG	CABOZANTINIB	Approved in same tumor type	RET|HRAS	1440.1151133238345	162.5821545383664
1354.827892295444	-4.428549837851904	0.8220000000000001	178	23	PCPG	CETUXIMAB	Approved in same tumor type	RET|HRAS	1269.6143647734907	255.2275702594369
1089.4827634683625	-5.442771254181366	0.622	178	22	PCPG	DASATINIB	Approved in other pathologies and in clinical trials in cancer	IDH1|FGFR1|HRAS	979.7443191203929	-130.99576158252484
1354.4368802537228	1.5025232330035294	0.8220000000000001	178	21	PCPG	ALPELISIB	Approved in same tumor type	BRAF|FGFR1|HRAS	1284.4076697957444	56.124920923744156
1360.5085115961972	-6.180811815555046	0.8220000000000001	178	21	PCPG	BEVACIZUMAB	Approved in same tumor type	VHL|IDH1|HRAS	1235.066007943714	-73.42493351410967
819.5654126232075	3.3146987382324085	0.422	178	21	PCPG	BUPARLISIB	Clinical trials in cancer	BRAF|FGFR1|HRAS	765.0559172056464	95.62779670077367
1089.5011879946426	6.876263384316843	0.622	178	20	PCPG	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	FGFR1|HRAS	1068.6349195579114	-116.89265040294428
808.2162676777514	-5.95490793208387	0.412	178	20	PCPG	AZD8055	Clinical trials in cancer	FGFR1|HRAS	683.5961936551412	23.999640632526763
536.41469908538	0.4317537137071952	0.212	178	20	PCPG	GEMCITABINE	Approved in other pathologies	BRAF|IDH1|HRAS	464.1991662572796	27.156726603535276
1494.1486394699546	-1.828945233927044	0.92	178	19	PCPG	DABRAFENIB	Approved in same tumor type	BRAF|HRAS	1440.0426646533315	165.00181371689496
1488.913826884362	-1.2462459713335363	0.92	178	19	PCPG	VEMURAFENIB	Approved in same tumor type	BRAF|HRAS	1499.8418266680103	-85.99239661737053
1077.3176420193863	-3.1423785308724064	0.612	178	19	PCPG	METFORMIN	Approved in other pathologies and in clinical trials in cancer	IDH1|HRAS	1051.4978450990916	18.275542706742527
809.1512717710717	1.311935350038823	0.412	178	19	PCPG	MK-2206	Clinical trials in cancer	BRAF|HRAS	707.2242880710744	-9.250781694847348
815.6836431525223	-0.57678282871737	0.422	178	19	PCPG	DACTOLISIB	Clinical trials in cancer	BRAF|HRAS	704.6520464395328	-103.57397357879162
820.7391262736722	-2.0540438962621295	0.422	178	19	PCPG	212631-79-3	Clinical trials in cancer	BRAF|HRAS	742.1541676768607	-78.12695135773443
809.0205744643374	6.798872759878407	0.412	178	19	PCPG	E6201	Clinical trials in cancer	BRAF|HRAS	775.6628109051323	-40.24815396679742
1359.2266219017454	-0.9551854186230457	0.8220000000000001	178	18	PCPG	DOCETAXEL	Approved in same tumor type	HRAS	1251.8755021336074	115.64958182565363
1364.1165871269652	-2.184209950365471	0.8220000000000001	178	18	PCPG	PANITUMUMAB	Approved in same tumor type	HRAS	1224.7718601987926	62.34952165570053
1347.2751707886428	-4.4251423482294	0.812	178	18	PCPG	STREPTOZOCIN	Approved in same tumor type	HRAS	1271.9960457654768	92.2181643766744
1073.9302141486837	0.7453094842725534	0.612	178	18	PCPG	HYDROXYCARBAMIDE	Approved in other pathologies and in clinical trials in cancer	HRAS	1011.5156005943101	170.4944499212695
1077.6726290332808	4.1277748109178845	0.612	178	18	PCPG	LONAFARNIB	Approved in other pathologies and in clinical trials in cancer	HRAS	1065.5561562438443	-143.77372397599868
803.7995678556615	6.162461063769911	0.412	178	18	PCPG	ANTIBIOTIC	Clinical trials in cancer	HRAS	761.1837104558442	-30.807896382982392
802.0535720883781	1.4283623222760298	0.412	178	18	PCPG	REOLYSIN	Clinical trials in cancer	HRAS	782.4725152905197	0.28575708943466793
803.5982457090643	-3.405903198110394	0.412	178	18	PCPG	RIGOSERTIB	Clinical trials in cancer	HRAS	702.1887169468498	-57.41613191735955
549.7060902371006	-2.090187815214307	0.2219999999999999	178	18	PCPG	LOSARTAN POTASSIUM	Approved in other pathologies	HRAS	468.5492899147069	29.473889336097898
549.7061004229586	2.9538121847754155	0.2219999999999999	178	18	PCPG	NITROGLYCERIN	Approved in other pathologies	HRAS	503.54826698453843	-56.695197884932995
265.0614307297603	0.3640387624722621	0.012	178	18	PCPG	INSULIN	Clinical trials	HRAS	275.85867810759987	89.18496608460327
248.84145458698615	0.4831254675119965	0.0008	178	18	PCPG	1,6-HEXANEDIOL	Experimental	HRAS	260.581733406063	-93.60814555525522
255.85358383491004	1.0724435035603221	0.0008	178	18	PCPG	2,2,2-TRIFLUOROETHANOL	Experimental	HRAS	155.00253250177664	-74.44878811817557
248.68032564257132	-7.514262213899684	0.0008	178	18	PCPG	GUANOSINE 5'-DIPHOSPHATE	Experimental	HRAS	208.74794852760618	-23.206038011851888
253.85995611915322	5.701226371280484	0.0008	178	18	PCPG	GUANOSINE TRIPHOSPHATE	Experimental	HRAS	94.5466276982901	18.217226384852808
254.57853156364345	-3.807343769619621	0.0008	178	18	PCPG	N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE	Experimental	HRAS	121.37069934049991	-115.65047688348473
249.24870203580835	7.752190459462355	0.0004	178	18	PCPG	167869-21-8	Experimental	HRAS	134.2251090679645	18.62021306349095
1485.3595437648792	0.8850240921466082	0.917	178	9	PCPG	REGORAFENIB	Approved in same tumor type	VHL|RET|FGFR1	1470.6217450275622	-43.04974604350798
811.7495223534758	-3.5738326678202554	0.413	178	9	PCPG	CEDIRANIB	Clinical trials in cancer	VHL|RET|FGFR1	692.2696081037129	-80.5726818525032
1504.4402847913998	0.3695345213089922	0.93	178	8	PCPG	VANDETANIB	Approved in same tumor type	IDH1|RET|FGFR1	1492.5044143705695	-35.70924821920576
1487.7061800795664	2.602042135194722	0.919	178	8	PCPG	SUNITINIB	Approved in same tumor type	VHL|RET|FGFR1	1384.868573559778	-116.00665951443648
1491.1908813574141	-4.572036311517991	0.92	178	8	PCPG	SORAFENIB	Approved in same tumor type	BRAF|RET|FGFR1	1483.7368923622284	17.905837713600988
1484.953545585628	-1.9947207017794426	0.914	178	8	PCPG	LENVATINIB	Approved in same tumor type	BRAF|RET|FGFR1	1414.289650461538	-5.394749308424537
1224.5353730759389	0.4291907719148469	0.7220000000000001	178	8	PCPG	FOSTAMATINIB	Approved in other pathologies and in clinical trials in cancer	BRAF|RET|FGFR1	1176.0868385293284	3.478350302893631
1497.5398276127273	0.13228722531667358	0.925	178	7	PCPG	PRALSETINIB	Approved in same tumor type	RET|FGFR1	1517.6161817043883	-24.164875999272397
1482.4363822453622	-1.0698831494742933	0.914	178	7	PCPG	SELPERCATINIB	Approved in same tumor type	RET|FGFR1	1365.6014023103521	-50.469456195338836
1484.1170870022586	3.3945766583420607	0.914	178	7	PCPG	ERDAFITINIB	Approved in same tumor type	RET|FGFR1	1428.454467618217	-116.25564982388431
1343.467747902832	-4.503868180798236	0.812	178	7	PCPG	ALECTINIB	Approved in same tumor type	RET|FGFR1	1267.8850841079823	40.318646058236055
1358.389706157313	2.75785675034831	0.8220000000000001	178	7	PCPG	ENTRECTINIB	Approved in same tumor type	RET|FGFR1	1232.2299578981335	84.27752598069384
1350.4174921229016	0.5169576899473327	0.8130000000000001	178	7	PCPG	PAZOPANIB	Approved in same tumor type	RET|FGFR1	1304.768940564134	21.458107317628247
1216.5882463052617	0.4295781652560038	0.7160000000000001	178	7	PCPG	PONATINIB	Approved in other pathologies and in clinical trials in cancer	RET|FGFR1	1174.4318680472902	-26.936800622507633
1210.0774002133728	0.4298458451343379	0.7110000000000001	178	7	PCPG	ROMIPLOSTIM	Approved in other pathologies and in clinical trials in cancer	RET|FGFR1	1142.4476441093184	82.04439962167294
948.7031781134237	0.989302526936342	0.518	178	7	PCPG	DOVITINIB	Clinical trials in cancer	RET|FGFR1	876.1838025826821	-7.1373704179491995
942.347957863062	1.3546947404586263	0.513	178	7	PCPG	TYROSINE KINASE-IN-1	Clinical trials in cancer	RET|FGFR1	919.552730921166	78.8832190205016
804.3558774112095	-7.131504587034556	0.412	178	7	PCPG	693228-63-6	Clinical trials in cancer	RET|FGFR1	772.2214235939655	-14.415491473561389
805.9866249724689	9.278637382687975	0.412	178	7	PCPG	ALISERTIB	Clinical trials in cancer	RET|FGFR1	727.9601765166545	8.468817442041967
805.8538019413638	-9.222295370558811	0.412	178	7	PCPG	CENISERTIB	Clinical trials in cancer	RET|FGFR1	697.8237223195197	7.604369950615364
807.1711235174939	-2.078576379226888	0.412	178	7	PCPG	CEP-11981	Clinical trials in cancer	RET|FGFR1	732.7718109041366	67.10931085662801
943.8817977493909	-0.7109523963670199	0.514	178	7	PCPG	ENMD-2076	Clinical trials in cancer	RET|FGFR1	924.4581409293015	-17.112431731351677
805.521100511287	-0.1295209829720818	0.412	178	7	PCPG	ILORASERTIB	Clinical trials in cancer	RET|FGFR1	770.228300298832	-67.91583205788316
946.3879763139398	-0.13004940346314697	0.516	178	7	PCPG	LUCITANIB	Clinical trials in cancer	RET|FGFR1	913.04311898647	-12.316609259319904
278.9439730727686	0.3344442327643833	0.022	178	7	PCPG	252003-65-9	Clinical trials	RET|FGFR1	249.20094961853653	83.51758288318166
250.5098671173371	3.8972285029603313	0.0004	178	7	PCPG	504433-23-2	Experimental	RET|FGFR1	190.67195741222017	76.50629006261823
246.22459029520766	-4.613022620025788	0.0004	178	7	PCPG	761439-42-3	Experimental	RET|FGFR1	205.07729415576821	-1.5687680048580717
245.03942134465134	0.32637106300924756	0.0004	178	7	PCPG	882531-87-5	Experimental	RET|FGFR1	251.48318219542944	28.002286120628668
246.01220294171196	-2.052144767122371	0.0004	178	7	PCPG	AST 487	Experimental	RET|FGFR1	215.7424603682731	1.4936039617566905
245.97300676097987	5.8016294392304815	0.0004	178	7	PCPG	HESPERADIN	Experimental	RET|FGFR1	262.06727129630974	78.53422709891788
248.43730191631215	-3.3029934366143436	0.0004	178	7	PCPG	JNJ-7706621	Experimental	RET|FGFR1	246.17187613846397	89.61637209701604
251.93812341513797	-9.48711745320071	0.0004	178	7	PCPG	PD0166285	Experimental	RET|FGFR1	181.26009748459995	31.710016334880066
250.9270911542219	-2.6845417359511146	0.0004	178	7	PCPG	PF-562271	Experimental	RET|FGFR1	162.72863440690134	-95.80832768572242
247.9629420240003	4.1692058631958275	0.0004	178	7	PCPG	PYRAZOLANTHRONE	Experimental	RET|FGFR1	221.45360208284637	-98.05832606738865
252.4602911884047	-0.6366182080839167	0.0004	178	7	PCPG	TAMATINIB	Experimental	RET|FGFR1	177.24677484992878	27.185385813300655
252.46022860259106	-6.97373602700489	0.0004	178	7	PCPG	TCMDC-125758	Experimental	RET|FGFR1	163.42522090587386	-99.2256085151182
245.80134503263065	2.7754044440364396	0.0004	178	7	PCPG	TOZASERTIB	Experimental	RET|FGFR1	150.23386467716222	-53.419040715011846
1482.721880560868	1.3702716245316537	0.914	178	6	PCPG	IMATINIB	Approved in same tumor type	BRAF|RET	1506.99895124141	-14.431430541252979
1480.0075786534242	-1.4586218540558207	0.912	178	6	PCPG	IMATINIB MESYLATE	Approved in same tumor type	IDH1|RET	1386.227619103123	-90.26282348320422
1480.431373115826	0.8502583746326877	0.912	178	6	PCPG	SORAFENIB TOSYLATE	Approved in same tumor type	BRAF|RET	1425.2719284177606	-113.05915131215527
1343.6713111697193	0.04770013500819914	0.812	178	6	PCPG	ERLOTINIB	Approved in same tumor type	BRAF|RET	1339.309955150316	-69.08410063002634
1349.9704661521287	-1.9022931232534006	0.812	178	6	PCPG	LAPATINIB	Approved in same tumor type	BRAF|RET	1263.459440843754	47.76254095084019
1345.7438724805565	-1.0612174627883917	0.812	178	6	PCPG	PALBOCICLIB	Approved in same tumor type	BRAF|RET	1307.4069379189177	22.259041778627818
252.18620505931023	2.0615490170238218	0.0008	178	6	PCPG	AGERAFENIB	Experimental	BRAF|RET	181.3528920807763	-68.45983068495804
1481.1536545219958	2.966388141134871	0.912	178	5	PCPG	SUNITINIB MALATE	Approved in same tumor type	RET	1387.6812904920962	-115.29847005275127
1347.9701442411538	-0.9058998261532452	0.812	178	5	PCPG	ALECTINIB HYDROCHLORIDE	Approved in same tumor type	RET	1240.016159685508	40.67374212559125
1343.8135589699436	-2.1876303407483135	0.812	178	5	PCPG	DEXAMETHASONE	Approved in same tumor type	RET	1264.7103980248003	54.84264421478633
1077.510169210756	0.5474587906160764	0.612	178	5	PCPG	GILTERITINIB	Approved in other pathologies and in clinical trials in cancer	RET	1042.1182246079438	6.145484906852914
946.6922517721243	2.199637763733108	0.515	178	5	PCPG	AMUVATINIB	Clinical trials in cancer	RET	898.2470901315118	60.99327798140018
944.6892751435045	1.4929124823660516	0.515	178	5	PCPG	MOTESANIB	Clinical trials in cancer	RET	901.2046896162733	-78.25588428670105
953.8192835598195	0.5281514884447347	0.522	178	5	PCPG	AT9283	Clinical trials in cancer	RET	917.530842282515	-76.22227019146268
940.4215048395056	0.014184768863742647	0.511	178	5	PCPG	SITRAVATINIB	Clinical trials in cancer	RET	851.8087704876871	50.24537084759936
812.8117915909027	1.7451281697002514	0.414	178	5	PCPG	LINIFANIB	Clinical trials in cancer	RET	758.0733586074692	-116.17296231089205
813.6251143616182	3.709007870667051	0.413	178	5	PCPG	QUIZARTINIB	Clinical trials in cancer	RET	705.528989138634	-48.662802411415754
815.6532726014434	3.1172257276430457	0.422	178	5	PCPG	AZD1480	Clinical trials in cancer	RET	771.7571091358155	-13.461417340958548
812.0162617922433	-1.0118900127226595	0.412	178	5	PCPG	GENISTEIN	Clinical trials in cancer	RET	730.7433088158699	56.17255571628314
805.5428307300932	2.191498961671101	0.412	178	5	PCPG	LESTAURTINIB	Clinical trials in cancer	RET	728.7468777677433	-0.5752837086678824
811.5455933709217	4.1129883114214465	0.412	178	5	PCPG	RIVOCERANIB	Clinical trials in cancer	RET	722.2323120611107	-22.185302446848226
809.4874051910042	-2.364499704931035	0.412	178	5	PCPG	SNS-314	Clinical trials in cancer	RET	764.739992368708	-16.244808058566093
806.6548146152381	4.001158414371304	0.412	178	5	PCPG	TANESPIMYCIN	Clinical trials in cancer	RET	765.4905354046651	-18.806988299675766
265.1327626752437	-3.2192513114053725	0.012	178	5	PCPG	TAFETINIB	Clinical trials	RET	286.41454961684894	2.1422795649375814
251.18814538820172	-5.000183849589888	0.0008	178	5	PCPG	172889-26-8	Experimental	RET	183.42761660610824	-48.38790919828398
252.58551355435594	9.052770242628185	0.0004	178	5	PCPG	331771-20-1	Experimental	RET	245.5684419224916	-54.20372947160125
590.0638656849693	0.43365536998882703	0.252	489	54	PRAD	GEMCITABINE	Approved in other pathologies	CDKN2A|PTEN|HRAS	519.1965677330494	-66.26836881097954
1376.4902993294754	-4.4969305153069286	0.8330000000000001	489	52	PRAD	CISPLATIN	Approved in cancer	BRCA2|KRAS|PTEN	1208.0674423071089	-126.08796330994551
1545.680374488519	0.43095698535867655	0.96	489	52	PRAD	ALPELISIB	Approved in cancer	KRAS|PTEN|HRAS	1542.1801177805685	-109.80949112691968
1453.8663664124936	0.44495318444782583	0.892	489	51	PRAD	PACLITAXEL	Approved in cancer	KRAS|CDKN2A|PTEN	1385.5897612759422	126.62336943577043
1362.4724205774041	0.7993217562887764	0.8230000000000001	489	51	PRAD	OLAPARIB	Approved in same tumor type	BRIP1|KRAS|PTEN	1188.1251110770036	-90.5536192948889
1249.050702792359	0.4327234754817937	0.7400000000000001	489	51	PRAD	DASATINIB	Approved in other pathologies and in clinical trials in cancer	TP53|KRAS|HRAS	1167.71948481046	43.703682849934324
1491.9006437451617	2.4597925775927934	0.92	489	50	PRAD	VEMURAFENIB	Approved in cancer	TP53|PTEN|HRAS	1489.7291024950864	-66.24774483492399
1385.9636317478758	-1.2322513134211022	0.8420000000000001	489	50	PRAD	VENETOCLAX	Approved in cancer	TP53|KRAS|PTEN	1378.486692925404	14.704064766555547
1116.5927514159484	0.4280034350651647	0.642	489	50	PRAD	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	KRAS|PTEN|HRAS	1069.3116048020536	-14.90424680412363
846.4264808537039	0.4272726176222932	0.442	489	50	PRAD	SAPANISERTIB	Clinical trials in cancer	KRAS|CDKN2A|PTEN	771.6216106669693	-47.21644296533648
1377.5037614146681	0.5320867632318311	0.8330000000000001	489	49	PRAD	CARBOPLATIN	Approved in cancer	KRAS|CDKN2A|PTEN	1399.6524959915916	-119.19883235852869
1361.3726373858224	-4.170819203959439	0.8220000000000001	489	49	PRAD	FLUOROURACIL	Approved in cancer	TP53|KRAS|PTEN	1342.8838757966955	104.51119265196104
1373.0018789440735	7.487029216081453	0.8320000000000001	489	49	PRAD	TOPOTECAN	Approved in cancer	PIK3CA|TP53|PTEN	1379.7866131409673	-20.172836085132047
1001.8851030862737	0.4322554064106896	0.557	489	49	PRAD	GEDATOLISIB	Clinical trials in cancer	TP53|KRAS|PTEN	972.4730846174012	-12.698710164263446
1588.9265609048239	0.4321613402683795	0.992	489	47	PRAD	TAMOXIFEN	Approved in cancer	IDH1|PIK3CA|TP53	1623.0223768383016	-77.62578746567146
1369.2655361507202	4.27590855907701	0.8320000000000001	489	47	PRAD	BEVACIZUMAB	Approved in cancer	TP53|KRAS|HRAS	1234.7212980219379	72.04040433447395
1104.512786539793	0.427464415517278	0.633	489	47	PRAD	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	TP53|KRAS|HRAS	1080.7382865879263	-21.06241387005238
946.714205177335	0.4322505667412315	0.516	489	47	PRAD	CAPIVASERTIB	Clinical trials in cancer	TP53|KRAS|PTEN	848.9203167669723	4.644868275768545
859.9197058382124	0.43026432242422175	0.452	489	47	PRAD	NAVITOCLAX	Clinical trials in cancer	TP53|KRAS|PTEN	807.5085711741966	-1.417118486416058
832.8353953043977	2.498034231499389	0.432	489	47	PRAD	MIRDAMETINIB	Clinical trials in cancer	TP53|KRAS|PTEN	761.7666608032526	-12.460118192378076
256.62263129676523	-7.770452935560172	0.0004	489	47	PRAD	1173900-33-8	Experimental	PIK3CA|TP53|PTEN	183.1314883497988	66.03759724528516
1399.6547679942298	-1.5843590440223068	0.8520000000000001	489	45	PRAD	TRAMETINIB	Approved in cancer	KRAS|CDKN2A|HRAS	1290.4717348122288	29.80763879008893
824.4905510637022	2.458269355522333	0.424	489	45	PRAD	DS-7423	Clinical trials in cancer	TP53|KRAS|PTEN	733.028101534798	65.87251048679448
256.43082799819433	10.401878107321949	0.0004	489	45	PRAD	ABT-737	Experimental	TP53|KRAS|PTEN	235.37117400024775	46.89908665984822
1369.1388991189003	-0.4433490878391808	0.8320000000000001	489	44	PRAD	IRINOTECAN	Approved in cancer	TP53|BRCA2|KRAS	1262.04416567196	45.89676906535189
1425.6351265577196	0.4411810965945051	0.8710000000000001	489	44	PRAD	ERLOTINIB	Approved in cancer	APC|TP53|PTEN	1382.0317288562965	41.54599798970037
955.9993661069544	0.4322647600415337	0.523	489	44	PRAD	RESVERATROL	Clinical trials in cancer	AKT1|PIK3CA|TP53	930.1036646549701	2.6352733198838507
1491.8950756974862	-2.34220419425543	0.92	489	43	PRAD	DABRAFENIB	Approved in cancer	TP53|KRAS|HRAS	1463.6841548004127	-64.0811028572878
1377.2265991960887	5.286428470953865	0.8330000000000001	489	43	PRAD	DOXORUBICIN	Approved in cancer	PIK3CA|TP53|KRAS	1275.8083557080154	107.23319745828024
1440.4480984059926	-1.527923162851721	0.882	489	43	PRAD	DOCETAXEL	Approved in same tumor type	TP53|KRAS|HRAS	1408.894473042037	68.90369188926306
832.8545948739138	-2.1419260459362306	0.432	489	42	PRAD	PIMASERTIB	Clinical trials in cancer	PIK3CA|TP53|KRAS	781.6696973695288	115.96230803436629
1399.649400136516	2.931637765775349	0.8520000000000001	489	41	PRAD	BORTEZOMIB	Approved in cancer	PIK3CA|TP53|KRAS	1309.6324615416418	-39.36366423847588
1361.8153745410987	5.516055734715621	0.8220000000000001	489	41	PRAD	TEMOZOLOMIDE	Approved in cancer	IDH1|TP53|PTEN	1269.3318721172427	4.88044619445094
968.0655400606796	0.4322763804450176	0.532	489	41	PRAD	NVP-CGM097	Clinical trials in cancer	PIK3CA|TP53|KRAS	935.1671758911164	-14.373656950398754
821.0556958263942	-4.177941041485269	0.422	489	41	PRAD	TANESPIMYCIN	Clinical trials in cancer	AR|PIK3CA|TP53	764.3234938651826	-14.684093095586121
278.4850345050766	0.4159121874221796	0.022	489	41	PRAD	EMODIN	Clinical trials	AR|PIK3CA|TP53	268.1248501082619	-1.3392128175465814
1503.697097785352	-0.5654095688736049	0.929	489	40	PRAD	ENCORAFENIB	Approved in cancer	TP53|KRAS|PTEN	1379.1615018224852	20.548953472781506
1500.8275325952031	2.599820001343886	0.927	489	40	PRAD	RALOXIFENE	Approved in cancer	ESR1|PIK3CA|TP53	1553.432857283773	62.34099558900846
1370.9789381805517	-4.481362730066365	0.8320000000000001	489	40	PRAD	VORINOSTAT	Approved in cancer	BRAF|TP53|PTEN	1337.1850168110477	-67.62377556613073
820.4115118173065	4.302691439441645	0.422	489	40	PRAD	ONC201	Clinical trials in cancer	AKT1|TP53|PTEN	717.4098007779651	-85.84267943004838
249.97639856025356	7.361354539682679	0.0004	489	40	PRAD	BENZETHONIUM CHLORIDE	Experimental	AR|IDH1|TP53	289.20876981483013	-53.22590894380971
249.82872846341888	14.61533332952601	0.0004	489	40	PRAD	DICHLOROPHEN	Experimental	AR|IDH1|TP53	255.0895593894255	-55.787192629578456
1440.4477260052972	2.8260768212224434	0.882	489	39	PRAD	DUVELISIB	Approved in cancer	PIK3CA|TP53	1425.0652874758841	-116.30994301035807
1373.5735536416396	2.923035057331248	0.8320000000000001	489	39	PRAD	DAUNORUBICIN HYDROCHLORIDE	Approved in cancer	AR|IDH1|TP53	1295.0038867119893	-139.8180496673625
1373.3261288927545	-8.00121194445535	0.8320000000000001	489	39	PRAD	DOXORUBICIN HYDROCHLORIDE	Approved in cancer	AR|IDH1|TP53	1309.3303056975358	-39.636969284349505
1089.7982115827035	2.2936252255149157	0.622	489	39	PRAD	AZACITIDINE	Approved in other pathologies and in clinical trials in cancer	AR|IDH1|TP53	994.6517123617621	-12.91474125476114
820.7477014097402	0.08321633451060961	0.422	489	39	PRAD	DEMCIZUMAB	Clinical trials in cancer	PIK3CA|TP53|KRAS	761.8647509692563	-32.44591306064234
817.251206307785	-2.2318485719364958	0.422	489	39	PRAD	FENRETINIDE	Clinical trials in cancer	AR|IDH1|TP53	780.5990977469093	-36.665627085538006
672.5726068178749	0.43247598588638425	0.313	489	39	PRAD	HEXACHLOROPHENE	Approved in other pathologies	AR|IDH1|TP53	609.287766751062	-14.302285069857334
713.0995918998286	0.43228925977351196	0.343	489	39	PRAD	PIMOZIDE	Approved in other pathologies	AR|IDH1|TP53	623.5392952343891	-46.08465878870621
536.5191069583127	0.4400480191698648	0.212	489	39	PRAD	SERTRALINE HYDROCHLORIDE	Approved in other pathologies	AR|IDH1|TP53	469.8012034364635	-1.8121223655341225
549.767045752598	-2.9363079028006496	0.2219999999999999	489	39	PRAD	TRIAMTERENE	Approved in other pathologies	AR|IDH1|TP53	487.38599986543363	34.536321279556404
252.04876075917505	11.009447843451625	0.0008	489	39	PRAD	ASTEMIZOLE	Experimental	AR|IDH1|TP53	288.3495575989647	2.8216417559198135
250.9663043462288	-13.987804518101058	0.0004	489	39	PRAD	PROPACHLOR	Experimental	AR|IDH1|TP53	261.7712801906467	72.54676436389445
259.0585463760639	-3.9820883390881647	0.0004	489	39	PRAD	SMR000031817	Experimental	CTNNB1|IDH1|TP53	250.77908375786927	80.53881885850103
1385.9763821824276	3.365731007807824	0.8420000000000001	489	38	PRAD	MITOXANTRONE HYDROCHLORIDE	Approved in same tumor type	AR|IDH1|TP53	1287.9483275524956	-73.22971682011493
252.2423220084375	-6.878010500977467	0.0004	489	38	PRAD	1,10-PHENANTHROLINE	Experimental	AR|IDH1|TP53	191.01198862881085	-134.04720241645452
246.93452908911905	-13.038086781709353	0.0004	489	38	PRAD	ALEXIDINE DIHYDROCHLORIDE	Experimental	AR|IDH1|TP53	242.55199939436403	105.1406946005904
254.8025021095486	-3.687253639493548	0.0004	489	38	PRAD	FENTICLOR	Experimental	AR|IDH1|TP53	190.37647797016234	139.00674857679132
241.61824010070222	-8.461043462451045	0.0004	489	38	PRAD	MICHLER'S KETONE	Experimental	AR|IDH1|TP53	184.09833736478282	-38.509987096274415
243.47165265664037	10.798918626748048	0.0004	489	38	PRAD	THIOMERSAL	Experimental	AR|IDH1|TP53	173.68376747211332	-63.5359608746557
817.04616413298	1.8730336073961382	0.422	489	37	PRAD	BERZOSERTIB	Clinical trials in cancer	TP53|BRCA2|KRAS	796.0775850681447	-146.17417315169695
1358.212709052699	-0.9440260580717563	0.8220000000000001	489	37	PRAD	PANITUMUMAB	Approved in cancer	TP53|PTEN|HRAS	1265.473526277154	54.29768495129284
1211.2406591824983	0.43252448573588254	0.7120000000000001	489	37	PRAD	THIORIDAZINE HYDROCHLORIDE	Approved in other pathologies and in clinical trials in cancer	KCNH2|IDH1|TP53	1146.4089251337623	-97.08796656344715
738.7204712977345	0.43208928744275	0.362	489	37	PRAD	CHLORPROMAZINE	Approved in other pathologies	KCNH2|IDH1|TP53	645.1585888453228	1.1024091302900558
547.7169878326589	0.6267296589011551	0.2219999999999999	489	37	PRAD	PAROXETINE HYDROCHLORIDE	Approved in other pathologies	KCNH2|IDH1|TP53	488.465886227229	53.53991452712239
245.70344012254733	14.197894983297658	0.0004	489	37	PRAD	148672-13-3	Experimental	KCNH2|IDH1|TP53	258.5529969963471	-25.68361933477553
245.61597122244723	-9.203437111565876	0.0004	489	37	PRAD	ELLIPTICINE	Experimental	KCNH2|IDH1|TP53	248.1528450644832	73.1487620949811
1358.4956125098602	3.031921833160112	0.8220000000000001	489	36	PRAD	CICLOPHOSPHAMIDE	Approved in cancer	CTNNB1|TP53|BRCA2	1291.0904527589303	26.91039054604775
1373.3573092426418	-1.1392133771296074	0.8320000000000001	489	36	PRAD	METHOTREXATE	Approved in cancer	IDH1|TP53	1291.570570944622	-82.85888899817505
1482.5832094430605	0.40544888773101206	0.913	489	36	PRAD	TAMOXIFEN CITRATE	Approved in cancer	KCNH2|AR|TP53	1497.7938726542507	-85.29432241449206
1143.6289025659132	0.43201632047745875	0.6619999999999999	489	36	PRAD	HALOPERIDOL	Approved in other pathologies and in clinical trials in cancer	MC4R|AR|TP53	1100.9344523489524	-66.89613952601027
1089.7974948754336	-1.774374711349708	0.622	489	36	PRAD	MERCAPTOPURINE	Approved in other pathologies and in clinical trials in cancer	IDH1|TP53	1008.372674537104	10.645808886094358
562.8942585757941	0.440182457799807	0.2319999999999999	489	36	PRAD	AZATHIOPRINE	Approved in other pathologies	IDH1|TP53	516.6048468075445	53.835231928874634
549.740493023527	4.062343957751182	0.2219999999999999	489	36	PRAD	PROCHLORPERAZINE	Approved in other pathologies	IDH1|TP53	493.8035731939218	-18.970723898847012
551.7039447485331	0.6418186583925376	0.2219999999999999	489	36	PRAD	SERTRALINE	Approved in other pathologies	IDH1|TP53	495.5839627899668	26.741231936544636
264.08287094661	0.43805589606733975	0.012	489	36	PRAD	TETRANDRINE	Clinical trials	IDH1|TP53	287.1326066571275	-52.484617409425795
257.0561455137981	-12.14089417533711	0.0004	489	36	PRAD	2,6-DIMETHOXY-1,4-BENZOQUINONE	Experimental	IDH1|TP53	219.8870934200416	-19.916107379031786
253.22882281464297	0.016792902846191282	0.0004	489	36	PRAD	2-(PYRIDIN-2-YLAMINO)QUINOLIN-8-OL	Experimental	IDH1|TP53	266.2410374308687	2.355885896882171
245.89827003842436	7.600785608246838	0.0004	489	36	PRAD	2-CHLOROADENOSINE	Experimental	IDH1|TP53	173.50575735191777	-89.03197581909086
251.68550283601965	3.666749895720727	0.0004	489	36	PRAD	3-METHYLTOXOFLAVIN	Experimental	IDH1|TP53	244.93524391370244	-43.570721471506005
257.9511509891166	6.374977923651215	0.0004	489	36	PRAD	BROXYQUINOLINE	Experimental	IDH1|TP53	224.54124027598397	-44.855089408757664
253.94100808104784	14.610558081352849	0.0004	489	36	PRAD	CHEMBL2002487	Experimental	IDH1|TP53	193.0822698587454	23.280450684813502
243.4604839536436	4.501050602068489	0.0004	489	36	PRAD	CHEMBL405317	Experimental	IDH1|TP53	184.24305882774456	57.59800015353696
254.02992843321078	6.823240215746267	0.0004	489	36	PRAD	CHLORANIL	Experimental	KCNH2|AR|TP53	240.39936286329373	39.247162884295136
242.50327634702268	-1.940391401327247	0.0004	489	36	PRAD	CLOFOCTOL	Experimental	IDH1|TP53	133.80575182204913	70.71242371193341
248.28401501604145	-6.238270709216948	0.0004	489	36	PRAD	DIIODOHYDROXYQUINOLINE	Experimental	IDH1|TP53	156.62181581420876	-114.36535920911746
257.1361075694468	-0.417354248692277	0.0004	489	36	PRAD	GNF-PF-4029	Experimental	IDH1|TP53	241.9312388680911	-45.56050364245104
245.15977943790924	0.9564740374978271	0.0004	489	36	PRAD	KINETIN RIBOSIDE	Experimental	IDH1|TP53	173.55653554852617	98.46750187398663
249.5205416736718	-9.954371745294821	0.0004	489	36	PRAD	MALONOBEN	Experimental	IDH1|TP53	187.02691254686633	69.32356463781679
244.2834142560104	-5.464316569734251	0.0004	489	36	PRAD	MANGOSTIN	Experimental	IDH1|TP53	226.2237455616802	-65.89868044531154
249.33621810218548	0.5430092656311558	0.0004	489	36	PRAD	MLS000073613	Experimental	IDH1|TP53	128.9214084613675	-60.46268559102124
253.38870577305	-10.724074165012581	0.0004	489	36	PRAD	N-OLEOYLDOPAMINE	Experimental	IDH1|TP53	229.17771943951223	49.639971364489554
259.50022668652434	2.7505259292445032	0.0004	489	36	PRAD	PHENYLMERCURIC ACETATE	Experimental	KCNH2|AR|TP53	186.12812621808283	-156.16451514387265
247.5919340800282	4.0601271071258225	0.0004	489	36	PRAD	PIPERLONGUMINE	Experimental	IDH1|TP53	163.63558720515329	46.69181954251752
250.82415490673213	-3.1104909720751266	0.0004	489	36	PRAD	RUFOCROMOMYCIN	Experimental	IDH1|TP53	186.19836714643037	-91.38848559548855
247.98865107128123	10.932010405495959	0.0004	489	36	PRAD	SMR000080328	Experimental	IDH1|TP53	234.47597786865342	13.82979019327857
246.9174691161464	-2.5692498291262496	0.0004	489	36	PRAD	TOXOFLAVIN	Experimental	IDH1|TP53	166.26709889959366	-62.82083202781884
255.58365884372486	3.2148878056855494	0.0004	489	36	PRAD	ZIRAM	Experimental	KCNH2|AR|TP53	155.7054932556063	-34.5943741158776
1499.5925787179856	-1.2761976612824526	0.926	489	35	PRAD	PAZOPANIB	Approved in cancer	TP53|BRCA2|KRAS	1451.2656764502667	20.573615079135635
1436.9376447830352	-65.28217177313032	0.892	149	121	READ	FLUOROURACIL	Approved in same tumor type	APC|TP53|ATM	1423.00993110112	-49.340070991583616
885.1120449051563	-5.0520439490184685	0.472	149	121	READ	SAPANISERTIB	Clinical trials in cancer	APC|TP53|RB1	845.6606619304827	-226.28073426598158
1143.1804505238697	-3.6837016359786787	0.6619999999999999	149	116	READ	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	APC|TP53|RB1	1104.411600221346	95.38440742344943
1187.8224618516679	-16.051648213439393	0.692	149	110	READ	DASATINIB	Approved in other pathologies and in clinical trials in cancer	KRAS|APC|TP53	1122.686279106178	68.80769494369409
1448.8712138072988	-35.78348762978251	0.893	149	109	READ	CARBOPLATIN	Approved in cancer	NRAS|TP53|BRCA2	1490.2196743460802	-216.89351396710364
1599.604639990795	0.4239902513076288	1	149	108	READ	ALPELISIB	Approved in cancer	KRAS|NRAS|TP53	1645.4834861667096	-137.42478716391736
1192.1400469410105	13.907878368344711	0.694	149	108	READ	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	KRAS|NRAS|TP53	1145.7495341843485	-143.11448979854526
1056.9534520630739	-5.9218090788638165	0.597	149	108	READ	GEDATOLISIB	Clinical trials in cancer	KRAS|NRAS|TP53	954.1689723469534	-16.25976086161694
1459.0402099864787	76.40228955546223	0.893	149	107	READ	CISPLATIN	Approved in cancer	TP53|MUTYH|ATM	1463.6650474679388	195.433511426483
1504.8747134696152	-23.060013222162667	0.93	149	107	READ	DABRAFENIB	Approved in cancer	KRAS|NRAS|TP53	1568.9539150817952	127.23396879018742
913.6183912100869	-42.034252943433216	0.492	149	107	READ	MIRDAMETINIB	Clinical trials in cancer	KRAS|NRAS|TP53	879.6100227144703	74.63289415205873
915.6589701802123	33.5598364529381	0.493	149	107	READ	PIMASERTIB	Clinical trials in cancer	KRAS|NRAS|TP53	897.9517769013262	27.14584016291164
1531.2299381964333	16.202679362851313	0.937	149	107	READ	REGORAFENIB	Approved in same tumor type	KRAS|APC|NRAS	1519.739640027315	-215.29142346366606
1482.2102131229012	57.9973127841082	0.894	149	106	READ	TRAMETINIB	Approved in cancer	NRAS|TP53|RB1	1453.300396331951	-15.677380536552135
617.2854461687275	0.43588221539548044	0.272	149	106	READ	GEMCITABINE	Approved in other pathologies	KRAS|NRAS|TP53	587.3891052812971	-85.25689551600591
1471.0257376244172	30.952302378267603	0.893	149	105	READ	PACLITAXEL	Approved in cancer	TP53|BRCA2|ATM	1397.6812193758951	231.25722575637445
1441.8503424338664	32.20154106639302	0.892	149	105	READ	DOXORUBICIN	Approved in cancer	KRAS|TP53|ATM	1501.90779945831	-174.78553067767857
1434.2960209082796	60.39235636199294	0.892	149	105	READ	IRINOTECAN	Approved in same tumor type	TP53|BRCA2|ATM	1478.4149508623082	-158.12689693376495
1488.806140240305	1.4164125967920143	0.912	149	104	READ	BINIMETINIB	Approved in cancer	APC|NRAS|ATM	1497.6832571216032	-100.71537088302469
1419.5498374548026	-39.36909780345292	0.882	149	104	READ	ABEMACICLIB	Approved in cancer	KRAS|NRAS|TP53	1440.3121897691053	-181.30975519856355
291.6816276904484	10.696592441603286	0.032	149	104	READ	LY3009120	Clinical trials	KRAS|NRAS|TP53	343.97609988597196	-31.61879710720919
1413.6799706733434	38.75679841071428	0.8720000000000001	149	103	READ	BEVACIZUMAB	Approved in same tumor type	PIK3CA|KRAS|TP53	1351.3115793430113	233.70377723942505
860.1499743970396	-23.5501671528678	0.452	149	103	READ	ADAVOSERTIB	Clinical trials in cancer	KRAS|NRAS|TP53	795.1509206623841	163.5590808475016
1532.449591584614	-13.505697639385431	0.94	149	103	READ	TRASTUZUMAB	Approved in cancer	PIK3CA|KRAS|APC	1564.6226131986457	167.23311493311093
1430.3617111543062	-12.869679396411613	0.892	149	102	READ	VENETOCLAX	Approved in cancer	PIK3CA|KRAS|TP53	1400.670275304159	-92.14666762526319
1475.828074640838	-24.11067391634623	0.892	149	102	READ	BORTEZOMIB	Approved in cancer	KRAS|TP53|RB1	1459.7293702373433	-235.29510369884886
1372.2621371099335	14.5345994269357	0.8330000000000001	149	102	READ	PEMBROLIZUMAB	Approved in same tumor type	KRAS|NRAS|TP53	1320.6927534054882	44.73332003196873
931.8216803440197	9.415654251271008	0.492	149	102	READ	NAVITOCLAX	Clinical trials in cancer	PIK3CA|KRAS|TP53	880.3471937833013	-21.57175469539385
1000.7709164062865	-6.191780453388446	0.552	149	102	READ	NVP-CGM097	Clinical trials in cancer	PIK3CA|KRAS|TP53	937.8929066608679	208.26786719046964
1469.1642656391957	-56.667761202716505	0.892	149	101	READ	PAZOPANIB	Approved in cancer	KRAS|TP53|BRCA2	1485.9553750158161	92.62579766728749
1517.2958810934579	41.83249704413561	0.93	149	101	READ	CRIZOTINIB	Approved in cancer	SMAD4|KRAS|TP53	1523.7787216797683	-156.2993117044487
1383.408435185688	-38.45494613068345	0.8420000000000001	149	101	READ	OLAPARIB	Approved in cancer	TP53|ATM|BRIP1	1325.5319062263516	-114.41230876292707
833.0049244349894	-3.777981577257947	0.432	149	101	READ	DEMCIZUMAB	Clinical trials in cancer	PIK3CA|KRAS|TP53	713.5384982119243	135.55403689284356
980.7915425088395	13.784082257752289	0.543	149	101	READ	BERZOSERTIB	Clinical trials in cancer	TP53|BRCA2|ATM	939.2293620549422	25.85054792521015
914.8215414212196	-13.157492609323128	0.492	149	101	READ	CAPIVASERTIB	Clinical trials in cancer	PIK3CA|KRAS|TP53	872.3858649237883	-160.7134340172906
869.9495105280914	21.76059494214587	0.462	149	101	READ	DS-7423	Clinical trials in cancer	PIK3CA|KRAS|TP53	831.2377628630081	18.18300196972973
246.01516778445182	25.005574300823326	0.0004	149	101	READ	ABT-737	Experimental	PIK3CA|KRAS|TP53	94.73497055755385	-92.176551514108
1556.1614703932798	1.8298576036531244	0.959	149	100	READ	ENCORAFENIB	Approved in same tumor type	PTEN|KRAS|TP53	1576.269541645508	-76.45932957779753
245.75055647058116	-24.51439674667057	0.0004	149	99	READ	PF-477736	Experimental	BRAF|KRAS|TP53	314.92248973335734	-23.79806776622891
1461.4925598355999	-83.42090155590876	0.892	149	99	READ	VANDETANIB	Approved in cancer	KRAS|APC|ATM	1479.1946021802319	34.41735752157339
1421.9877837211939	12.93793913957549	0.882	149	92	READ	DOCETAXEL	Approved in cancer	PIK3CA|KRAS|TP53	1301.6050258725882	-96.1136744869868
1372.1047351080263	40.93918638256986	0.8320000000000001	149	78	READ	TOPOTECAN	Approved in cancer	PIK3CA|TP53|RB1	1226.1144066134289	-80.5221895752112
976.144163182764	-10.672268684179244	0.542	149	77	READ	RESVERATROL	Clinical trials in cancer	ITGB3|PIK3CA|TP53	901.6251014252834	130.0098471637246
245.85925708221106	0.11357740680062989	0.0004	149	77	READ	1173900-33-8	Experimental	PIK3CA|TP53|ATM	267.73522732773597	61.071512112662845
1505.937406182742	19.812496926752857	0.922	149	76	READ	TAMOXIFEN	Approved in cancer	AR|PIK3CA|TP53	1500.4832684219332	208.91011125833182
822.8093494942012	-26.34121200804819	0.422	149	76	READ	TANESPIMYCIN	Clinical trials in cancer	AR|PIK3CA|TP53	706.9213192965897	-185.08777713701673
310.86500092395545	-5.588962122285068	0.042	149	76	READ	EMODIN	Clinical trials	AR|PIK3CA|TP53	331.4578591984751	-101.68873073068778
1169.2933693154782	2.144331505260709	0.692	149	76	READ	SULINDAC	Approved in other pathologies and in clinical trials in cancer	PIK3CA|APC	1135.368069312583	45.24629195449069
1490.5207036561628	-44.16720052302864	0.893	149	76	READ	EVEROLIMUS	Approved in cancer	BRCA2|ATM|RB1	1415.4424013127202	-155.20186552389217
1357.773190047465	-5.542648548834336	0.8320000000000001	149	75	READ	RALOXIFENE	Approved in cancer	PIK3CA|TP53	1299.6531289184384	31.71703610458073
1454.9108185927587	-10.993240319246297	0.892	149	75	READ	DUVELISIB	Approved in cancer	PIK3CA|TP53	1422.323442436166	151.8619170355165
1525.8038040637339	-37.48347070365176	0.94	149	75	READ	SORAFENIB	Approved in cancer	SMARCA4|KRAS|NRAS	1557.1972667560967	-180.029037742932
1444.4470501855587	7.365184507580324	0.892	149	74	READ	PALBOCICLIB	Approved in cancer	KRAS|NRAS|RB1	1400.0721520448562	207.1344478711177
1457.3880769564726	51.483873387385756	0.892	149	72	READ	CICLOPHOSPHAMIDE	Approved in cancer	BRCA2|MUTYH|ATM	1352.0799510241604	139.8047853372691
291.7383735201689	-13.929350611824304	0.032	149	72	READ	INOSITOL	Clinical trials	NRAS|TP53	313.0041868593899	-111.2742258015498
1392.3925148317767	50.85211087725153	0.8520000000000001	149	72	READ	FOLINIC ACID	Approved in same tumor type	ERBB2|BRAF|APC	1372.1808121769204	78.18824021016525
1390.5266406009691	30.638139833400515	0.8420000000000001	149	72	READ	VINORELBINE	Approved in cancer	SMARCA4|APC|BRCA2	1440.4567006243471	151.47371044448676
1465.0421608162778	7.17384974910135	0.894	149	72	READ	COBIMETINIB	Approved in cancer	PIK3CA|KRAS|NRAS	1386.413671037151	154.31578519998095
907.4678676537616	9.909106805381725	0.492	149	72	READ	TAK-733	Clinical trials in cancer	PIK3CA|KRAS|NRAS	881.9876377244175	-196.09467069293058
1388.3332101045178	-3.3580249972116576	0.8420000000000001	149	70	READ	ETOPOSIDE	Approved in cancer	TP53|BRCA2|ATM	1300.5850814670325	128.78370462626873
827.9215782942383	20.826933928159605	0.422	149	70	READ	AZD6738	Clinical trials in cancer	TP53|BRCA2|ATM	768.8142848975451	69.07712589268547
1407.9453886554365	-4.688037578441737	0.8520000000000001	149	69	READ	VORINOSTAT	Approved in cancer	PTEN|TP53|RB1	1221.8055737180937	128.51365114650417
1399.4355089043545	12.850556297625275	0.8520000000000001	149	69	READ	ERLOTINIB	Approved in cancer	PTEN|APC|TP53	1192.0980750184667	92.03887494813989
1102.0663380234373	-4.507832751067866	0.632	149	69	READ	CHLORAMBUCIL	Approved in other pathologies and in clinical trials in cancer	ERBB2|TP53|BRCA2	1094.0239755076504	-195.93250845097597
1401.5954893195515	-23.133076140902546	0.8520000000000001	149	69	READ	LIOTHYRONINE	Approved in cancer	APC	1386.4840926104284	193.18764802055915
859.2000835101655	0.5026883607393984	0.452	149	69	READ	VANTICTUMAB	Clinical trials in cancer	APC	853.892288952222	-44.468492111540485
644.258022935119	0.43591461039449086	0.292	149	69	READ	IBUPROFEN	Approved in other pathologies	APC	598.6823285312825	0.953414110819125
1512.7777604673124	0.15384781281426285	0.927	149	68	READ	LORLATINIB	Approved in cancer	ALK|TP53|RB1	1541.9624795816342	169.69570037730523
1156.7486188568264	18.14239813088534	0.6719999999999999	149	68	READ	HALOPERIDOL	Approved in other pathologies and in clinical trials in cancer	GRIN2A|AR|TP53	1128.2384058214266	91.84692078302879
812.7375584799057	8.564495237707689	0.422	149	68	READ	GANETESPIB	Clinical trials in cancer	ALK|BRAF|TP53	731.2913693370997	19.60792866840393
264.00025460975036	9.597088198746263	0.0004	149	68	READ	COUMARIN 7	Experimental	TP53|ATM	274.09885275630285	205.4724592657335
263.84660089765293	-9.65829874972519	0.0004	149	68	READ	RUFOCROMOMYCIN	Experimental	TP53|ATM	202.09095501191507	71.80757539869111
1410.3068780037374	62.314133783211446	0.8720000000000001	149	67	READ	METHOTREXATE	Approved in cancer	FOXP3|TP53|RB1	1392.5181546368174	-179.00160733287944
1354.6216718870635	30.338255385134005	0.8320000000000001	149	67	READ	CAPMATINIB	Approved in cancer	BRAF|TP53	1453.4355224972342	-60.25713017640453
1400.825553761872	-54.286939195773314	0.8520000000000001	149	67	READ	DAUNORUBICIN HYDROCHLORIDE	Approved in cancer	AR|KMT2A|TP53	1317.6930455710294	127.67255619470211
1374.4002808740074	-16.73151061270795	0.8320000000000001	149	67	READ	DOXORUBICIN HYDROCHLORIDE	Approved in cancer	AR|TP53	1333.446431757837	220.03795425016943
1337.846193595534	-3.266701860101307	0.8220000000000001	149	67	READ	MECHLORETHAMINE HYDROCHLORIDE	Approved in cancer	AR|TP53	1206.5638649315342	-40.441765672576935
1362.5477756175897	-49.363531256952	0.8320000000000001	149	67	READ	MELPHALAN	Approved in cancer	AR|TP53	1200.0643185640315	-25.180095735753753
1348.6850980826287	12.315935552548694	0.8220000000000001	149	67	READ	METHYLPREDNISOLONE	Approved in cancer	AR|TP53	1255.6195418016828	214.29252681912232
1361.2683997626946	-30.428350843423544	0.8320000000000001	149	67	READ	MITOXANTRONE HYDROCHLORIDE	Approved in cancer	AR|TP53	1202.1943248807195	234.53993099297452
1494.377095600897	36.372611613418	0.912	149	67	READ	TAMOXIFEN CITRATE	Approved in cancer	AR|TP53	1493.8271452843092	-122.59217876572862
1344.847656622868	-20.894033347198103	0.8220000000000001	149	67	READ	TRIFLURIDINE	Approved in same tumor type	ERBB2|TP53	1265.4058068381075	-85.20563968600008
1319.1774572557385	0.4743404989358453	0.792	149	67	READ	ASPIRIN	Approved in other pathologies and in clinical trials in cancer	ITGB3|TP53	1171.0208151962165	33.10418502276477
1119.0117985919348	4.631348355646992	0.642	149	67	READ	AZACITIDINE	Approved in other pathologies and in clinical trials in cancer	AR|TP53	1120.920112800293	-23.81306182024423
1118.70501322573	23.61304371551509	0.642	149	67	READ	DAUNORUBICIN	Approved in other pathologies and in clinical trials in cancer	AR|TP53	1103.2349463409673	120.4739705139736
1101.9175079039608	14.742896988242848	0.632	149	67	READ	FENOFIBRATE	Approved in other pathologies and in clinical trials in cancer	AR|TP53	1072.3431512778661	92.87512748432721
1211.753941287995	-0.7523490631352274	0.7120000000000001	149	67	READ	FLUPHENAZINE	Approved in other pathologies and in clinical trials in cancer	AR|TP53	1136.3760395044344	-20.23680728297151
1118.6239732267618	-14.345868784535753	0.642	149	67	READ	LOPERAMIDE	Approved in other pathologies and in clinical trials in cancer	AR|TP53	1080.5488155132884	74.26230977828902
1102.1322185754354	-23.75682899896995	0.632	149	67	READ	MERCAPTOPURINE	Approved in other pathologies and in clinical trials in cancer	TP53|RB1	1047.900227749375	40.734676131400676
1085.4720750704296	5.2512225967385575	0.622	149	67	READ	METHYLENE BLUE CATION	Approved in other pathologies and in clinical trials in cancer	AR|TP53	1013.9755526955887	103.69541594903967
893.4128635430889	23.652971742391117	0.483	149	67	READ	SELICICLIB	Clinical trials in cancer	TP53|RB1	875.0983686402229	-56.83080401757887
1047.1918084544623	16.538609752014082	0.592	149	67	READ	2-PHENYLETHYL ISOTHIOCYANATE	Clinical trials in cancer	ACTA2|TP53	1020.2221179152303	27.611079443189652
846.4024941151034	34.24724947728046	0.442	149	67	READ	FENRETINIDE	Clinical trials in cancer	AR|TP53	718.6003197070426	158.60855638462465
846.8486283997278	15.264491310695405	0.442	149	67	READ	NORDIHYDROGUAIARETIC ACID	Clinical trials in cancer	AR|TP53	739.5871864555327	-40.36262769367596
810.4022332736154	-10.414365112093208	0.422	149	67	READ	ONC201	Clinical trials in cancer	PTEN|TP53	744.5215769038086	-181.53132549444427
576.8400202978587	-18.549802465062072	0.242	149	67	READ	CLOTRIMAZOLE	Approved in other pathologies	AR|TP53	531.2058703464214	-22.363950111837312
549.9221845047596	9.927291475479564	0.2219999999999999	149	67	READ	ECONAZOLE NITRATE	Approved in other pathologies	AR|TP53	454.66943114133505	34.18374529658033
576.8404893211207	19.419625327698725	0.242	149	67	READ	HEXACHLOROPHENE	Approved in other pathologies	AR|TP53	548.5456615530793	-28.54622098813593
549.9221916370548	-9.0607085245191	0.2219999999999999	149	67	READ	NITAZOXANIDE	Approved in other pathologies	AR|TP53	501.90478625167884	17.174824210932343
576.7313813578203	0.4319388058409288	0.242	149	67	READ	PIMOZIDE	Approved in other pathologies	AR|TP53	542.0286864418038	84.12084638409453
860.2220616387659	-4.610835637200097	0.452	234	61	SARC	SAPANISERTIB	Clinical trials in cancer	KRAS|TP53|RB1	708.1166859399436	118.78681270770858
1384.4406325509462	9.610662474237984	0.8420000000000001	234	60	SARC	TOPOTECAN	Approved in cancer	PIK3CA|TP53|RB1	1211.160623985446	-17.405608319554204
1462.9614530235963	11.464412263494808	0.893	234	60	SARC	TRAMETINIB	Approved in cancer	NF1|TP53|RB1	1463.12433031104	-154.52305279865055
1143.624716061051	4.884679763056766	0.6619999999999999	234	60	SARC	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	KRAS|TP53|RB1	1101.4501862633156	-0.9151416642996537
1463.6094520200563	0.31082489009259007	0.892	234	59	SARC	BORTEZOMIB	Approved in cancer	KRAS|TP53|RB1	1332.6983596577713	75.7160836875093
1158.6223122817441	-3.9943513637966817	0.6729999999999999	234	59	SARC	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	NRAS|NF1|TP53	1107.421308195204	3.8166295565002315
1403.7496404248313	0.620281500846886	0.8520000000000001	234	58	SARC	VORINOSTAT	Approved in cancer	PTEN|TP53|RB1	1311.8441531844576	-110.40815084014746
1463.2668706878005	-10.597122056296854	0.893	234	57	SARC	CISPLATIN	Approved in cancer	KRAS|NRAS|TP53	1439.174757940584	-59.369448041206695
1545.5719829794618	0.42963861685180404	0.96	234	57	SARC	ALPELISIB	Approved in cancer	KRAS|NRAS|TP53	1424.6368817151601	136.06386307217247
1522.6396119860106	0.4261039915653555	0.943	234	57	SARC	FLUOROURACIL	Approved in cancer	KRAS|DPYD|TP53	1491.4512931158727	-57.25342979280772
1445.1751467665304	-0.58329044348298	0.893	234	56	SARC	PACLITAXEL	Approved in cancer	PIK3CA|KRAS|TP53	1480.2358156680978	-138.09699142529217
1386.2429671999585	-10.899974739781129	0.8420000000000001	234	56	SARC	CARBOPLATIN	Approved in cancer	KRAS|NRAS|TP53	1258.9998049047779	12.272106248628546
1364.4774466195129	16.999155060459486	0.8220000000000001	234	56	SARC	LORLATINIB	Approved in cancer	TP53|RB1	1221.176831400292	-230.6451972165994
1453.9914129759163	5.259918919966452	0.892	234	56	SARC	METHOTREXATE	Approved in cancer	IDH1|TP53|RB1	1327.6561252104248	-15.484662687047006
1427.1956305608303	-0.8808501395991755	0.8730000000000001	234	56	SARC	VENETOCLAX	Approved in cancer	PIK3CA|KRAS|TP53	1333.027348583986	-100.83081678653859
1085.3163516877717	4.896680094242697	0.622	234	56	SARC	MERCAPTOPURINE	Approved in other pathologies and in clinical trials in cancer	IDH1|TP53|RB1	1019.5822472010599	13.34661423752516
887.3150984217546	-4.2981367726123665	0.472	234	56	SARC	SELICICLIB	Clinical trials in cancer	TP53|RB1	835.9641673194415	-160.33569738103108
917.3236424809044	-9.725419747973035	0.492	234	56	SARC	NAVITOCLAX	Clinical trials in cancer	PIK3CA|KRAS|TP53	882.3635838272066	33.96159437760622
860.2279088205061	6.389162808730049	0.452	234	56	SARC	CAPIVASERTIB	Clinical trials in cancer	PIK3CA|KRAS|TP53	814.1405965946828	-59.526483100742496
833.3770031876838	0.44113447018975194	0.432	234	56	SARC	DS-7423	Clinical trials in cancer	PIK3CA|KRAS|TP53	820.9531460628062	3.151174287825114
989.9553956311439	-1.3450429188451665	0.547	234	56	SARC	GEDATOLISIB	Clinical trials in cancer	KRAS|NRAS|TP53	949.7501486025744	58.40472464392562
908.4949152807945	-3.908730627796672	0.492	234	56	SARC	MIRDAMETINIB	Clinical trials in cancer	KRAS|NRAS|TP53	887.3259317846399	40.68252458661809
917.9476097559564	0.8294226230875097	0.492	234	56	SARC	PIMASERTIB	Clinical trials in cancer	NRAS|NF1|TP53	866.0784564798707	-197.65083178799694
252.1705937897375	20.746098536433294	0.0004	234	56	SARC	ABT-737	Experimental	PIK3CA|KRAS|TP53	149.59578771156896	-93.20017261290961
1395.6871200284593	-6.35627403506183	0.8520000000000001	234	55	SARC	DOXORUBICIN	Approved in cancer	KRAS|TP53|KMT2A	1402.9242526684948	247.28440630108577
1393.5850605056062	3.8264783678244783	0.8420000000000001	234	55	SARC	IRINOTECAN	Approved in cancer	KRAS|DPYD|TP53	1320.072625061832	223.56586400133068
1374.256603176761	13.249622360914145	0.8320000000000001	234	55	SARC	OLAPARIB	Approved in cancer	PIK3CA|KRAS|TP53	1315.011996062624	28.49141632749985
1413.7560226411672	-4.297167026305374	0.8620000000000001	234	55	SARC	VEMURAFENIB	Approved in cancer	PIK3CA|NRAS|TP53	1368.0406429456243	-195.10497130715007
576.8105809222152	0.4325285622885815	0.242	234	55	SARC	GEMCITABINE	Approved in other pathologies	KRAS|NRAS|TP53	540.2575259563209	16.153164154261844
251.60502012440472	-19.88928204008343	0.0004	234	55	SARC	1173900-33-8	Experimental	PTEN|PIK3CA|TP53	240.44738179034246	-95.08388903138544
1453.0522247271422	15.622807161624507	0.892	234	54	SARC	ENCORAFENIB	Approved in cancer	PTEN|KRAS|TP53	1498.4849613081394	40.546292298651935
1413.1199041529392	5.998861927912401	0.8620000000000001	234	54	SARC	BEVACIZUMAB	Approved in cancer	PIK3CA|KRAS|TP53	1287.1815597574266	61.34644268968074
1444.6357841281006	9.807468576030232	0.892	234	54	SARC	DABRAFENIB	Approved in cancer	KRAS|NRAS|TP53	1493.7815012261124	44.44303834058914
1184.0593798922669	0.43382113965969893	0.692	234	54	SARC	DASATINIB	Approved in other pathologies and in clinical trials in cancer	PIK3CA|KRAS|TP53	1087.141294006875	86.23240753789742
980.2277944368469	2.3394351995197553	0.542	234	54	SARC	NVP-CGM097	Clinical trials in cancer	PIK3CA|KRAS|TP53	953.6001980330259	94.92552380580338
819.8599061290361	-9.552495265259097	0.422	234	54	SARC	DEMCIZUMAB	Clinical trials in cancer	PIK3CA|KRAS|TP53	746.897581323569	-100.34584807086934
1454.4872666787542	-5.0359902972091675	0.892	234	53	SARC	TAMOXIFEN	Approved in cancer	IDH1|PIK3CA|TP53	1463.0785041267836	125.19097808099161
1366.3072883400291	6.816085989577886	0.8220000000000001	234	53	SARC	CRIZOTINIB	Approved in cancer	FGFR1|KRAS|TP53	1299.7563621976017	142.02444317117016
1436.1080127812681	4.310339167111977	0.882	234	53	SARC	DOCETAXEL	Approved in cancer	PIK3CA|KRAS|TP53	1455.9754249701143	-192.8705099504368
1454.640562613434	-16.41069627908118	0.892	234	53	SARC	DUVELISIB	Approved in cancer	PIK3CA|TP53	1474.3842108791473	-14.021651437591288
1446.2657750136357	-10.836960309807239	0.892	234	53	SARC	PAZOPANIB	Approved in cancer	FGFR1|KRAS|TP53	1426.085950706779	-193.08366630058717
1375.6543654642594	3.1222157331253015	0.8320000000000001	234	53	SARC	RALOXIFENE	Approved in cancer	PIK3CA|TP53	1410.172743994481	-18.338508968270048
1351.089398988942	-6.07297566010638	0.8220000000000001	234	53	SARC	TEMOZOLOMIDE	Approved in cancer	IDH1|PTEN|TP53	1266.9036830437944	178.0787693212614
820.2071396114882	0.5841790671935314	0.422	234	53	SARC	ONC201	Clinical trials in cancer	PTEN|TP53	857.2553262400268	-69.05572634847645
909.248810701134	6.379784928826325	0.492	234	53	SARC	RESVERATROL	Clinical trials in cancer	PIK3CA|TP53	866.1086992340407	120.39810542696728
819.8545506544064	10.63799829302772	0.422	234	53	SARC	TANESPIMYCIN	Clinical trials in cancer	PIK3CA|TP53	676.7491937997454	8.825321124117977
774.4633117786705	0.4347773607413785	0.392	234	53	SARC	ZINC	Approved in other pathologies	GLRA1|TP53	661.9763265949875	91.32124280610327
784.5266893172418	0.4345078716222872	0.392	234	53	SARC	ZINC ACETATE	Approved in other pathologies	GLRA1|TP53	702.2803759006035	-110.18542789459362
779.4974251454041	-8.27714786921075	0.392	234	53	SARC	ZINC CHLORIDE	Approved in other pathologies	GLRA1|TP53	659.8237471536056	-9.89583346450243
779.4978917583028	9.146432989202452	0.392	234	53	SARC	ZINC SULFATE	Approved in other pathologies	GLRA1|TP53	647.2164755530141	23.25408605665922
279.3679599666154	-4.4778074540597	0.022	234	53	SARC	EMODIN	Clinical trials	PIK3CA|TP53	296.3280913921177	-25.76177650343277
1376.8880072014776	-6.777601339721258	0.8320000000000001	234	52	SARC	ABEMACICLIB	Approved in cancer	KRAS|NRAS|TP53	1408.776241994594	-141.85711002377593
1354.6276222649697	19.74785251998145	0.8220000000000001	234	52	SARC	DAUNORUBICIN HYDROCHLORIDE	Approved in cancer	IDH1|TP53|KMT2A	1285.4173917883127	-72.489492281106
1349.3624058197856	3.7326216346089893	0.8220000000000001	234	52	SARC	DOXORUBICIN HYDROCHLORIDE	Approved in cancer	IDH1|NR1H4|TP53	1332.0639976955015	232.85562199694965
1401.063882843823	10.670745044261366	0.8520000000000001	234	52	SARC	ETOPOSIDE	Approved in cancer	FGFR1|TP53	1310.3956746376164	-166.88320235049443
1358.6663324977658	0.409082124379637	0.8220000000000001	234	52	SARC	MELPHALAN	Approved in cancer	NR1H4|TP53	1183.1280399823731	93.27539006208599
1356.905453625622	10.133320287198814	0.8220000000000001	234	52	SARC	PANITUMUMAB	Approved in cancer	PTEN|TP53	1267.075499221754	188.70887549081323
1094.730668192573	8.911785912604103	0.622	234	52	SARC	METHYLENE BLUE CATION	Approved in other pathologies and in clinical trials in cancer	NR1H4|TP53	1029.3526557818434	7.7475180111577515
846.8488637336345	-4.4957211826678645	0.442	234	52	SARC	ADAVOSERTIB	Clinical trials in cancer	KRAS|NRAS|TP53	708.4972014430429	-56.380772242691336
846.8505850974535	5.39227866749934	0.442	234	52	SARC	BERZOSERTIB	Clinical trials in cancer	IDH1|KRAS|TP53	780.2719877715174	62.433618611334396
887.3230198678892	5.931860160461014	0.472	234	52	SARC	GENISTEIN	Clinical trials in cancer	NR1H4|TP53	791.258934111822	-33.28723914000878
279.377712370085	5.496187778073988	0.022	234	52	SARC	LY3009120	Clinical trials	KRAS|NRAS|TP53	186.12002561351457	-54.27087816225327
243.52155359406686	15.297038068488831	0.0004	234	52	SARC	93718-83-3	Experimental	TP53|KMT2A	290.82077628192576	-57.67746953638532
260.25295512145294	-14.5943693000211	0.0004	234	52	SARC	BENZO[K]FLUORANTHENE	Experimental	NR1H4|TP53	177.74667716290736	103.19891699809398
243.11335637816097	-14.353171368098657	0.0004	234	52	SARC	DICHLOROPHEN	Experimental	IDH1|NR1H4|TP53	169.96466047190802	-68.65843759613846
243.41586750017171	5.420726572133418	0.0004	234	52	SARC	GNF-PF-4029	Experimental	IDH1|TP53|KMT2A	110.91072469799127	58.4099892688744
260.52604110424846	5.175608470937931	0.0004	234	52	SARC	HOMIDIUM BROMIDE	Experimental	NR1H4|TP53	230.5323300447636	160.78523549682103
260.38712185476703	-4.711967344630239	0.0004	234	52	SARC	OCHRATOXIN A	Experimental	NR1H4|TP53	60.29467355279513	3.6651371835499162
260.66828379539027	15.057409967461012	0.0004	234	52	SARC	PENTACHLOROPHENOL	Experimental	NR1H4|TP53	216.49906023801856	74.77304845300807
251.75885183554138	-9.542292825867804	0.0004	234	52	SARC	PF-477736	Experimental	KRAS|TP53	191.69149188685702	131.7727886391378
234.79145648060225	0.5982737310257562	0.0004	234	52	SARC	SMR000065948	Experimental	TP53|KMT2A	184.8319320846286	101.6238885641913
251.89930950321505	0.35406629559659564	0.0004	234	52	SARC	TETRABROMOBISPHENOL A	Experimental	NR1H4|TP53	85.26316058909481	71.31441858861848
252.0285649371642	10.248272649412712	0.0004	234	52	SARC	THIOMERSAL	Experimental	IDH1|NR1H4|TP53	169.79022862320537	24.37683087507338
243.2718322334389	-4.4769977635210125	0.0004	234	52	SARC	TRACAZOLATE	Experimental	TP53|KMT2A	248.04404458458532	105.87063457321233
1367.87120584028	-2.9630154123293835	0.8220000000000001	234	51	SARC	CAPMATINIB	Approved in cancer	TP53	1358.9201047714985	45.52013913516603
1405.2069407545957	-9.594099424222378	0.8520000000000001	234	51	SARC	CICLOPHOSPHAMIDE	Approved in cancer	TP53	1262.9329267648475	116.48804731750994
1384.7017181216188	-0.8737821423587206	0.8420000000000001	234	51	SARC	ERLOTINIB	Approved in cancer	PTEN|TP53	1226.1738112294208	51.34878378604685
1341.7829317069363	-2.779392201966516	0.812	234	51	SARC	IFOSFAMIDE	Approved in cancer	TP53	1247.8149305592476	-140.89215591651325
1347.2436938344151	13.30875535095413	0.812	234	51	SARC	MECHLORETHAMINE HYDROCHLORIDE	Approved in cancer	TP53	1245.0759246780674	97.69480422027289
1360.4398279456418	-9.227636250685691	0.8220000000000001	234	51	SARC	METHYLPREDNISOLONE	Approved in cancer	TP53	1244.1076935818862	39.19364466726907
1369.3744465847753	-13.050298983347574	0.8220000000000001	234	51	SARC	MITOXANTRONE HYDROCHLORIDE	Approved in cancer	IDH1|TP53	1289.8958911300936	-85.05132007198254
1362.1462366318513	-19.537881569945085	0.8220000000000001	234	51	SARC	RITUXIMAB	Approved in cancer	TP53	1258.5713269188802	-241.4057831110162
1353.212368082193	-15.718634476657314	0.8220000000000001	234	51	SARC	TAMOXIFEN CITRATE	Approved in cancer	TP53	1256.3508032611571	54.73354231470316
1340.0504911116805	6.777408584088619	0.812	234	51	SARC	TRABECTEDIN	Approved in cancer	TP53	1315.9609920087305	-126.30164458981012
1343.4619942168003	-12.344761495625733	0.812	234	51	SARC	TRIFLURIDINE	Approved in cancer	TP53	1197.581073221085	99.74520688878584
1319.763398238699	0.4239038574692131	0.792	234	51	SARC	ASPIRIN	Approved in other pathologies and in clinical trials in cancer	TP53	1309.5731063293974	-151.43505580664717
1093.692487812586	-0.8274823088694347	0.622	234	51	SARC	CLADRIBINE	Approved in other pathologies and in clinical trials in cancer	TP53	1013.6685046974526	13.473868685730963
1102.0886431940783	-6.64601548411818	0.632	234	51	SARC	AZACITIDINE	Approved in other pathologies and in clinical trials in cancer	IDH1|TP53	1025.6056287545275	3.4689825756611583
1093.1955655322495	-10.530258669797945	0.622	234	51	SARC	CHLORAMBUCIL	Approved in other pathologies and in clinical trials in cancer	TP53	1063.9882989702319	109.41795676216947
1110.7401715569868	-2.223258721820798	0.632	234	51	SARC	DAUNORUBICIN	Approved in other pathologies and in clinical trials in cancer	TP53	1039.2638999552814	106.12958220858684
1084.5386780494412	-14.945206732644039	0.622	234	51	SARC	ENALAPRIL	Approved in other pathologies and in clinical trials in cancer	TP53	1031.3321008646335	-25.056713083868402
1086.9773767070635	14.903295533840861	0.622	234	51	SARC	FENOFIBRATE	Approved in other pathologies and in clinical trials in cancer	TP53	1056.018942168931	-45.523205385525785
1130.15130541101	0.4249055525424126	0.652	234	51	SARC	FLUPHENAZINE	Approved in other pathologies and in clinical trials in cancer	TP53	1111.4885543504242	-111.1941133313983
1156.644287382196	6.215811098013631	0.6719999999999999	234	51	SARC	HALOPERIDOL	Approved in other pathologies and in clinical trials in cancer	CACNA1C|TP53	1127.631572600404	-15.533334755742118
1076.5332968717196	-0.17135533127870417	0.612	234	51	SARC	HYDRALAZINE HYDROCHLORIDE	Approved in other pathologies and in clinical trials in cancer	TP53	1050.0409080631357	-24.18374321480337
1143.608636022135	-5.601307907751732	0.6619999999999999	234	51	SARC	LOPERAMIDE	Approved in other pathologies and in clinical trials in cancer	TP53	1081.6946116462832	-24.32451024459229
1103.7697193371514	12.69990927794646	0.632	234	51	SARC	THIAMAZOLE	Approved in other pathologies and in clinical trials in cancer	TP53	1083.000922283074	-95.06487790976888
1085.0395509812697	-5.242125660964945	0.622	234	51	SARC	THIORIDAZINE HYDROCHLORIDE	Approved in other pathologies and in clinical trials in cancer	IDH1|TP53	1062.6354034396759	-53.88463510603293
1102.5859958272758	3.056286796306466	0.632	234	51	SARC	WARFARIN	Approved in other pathologies and in clinical trials in cancer	TP53	1063.3173233686616	-45.455188824533195
918.0034773661513	10.976344031506613	0.492	234	51	SARC	2-PHENYLETHYL ISOTHIOCYANATE	Clinical trials in cancer	TP53	889.5135930733239	9.452471656990525
1570.854371103845	22.40935800353833	0.99	410	339	SKCM	TRAMETINIB	Approved in same tumor type	NF1|RB1|STK11	1598.879572952643	-56.02935126839054
1584.2472259287003	53.082991953706	0.997	410	327	SKCM	BINIMETINIB	Approved in same tumor type	HRAS|NF1|ATM	1660.619135578471	-87.14734694992447
1032.7727605847774	31.878800441790872	0.586	410	323	SKCM	MIRDAMETINIB	Clinical trials in cancer	PTEN|TP53|STK11	972.1871076418588	-42.24335688208541
1025.3357084812624	-12.909383988786857	0.586	410	321	SKCM	PIMASERTIB	Clinical trials in cancer	NRAS|TP53|NF1	979.7733795199842	151.8578950559223
1638.4126955548688	3.5365476045077457	1	410	319	SKCM	COBIMETINIB	Approved in same tumor type	KRAS|NRAS|NF1	1636.7526686601905	154.60157839850854
1609.66281093192	-52.75173417494335	0.999	410	314	SKCM	REGORAFENIB	Approved in cancer	VHL|KRAS|NRAS	1616.3376910904674	129.9975395236322
1544.3859470522764	-26.59343365132571	0.97	410	314	SKCM	EVEROLIMUS	Approved in cancer	RB1|ATM|STK11	1560.3664210092393	45.71482414030561
1032.110973519033	-44.14773113768814	0.586	410	314	SKCM	TAK-733	Clinical trials in cancer	GNA11|KRAS|NRAS	961.6192170117369	226.9747640889675
1624.063341819091	-24.74920530004701	1	410	311	SKCM	ALPELISIB	Approved in cancer	PTEN|HRAS|TP53	1647.4534898474872	124.90059173883753
1616.2476014639847	50.330493403928045	1	410	311	SKCM	DABRAFENIB	Approved in same tumor type	NRAS|HRAS|TP53	1670.210501723401	73.44573425770227
1514.1687626520227	-18.096198639835706	0.939	410	310	SKCM	PALBOCICLIB	Approved in cancer	NRAS|PTEN|RB1	1518.002440466732	161.87530955751134
1548.1461437806338	45.76559226695829	0.973	410	309	SKCM	LENVATINIB	Approved in cancer	BRAF|KIT|NRAS	1583.3177345004642	-27.594599956643947
991.0031965670241	-2.311470873155457	0.55	410	308	SKCM	MK-2206	Clinical trials in cancer	NRAS|PTEN|HRAS	916.8933701796786	56.462277345214744
1513.0632828456928	12.99383106224451	0.937	410	307	SKCM	RIBOCICLIB	Approved in cancer	CDKN2A|NRAS|RB1	1518.8636653600536	131.11084327586826
1057.0251207260203	52.33889520920303	0.597	410	307	SKCM	GEDATOLISIB	Clinical trials in cancer	PTEN|TP53|STK11	1022.33195796362	198.6035032939003
268.6806480233293	-37.462192546462745	0.0004	410	307	SKCM	DEL-22379	Experimental	MAP2K1|KRAS|NRAS	233.78316304658756	-30.223417202353772
1297.6406577909659	3.4103077999735945	0.777	410	306	SKCM	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	TP53|NF1|STK11	1178.826204450469	-10.971409892341796
380.6655122178182	-13.978045144453091	0.096	410	306	SKCM	OMIPALISIB	Clinical trials	GNAQ|NRAS|PTEN	379.8592818014894	-57.36534125225839
298.5389515616076	3.030945127520795	0.034	410	306	SKCM	LY3009120	Clinical trials	KRAS|NRAS|TP53	343.68680699091317	21.01336976985607
1593.068505471066	-26.32651525832094	1	410	305	SKCM	VEMURAFENIB	Approved in same tumor type	PTEN|HRAS|TP53	1625.1356689454776	-8.249705676366403
840.8167245407654	9.102525362463894	0.434	410	304	SKCM	E6201	Clinical trials in cancer	NRAS|PTEN|HRAS	703.9489395591569	84.78354392346557
1062.7873336158573	22.142722493329643	0.594	410	303	SKCM	LIFIRAFENIB	Clinical trials in cancer	BRAF|KRAS|NRAS	1021.0182954074825	229.92994540163943
816.1766599259056	-8.737414123336777	0.422	410	299	SKCM	XL888	Clinical trials in cancer	BRAF|NRAS	724.7134682833527	-167.22125897211788
372.90195394856033	15.529738693033465	0.092	410	299	SKCM	OBATOCLAX	Clinical trials	BRAF|NRAS	389.4085975623872	32.50789634570506
1607.5359021454253	0.9943683386348141	1	410	296	SKCM	SORAFENIB	Approved in cancer	KRAS|NRAS|PTEN	1671.571525441269	41.272693443592004
1369.1421386788413	-8.25475863093223	0.8330000000000001	410	286	SKCM	PEMBROLIZUMAB	Approved in same tumor type	NRAS|TP53|MSH2	1251.9438487979237	-105.19792100110072
1488.333964692141	-3.308395337729962	0.923	410	280	SKCM	AFATINIB	Approved in cancer	ERBB4|BRAF|NRAS	1502.3164222613032	267.78910274053277
630.7497932174481	0.4338582573986116	0.282	410	279	SKCM	GEMCITABINE	Approved in other pathologies	PTEN|HRAS|TP53	585.9695626947271	28.017414103343782
1453.7404683782481	30.638559182729125	0.892	410	278	SKCM	GEFITINIB	Approved in cancer	BRAF|NRAS|PTEN	1368.1072920221345	-144.45970559953963
260.27019620166	-65.52400222738352	0.0004	410	273	SKCM	SCH772984	Experimental	BRAF|NRAS	200.09823517520573	49.58497416105689
1060.9161300933074	-44.585467336560015	0.596	410	256	SKCM	BUPARLISIB	Clinical trials in cancer	NRAS|PTEN|HRAS	1018.2654867166909	-32.36650120780058
1449.8620435506255	4.854514960582833	0.892	410	232	SKCM	BEVACIZUMAB	Approved in cancer	KRAS|HRAS|TP53	1437.9767736512244	126.17682576925108
996.7778788749476	24.16269457993019	0.554	410	227	SKCM	SAPANISERTIB	Clinical trials in cancer	TP53|RB1|STK11	922.0172645119655	-198.89456033440274
1598.3846869134875	29.17554335265254	1	410	222	SKCM	IMATINIB	Approved in same tumor type	ABCB4|KIT|CDKN2A	1637.3196194936104	-162.35600795795318
1329.8225992553764	9.23921751907696	0.8	410	222	SKCM	DASATINIB	Approved in other pathologies and in clinical trials in cancer	KRAS|HRAS|TP53	1196.8309887922808	-54.58499260785838
1459.795718031766	-33.736355337466364	0.892	410	221	SKCM	VENETOCLAX	Approved in cancer	KRAS|PTEN|TP53	1486.9495488658188	57.06681105494755
253.38436314736478	44.14124218555108	0.0004	410	221	SKCM	PF-477736	Experimental	KRAS|CDKN2A|TP53	269.9491186224078	134.3413195060894
1620.2431316981674	23.790514780751664	0.999	410	219	SKCM	ENCORAFENIB	Approved in same tumor type	KRAS|PTEN|TP53	1652.7451365248592	98.33573299912553
1319.996641355018	-11.016632607758424	0.792	410	219	SKCM	FOSTAMATINIB	Approved in other pathologies and in clinical trials in cancer	KIT|BTK|RB1	1175.981446530012	-130.90041751618966
1001.8209234325919	-26.62037708723139	0.562	410	217	SKCM	NVP-CGM097	Clinical trials in cancer	GNA11|KRAS|TP53	939.0354603122245	71.18091595850976
501.9506878029023	-9.797832132446047	0.186	410	215	SKCM	REFAMETINIB	Clinical trials	GNAQ|KRAS|PTEN	417.55268758767704	32.98148493390332
1443.9390573722942	-18.179906164211644	0.892	410	214	SKCM	FLUOROURACIL	Approved in same tumor type	PTEN|TP53|ATM	1359.2053745807439	208.47573092295096
1428.4352386462497	-2.767840125201303	0.882	410	214	SKCM	IRINOTECAN	Approved in cancer	KRAS|TP53|ATM	1489.1308113038222	-262.71623188221736
1464.9129140794523	-12.152418385789872	0.893	410	213	SKCM	DOXORUBICIN	Approved in cancer	KRAS|TP53|ATM	1417.3878522027962	-23.977745527179906
914.2820768631083	11.114451235595908	0.492	410	212	SKCM	SARACATINIB	Clinical trials in cancer	IDH1|VHL|KRAS	839.6983836191721	-21.8261930837715
1431.9683969329249	18.671044715059566	0.882	410	211	SKCM	VORINOSTAT	Approved in cancer	PTEN|TP53|RB1	1259.7214857513704	65.90700014669707
1070.318353394333	-22.751806882082292	0.595	410	211	SKCM	212631-79-3	Clinical trials in cancer	KRAS|HRAS|STK11	982.6321684245326	210.8827345957459
1589.5611231523692	-70.12431611750584	0.992	410	210	SKCM	SORAFENIB TOSYLATE	Approved in cancer	RAF1|BRAF|KIT	1615.2678448457848	-161.36961466565236
914.2786329457396	-10.471548489675854	0.492	410	210	SKCM	NAVITOCLAX	Clinical trials in cancer	KRAS|PTEN|TP53	869.2221057021065	-213.36722906239825
496.152244317841	11.146328799674166	0.183	410	210	SKCM	RO4987655	Clinical trials	MAP2K2|MAP2K1|KRAS	422.1783153748458	-1.7876567123512075
278.0683572807695	-13.106702006539479	0.0004	410	208	SKCM	1173900-33-8	Experimental	PTEN|TP53|ATM	130.20465260074383	82.12355536395683
1582.330845273372	-2.5975656396348086	0.995	410	207	SKCM	RIPRETINIB	Approved in cancer	BRAF|KIT	1587.3895432589172	-2.687478766229219
1538.4081315938472	19.099981861699263	0.947	410	207	SKCM	PEXIDARTINIB	Approved in cancer	BRAF|KIT	1573.8187892264011	189.92012894055824
1556.848876327782	-1.4070781097659903	0.972	410	207	SKCM	TIVOZANIB	Approved in cancer	BRAF|KIT	1589.524952395931	-191.0193938891782
1534.550797377872	-1.6912249917747033	0.95	410	206	SKCM	TEMSIROLIMUS	Approved in cancer	PIK3CA|KRAS|PTEN	1532.781834405147	-7.376950657924823
1015.0855987463376	11.74455159198385	0.5740000000000001	410	206	SKCM	CEDIRANIB	Clinical trials in cancer	MAP2K2|KIT|VHL	973.6928266636431	-189.25852072537145
1410.6226125844141	9.179481346015933	0.8620000000000001	410	205	SKCM	CAPMATINIB	Approved in cancer	BRAF|TP53	1300.1267659128196	258.73135980403026
840.4796178259306	-16.728974479432367	0.432	410	205	SKCM	GANETESPIB	Clinical trials in cancer	BRAF|TP53	769.6894045377488	24.451549947164068
333.57760301094004	0.4932237523227343	0.062	410	205	SKCM	PF-04217903	Clinical trials	BRAF|TP53	365.1000150215741	75.5975607412712
1409.3389375014335	-12.391548946655888	0.8620000000000001	410	204	SKCM	TOPOTECAN	Approved in cancer	PTEN|TP53|RB1	1345.7836020257957	-98.07446436453289
862.8129552717485	-4.338475132611194	0.452	410	204	SKCM	CAMPTOTHECIN	Clinical trials in cancer	PIK3CA|CDK4|KRAS	818.1460887914633	214.0919459680739
1087.4436505823458	15.171461017929175	0.597	410	202	SKCM	PILARALISIB	Clinical trials in cancer	KRAS|PTEN|STK11	1061.6749242034382	77.09612512245445
1049.2296999096643	-24.37697374872667	0.593	410	202	SKCM	IZORLISIB	Clinical trials in cancer	PIK3R1|KRAS|PTEN	996.34585970655	172.27670760193678
243.30327984292197	63.25881802191796	0.0008	410	202	SKCM	918505-84-7	Experimental	PTPN11|MAP2K1|PTEN	90.59739174324307	125.46318626162252
1370.06320450283	16.483901755786775	0.8320000000000001	410	201	SKCM	ATEZOLIZUMAB	Approved in same tumor type	BRAF|KRAS	1221.9097361742288	-37.04866727359871
1390.4126787496923	-20.91693584220951	0.8420000000000001	410	201	SKCM	PANOBINOSTAT	Approved in cancer	BRAF|KRAS	1331.4245280925625	63.00032599168776
885.9338211223333	0.397485223503935	0.471	410	201	SKCM	ULIXERTINIB	Clinical trials in cancer	BRAF|KRAS	817.407578569131	193.83144851720317
956.1838196400244	0.4342190184386254	0.523	410	201	SKCM	VORUCICLIB	Clinical trials in cancer	BRAF|MAP2K2|CDK4	887.8013098734397	-42.46012113512495
274.7282988852646	41.18826138111376	0.0004	410	201	SKCM	TW-37	Experimental	BRAF|KRAS	275.4411443078615	-29.72927555989139
1078.28952949005	-3.2808953992820307	0.598	410	200	SKCM	RAF265	Clinical trials in cancer	RAF1|BRAF	1040.442876139747	-35.79956604002831
1057.943565065612	-5.720249788544976	0.594	410	200	SKCM	PLX8394	Clinical trials in cancer	RAF1|BRAF	995.7570145813539	132.55811674719797
263.9066678523289	62.893772868349544	0.0008	410	200	SKCM	AGERAFENIB	Experimental	RAF1|BRAF	149.69987928228647	32.18408630579523
224.71855497622883	-45.23261533142332	0.0008	410	200	SKCM	BMS-908662	Experimental	RAF1|BRAF	222.70793281909013	120.30264113871038
225.01800061712223	-24.750688636915413	0.0004	410	200	SKCM	ARQ-736	Experimental	RAF1|BRAF	220.60982131335913	-216.324737202739
237.2319771339	-8.320512312092461	0.0004	410	200	SKCM	LGX-806	Experimental	RAF1|BRAF	53.82789428954362	76.54585371686352
231.96195094736566	46.07711272674692	0.0004	410	200	SKCM	SB590885	Experimental	RAF1|BRAF	254.4163245339581	-14.573784561783754
220.80447345362296	28.880573641121885	0.0004	410	200	SKCM	TOVORAFENIB	Experimental	RAF1|BRAF	98.00642957469762	-67.71800127758068
1390.3378249586835	19.590380324314623	0.8420000000000001	410	199	SKCM	FOLINIC ACID	Approved in cancer	GATA3|BRAF|APC	1293.4653547333048	230.67169970843258
1470.2838462709908	12.944524132613623	0.893	410	198	SKCM	IDELALISIB	Approved in cancer	BRAF|PIK3CA|PTEN	1454.8352729081878	-164.25069908666384
1042.171431252445	7.240119942677865	0.593	410	198	SKCM	GSK2636771	Clinical trials in cancer	PIK3CA|PIK3R1|PTEN	978.4477874420728	-118.41334264300883
241.10837295113598	26.636830506979408	0.0008	410	198	SKCM	SAR-260301	Experimental	BRAF|PIK3CA|PTEN	260.66217953390435	-133.74562645696784
245.36373891114698	-26.913732956207497	0.0008	410	198	SKCM	NVP-AEW541	Experimental	BRAF|PIK3CA|PTEN	170.0257869536576	-5.126856376380374
1583.906355747549	-50.09427312203198	0.994	410	197	SKCM	DABRAFENIB + TRAMETINIB	Approved in same tumor type	BRAF	1625.745306133838	-56.77168369113515
1568.8308302319078	-18.262872310275668	0.992	410	197	SKCM	DABRAFENIB MESYLATE	Approved in same tumor type	BRAF	1586.0869741434315	-152.48746868208443
1567.4104269446232	-38.432920224247994	0.992	410	197	SKCM	ENCORAFENIB + PANITUMUMAB	Approved in cancer	BRAF	1624.9032655211918	-123.07818935427686
1341.176643437874	-8.945345764709998	0.8140000000000001	410	197	SKCM	CETUXIMAB + ENCORAFENIB	Approved in cancer	BRAF	1300.9844894843673	-223.3121052114356
1347.0638664274065	28.348950150857576	0.8140000000000001	410	197	SKCM	COBIMETINIB + VEMURAFENIB	Approved in same tumor type	BRAF	1209.4365043386883	193.87494341931665
1352.1110436010895	-25.947532536555286	0.8130000000000001	410	197	SKCM	BINIMETINIB + ENCORAFENIB	Approved in same tumor type	BRAF	1268.174592339491	-21.727157178169875
1351.258678257769	8.568860323917875	0.812	410	197	SKCM	ATEZOLIZUMAB + COBIMETINIB + VEMURAFENIB	Approved in same tumor type	BRAF	1367.3061306945413	-165.91387233096702
1392.4855754009734	-0.613784888294532	0.8420000000000001	410	197	SKCM	NIVOLUMAB	Approved in same tumor type	BRAF|PTEN	1441.716614610535	-218.98186709515602
797.856189631923	8.558366464624186	0.413	410	197	SKCM	GSK2118436	Clinical trials in cancer	BRAF	635.7161576524396	93.08466526475593
816.4683098786301	16.4600991810251	0.422	410	197	SKCM	PAC-1	Clinical trials in cancer	BRAF	689.4191436240803	134.6014097175704
261.2777080618296	24.295114320523936	0.0008	410	197	SKCM	CHEMBL526479	Experimental	BRAF	144.06015661377643	128.11324460807748
217.06565765394197	-5.949365248075196	0.0008	410	197	SKCM	N-{2,4-DIFLUORO-3-[(5-PYRIDIN-3-YL-1H-PYRROLO[2,3-B]PYRIDIN-3-YL)CARBONYL]PHENYL}ETHANESULFONAMIDE	Experimental	BRAF	185.1058789739913	-78.22760558302956
257.4626494650779	-10.707510942926575	0.0008	410	197	SKCM	RO-5212054	Experimental	BRAF	149.9268563047991	89.25682777492375
281.3531860152449	21.887765871721996	0.0004	410	197	SKCM	878739-06-1	Experimental	BRAF	151.8616620099811	49.66820217634202
269.2949676467423	5.679488437009923	0.0004	410	197	SKCM	GDC-0879	Experimental	BRAF	159.93144449410676	-23.12555646594666
229.12270599550817	10.279453714274268	0.0004	410	197	SKCM	PRT062607	Experimental	BRAF	292.44666929257306	-93.92024802512023
244.9936742861317	-47.17436521676791	0.0004	410	197	SKCM	RG-7256	Experimental	BRAF	251.65516005923288	144.94469144908163
249.21957785593	8.051418388707646	0.0004	410	197	SKCM	VX-11E	Experimental	BRAF	221.3138141055951	-128.89024732419549
1469.1633925608805	-30.032523719595304	0.893	403	191	STAD	PACLITAXEL	Approved in cancer	ATM|TP53|BRCA1	1457.9961843471215	134.34142145598452
984.0602019583844	16.78715456872078	0.544	403	190	STAD	SAPANISERTIB	Clinical trials in cancer	PTEN|TP53|RB1	927.9000927448916	-109.27496069070187
1443.507566075044	5.8881310079548825	0.892	403	189	STAD	FLUOROURACIL	Approved in same tumor type	PTEN|ATM|TP53	1435.9655727962102	97.15899028441282
1469.9456916896909	22.51463357044301	0.893	403	185	STAD	CARBOPLATIN	Approved in cancer	BRCA2|TP53|BRCA1	1383.5341612955804	-104.59125607185868
1430.2199885759187	20.004992985631077	0.882	403	182	STAD	IRINOTECAN	Approved in cancer	ATM|TP53|BRCA1	1400.928491266406	-47.42173529358041
1476.5802220084693	2.445074547768371	0.893	403	181	STAD	DOXORUBICIN	Approved in same tumor type	ATM|TP53|BRCA1	1453.1653917979227	9.013313272474761
1187.234691640756	-4.269948697928953	0.694	403	180	STAD	DASATINIB	Approved in other pathologies and in clinical trials in cancer	SMAD3|KRAS|TP53	1127.5485516885656	-128.18433301108638
1061.8293607655523	5.976133053805086	0.597	403	180	STAD	GEDATOLISIB	Clinical trials in cancer	NRAS|PTEN|TP53	973.1110835801193	-170.40633728610044
1600.8931319465114	7.820319456385164	1	403	179	STAD	ALPELISIB	Approved in cancer	NRAS|PTEN|TP53	1683.458005793379	-1.2761664307080025
1258.5101910936448	0.43268023739835826	0.7470000000000001	403	178	STAD	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	PTEN|TP53|NF1	1152.6044259870887	-105.34393816057738
1442.1992238415503	34.43376516495971	0.892	403	176	STAD	CISPLATIN	Approved in cancer	PTEN|TP53|BRCA1	1494.318327026468	-141.62578341470942
1530.4883609189164	1.0652617459226974	0.949	403	175	STAD	TRAMETINIB	Approved in cancer	TP53|NF1|RB1	1529.578682678937	-62.50025259206171
990.1146046208322	-15.205050106518058	0.546	403	175	STAD	MIRDAMETINIB	Clinical trials in cancer	NRAS|PTEN|TP53	939.1918916857693	165.67631525561103
996.1933834553017	2.081270436570577	0.552	403	174	STAD	DS-7423	Clinical trials in cancer	KRAS|PTEN|TP53	965.2449034488268	132.4909224743369
1460.0735569012113	38.466288605090796	0.892	403	173	STAD	VENETOCLAX	Approved in cancer	KRAS|PTEN|TP53	1419.6333108467513	-258.4356322685391
914.2456588771422	0.43268883137525904	0.492	403	173	STAD	NAVITOCLAX	Clinical trials in cancer	KRAS|PTEN|TP53	871.6176429812308	23.833397161526875
1037.1355499336848	-10.101584685379436	0.586	403	173	STAD	CAPIVASERTIB	Clinical trials in cancer	KRAS|PTEN|TP53	956.59376304109	5.759328378297425
978.3420914129525	-1.2963642147010148	0.545	403	172	STAD	PIMASERTIB	Clinical trials in cancer	NRAS|TP53|NF1	919.9037748706152	135.64737806931555
631.309996100937	0.4319701447312809	0.282	403	172	STAD	GEMCITABINE	Approved in other pathologies	PTEN|TP53|BRCA1	586.6412744664503	-61.49558653884186
232.14028692147033	-6.306088505567857	0.0004	403	172	STAD	ABT-737	Experimental	KRAS|PTEN|TP53	170.0037124850753	55.78759674127599
1439.4356401054222	-24.960023998977732	0.892	403	171	STAD	BEVACIZUMAB	Approved in cancer	PIK3CA|KRAS|TP53	1461.1202992654207	-83.95381291375573
1584.4813467655908	-0.3237598075532162	0.99	403	170	STAD	DABRAFENIB	Approved in cancer	KRAS|NRAS|TP53	1591.7367598362284	128.61327599530142
1286.877282865188	0.4305935963105014	0.768	403	170	STAD	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	KRAS|TP53|RB1	1152.5316516963126	-27.489364756205674
1451.9372369291125	-37.738221241213296	0.892	403	169	STAD	BORTEZOMIB	Approved in cancer	KRAS|TP53|RB1	1414.4887450572958	246.87299109760914
1013.3418386514251	-3.294294503301842	0.562	403	168	STAD	NVP-CGM097	Clinical trials in cancer	PIK3CA|KRAS|TP53	963.5449576418873	-126.54460242742604
819.2716604309119	1.7192731879537178	0.422	403	167	STAD	DEMCIZUMAB	Clinical trials in cancer	PIK3CA|KRAS|TP53	730.6014632963469	-144.19743469201404
1422.8545131628007	-17.926419903973766	0.8720000000000001	403	165	STAD	OLAPARIB	Approved in cancer	BRCA2|TP53|BRCA1	1389.2981114569313	-138.7738818130881
245.5383982948839	32.60791066442732	0.0004	403	163	STAD	1173900-33-8	Experimental	PTEN|ATM|TP53	130.32181663189374	100.87545772012953
1400.65055663648	9.811000538377243	0.8520000000000001	403	154	STAD	TOPOTECAN	Approved in cancer	PTEN|TP53|RB1	1271.314028288272	-239.8990891041604
1546.377078589367	-5.724806750241328	0.96	403	153	STAD	VEMURAFENIB	Approved in cancer	NRAS|PTEN|TP53	1561.2702478427377	-198.24105388886096
1561.8383249036608	0.42330266151336104	0.972	403	151	STAD	TAMOXIFEN	Approved in cancer	PIK3CA|TP53|BRCA1	1616.655376286996	58.955102060563405
333.5258203274915	0.4157481439518733	0.062	403	150	STAD	EMODIN	Clinical trials	PIK3CA|TP53|BRCA1	347.25350319931783	80.2537883001902
1054.1097641099855	-9.54110544186878	0.593	403	149	STAD	RESVERATROL	Clinical trials in cancer	PPARG|TP53|BRCA1	974.0054192229911	-22.04624765358986
844.9844414534476	-10.33627493218907	0.442	403	149	STAD	TANESPIMYCIN	Clinical trials in cancer	AR|PIK3CA|TP53	764.6131770008207	-74.60087541731825
1598.6801108619734	-9.265990968453053	0.999	403	148	STAD	ENCORAFENIB	Approved in cancer	KRAS|PTEN|TP53	1617.0511132470058	-72.03124984983661
1032.4334144259699	6.116788631824392	0.583	403	147	STAD	BERZOSERTIB	Clinical trials in cancer	ATM|TP53|BRCA1	972.3291136070202	247.8641944223965
1452.5725017014258	20.998002006977885	0.892	403	146	STAD	DUVELISIB	Approved in cancer	PIK3CA|TP53	1406.0304385645477	-168.2963105315079
1406.4547012266999	-17.066437477847245	0.8620000000000001	403	146	STAD	CRIZOTINIB	Approved in cancer	CDKN2A|SMAD4|TP53	1266.9578917166348	140.12797699479586
1413.215123864261	-2.4762726424906703	0.8620000000000001	403	146	STAD	RALOXIFENE	Approved in cancer	UGT1A8|PIK3CA|TP53	1369.0790711751831	221.26757798022896
1462.2491691973971	-6.755115512255202	0.892	403	142	STAD	DOCETAXEL	Approved in same tumor type	PIK3CA|KRAS|TP53	1472.6735411313914	124.76371331000928
247.98751491871468	-10.902377721833972	0.0004	403	141	STAD	PF-477736	Experimental	KRAS|CDKN2A|TP53	201.08945902251492	182.03641695651544
1447.849708550022	-10.845348479888287	0.892	403	140	STAD	ABEMACICLIB	Approved in cancer	CDKN2A|NRAS|TP53	1353.64789924987	12.708034153557492
1460.635884044909	8.137995181183953	0.892	403	140	STAD	PAZOPANIB	Approved in cancer	BRCA2|TP53|BRCA1	1477.148442209768	74.56892206956189
1387.0235155714008	2.2550991729290217	0.8430000000000001	403	140	STAD	PEMBROLIZUMAB	Approved in same tumor type	NRAS|TP53|MSH2	1271.8196967202473	85.37430407687123
845.6011137116567	13.914766676387842	0.442	403	139	STAD	ADAVOSERTIB	Clinical trials in cancer	NRAS|TP53|BRCA1	756.2643879026015	182.40177693490068
281.6042142086604	0.7352417478503241	0.024	403	138	STAD	LY3009120	Clinical trials	KRAS|NRAS|TP53	250.07312471628452	-63.961901151283485
1426.68476310018	3.7663964191442005	0.881	403	133	STAD	CICLOPHOSPHAMIDE	Approved in cancer	ATM|TP53|BRCA1	1420.362029273329	-203.77745952280645
1474.8829692405607	-14.006609408948094	0.893	403	132	STAD	ERLOTINIB	Approved in cancer	APC|PTEN|TP53	1477.8177564073621	-192.77954908123232
1415.5543069676708	12.404935080633635	0.8620000000000001	403	131	STAD	VORINOSTAT	Approved in cancer	PTEN|TP53|RB1	1409.0535690369645	-117.80495450375409
834.8821490420613	4.83290439893787	0.432	403	124	STAD	ONC201	Clinical trials in cancer	AKT1|PTEN|TP53	731.9753058533979	47.88575134076214
260.6905448250224	34.35557843689003	0.0004	403	124	STAD	93718-83-3	Experimental	SMAD3|MEN1|TP53	237.37148786879027	99.81798440903589
1434.1867180222762	-7.691431290840399	0.882	403	123	STAD	ETOPOSIDE	Approved in cancer	BRCA2|ATM|TP53	1272.6594417456363	61.20963616065603
1388.2023461815131	17.602094005133154	0.8430000000000001	403	122	STAD	IBRUTINIB	Approved in cancer	SMAD3|ATM|TP53	1373.4482334567838	93.97629338844922
1399.114568118029	-4.796576529943735	0.8520000000000001	403	122	STAD	TEMOZOLOMIDE	Approved in cancer	PTEN|TP53|BRCA1	1413.483710131765	262.0280010782672
234.39032073659317	9.101090593764582	0.0004	403	122	STAD	RUFOCROMOMYCIN	Experimental	SMAD3|ATM|TP53	210.7252000742818	-33.023683262307344
1545.5477150910306	8.84961468553061	0.96	403	121	STAD	PANITUMUMAB	Approved in cancer	MAP2K1|PTEN|TP53	1565.4525447175117	146.5659656295847
1046.2764089182688	2.529832012493074	0.592	403	121	STAD	GENISTEIN	Clinical trials in cancer	CFTR|SMAD3|TP53	990.7792946514023	10.68600314496959
263.76396567786844	-27.819570486668567	0.0004	403	120	STAD	COUMARIN 7	Experimental	ATM|TP53	238.11720541031158	-106.43864441550367
1379.9690899319776	-9.668586884784133	0.8420000000000001	403	119	STAD	DAUNORUBICIN HYDROCHLORIDE	Approved in cancer	KMT2A|TP53|BRCA1	1442.417131153926	193.8795864023706
234.87451456873285	22.068634138975227	0.0004	403	119	STAD	SMR000031817	Experimental	CTNNB1|TP53	310.36487322445095	23.618673287055145
1371.6445978418321	-0.005087417497776414	0.8320000000000001	403	118	STAD	DOXORUBICIN HYDROCHLORIDE	Approved in same tumor type	SMAD3|TP53|BRCA1	1307.6197244149666	-237.51836097702227
1103.0988572940714	-11.861085877922903	0.632	403	118	STAD	CHLORAMBUCIL	Approved in other pathologies and in clinical trials in cancer	BRCA2|TP53|BRCA1	1044.8788756139747	67.89704417499544
1183.3292174066519	11.02944249932952	0.692	403	118	STAD	HALOPERIDOL	Approved in other pathologies and in clinical trials in cancer	LDLR|AR|TP53	1152.3550856193208	-14.369788370218458
245.67678436604274	15.329390420383845	0.0004	403	118	STAD	GNF-PF-4029	Experimental	KMT2A|MEN1|TP53	306.1130963429357	-86.42406936326228
254.29845695508192	-36.46678552686973	0.0004	403	118	STAD	GOSSYPOL	Experimental	BLM|SMAD3|TP53	180.23584686459344	-62.76318959569177
267.9981430461722	17.858663940085222	0.0004	403	118	STAD	SMR000065948	Experimental	KMT2A|MEN1|TP53	82.98539898331293	-74.81197916902917
238.15613884784165	-20.61559571449547	0.0004	403	118	STAD	TRACAZOLATE	Experimental	KMT2A|MEN1|TP53	277.22079747254776	-162.64898091348707
1376.8688276003343	11.528657383514314	0.8420000000000001	403	117	STAD	CAPMATINIB	Approved in cancer	EGFR|BRAF|TP53	1413.87794984569	22.653172624211265
1454.6047637708916	-22.810220433538348	0.892	403	117	STAD	METHOTREXATE	Approved in cancer	PPARG|TP53|RB1	1412.7107777217616	160.83219528300617
852.1878736782311	1.897229419205928	0.442	403	117	STAD	FENRETINIDE	Clinical trials in cancer	AR|SMARCB1|TP53	751.9186255256769	8.276198679871442
1048.9648971146758	15.05453284291275	0.592	403	117	STAD	2-PHENYLETHYL ISOTHIOCYANATE	Clinical trials in cancer	ACTA2|ACTB|TP53	1004.3166921870678	-169.43288138577503
834.2123000387484	-19.586777738766443	0.432	403	117	STAD	AZD6738	Clinical trials in cancer	BRCA2|ATM|TP53	656.5931518304727	48.748570319428694
832.3628734239188	17.539169208246335	0.432	403	117	STAD	GANETESPIB	Clinical trials in cancer	EGFR|BRAF|TP53	798.0966329713665	-162.96626849213445
779.4063061762224	11.331340678233346	0.392	403	117	STAD	ZINC	Approved in other pathologies	FGA|TP73|TP53	638.5709575623705	4.5198776110209735
779.4047601749542	-10.461748931437683	0.392	403	117	STAD	ZINC ACETATE	Approved in other pathologies	FGA|TP73|TP53	737.240504508307	-121.9992630694658
563.3267676830997	0.43170822550845855	0.2319999999999999	403	117	STAD	RIBAVIRIN	Approved in other pathologies	LDLR|VWF|TP53	522.3267536792034	-89.26850531744873
268.7388407616386	5.238168679956544	0.0004	403	117	STAD	ROTENONE	Experimental	AR|PPARG|TP53	147.8252367751473	-34.21265629989526
1391.430944260592	-15.044603590820827	0.8420000000000001	403	116	STAD	MITOXANTRONE HYDROCHLORIDE	Approved in cancer	WRN|BLM|TP53	1212.429890009421	-24.00490347224016
1157.1288299011576	0.4631497000891329	0.6719999999999999	403	116	STAD	LOPERAMIDE	Approved in other pathologies and in clinical trials in cancer	MTOR|AR|TP53	1088.5925431512776	-122.80511462622101
1116.5683540594155	0.4419174570435018	0.642	403	116	STAD	WARFARIN	Approved in other pathologies and in clinical trials in cancer	MTHFR|VWF|TP53	1103.8029951435637	76.84076658523009
785.6615379392144	0.43494357539941575	0.392	403	116	STAD	ZINC CHLORIDE	Approved in other pathologies	FGA|TP73|TP53	651.8415254236945	95.87991954553496
773.1495379708283	0.4358330161274182	0.392	403	116	STAD	ZINC SULFATE	Approved in other pathologies	FGA|TP73|TP53	651.6784387979001	-58.697851183481646
616.017996101275	0.4318684979233183	0.272	403	116	STAD	PIMOZIDE	Approved in other pathologies	MTOR|AR|TP53	564.724939482244	7.722268296426279
295.1926140587522	0.1379578314773653	0.032	403	116	STAD	PF-04217903	Clinical trials	BRAF|TP53	274.289044913174	183.8976803125779
246.68185067778302	2.760460758880214	0.0004	403	116	STAD	1,10-PHENANTHROLINE	Experimental	MTOR|AR|TP53	262.49090782916187	118.79396183612255
270.4626627738684	-7.21648748194454	0.0004	403	116	STAD	148672-13-3	Experimental	MTOR|SMAD3|TP53	301.85508594496827	-58.24134891620206
260.9968983607218	-15.409477099455898	0.0004	403	116	STAD	167869-21-8	Experimental	ERBB2|DSG1|TP53	217.12570840308064	-188.033972818334
242.30823064385734	-32.529023559737084	0.0004	403	116	STAD	CHEMBL591618	Experimental	MTOR|SMAD3|TP53	295.7142178550001	6.207243600175531
251.59291584446248	-24.141845044805876	0.0004	403	116	STAD	PLUMBAGIN	Experimental	EGFR|ERBB2|TP53	235.9498016409162	-8.505856362081943
258.8590018288286	-2.5559764119945783	0.0004	403	116	STAD	TCMDC-125575	Experimental	MTOR|TP53|BRCA1	275.5810124879371	81.69654564965896
256.1897794305336	22.290644415872464	0.0004	403	116	STAD	THUNBERGINOL B	Experimental	WRN|ALPL|TP53	140.48446085175104	19.927236601118437
257.02369781859716	9.806465464616423	0.0004	403	116	STAD	VANOXERINE	Experimental	MTOR|AR|TP53	144.42379549339853	183.33872450196276
1359.0970223532547	0.6216158035928743	0.8220000000000001	403	115	STAD	TRIFLURIDINE	Approved in same tumor type	ERBB2|TP53	1304.833860895741	219.8513795465562
1319.3488757352761	0.43018714089316745	0.792	403	115	STAD	ASPIRIN	Approved in other pathologies and in clinical trials in cancer	UGT1A6|PPARG|TP53	1264.498395181402	85.15126080877354
1103.4751635439907	0.6931912737368009	0.632	403	115	STAD	AZACITIDINE	Approved in other pathologies and in clinical trials in cancer	AR|SMAD3|TP53	1049.8901787790758	-104.04745823140067
1143.7061781163325	0.4539243980411527	0.6619999999999999	403	115	STAD	DAUNORUBICIN	Approved in other pathologies and in clinical trials in cancer	AR|BLM|TP53	1086.100483009945	97.50338482057498
1103.0876727232662	13.103143202046994	0.632	403	115	STAD	MERCAPTOPURINE	Approved in other pathologies and in clinical trials in cancer	MTHFR|TP53|RB1	1062.8235268858423	45.57294439971176
1216.564884099614	0.4425473724087965	0.7160000000000001	403	115	STAD	THIAMAZOLE	Approved in other pathologies and in clinical trials in cancer	GFAP|TPO|TP53	1139.1749621724985	81.52424241253931
831.128206803625	-7.45877030499318	0.432	403	115	STAD	NORDIHYDROGUAIARETIC ACID	Clinical trials in cancer	AR|WRN|TP53	760.3547317071205	194.37611977996113
590.2977621832424	0.4318208371527419	0.252	403	115	STAD	HEXACHLOROPHENE	Approved in other pathologies	AR|SMAD3|TP53	527.0681764414232	-77.57653090718733
1520.2170790662815	8.71830662865898	0.94	124	29	TGCT	SORAFENIB	Approved in cancer	KRAS|KIT|NRAS	1484.1362176624796	-175.90103571872874
1377.3542612174494	2.8156527715364916	0.8340000000000001	124	29	TGCT	TRAMETINIB	Approved in cancer	KRAS|KIT|NRAS	1286.570713586978	196.04365947893285
1518.0023085031578	-6.2077952478266525	0.939	124	29	TGCT	REGORAFENIB	Approved in cancer	KRAS|KIT|NRAS	1516.5617396287573	-65.24041600848983
831.8736504307406	0.5705659658857485	0.432	124	29	TGCT	MIRDAMETINIB	Clinical trials in cancer	KRAS|KIT|NRAS	800.1851528291037	-151.87859146829925
1361.0844912848904	-5.95580944030246	0.8230000000000001	124	26	TGCT	PEMBROLIZUMAB	Approved in cancer	KRAS|KIT|NRAS	1242.6161917378272	33.810507506055586
1510.1628979332907	0.01699735828020721	0.933	124	26	TGCT	INFIGRATINIB	Approved in cancer	PIK3CA|KRAS|KIT	1502.1672881553327	140.78474283227484
1358.099647918797	7.927426831481739	0.8220000000000001	124	26	TGCT	BEVACIZUMAB	Approved in cancer	PIK3CA|KRAS|KIT	1442.3869168278945	-44.71245143398207
1242.1949736685954	3.149956427471011	0.7340000000000001	124	26	TGCT	PONATINIB	Approved in other pathologies and in clinical trials in cancer	PIK3CA|KRAS|KIT	1140.429253750381	60.65594297474695
1228.0501558203282	-2.6592235568144815	0.7260000000000001	124	26	TGCT	MIDOSTAURIN	Approved in other pathologies and in clinical trials in cancer	PIK3CA|KRAS|KIT	1120.790929537792	49.95990863944084
1237.0842886345285	-4.531372444140317	0.7300000000000001	124	25	TGCT	DASATINIB	Approved in other pathologies and in clinical trials in cancer	CBL|KRAS|KIT	1126.9970424591825	-47.482164680871165
1495.9932063314516	9.68281623156048	0.923	124	23	TGCT	CABOZANTINIB	Approved in cancer	KRAS|KIT	1501.5216328018018	98.65204746009385
1491.2612963142576	-5.2656149609295255	0.922	124	23	TGCT	ERDAFITINIB	Approved in cancer	KRAS|KIT	1428.8430792183087	-30.874824537314908
1499.0881048025017	-8.997212053966848	0.926	124	23	TGCT	PAZOPANIB	Approved in cancer	KRAS|KIT	1496.7940739368496	-160.01337199510397
1504.4620489463757	6.857576341265371	0.93	124	23	TGCT	SUNITINIB	Approved in cancer	KRAS|KIT	1518.8130757298704	90.61034066352323
1228.9500618709312	6.199026926046827	0.7250000000000001	124	23	TGCT	NILOTINIB	Approved in other pathologies and in clinical trials in cancer	KRAS|KIT	1159.1567806264059	27.449787455085072
561.9514093182156	0.43242658809114687	0.2309999999999999	124	19	TGCT	GEMCITABINE	Approved in other pathologies	CBL|KRAS|NRAS	520.1223348651849	49.56039582208692
1523.2080259348147	0.6188504635418326	0.94	124	18	TGCT	ALPELISIB	Approved in cancer	PIK3CA|KRAS|NRAS	1489.0978062765423	75.26697343577632
1380.9259671988239	-4.9895389799912095	0.8340000000000001	124	18	TGCT	COBIMETINIB	Approved in cancer	PIK3CA|KRAS|NRAS	1243.7972746983808	104.85542318129745
1369.334069648907	5.878589329479382	0.8320000000000001	124	18	TGCT	DABRAFENIB	Approved in cancer	PIK3CA|KRAS|NRAS	1427.686314380706	-68.71058071565905
1363.3935286118442	1.8040705747336574	0.8230000000000001	124	18	TGCT	EVEROLIMUS	Approved in cancer	PIK3CA|KRAS|NRAS	1319.1246311846596	-101.02735500518763
1374.0855481797194	10.750980888678583	0.8320000000000001	124	18	TGCT	PALBOCICLIB	Approved in cancer	PIK3CA|KRAS|NRAS	1314.5502151481603	-107.25449428082383
1369.6254991379362	-0.9173494935175199	0.8310000000000001	124	18	TGCT	CARBOPLATIN	Approved in cancer	PIK3CA|KRAS|NRAS	1357.6987480867642	195.60309746796787
1368.990807740924	-7.70042923373839	0.8310000000000001	124	18	TGCT	CISPLATIN	Approved in cancer	PIK3CA|KRAS|NRAS	1319.0674954218348	28.15256261360429
1105.8154520269304	0.4324176547996217	0.634	124	18	TGCT	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	PIK3CA|KRAS|NRAS	1090.7023318799957	31.974187349594388
820.4088809510176	8.791426092499194	0.422	124	18	TGCT	MK-2206	Clinical trials in cancer	PIK3CA|KIT|NRAS	739.1427094275316	-155.0725382981732
974.6303089960012	-2.5459969081690303	0.537	124	18	TGCT	GEDATOLISIB	Clinical trials in cancer	PIK3CA|KRAS|NRAS	941.1067149041897	-107.403250765322
834.9701848095468	8.573202452296528	0.433	124	18	TGCT	PIMASERTIB	Clinical trials in cancer	PIK3CA|KRAS|NRAS	726.5190072588905	147.39695742102032
832.9415089938409	-7.943526754153936	0.432	124	18	TGCT	TAK-733	Clinical trials in cancer	PIK3CA|KRAS|NRAS	780.2862078905217	101.14643134922215
1511.8544749655093	7.770866932988241	0.933	124	17	TGCT	LENVATINIB	Approved in cancer	KIT|NRAS	1486.0382344439747	73.0417249411127
972.4900711083378	3.745958096772597	0.536	124	17	TGCT	BUPARLISIB	Clinical trials in cancer	PIK3CA|KRAS|NRAS	887.930046294593	-55.620821132089134
818.867828548764	-7.283238659127619	0.422	124	17	TGCT	LUCITANIB	Clinical trials in cancer	PIK3CA|KIT	726.4506370873086	3.034690019836148
1374.5920171849064	-10.643719685017373	0.8330000000000001	124	15	TGCT	BINIMETINIB	Approved in cancer	KRAS|NRAS	1260.850249353176	49.17673501618572
1374.6146647602682	-4.803763599256996	0.8320000000000001	124	15	TGCT	ABEMACICLIB	Approved in cancer	KRAS|NRAS	1378.3293302022348	-131.07346350756677
1346.7078234560026	0.41759374036203667	0.812	124	15	TGCT	CHEMOTHERAPY + PANITUMUMAB	Approved in cancer	KRAS|NRAS	1250.1242771672426	67.82497910357748
1076.129763212776	0.4321648467396244	0.612	124	15	TGCT	LONAFARNIB	Approved in other pathologies and in clinical trials in cancer	KRAS|NRAS	938.9907482654711	-8.417827797296212
815.9124412957771	4.346497899116599	0.422	124	15	TGCT	LIFIRAFENIB	Clinical trials in cancer	KRAS|NRAS	778.8983407260306	-60.7848010555151
952.1310143216472	3.238768847251407	0.521	124	15	TGCT	SALIRASIB	Clinical trials in cancer	KRAS|NRAS	871.0153845967217	89.74187515458539
817.3470485778176	-1.3147085555957574	0.422	124	15	TGCT	ADAVOSERTIB	Clinical trials in cancer	KRAS|NRAS	721.7772766123978	49.909709136285784
823.0149952770605	-2.723303793029743	0.422	124	15	TGCT	DINACICLIB	Clinical trials in cancer	KRAS|NRAS	761.7912269667036	50.79132547080562
279.12618578660215	3.0613898268918263	0.022	124	15	TGCT	LY3009120	Clinical trials	KRAS|NRAS	246.93033632593773	-54.19403505253038
251.10607665296192	-12.362562166976858	0.0004	124	15	TGCT	DEL-22379	Experimental	KRAS|NRAS	206.46436903854948	-51.843371284682405
812.7128050227104	-4.84422738942277	0.415	124	15	TGCT	QUIZARTINIB	Clinical trials in cancer	CBL|KIT	772.4830708940677	-41.999327618809986
1502.7296183953995	-0.38709798031840137	0.93	124	14	TGCT	IMATINIB	Approved in cancer	KIT	1547.674057631638	32.09516076692131
1510.165554658584	-7.435947823628879	0.935	124	14	TGCT	RIPRETINIB	Approved in cancer	KIT	1445.3889992870488	178.09621058236814
1497.5208240029929	-2.2175320616864553	0.922	124	14	TGCT	IMATINIB MESYLATE	Approved in cancer	KIT	1494.5872396830248	27.20297278714878
1505.0442806800029	-5.386848346647611	0.932	124	14	TGCT	SORAFENIB TOSYLATE	Approved in cancer	KIT	1502.976076237175	-53.73702745770714
1487.8549453880362	0.8132932057152402	0.917	124	14	TGCT	PEXIDARTINIB	Approved in cancer	KIT	1495.0139217523551	37.83277542608221
1498.5421400711473	3.2071022792658823	0.925	124	14	TGCT	AXITINIB	Approved in cancer	KIT	1502.4235526099533	124.2933575935507
1492.8303455535056	-12.052665420850047	0.922	124	14	TGCT	PAZOPANIB HYDROCHLORIDE	Approved in cancer	KIT	1446.5853459251116	53.187189026179254
1493.3383059469352	1.381765528384392	0.922	124	14	TGCT	SUNITINIB MALATE	Approved in cancer	KIT	1527.6453067420978	146.99839595570984
1490.1509892535432	5.88368381377424	0.922	124	14	TGCT	TIVOZANIB	Approved in cancer	KIT	1468.1577136901378	-10.508445683192576
1357.3734157040506	0.5078965174375583	0.8220000000000001	124	14	TGCT	ENTRECTINIB	Approved in cancer	KIT	1312.9723705259466	33.5650909782149
1234.781642073935	2.385144870504064	0.7320000000000001	124	14	TGCT	FOSTAMATINIB	Approved in other pathologies and in clinical trials in cancer	KIT	1142.869683476435	54.6258736412949
1215.550808329995	0.4580696056438285	0.7150000000000001	124	14	TGCT	AVAPRITINIB	Approved in other pathologies and in clinical trials in cancer	KIT	1147.8574897553149	55.09298381979036
1210.034818515692	0.4474692051362865	0.7110000000000001	124	14	TGCT	ROMIPLOSTIM	Approved in other pathologies and in clinical trials in cancer	KIT	1142.7207339020351	-108.4106580834438
953.9059529675958	-2.15146632941088	0.524	124	14	TGCT	CENISERTIB	Clinical trials in cancer	KIT	937.7221426377724	-14.093409713027313
948.9977055161263	-4.662011401751215	0.517	124	14	TGCT	MASITINIB	Clinical trials in cancer	KIT	876.8472268981918	-37.868409787572176
947.1462208721567	0.5319140269311617	0.516	124	14	TGCT	AMUVATINIB	Clinical trials in cancer	KIT	934.9018107836373	52.441582436684854
963.0030630028102	0.5564064684675998	0.526	124	14	TGCT	MOTESANIB	Clinical trials in cancer	KIT	835.9051216663738	-61.863694874018904
961.49099582208	5.858374446072986	0.525	124	14	TGCT	DOVITINIB	Clinical trials in cancer	KIT	896.2035227821962	-96.65924161304191
945.2945648390461	5.727757996104884	0.515	124	14	TGCT	TANDUTINIB	Clinical trials in cancer	KIT	883.1402575745612	27.18315759862091
959.2583709871	-3.4901094852246217	0.525	124	14	TGCT	VATALANIB	Clinical trials in cancer	KIT	940.3285084081631	143.07640745396077
956.1508237924667	7.2422139547363145	0.524	124	14	TGCT	LINIFANIB	Clinical trials in cancer	KIT	932.7960854922035	10.84849322888445
957.6490834104486	1.8979498436935671	0.524	124	14	TGCT	OSI-930	Clinical trials in cancer	KIT	894.8044340496008	-25.44178396285966
943.5701544479921	-3.6676188370050227	0.514	124	14	TGCT	TELATINIB	Clinical trials in cancer	KIT	856.6581348739386	-185.58992716656988
955.4240159884159	-7.45545659417661	0.523	124	14	TGCT	FAMITINIB	Clinical trials in cancer	KIT	899.5369451671713	61.42037886276705
941.7185006808861	1.5283059432448454	0.513	124	14	TGCT	XL-820	Clinical trials in cancer	KIT	889.3729674966216	1.3586738256159947
825.848236168598	5.89044351915345	0.423	124	14	TGCT	ENMD-2076	Clinical trials in cancer	KIT	712.4433258111106	-67.6737562418326
807.3770445582138	-2.8904935598980614	0.413	124	14	TGCT	ILORASERTIB	Clinical trials in cancer	KIT	791.904203343377	-63.4051510610081
811.5562564566306	0.7081950327184927	0.413	124	14	TGCT	SEMAXANIB	Clinical trials in cancer	KIT	663.4008855632843	-13.843021412536672
808.3358524592195	-8.44912879249975	0.412	124	14	TGCT	693228-63-6	Clinical trials in cancer	KIT	675.3813869377266	15.034591556730987
803.1837853779084	-6.479770689126042	0.412	124	14	TGCT	AKN-028	Clinical trials in cancer	KIT	705.5697081119282	47.60803136741015
804.044525050725	-11.920865600656896	0.412	124	14	TGCT	CATEQUENTINIB	Clinical trials in cancer	KIT	725.254398260049	8.956562938113905
810.5290499092017	6.127468966448276	0.412	124	14	TGCT	CRENOLANIB	Clinical trials in cancer	KIT	706.064661832025	-51.13283817804185
805.3205095713121	7.949654038800645	0.412	124	14	TGCT	HENATINIB	Clinical trials in cancer	KIT	779.6112262409495	32.2286033826594
802.1679840997122	-1.0685158364350968	0.412	124	14	TGCT	RIVOCERANIB	Clinical trials in cancer	KIT	707.9726470296935	-6.218477936656342
806.3511847921332	2.531777504314192	0.412	124	14	TGCT	SITRAVATINIB	Clinical trials in cancer	KIT	735.2157449595762	-10.711506843120702
801.1450912355799	4.354644989442562	0.412	124	14	TGCT	SNS-314	Clinical trials in cancer	KIT	702.8231536047947	45.95176065530825
809.492718368166	11.547540398150744	0.412	124	14	TGCT	TYROSINE KINASE-IN-1	Clinical trials in cancer	KIT	721.9244661879382	3.561073100284517
821.3468678687599	2.702350162316719	0.422	124	14	TGCT	VOROLANIB	Clinical trials in cancer	KIT	782.8707287206953	-35.42378487694245
279.12046089142007	-2.6166072870185815	0.022	124	14	TGCT	FLUMBATINIB	Clinical trials	KIT	188.85255995590472	-36.175010473206186
265.34195818558317	0.36538206041606713	0.012	124	14	TGCT	EDICOTINIB	Clinical trials	KIT	246.21924228836352	-110.065838498769
250.77172397283027	13.20961341641555	0.0004	124	14	TGCT	PYRAZOLANTHRONE	Experimental	KIT	286.9437349135177	9.27406716917838
242.5210591569765	5.89239445481337	0.0008	124	14	TGCT	AMG-191	Experimental	KIT	251.14503366620949	-112.5445306580629
246.64765021022097	9.550941545275975	0.0008	124	14	TGCT	ANCESTIM	Experimental	KIT	304.7893617581778	-49.71832636771586
256.0023227524693	11.457895781794065	0.0008	124	14	TGCT	BARZOLVOLIMAB	Experimental	KIT	125.43942282870475	-16.97859431103265
254.06821868126275	-3.0065952237897875	0.0008	124	14	TGCT	BRIQUILIMAB	Experimental	KIT	200.57959590718502	-33.253900342055175
251.87362173944044	7.805978983375411	0.0008	124	14	TGCT	O-PHOSPHO-L-TYROSINE	Experimental	KIT	288.8073622648232	-81.41040742871317
247.74849438380906	4.149526687335964	0.0004	124	14	TGCT	2-N,4-N-DIPHENYLPYRIMIDINE-2,4-DIAMINE	Experimental	KIT	263.74315336496704	25.624803731698023
259.29621759156413	-4.752351812863907	0.0004	124	14	TGCT	452105-23-6	Experimental	KIT	184.59901410068682	-36.256362801557856
245.81207027579745	-10.319491100692602	0.0004	124	14	TGCT	732983-37-8	Experimental	KIT	205.23569677101898	-0.6189116839775863
257.1012259163297	6.05308636220289	0.0004	124	14	TGCT	882531-87-5	Experimental	KIT	237.82997224960252	23.89964157442307
258.20066647360517	0.6433052922222657	0.0004	124	14	TGCT	885692-52-4	Experimental	KIT	183.83443030472517	-50.29632640228033
244.7118771468311	-4.9181762410791805	0.0004	124	14	TGCT	AST 487	Experimental	KIT	172.82009729833393	25.704878887920756
248.847325911927	-1.2622518404858454	0.0004	124	14	TGCT	BARASERTIB	Experimental	KIT	260.02542167416385	24.86254868011636
252.97221643566968	2.394145848342987	0.0004	124	14	TGCT	GTP-14564	Experimental	KIT	214.0042429526964	-159.8542507092956
243.62120706726762	0.49210445421084614	0.0004	124	14	TGCT	GW843682X	Experimental	KIT	225.63126036046472	46.335490596290214
249.94179937218797	-6.661358156237895	0.0004	124	14	TGCT	JNJ-7706621	Experimental	KIT	267.4796038056808	-40.07502654063481
255.17320144838243	-8.410268762864291	0.0004	124	14	TGCT	KI20227	Experimental	KIT	181.77746494434706	-90.40297007825603
1517.2786278082215	1.5365856406661749	0.939	124	13	TGCT	COPANLISIB	Approved in cancer	PIK3CA|KRAS	1412.5701925420376	-64.58820075896287
1482.278558249242	-35.6230529621113	0.922	488	337	THCA	BINIMETINIB	Approved in cancer	APC|NRAS|HRAS	1548.2068356126254	-221.48619208467227
1434.8307182605286	29.513292747319724	0.8620000000000001	488	337	THCA	ALPELISIB	Approved in cancer	NRAS|HRAS|TP53	1349.2344829947642	78.86857281527784
1092.427743944521	0.4290593146068602	0.624	488	337	THCA	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	NRAS|HRAS|TP53	1068.118998798553	-99.92886834172019
549.7886564485261	0.43054481495107666	0.2219999999999999	488	337	THCA	GEMCITABINE	Approved in other pathologies	NRAS|HRAS|TP53	454.0443759090793	68.64615222405624
1504.7487854121375	48.62555657108217	0.93	488	336	THCA	DABRAFENIB	Approved in same tumor type	NRAS|HRAS|TP53	1543.639832562771	115.44131636234346
1408.8587232702023	41.43272019940309	0.8370000000000001	488	336	THCA	TRAMETINIB	Approved in same tumor type	NRAS|HRAS|TP53	1204.041875373468	-93.00778731852563
1411.5374915419964	13.045657969480828	0.8420000000000001	488	336	THCA	EVEROLIMUS	Approved in cancer	KRAS|NRAS|HRAS	1303.832619576144	187.45720149078858
1510.7035262736952	-37.72892419111329	0.93	488	334	THCA	VEMURAFENIB	Approved in cancer	NRAS|HRAS|TP53	1534.9962475207524	-124.91596614896932
869.8862407706742	38.57501812678149	0.462	488	333	THCA	BUPARLISIB	Clinical trials in cancer	KRAS|NRAS|HRAS	822.6216492887612	170.16336408630252
826.3026710074922	-17.198368360601563	0.423	488	333	THCA	E6201	Clinical trials in cancer	PTEN|NRAS|HRAS	658.1777810459935	9.18508718114657
973.6483296385147	-13.707997596353863	0.53	488	333	THCA	MK-2206	Clinical trials in cancer	PTEN|NRAS|HRAS	907.6409286095308	-177.56521810031765
815.2947096542715	-42.671112754929624	0.422	488	320	THCA	MIRDAMETINIB	Clinical trials in cancer	KRAS|NRAS|TP53	670.3829349494433	-98.70829690760125
893.0994040961748	-4.5550015946270435	0.462	488	320	THCA	GEDATOLISIB	Clinical trials in cancer	KRAS|NRAS|TP53	793.2054988824954	-8.37717875047042
1533.6600572869415	22.55553806998998	0.94	488	319	THCA	SORAFENIB	Approved in same tumor type	PTEN|KRAS|NRAS	1555.0486414189013	-35.55553949384063
1327.0163046833225	-17.20921146250069	0.8220000000000001	488	319	THCA	PALBOCICLIB	Approved in cancer	KRAS|CDKN2A|NRAS	1227.5751845193925	99.06129008967963
1518.912276857628	-0.23202107111936243	0.937	488	319	THCA	REGORAFENIB	Approved in cancer	KRAS|APC|NRAS	1550.228386685453	-70.28222713604326
1341.8286838633867	-71.03066670353238	0.8230000000000001	488	319	THCA	PEMBROLIZUMAB	Approved in cancer	KRAS|NRAS|TP53	1177.2560029478848	-173.81922899723855
814.0039364459711	28.311517778603644	0.423	488	319	THCA	PIMASERTIB	Clinical trials in cancer	KRAS|NRAS|TP53	709.078449200772	-141.37455233518358
273.9107496402732	28.929593092865503	0.014	488	319	THCA	LY3009120	Clinical trials	KRAS|NRAS|TP53	290.8153728346317	69.00260264715732
1379.566047948181	-28.838084357945235	0.8250000000000001	488	318	THCA	COBIMETINIB	Approved in cancer	BRAF|KRAS|NRAS	1188.6319427484295	-252.91795112517804
816.2526696287982	55.30184529494153	0.422	488	318	THCA	TAK-733	Clinical trials in cancer	BRAF|KRAS|NRAS	744.2541407629967	114.53106233677556
954.8746868271769	27.78761316029619	0.524	488	318	THCA	LIFIRAFENIB	Clinical trials in cancer	BRAF|KRAS|NRAS	910.9273209215863	-37.95527025025223
269.94543515019654	-15.614195316724789	0.0004	488	318	THCA	DEL-22379	Experimental	BRAF|KRAS|NRAS	295.45301059035967	-193.46087430814254
1386.0466841433447	25.755457108807832	0.8320000000000001	488	316	THCA	GEFITINIB	Approved in cancer	BRAF|PTEN|NRAS	1194.1523921906255	-150.04898001462078
333.58911127784154	0.4268055522626355	0.062	488	316	THCA	OMIPALISIB	Clinical trials	BRAF|PTEN|NRAS	354.2733093807053	-5.851998875495411
1351.8515608897465	-27.57113014747253	0.8220000000000001	488	315	THCA	RIBOCICLIB	Approved in cancer	BRAF|CDKN2A|NRAS	1284.8485982291493	-1.1438535935284335
1354.6693177226084	-94.73538039393598	0.8220000000000001	488	315	THCA	AFATINIB	Approved in cancer	BRAF|NRAS	1287.347349416759	-53.72357156910712
1403.762719684143	68.63957790459875	0.8320000000000001	488	315	THCA	LENVATINIB	Approved in same tumor type	BRAF|NRAS	1248.8606026762836	186.45546767765006
791.4905896979359	43.13028939771928	0.412	488	315	THCA	XL888	Clinical trials in cancer	BRAF|NRAS	638.9495759940182	46.09437634726365
300.5592189598678	24.772457159438517	0.022	488	315	THCA	OBATOCLAX	Clinical trials	BRAF|NRAS	306.1829601142341	43.106072698092305
261.4892786378935	52.850527850021024	0.0004	488	315	THCA	SCH772984	Experimental	BRAF|NRAS	210.96031845835063	-67.48467519270227
1383.9679764863051	51.73860348822808	0.8320000000000001	488	297	THCA	BEVACIZUMAB	Approved in cancer	KRAS|HRAS|TP53	1208.9234261775703	-69.77438922120643
1146.4608816562913	0.4288358295355579	0.6639999999999999	488	297	THCA	DASATINIB	Approved in other pathologies and in clinical trials in cancer	APC|HRAS|TP53	1101.6488256437492	19.581815866214242
947.9783830042371	-21.352759279388465	0.521	488	296	THCA	212631-79-3	Clinical trials in cancer	BRAF|KRAS|HRAS	917.4258910033874	10.117197533553252
890.4681615256986	21.51659062795366	0.462	488	295	THCA	DACTOLISIB	Clinical trials in cancer	KRAS|APC|HRAS	818.757257577788	126.12086309456197
1362.3717875595926	39.85692387822908	0.8220000000000001	488	282	THCA	FLUOROURACIL	Approved in cancer	KRAS|APC|TP53	1246.390501516581	18.07991178142632
850.6221462742365	20.85452214729213	0.432	488	282	THCA	SAPANISERTIB	Clinical trials in cancer	CDKN2A|APC|TP53	729.1140366362524	94.03442539592464
1531.8721313742408	-22.28496529712382	0.939	488	281	THCA	ENCORAFENIB	Approved in cancer	PTEN|KRAS|TP53	1530.6323457955727	-28.575572448991267
1392.3956640740444	-75.92524834942618	0.8320000000000001	488	281	THCA	VENETOCLAX	Approved in cancer	PTEN|KRAS|TP53	1219.2011294877339	214.6680700751134
1357.561612076451	87.13479060226871	0.8220000000000001	488	281	THCA	TRASTUZUMAB	Approved in cancer	PTEN|KRAS|APC	1273.0675255676874	224.38894493474857
839.7890979415652	-50.16932350134488	0.432	488	281	THCA	NAVITOCLAX	Clinical trials in cancer	PTEN|KRAS|TP53	693.6501528373234	33.384343016074354
1382.4157982601882	-54.117417674800976	0.8330000000000001	488	280	THCA	TEMSIROLIMUS	Approved in cancer	BRAF|PTEN|KRAS	1281.8836387697654	-135.51663908415807
1423.8750426696922	-30.80286396227669	0.8420000000000001	488	280	THCA	DOXORUBICIN	Approved in same tumor type	BRAF|KRAS|TP53	1229.663496775352	-97.28407630548757
1379.452325637506	75.96196432073884	0.8220000000000001	488	280	THCA	IRINOTECAN	Approved in cancer	BRAF|KRAS|TP53	1301.6599529706161	-122.10144030757729
870.4446706780228	7.314417746198274	0.462	488	280	THCA	IZORLISIB	Clinical trials in cancer	BRAF|PTEN|KRAS	843.7074292676924	38.31240673845545
930.4949196932586	-4.025168642176425	0.512	488	280	THCA	NVP-CGM097	Clinical trials in cancer	BRAF|KRAS|TP53	890.2591101852139	-126.98586555108075
870.5298562319836	-16.6426586013651	0.462	488	280	THCA	PILARALISIB	Clinical trials in cancer	BRAF|PTEN|KRAS	845.5868063739547	-125.0197501875384
284.40509751787465	-36.59824851274081	0.022	488	280	THCA	REFAMETINIB	Clinical trials	BRAF|PTEN|KRAS	324.03132475875987	165.55125095577677
242.86609523306237	-55.80052234041733	0.0004	488	280	THCA	PF-477736	Experimental	KRAS|CDKN2A|TP53	159.841909660378	193.03590724413573
1304.2692527712156	-5.7937766924247	0.812	488	279	THCA	ATEZOLIZUMAB	Approved in cancer	BRAF|KRAS	1259.8965414340578	-205.4968453071125
1404.4071085371895	-16.972489241323984	0.8320000000000001	488	279	THCA	ERLOTINIB	Approved in cancer	PTEN|APC|TP53	1290.507632063909	-243.9754164147622
1402.0856446164532	-40.687280798233616	0.8320000000000001	488	279	THCA	NERATINIB	Approved in cancer	BRAF|KRAS	1396.1054024072707	66.70559434434327
1368.5500489469498	-73.59014162052839	0.8220000000000001	488	279	THCA	OXALIPLATIN	Approved in cancer	BRAF|PTEN|KRAS	1266.0903768012931	-66.49682784965333
1358.6126975071859	-51.889209371318515	0.8220000000000001	488	279	THCA	PANOBINOSTAT	Approved in cancer	BRAF|KRAS	1375.183286556213	-48.65639233559739
830.0470811420004	8.558229582262754	0.421	488	279	THCA	ULIXERTINIB	Clinical trials in cancer	BRAF|KRAS	807.6120752748462	-28.59863330259634
869.5648059680324	-41.38740614469833	0.462	488	279	THCA	PICTILISIB	Clinical trials in cancer	BRAF|PTEN|KRAS	851.9070049129537	-85.42719219335368
849.8247023183251	-4.748189568950949	0.432	488	279	THCA	SARACATINIB	Clinical trials in cancer	BRAF|KRAS	777.5124409149289	232.94546516762813
807.4677505020121	0.958512689013844	0.421	488	279	THCA	CAMPTOTHECIN	Clinical trials in cancer	BRAF|KRAS	683.5950146428058	-140.2553801057266
284.0533504383359	5.543762454646384	0.022	488	279	THCA	RO4987655	Clinical trials	BRAF|KRAS	211.13291320552614	90.59938886656238
248.49780968656498	31.08402105258631	0.0004	488	279	THCA	TW-37	Experimental	BRAF|KRAS	139.84139607175666	-3.2929850976582884
1335.2715198781257	-46.47279736440399	0.8220000000000001	488	278	THCA	VORINOSTAT	Approved in cancer	BRAF|PTEN|TP53	1208.3037609509156	112.30616933965632
1366.356600149648	-7.265990606456512	0.8220000000000001	488	278	THCA	TOPOTECAN	Approved in cancer	BRAF|PTEN|TP53	1202.5816460730548	37.58313675115198
221.5044764173452	-7.811603828372455	0.0004	488	278	THCA	1173900-33-8	Experimental	BRAF|PTEN|TP53	293.1348183511134	-9.593630782632374
1362.668947324411	16.2343859990618	0.8220000000000001	488	277	THCA	CAPMATINIB	Approved in cancer	BRAF|TP53	1195.6028666821067	-126.05268747059534
1337.1669838226646	71.7239130510028	0.8220000000000001	488	277	THCA	FOLINIC ACID	Approved in cancer	BRAF|APC	1215.5209831879984	-114.54755478887226
1427.8711105314903	-7.317819375749963	0.8620000000000001	488	277	THCA	IDELALISIB	Approved in cancer	BRAF|PTEN	1337.091552970951	-52.66185269207517
1318.4436756216392	33.08631743832086	0.812	488	277	THCA	NIVOLUMAB	Approved in cancer	BRAF|PTEN	1287.3710224442164	-24.133988923584695
789.8278529683694	-42.79066251769632	0.412	488	277	THCA	GANETESPIB	Clinical trials in cancer	BRAF|TP53	699.9300732256835	-19.816585402838143
890.3611706178607	-29.854159308884107	0.462	488	277	THCA	GSK2636771	Clinical trials in cancer	BRAF|PTEN	782.875222823061	-73.48358955258468
295.30368198653525	-15.413428073798457	0.022	488	277	THCA	PF-04217903	Clinical trials	BRAF|TP53	292.00117297798226	22.489708847572558
266.55968985689503	-53.08020210840445	0.0008	488	277	THCA	918505-84-7	Experimental	BRAF|PTEN	204.68902923944032	-96.60230940093608
252.53499493646436	-34.013504464680125	0.0004	488	277	THCA	NVP-AEW541	Experimental	BRAF|PTEN	175.0135554934742	211.40957887897213
236.57651723396094	10.509689150077463	0.0004	488	277	THCA	SAR-260301	Experimental	BRAF|PTEN	190.3459631973684	-22.82420526892929
1490.4351099550688	7.351696292410281	0.924	488	276	THCA	DABRAFENIB + TRAMETINIB	Approved in same tumor type	BRAF	1534.2657846013096	86.38364940821612
1485.957087154855	30.53362383499993	0.922	488	276	THCA	DABRAFENIB MESYLATE	Approved in same tumor type	BRAF	1503.4407414369693	71.86317142608598
1498.2266894509041	-14.943260574899028	0.922	488	276	THCA	ENCORAFENIB + PANITUMUMAB	Approved in cancer	BRAF	1521.9768495127535	42.08386103139074
1475.0186499253743	-10.52961403826788	0.922	488	276	THCA	RIPRETINIB	Approved in cancer	BRAF	1522.90536308662	-189.43476122104673
1508.2824875194044	22.808996210414506	0.932	488	276	THCA	SORAFENIB TOSYLATE	Approved in same tumor type	BRAF	1458.0701785813067	-39.60645797724288
1318.0435596675652	56.741852357056416	0.8140000000000001	488	276	THCA	CETUXIMAB + ENCORAFENIB	Approved in cancer	BRAF	1193.7093969652524	156.53795921683923
1317.8767096824076	-62.59203049190698	0.8140000000000001	488	276	THCA	COBIMETINIB + VEMURAFENIB	Approved in cancer	BRAF	1211.215044950039	-198.35310631351282
1322.1996423064188	9.72343218330235	0.8130000000000001	488	276	THCA	BINIMETINIB + ENCORAFENIB	Approved in cancer	BRAF	1284.3346880949985	74.75619128829328
1312.9898746230535	-38.324382460304435	0.812	488	276	THCA	ATEZOLIZUMAB + COBIMETINIB + VEMURAFENIB	Approved in cancer	BRAF	1368.2469031672433	15.416921778560209
1359.3044430315729	63.34410772016116	0.8320000000000001	488	276	THCA	IMATINIB	Approved in cancer	BRAF|CDKN2A	1315.6333125026056	69.05394836457157
1388.6744122442544	0.7203214317642335	0.8320000000000001	488	276	THCA	LAPATINIB	Approved in cancer	BRAF	1316.1053050418711	-208.0088571448301
1344.286393783244	1.3060807797409382	0.8220000000000001	488	276	THCA	PEXIDARTINIB	Approved in cancer	BRAF	1228.8360498965126	4.036587595853717
1340.0729017154201	48.23126533504137	0.8220000000000001	488	276	THCA	TIVOZANIB	Approved in cancer	BRAF	1303.2772225883032	89.07811656416914
1340.55090531405	24.612102962999558	0.8210000000000001	488	276	THCA	EPIRUBICIN	Approved in cancer	BRAF	1216.0801235217605	-158.26652597266633
1287.4557350860912	10.972743717980137	0.772	488	276	THCA	FOSTAMATINIB	Approved in other pathologies and in clinical trials in cancer	MAP3K1|BRAF	1169.598488273005	-149.50725631873195
974.888464154977	12.225779243797234	0.528	488	276	THCA	RAF265	Clinical trials in cancer	BRAF	913.2891205450802	-88.37454392388459
953.3635009874132	2.490824871826902	0.524	488	276	THCA	PLX8394	Clinical trials in cancer	BRAF	902.7631615915782	86.85574423527282
800.7801664108132	-21.81864248819096	0.422	488	276	THCA	VORUCICLIB	Clinical trials in cancer	BRAF	738.7491556582218	138.82584064264768
790.8556641101874	17.930761907209785	0.413	488	276	THCA	GSK2118436	Clinical trials in cancer	BRAF	647.8792280328737	-110.54307526605409
849.6461323066237	-28.493518113800434	0.432	488	276	THCA	CEDIRANIB	Clinical trials in cancer	BRAF	700.4874020300653	-70.42686683900185
784.4064202354655	-4.795888295604755	0.412	488	276	THCA	PAC-1	Clinical trials in cancer	BRAF	644.383419530438	-12.345257224691693
836.4941998669356	40.078197531524324	0.432	488	276	THCA	UPROSERTIB	Clinical trials in cancer	AKT1|BRAF|PTEN	801.8805736634537	90.83315293603908
229.16978896331392	-30.221385706714415	0.0008	488	276	THCA	AGERAFENIB	Experimental	BRAF	291.3426849803244	141.71063749985825
236.31549830297456	51.48678554559902	0.0008	488	276	THCA	BMS-908662	Experimental	BRAF	330.98740030483884	46.05381311149287
224.69729875657254	30.917127909586327	0.0008	488	276	THCA	CHEMBL526479	Experimental	BRAF	108.41665469615485	41.84069763155523
244.92642313470617	-11.61373610481084	0.0008	488	276	THCA	N-{2,4-DIFLUORO-3-[(5-PYRIDIN-3-YL-1H-PYRROLO[2,3-B]PYRIDIN-3-YL)CARBONYL]PHENYL}ETHANESULFONAMIDE	Experimental	BRAF	272.65126253197246	-100.45413179227448
260.062349062536	7.6966020125848615	0.0008	488	276	THCA	RO-5212054	Experimental	BRAF	245.65720344418864	59.50704511410595
1359.546799501357	1.8648205169953656	0.8220000000000001	121	13	THYM	TRAMETINIB	Approved in cancer	KRAS|NRAS|HRAS	1263.9503790325298	8.362606004151104
1102.8895081953433	0.47317469167498416	0.632	121	12	THYM	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	KRAS|NRAS|HRAS	1037.3637163334886	-23.53490522405835
590.0187927581023	0.42951036193915115	0.252	121	12	THYM	GEMCITABINE	Approved in other pathologies	KRAS|NRAS|HRAS	524.1948456861903	-64.86395220905486
1453.788724003961	0.5077614148292753	0.892	121	11	THYM	ALPELISIB	Approved in cancer	KRAS|NRAS|HRAS	1479.1634770213939	48.29882029276379
1426.6568648928017	0.40972912103219983	0.8720000000000001	121	11	THYM	DABRAFENIB	Approved in cancer	KRAS|NRAS|HRAS	1469.6717799280393	-72.68261500676263
1400.4465618561885	1.8116424770744572	0.8520000000000001	121	11	THYM	BEVACIZUMAB	Approved in cancer	TP53|KRAS|HRAS	1274.7936213038697	-32.35299198360579
1222.0378412807158	0.43212582075662453	0.7200000000000001	121	11	THYM	DASATINIB	Approved in other pathologies and in clinical trials in cancer	TP53|KRAS|HRAS	1134.1633248003996	58.39497883508082
1413.1140289156963	-1.4816259556706655	0.8620000000000001	121	10	THYM	VEMURAFENIB	Approved in cancer	TP53|NRAS|HRAS	1310.3327616056436	-160.3120888444525
1359.2634603523443	-2.763135721028874	0.8220000000000001	121	9	THYM	BINIMETINIB	Approved in cancer	KRAS|NRAS|HRAS	1309.3946508428794	-105.67658339528549
1413.13404908252	2.6587287196910836	0.8620000000000001	121	9	THYM	DOCETAXEL	Approved in cancer	TP53|KRAS|HRAS	1338.9607773396838	-110.3905947843416
1348.6478913612389	1.8704709940141129	0.8130000000000001	121	8	THYM	EVEROLIMUS	Approved in cancer	KRAS|NRAS|HRAS	1301.3441634917654	-1.7287450397810176
1401.293426367118	-2.241699304813068	0.8520000000000001	121	8	THYM	PANITUMUMAB	Approved in cancer	TP53|HRAS	1350.0915585410835	-51.34601320525036
1075.234343586459	1.1092802995804334	0.612	121	8	THYM	LONAFARNIB	Approved in other pathologies and in clinical trials in cancer	KRAS|NRAS|HRAS	1052.9945981248475	-40.20925949054012
1078.656733901109	-0.14835863101518498	0.613	121	8	THYM	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	TP53|KRAS|HRAS	1027.9417411719196	-2.7860613670784744
817.9264873731166	-2.198186401592409	0.422	121	8	THYM	MK-2206	Clinical trials in cancer	KIT|NRAS|HRAS	768.9582568614381	97.77856208214513
818.83749373556	3.4560026537039903	0.422	121	8	THYM	BUPARLISIB	Clinical trials in cancer	KRAS|NRAS|HRAS	730.5169804658963	107.8112042270372
247.91065136239004	1.9427984823276176	0.0004	121	8	THYM	167869-21-8	Experimental	TP53|HRAS	247.27981780252946	-41.0233023611531
1482.568219053874	0.4197941615109073	0.913	121	7	THYM	CABOZANTINIB	Approved in cancer	KIT|KRAS|HRAS	1382.553953816989	-129.31743395207474
1075.9234424066467	-2.301639606437675	0.612	121	7	THYM	METFORMIN	Approved in other pathologies and in clinical trials in cancer	IDH1|KRAS|HRAS	1024.677244549714	-12.486440647465088
806.105716282518	-2.6387643602803337	0.412	121	7	THYM	E6201	Clinical trials in cancer	NRAS|HRAS	696.1247282769208	20.30787414984124
809.0507202855298	-1.1094230323176362	0.412	121	7	THYM	REOLYSIN	Clinical trials in cancer	NRAS|HRAS	752.4359634378369	-35.91640937534265
1373.2253555284744	-0.6071797229854781	0.8320000000000001	121	7	THYM	PEMBROLIZUMAB	Approved in cancer	KRAS|NRAS|MSH2	1308.4716584787452	25.504838270428735
821.8531312820058	1.719518307154118	0.422	121	7	THYM	MIRDAMETINIB	Clinical trials in cancer	TP53|KRAS|NRAS	803.3420157727446	-80.58166225385264
821.3470175098837	-1.5586746815041295	0.422	121	7	THYM	PIMASERTIB	Clinical trials in cancer	TP53|KRAS|NRAS	762.6616918552597	15.628650539883353
832.7265535718823	0.43422391119898407	0.432	121	6	THYM	212631-79-3	Clinical trials in cancer	KRAS|HRAS	689.115431914937	69.90888646610784
816.7350015315368	0.8937679607388702	0.422	121	6	THYM	DACTOLISIB	Clinical trials in cancer	KRAS|HRAS	794.9402567687358	6.411495739824488
804.945157804689	2.2755273106071456	0.412	121	6	THYM	AZD8055	Clinical trials in cancer	KRAS|HRAS	763.3915170304815	-27.39162004768025
806.8950489668262	4.533904975917579	0.412	121	6	THYM	RIGOSERTIB	Clinical trials in cancer	KRAS|HRAS	775.6086570046899	99.73054901266715
1396.7551235391606	0.8639715331110267	0.8520000000000001	121	6	THYM	ABEMACICLIB	Approved in cancer	TP53|KRAS|NRAS	1333.4520296354247	79.72274748338333
1386.8092605136737	-1.29667143378353	0.8420000000000001	121	6	THYM	CARBOPLATIN	Approved in cancer	TP53|KRAS|NRAS	1280.2891499129898	-13.256983878386933
1348.6909633598304	-1.4455340930211378	0.8130000000000001	121	6	THYM	CISPLATIN	Approved in cancer	TP53|KRAS|NRAS	1214.0868621787545	66.47181471665442
914.0465745487722	-0.26453297203093484	0.492	121	6	THYM	GEDATOLISIB	Clinical trials in cancer	TP53|KRAS|NRAS	842.2665382790941	65.91074509155371
808.4421008291738	1.982972067135762	0.412	121	6	THYM	ADAVOSERTIB	Clinical trials in cancer	TP53|KRAS|NRAS	740.2742794626079	13.003905671645185
263.48003867555286	0.0016268031384925052	0.012	121	6	THYM	LY3009120	Clinical trials	TP53|KRAS|NRAS	198.1661693654986	-59.30508273872566
1345.5186223729254	2.2240303762863505	0.812	121	5	THYM	CETUXIMAB	Approved in cancer	HRAS	1266.8452321039067	57.567053062713285
1346.1063373774464	-2.569253399828426	0.812	121	5	THYM	STREPTOZOCIN	Approved in cancer	HRAS	1327.0436810370668	-26.261006935008027
1075.7863925221031	4.208417735709219	0.612	121	5	THYM	HYDROXYCARBAMIDE	Approved in other pathologies and in clinical trials in cancer	HRAS	1032.8688518198474	-74.11122607956877
804.1090837229747	-0.41781287689963165	0.412	121	5	THYM	ANTIBIOTIC	Clinical trials in cancer	HRAS	722.5611829968525	75.78111979702186
535.7159000415265	0.12837290366078946	0.212	121	5	THYM	LOSARTAN POTASSIUM	Approved in other pathologies	HRAS	445.53983859951325	-1.7384295510682648
536.1091253080353	2.75093773256728	0.212	121	5	THYM	NITROGLYCERIN	Approved in other pathologies	HRAS	464.7861390497729	23.623464508209167
265.007125325568	2.3708600261938955	0.012	121	5	THYM	INSULIN	Clinical trials	HRAS	184.19071693651819	-45.75694312338055
255.93797409833874	-2.317987360325219	0.0008	121	5	THYM	1,6-HEXANEDIOL	Experimental	HRAS	194.42686547642424	10.778277005309775
248.9604219794342	-1.0210799688361476	0.0008	121	5	THYM	2,2,2-TRIFLUOROETHANOL	Experimental	HRAS	259.779978150871	-25.52617994012124
253.12107580186787	5.522096328084245	0.0008	121	5	THYM	GUANOSINE 5'-DIPHOSPHATE	Experimental	HRAS	287.7511446786756	4.117592046914524
248.19217609616308	5.079047903687666	0.0008	121	5	THYM	GUANOSINE TRIPHOSPHATE	Experimental	HRAS	244.3297980879068	91.46812544327065
252.0296972748951	-5.497921942118381	0.0008	121	5	THYM	N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE	Experimental	HRAS	181.77976163191093	0.9792912017360038
266.2992762442592	0.055416527149816375	0.012	121	5	THYM	INOSITOL	Clinical trials	TP53|NRAS	194.61846973477705	8.73226639360044
1486.4208378774122	0.42074425309183994	0.916	121	5	THYM	PAZOPANIB	Approved in cancer	KIT|TP53|KRAS	1464.1716497217985	-27.90790187282738
1373.2427392029826	2.3767696411678685	0.8320000000000001	121	5	THYM	VENETOCLAX	Approved in cancer	IDH1|TP53|KRAS	1240.0903181010685	-69.44730675730413
873.3591845763493	0.43661951560065404	0.462	121	5	THYM	BERZOSERTIB	Clinical trials in cancer	IDH1|TP53|KRAS	828.085944627233	-19.05685834813883
254.93475359816833	2.5419065025011207	0.0004	121	5	THYM	PF-477736	Experimental	TP53|CHEK2|KRAS	184.61214067719567	0.8876882092838798
1350.9401778606327	-0.0398896994181257	0.8140000000000001	121	4	THYM	COBIMETINIB	Approved in cancer	NF1|KRAS|NRAS	1181.7627401059528	88.65304241159782
1491.663181066291	0.43332109964413235	0.92	121	4	THYM	SORAFENIB	Approved in cancer	KIT|KRAS|NRAS	1470.1498884720356	-18.68545077404218
1489.3392543198013	0.4148690821387788	0.919	121	4	THYM	REGORAFENIB	Approved in cancer	KIT|KRAS|NRAS	1461.573468107674	102.20612825520101
1453.8379866843316	-2.9719245802568537	0.892	121	4	THYM	ENCORAFENIB	Approved in cancer	TP53|KRAS	1379.281546014765	22.553427436880952
1456.0174380195567	-2.16509877668841	0.893	121	4	THYM	PACLITAXEL	Approved in cancer	TP53|KRAS	1398.3475651574815	79.41728164038955
1453.9799298543103	3.9818414889966505	0.892	121	4	THYM	TAMOXIFEN	Approved in cancer	IDH1|TP53	1443.698201526508	75.15004207148775
1398.552010545493	-3.4241268821751305	0.8520000000000001	121	4	THYM	CRIZOTINIB	Approved in cancer	TP53|KRAS	1424.2001875565998	-101.5133306564398
1387.9385081875719	1.1053341589299635	0.8420000000000001	121	4	THYM	BORTEZOMIB	Approved in cancer	TP53|KRAS	1303.775529113793	-108.60303490471391
1415.605112071559	0.7051812532034774	0.8630000000000001	121	4	THYM	DOXORUBICIN	Approved in cancer	TP53|KRAS	1416.3427610186973	-35.560881983827244
1398.5383012745926	-1.1001673180633134	0.8520000000000001	121	4	THYM	FLUOROURACIL	Approved in cancer	TP53|KRAS	1236.993566412082	-70.88513539473506
1385.6135980410359	1.0729584326113866	0.8420000000000001	121	4	THYM	IRINOTECAN	Approved in cancer	TP53|KRAS	1366.422634509301	-55.40595773719055
1386.7470804705736	3.1017988851646408	0.8420000000000001	121	4	THYM	METHOTREXATE	Approved in cancer	IDH1|TP53	1412.912214375548	-4.770801397544204
1361.9393665581708	-1.1012013127385671	0.8220000000000001	121	4	THYM	MITOXANTRONE HYDROCHLORIDE	Approved in cancer	IDH1|TP53	1263.1899129258215	-115.74187281580369
1346.4084147664578	-0.0976962846887659	0.812	121	4	THYM	DAUNORUBICIN HYDROCHLORIDE	Approved in cancer	IDH1|TP53	1327.072935007877	74.70391450281278
1344.2364146137716	-0.9243711380070465	0.812	121	4	THYM	DOXORUBICIN HYDROCHLORIDE	Approved in cancer	IDH1|TP53	1314.86365624863	108.5896701295959
1089.2814072467004	0.5806752997323485	0.622	121	4	THYM	THIORIDAZINE HYDROCHLORIDE	Approved in other pathologies and in clinical trials in cancer	IDH1|TP53	1012.9287189877671	20.708181483955286
1078.1516463276996	4.985929647611641	0.613	121	4	THYM	AZACITIDINE	Approved in other pathologies and in clinical trials in cancer	IDH1|TP53	1005.9704533548177	11.338066262852777
1077.7627114538436	2.6947060314985833	0.612	121	4	THYM	MERCAPTOPURINE	Approved in other pathologies and in clinical trials in cancer	IDH1|TP53	1016.4116391765771	-18.433599490695514
914.0467515288611	2.389467022068146	0.492	121	4	THYM	NAVITOCLAX	Clinical trials in cancer	TP53|KRAS	875.7519599162783	-4.525558982148738
859.9540374296867	1.5983524548991284	0.452	121	4	THYM	SAPANISERTIB	Clinical trials in cancer	TP53|KRAS	852.1700897586245	52.441534921850234
859.9540869681495	-0.7256475445728938	0.452	121	4	THYM	DS-7423	Clinical trials in cancer	TP53|KRAS	810.9659071210042	-66.75200712944627
846.4742322334804	0.4365894999046418	0.442	121	4	THYM	CAPIVASERTIB	Clinical trials in cancer	TP53|KRAS	795.1421426563409	19.66413280186825
981.660474967446	0.43604520579680184	0.542	121	4	THYM	NVP-CGM097	Clinical trials in cancer	TP53|KRAS	921.0645956941784	-27.094905156717232
819.347639920504	0.4270382257250276	0.422	121	4	THYM	FENRETINIDE	Clinical trials in cancer	IDH1|TP53	764.9450036941284	-18.924443755554705
806.5324193762212	0.14573682928465814	0.412	121	4	THYM	DEMCIZUMAB	Clinical trials in cancer	TP53|KRAS	704.5005643306181	-51.35326951189208
644.1871814450149	0.43189851613942665	0.292	121	4	THYM	AZATHIOPRINE	Approved in other pathologies	IDH1|TP53	597.0707912661064	11.436435570149314
549.5238492515427	-0.9476381299059256	0.2219999999999999	121	4	THYM	CHLORPROMAZINE	Approved in other pathologies	IDH1|TP53	509.7427888034562	3.0752724512704503
576.552629377628	0.4284519428136093	0.242	121	4	THYM	PIMOZIDE	Approved in other pathologies	IDH1|TP53	535.1653973957548	11.375520168886936
562.9944843867546	0.4228321985023342	0.2319999999999999	121	4	THYM	SERTRALINE	Approved in other pathologies	IDH1|TP53	512.0458002618998	31.570553251819234
550.6539475244762	1.0843227507986342	0.2219999999999999	121	4	THYM	PAROXETINE HYDROCHLORIDE	Approved in other pathologies	IDH1|TP53	503.26960265344746	-53.021752607975
548.3302367875588	1.0476565394639579	0.2219999999999999	121	4	THYM	PROCHLORPERAZINE	Approved in other pathologies	IDH1|TP53	480.533492834709	12.523606817860895
535.8217915400332	-2.357208872134663	0.212	121	4	THYM	HEXACHLOROPHENE	Approved in other pathologies	IDH1|TP53	474.3995249729694	14.078597060363592
537.8293649843791	-1.1880359382104473	0.212	121	4	THYM	SERTRALINE HYDROCHLORIDE	Approved in other pathologies	IDH1|TP53	473.6586825962502	8.221284995363987
537.9955535032517	1.1300144012280668	0.212	121	4	THYM	TRIAMTERENE	Approved in other pathologies	IDH1|TP53	475.9801004849013	8.330759405350221
265.0826060556838	-2.114804118825589	0.012	121	4	THYM	TETRANDRINE	Clinical trials	IDH1|TP53	211.40861559541008	59.39485982763776
246.50582350003057	-0.690898939886381	0.0004	121	4	THYM	ASTEMIZOLE	Experimental	IDH1|TP53	223.58807735736875	49.792661238047685
255.27812222161776	0.08070145947948504	0.0004	121	4	THYM	AZD7762	Experimental	TP53|CHEK2	225.25069065847524	22.66257712085681
250.68568016065544	6.032684543471021	0.0004	121	4	THYM	1,10-PHENANTHROLINE	Experimental	IDH1|TP53	182.7942633323635	-44.62587507990929
247.30064174253818	-2.8720927442164736	0.0004	121	4	THYM	148672-13-3	Experimental	IDH1|TP53	256.1970011599447	-54.3229128504764
252.52527237132227	3.1161155659181077	0.0004	121	4	THYM	2,6-DIMETHOXY-1,4-BENZOQUINONE	Experimental	IDH1|TP53	210.1521614517412	0.8542327497897872
253.98633473583965	-3.8609155097140615	0.0004	121	4	THYM	2-(PYRIDIN-2-YLAMINO)QUINOLIN-8-OL	Experimental	IDH1|TP53	201.9665734229478	-10.118775723693602
253.0952804124068	0.8644277143294232	0.0004	121	4	THYM	2-CHLOROADENOSINE	Experimental	IDH1|TP53	183.46794023650833	-1.315018662955481
251.8290245024134	-3.02837145497233	0.0004	121	4	THYM	3-METHYLTOXOFLAVIN	Experimental	IDH1|TP53	300.25822892519835	1.347678336408137
253.59720655991518	-1.5117705042432874	0.0004	121	4	THYM	ABT-737	Experimental	TP53|KRAS	263.6457284520256	-7.864838015508241
251.41092181499513	-0.7491885848746165	0.0004	121	4	THYM	ALEXIDINE DIHYDROCHLORIDE	Experimental	IDH1|TP53	235.48736089145987	10.934099975342718
250.28333103533294	3.751865740204522	0.0004	121	4	THYM	BENZETHONIUM CHLORIDE	Experimental	IDH1|TP53	211.561694920176	65.14513045532038
249.54561227028265	-3.4377930113586217	0.0004	121	4	THYM	BROXYQUINOLINE	Experimental	IDH1|TP53	212.65718830150746	0.8116720766328456
249.5554221397797	-5.761771589234712	0.0004	121	4	THYM	CHEMBL2002487	Experimental	IDH1|TP53	185.89985232958665	-153.03885417899545
250.85262344474023	1.4986719965266388	0.0004	121	4	THYM	CHEMBL405317	Experimental	IDH1|TP53	200.42672915407485	-11.60633366664544
1617.554242703389	32.58916220182411	1	447	364	UCEC	ALPELISIB	Approved in cancer	TP53|PTEN|PIK3R1	1646.8959753761399	21.33516769484416
1085.1745107968227	37.905431628561104	0.597	447	358	UCEC	GEDATOLISIB	Clinical trials in cancer	TP53|PTEN|PIK3R1	1006.190435481788	-237.5607104632183
1297.6214311277593	8.443100280462176	0.777	447	353	UCEC	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	TP53|NF1|PTEN	1177.0091653750185	-105.3131527022131
1448.962161546366	-23.42911895232055	0.893	447	351	UCEC	PACLITAXEL	Approved in cancer	TP53|PTEN|ATM	1467.6657202538463	-108.26359129995885
1472.7693371604253	-45.428640156724384	0.893	447	351	UCEC	CARBOPLATIN	Approved in cancer	BRCA1|TP53|PTEN	1518.2204031664396	14.89415685241346
1049.5456985312444	-71.80356775541057	0.592	447	349	UCEC	DS-7423	Clinical trials in cancer	TP53|PTEN|PIK3R1	986.6781682097828	66.8618510178978
1442.4014071390538	8.022022436857299	0.892	447	345	UCEC	FLUOROURACIL	Approved in cancer	TP53|PTEN|ATM	1441.477642434341	36.6353003595178
1019.7834999193691	-59.52014690524726	0.586	447	345	UCEC	CAPIVASERTIB	Clinical trials in cancer	KRAS|TP53|PTEN	1045.0836144074187	-122.2800800640791
996.6488503502504	41.157846476497156	0.5640000000000001	447	344	UCEC	MIRDAMETINIB	Clinical trials in cancer	NRAS|TP53|PTEN	942.2638906301686	124.53989063409819
1013.5811025986133	14.36206510281508	0.584	447	343	UCEC	SAPANISERTIB	Clinical trials in cancer	TP53|PTEN|RB1	985.5519981085112	-212.6383433229931
1442.191763653197	-54.67249259630729	0.892	447	341	UCEC	VENETOCLAX	Approved in cancer	KRAS|TP53|PTEN	1457.1576085349654	86.33842446453849
918.0979943157791	-1.9268394886420879	0.492	447	339	UCEC	NAVITOCLAX	Clinical trials in cancer	KRAS|TP53|PTEN	868.7433591817546	48.74047675426979
238.57798648642884	30.075781996408494	0.0004	447	339	UCEC	ABT-737	Experimental	KRAS|TP53|PTEN	162.24725973859074	111.89994650772434
232.86724855959392	-0.5987906395813241	0.0004	447	336	UCEC	1173900-33-8	Experimental	PTEN|ATM|PIK3R1	209.47844115568037	17.201983886372375
1461.124736799187	60.284231892904614	0.895	447	335	UCEC	CISPLATIN	Approved in cancer	TP53|PTEN|ATM	1473.0542530505543	7.060332586222074
1419.045649023469	-34.37351070709835	0.8720000000000001	447	325	UCEC	TOPOTECAN	Approved in same tumor type	TP53|PTEN|RB1	1392.2989198504645	-29.203344153744126
1411.657652487174	11.143427648208075	0.882	447	324	UCEC	OLAPARIB	Approved in cancer	BRIP1|PTEN|ATM	1454.6694862303648	-139.0993794677242
1538.6593304601056	18.944692921408745	0.959	447	312	UCEC	TRAMETINIB	Approved in cancer	TP53|NF1|RB1	1575.0669459595827	19.473602189411565
1581.0106067909521	52.781804349824654	0.99	447	308	UCEC	EVEROLIMUS	Approved in cancer	RB1|ATM|PIK3R1	1595.3996450162206	65.37431096243947
645.6788122496848	0.43489630976233684	0.293	447	308	UCEC	GEMCITABINE	Approved in other pathologies	BRCA1|TP53|PTEN	607.0125926804001	-50.15352807547373
1575.1261685314912	-49.471146346519106	0.99	447	299	UCEC	TEMSIROLIMUS	Approved in cancer	PIK3CA|KRAS|PTEN	1556.0114142631523	-106.54451414684812
1077.6601097467137	-19.14220712429838	0.595	447	298	UCEC	APITOLISIB	Clinical trials in cancer	KRAS|PTEN|PIK3R1	997.9103160095137	-185.6536826439654
1622.5153768572513	-36.058036300401795	1	447	297	UCEC	INFIGRATINIB	Approved in cancer	KRAS|PTEN|PIK3R1	1628.6238854012313	102.66756583418157
1079.1345781490131	-68.78027233914577	0.597	447	293	UCEC	PICTILISIB	Clinical trials in cancer	PTEN|RB1|PIK3R1	1023.6193406418153	-103.75764604864158
1602.1239261873761	-54.277221265510704	0.999	447	292	UCEC	COPANLISIB	Approved in cancer	KRAS|PTEN|PIK3R1	1679.8800039717833	-54.23706929396455
1485.2372383865456	-18.479096151699252	0.893	447	291	UCEC	PALBOCICLIB	Approved in cancer	DYRK1A|PTEN|RB1	1451.8446031682931	221.2954760435489
1102.0051501699008	-6.74127730766179	0.597	447	291	UCEC	PILARALISIB	Clinical trials in cancer	KRAS|PTEN|PIK3R1	1033.0673073327448	146.90543252861903
1051.077304607847	-25.385963988126235	0.596	447	291	UCEC	PF-04691502	Clinical trials in cancer	KRAS|PTEN|PIK3R1	968.3232871420703	-148.3857028922252
1056.5462662615066	85.04922824512425	0.593	447	291	UCEC	IZORLISIB	Clinical trials in cancer	KRAS|PTEN|PIK3R1	1003.7459132003396	-61.92904406540201
1041.4720284573189	62.63453836934795	0.592	447	291	UCEC	VOXTALISIB	Clinical trials in cancer	KRAS|PTEN|PIK3R1	1011.2571419152627	-151.78688862079298
870.4187417261887	18.491174694348587	0.462	447	291	UCEC	PANULISIB	Clinical trials in cancer	KRAS|PTEN|PIK3R1	836.1304122496804	146.0173248502698
1487.8305023750588	8.357601729522855	0.893	447	289	UCEC	DOXORUBICIN	Approved in cancer	BRCA1|TP53|ATM	1489.9685600125665	243.11874554238204
1601.093081753831	7.343965657441174	0.999	447	288	UCEC	ENCORAFENIB	Approved in cancer	KRAS|TP53|PTEN	1608.1637556579153	158.64731954859138
1593.0802256180818	-28.993330802348794	1	447	286	UCEC	SORAFENIB	Approved in cancer	KRAS|NRAS|PTEN	1633.4591371291315	-35.14740787110276
1157.0396379464703	0.4203919364730666	0.6719999999999999	447	286	UCEC	METFORMIN	Approved in other pathologies and in clinical trials in cancer	HRAS|PTEN|ATM	1134.4654105753389	-63.66329780590826
1042.2114972160305	19.131712363794605	0.589	447	285	UCEC	IPATASERTIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	963.2078781406265	198.00232364618603
1024.9804863134746	-30.84760532345254	0.585	447	284	UCEC	AZD8055	Clinical trials in cancer	KRAS|HRAS|PTEN	1007.8531497204966	46.45682223935614
1433.8046801259782	51.69165929698127	0.882	447	283	UCEC	IRINOTECAN	Approved in cancer	BRCA1|TP53|ATM	1328.5865806780641	110.01604874424521
1407.4327895739611	38.9789023575716	0.8620000000000001	447	283	UCEC	CAPECITABINE	Approved in cancer	KRAS|CDH1|PTEN	1346.2206810567793	51.37755553395223
513.5288444196112	-7.956955109726806	0.195	447	283	UCEC	TASELISIB	Clinical trials	KRAS|PTEN|PIK3R1	436.42682341997215	47.551870518288155
925.515593662036	25.8862002853856	0.494	447	282	UCEC	FIMEPINOSTAT	Clinical trials in cancer	HDAC8|KRAS|PTEN	874.378664487328	-76.62416146369979
380.45150576284993	11.552937047614847	0.096	447	282	UCEC	OMIPALISIB	Clinical trials	NRAS|PTEN|PIK3R1	383.1149811826706	60.0404082324535
257.1415601214372	-15.828613977577959	0.0004	447	282	UCEC	1056901-62-2	Experimental	PIK3CA|KRAS|PTEN	133.59006587764992	148.28265099095347
1014.9230236577857	63.599817991364944	0.584	447	281	UCEC	ONATASERTIB	Clinical trials in cancer	FLT4|KRAS|PTEN	960.4465653331368	171.82390282562767
889.4694306233342	0.007954272002564267	0.473	447	280	UCEC	RIGOSERTIB	Clinical trials in cancer	KRAS|HRAS|PTEN	868.1485429776068	-134.60560713616536
863.2325711715444	-19.340053712644334	0.452	447	280	UCEC	AZD8835	Clinical trials in cancer	PIK3CA|KRAS|PTEN	773.0378653615242	46.56314612690335
1026.893282088694	40.40665416465447	0.585	447	280	UCEC	LINSITINIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	984.265461742168	-4.6431698541902335
259.29400488698394	10.21993336622316	0.0004	447	280	UCEC	PKI-402	Experimental	PIK3CA|KRAS|PTEN	98.98626719701207	-4.428352909459107
983.3572737099329	-19.55457116281474	0.555	447	279	UCEC	PIMASERTIB	Clinical trials in cancer	NRAS|TP53|NF1	973.8502699827346	18.62016962277434
1567.370901748746	-23.838633946593546	0.98	447	278	UCEC	TRASTUZUMAB	Approved in cancer	PIK3CA|KRAS|PTEN	1566.0182867724684	99.9663002429233
1565.1293917344037	30.85691301164033	0.992	447	275	UCEC	BORTEZOMIB	Approved in cancer	KRAS|TP53|RB1	1583.890933122931	148.81145011587125
1626.907988032943	3.7452653725245	1	447	273	UCEC	DABRAFENIB	Approved in cancer	NRAS|HRAS|TP53	1641.9841258813021	76.93271995815587
1329.4600027093036	10.53771444212677	0.8	447	272	UCEC	DASATINIB	Approved in other pathologies and in clinical trials in cancer	KRAS|HRAS|TP53	1186.975957999807	19.0092367523321
1034.0730046818844	-5.459867627100579	0.593	447	272	UCEC	VS-5584	Clinical trials in cancer	PIK3CA|PTEN|PIK3R1	992.9501062692219	100.8065034070944
1557.8654965895016	-0.10637134974805917	0.99	447	271	UCEC	VEMURAFENIB	Approved in cancer	HRAS|TP53|PTEN	1624.6972732706138	40.64702638358216
1000.38669780661	-38.617095719482165	0.5740000000000001	447	270	UCEC	OSI-027	Clinical trials in cancer	PIK3CA|KRAS|PTEN	964.2775246231423	49.13143495953679
1069.3191028138185	62.29392411533314	0.594	447	270	UCEC	SAMOTOLISIB	Clinical trials in cancer	PIK3CA|PTEN|PIK3R1	970.1852515481821	90.30034732979067
1058.80221758884	-0.7051317464105864	0.593	447	270	UCEC	BGT-226 FREE BASE	Clinical trials in cancer	PIK3CA|PTEN|PIK3R1	999.1510110566793	22.27895492565193
1055.9524047897821	41.02154788918941	0.593	447	270	UCEC	GSK2636771	Clinical trials in cancer	PIK3CA|PTEN|PIK3R1	1046.1785944595304	-179.61316615098596
1477.1358643819542	37.29976713860228	0.892	447	269	UCEC	BEVACIZUMAB	Approved in same tumor type	KRAS|HRAS|TP53	1464.414984420652	58.99192543525817
888.0343185725781	-25.513159123429148	0.472	447	269	UCEC	PAXALISIB	Clinical trials in cancer	PIK3CA|PTEN|PIK3R1	848.8904896398245	-172.43483578763292
1312.079552808908	-16.393820389308274	0.788	447	267	UCEC	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	KRAS|TP53|RB1	1158.6386785838542	-190.9431496833456
986.7124336763416	5.650644646405084	0.562	447	267	UCEC	NVP-CGM097	Clinical trials in cancer	PIK3CA|KRAS|TP53	962.8895041699783	-103.48315416584846
912.6582214124039	-29.458694944642218	0.492	447	266	UCEC	AFURESERTIB	Clinical trials in cancer	AKT1|PIK3CA|PTEN	883.3341853123919	117.7280389495429
827.8045531103273	11.709987399070314	0.432	447	266	UCEC	DEMCIZUMAB	Clinical trials in cancer	PIK3CA|KRAS|TP53	750.655388030654	-65.64181319052183
1064.3701093833279	-47.50310708291454	0.592	447	265	UCEC	M2698 FREE BASE	Clinical trials in cancer	AKT1|PIK3CA|PTEN	994.7027446815737	-26.809171564171947
831.2935906350874	-12.71588063295789	0.432	447	263	UCEC	ONC201	Clinical trials in cancer	AKT1|TP53|PTEN	719.5112166624648	62.998787421948236
1524.5558312472585	-3.7076990424972394	0.946	447	262	UCEC	VORINOSTAT	Approved in cancer	TP53|PTEN|RB1	1425.9890068330008	-88.26392137695518
850.4896958220907	2.345019854686825	0.443	447	260	UCEC	PKI-179	Clinical trials in cancer	MTOR|PIK3CA|PTEN	785.7943515093069	-50.024155207987775
1452.0628750411265	34.277430736331496	0.893	447	258	UCEC	IDELALISIB	Approved in cancer	BRAF|PIK3CA|PTEN	1498.076751470932	-4.910358749165255
255.48869141243003	-40.936530151228766	0.0008	447	258	UCEC	SAR-260301	Experimental	BRAF|PIK3CA|PTEN	157.48235451614465	13.147781893747862
279.59394736791245	-4.490611038326421	0.0008	447	258	UCEC	NVP-AEW541	Experimental	BRAF|PIK3CA|PTEN	113.62456118026678	-37.8986149414452
1007.4079221728304	-12.76849397673405	0.5730000000000001	447	257	UCEC	VISTUSERTIB	Clinical trials in cancer	PIK3CA|KRAS|PTEN	934.103946279855	-149.87369566642082
374.6448540666167	-12.882615986409803	0.093	447	257	UCEC	ACALISIB	Clinical trials	PIK3CB|PIK3CA|PTEN	378.18192011349095	-16.746915826452295
235.1997022492319	-28.037899137650385	0.0004	447	257	UCEC	CCT128930	Experimental	PIK3CA|PTEN	143.97538997274268	-201.34932079587864
265.9186969804763	34.34778603454572	0.0004	447	257	UCEC	GSK2334470	Experimental	PIK3CA|PTEN	201.8087246306635	112.63896929356326
1392.4276930289905	-32.4324867499906	0.8520000000000001	447	249	UCEC	FULVESTRANT	Approved in cancer	ERBB2|PIK3CA|PTEN	1364.1674165953943	266.5271589900275
1387.073846797006	1.0163056755324646	0.8430000000000001	447	248	UCEC	TEMOZOLOMIDE	Approved in cancer	BRCA1|TP53|PTEN	1298.0553050995543	54.085210400961074
1081.4532749582393	7.027467855459605	0.593	447	241	UCEC	RESVERATROL	Clinical trials in cancer	PPARG|BRCA1|TP53	1007.6419193900891	82.25207216588251
1589.9257124024525	29.072994390132948	0.992	447	236	UCEC	TAMOXIFEN	Approved in cancer	PIK3CA|BRCA1|TP53	1591.1923941748576	40.10256800098949
1086.989310543193	-42.04699359338457	0.596	447	233	UCEC	BUPARLISIB	Clinical trials in cancer	NRAS|PTEN|PIK3R1	980.108128162505	119.82006819780986
333.77078711247555	0.4239632374615212	0.062	447	233	UCEC	EMODIN	Clinical trials	PIK3CA|BRCA1|TP53	367.7260773343744	-102.01871757034651
846.875457869352	25.07344874894582	0.442	447	232	UCEC	TANESPIMYCIN	Clinical trials in cancer	MTOR|PIK3CA|TP53	722.5942691837499	-74.30010216921231
1466.5479321384682	-3.0607558411645073	0.892	447	228	UCEC	DUVELISIB	Approved in cancer	PIK3CB|PIK3CA|TP53	1382.805607943928	174.43902222373828
1404.1141239746157	-13.395474969204884	0.8620000000000001	447	228	UCEC	RALOXIFENE	Approved in cancer	UGT1A8|PIK3CA|TP53	1402.2683728895154	173.4574839769101
1611.8541570738535	-14.130390514901592	0.998	447	227	UCEC	BINIMETINIB	Approved in cancer	NF1|PTEN|ATM	1604.3027589335763	100.22480634933197
902.8548542934155	19.32292008016148	0.492	447	223	UCEC	UPROSERTIB	Clinical trials in cancer	BRAF|PIK3CA|PTEN	841.2244151910352	-103.97373075575112
1542.6244618689957	-17.299485292359947	0.961	447	221	UCEC	DOCETAXEL	Approved in cancer	PIK3CA|KRAS|TP53	1579.2503312729968	-99.88922409790328
1577.7682273339221	11.410150599016674	0.996	447	221	UCEC	VANDETANIB	Approved in cancer	KRAS|PTEN|ATM	1559.6438931506748	-130.3598688410694
1605.2314855084735	56.64276336841937	0.999	447	218	UCEC	REGORAFENIB	Approved in cancer	FLT4|KRAS|NRAS	1634.7844883482235	-75.64574415120254
964.568441550747	1.0838397457148403	0.53	447	216	UCEC	MK-2206	Clinical trials in cancer	NRAS|HRAS|PTEN	903.4825612377463	-15.45201665895334
511.59725104271246	15.110312847842891	0.194	447	212	UCEC	BMS-754807	Clinical trials	AKT1|KRAS|PTEN	430.47811032803804	-40.571096804978424
1466.3551112342873	17.580343550554204	0.893	447	211	UCEC	ERLOTINIB	Approved in cancer	CDH1|TP53|PTEN	1351.8296754117325	-12.44629540021836
1333.8457418879507	-11.55297160290678	0.797	447	209	UCEC	PONATINIB	Approved in other pathologies and in clinical trials in cancer	FGFR1|PIK3CA|KRAS	1159.3485665086598	-42.4945454008305
1042.1871578457346	-46.960191106937714	0.596	447	209	UCEC	SONOLISIB	Clinical trials in cancer	PIK3CA|KRAS|PIK3R1	1014.9682065515391	133.22054410363336
1065.3438414298485	20.70709165351036	0.593	447	209	UCEC	AZD8186	Clinical trials in cancer	PIK3CA|KRAS|PTEN	1002.5309134009984	213.91334199156876
1583.6196071667762	-7.9175235289801265	0.987	447	208	UCEC	COBIMETINIB	Approved in cancer	KRAS|NRAS|NF1	1572.8278750048516	-50.66481695233921
1424.3167859866976	-10.135452945764172	0.882	447	207	UCEC	CETUXIMAB	Approved in cancer	PIK3CA|HRAS|PTEN	1404.1019785058322	-9.184160911477704
1428.2784844973064	29.441251866648543	0.8720000000000001	447	207	UCEC	PANITUMUMAB	Approved in cancer	HRAS|TP53|PTEN	1364.6515503794553	-3.0063897177977026
471.5132045670293	0.44331421717643593	0.164	447	207	UCEC	REFAMETINIB	Clinical trials	PTPN11|KRAS|PTEN	409.29509124549463	14.165665083281255
1572.7066420108395	0.42063231438345383	0.98	56	46	UCS	ALPELISIB	Approved in cancer	KRAS|TP53|PTEN	1606.833053963782	16.89309162633276
1440.5307033663894	77.01348085925741	0.8630000000000001	56	46	UCS	PACLITAXEL	Approved in cancer	KRAS|TP53|PTEN	1412.8619212662784	103.94507123902793
1354.4528370427481	-33.650564526250605	0.8430000000000001	56	46	UCS	CARBOPLATIN	Approved in cancer	KRAS|TP53|PTEN	1395.92340197914	16.509139212723056
1413.670248005498	-2.5570696730015072	0.8520000000000001	56	46	UCS	FLUOROURACIL	Approved in cancer	KRAS|TP53|PTEN	1326.2054809687497	-82.25082857025487
1380.4382843203225	78.67589217294477	0.8420000000000001	56	46	UCS	OLAPARIB	Approved in cancer	KRAS|TP53|PTEN	1263.7476543722203	-157.08781348183058
1435.3950294862693	-55.390648889679085	0.8620000000000001	56	46	UCS	VENETOCLAX	Approved in cancer	KRAS|TP53|PTEN	1402.0474410708857	136.02714183189283
1145.6663207530196	-18.45403542871307	0.654	56	46	UCS	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	TP53|NF1|PTEN	1110.785742766766	-175.16266699195018
1021.4318630779212	-13.973267095668888	0.5770000000000001	56	46	UCS	GEDATOLISIB	Clinical trials in cancer	KRAS|TP53|PTEN	976.2173316725291	-74.29870843604736
842.5908246582566	-14.554739684664412	0.452	56	46	UCS	CAPIVASERTIB	Clinical trials in cancer	KRAS|TP53|PTEN	790.0018071824632	132.7867412612814
895.4002184575844	-35.152107787274474	0.462	56	46	UCS	NAVITOCLAX	Clinical trials in cancer	KRAS|TP53|PTEN	825.210700163115	-77.95509334649505
853.2146648703513	17.577657521149632	0.444	56	46	UCS	DS-7423	Clinical trials in cancer	KRAS|TP53|PTEN	778.3066713007973	-151.37986883048862
875.7322338299723	-7.642900783378536	0.452	56	46	UCS	MIRDAMETINIB	Clinical trials in cancer	KRAS|TP53|PTEN	817.9435456556736	46.61380738107874
876.674319105272	-63.33593637008384	0.453	56	46	UCS	SAPANISERTIB	Clinical trials in cancer	KRAS|TP53|PTEN	816.7096247767399	-116.22239276552061
251.51395459849638	-28.175626109288828	0.0004	56	46	UCS	ABT-737	Experimental	KRAS|TP53|PTEN	117.51214875386259	122.90035561176461
1446.5794105856253	44.07708455597498	0.8620000000000001	56	45	UCS	BORTEZOMIB	Approved in cancer	PIK3CA|KRAS|TP53	1357.7207037031312	115.95760066238512
1410.0664425401742	63.20106512934214	0.8530000000000001	56	45	UCS	CISPLATIN	Approved in cancer	KRAS|TP53|PTEN	1273.5012085144697	25.035594665328745
1383.1528750900225	-16.35939399119789	0.8430000000000001	56	45	UCS	DOXORUBICIN	Approved in cancer	PIK3CA|KRAS|TP53	1243.9489347968586	-23.49630057341892
1408.9606999201876	96.23535832543809	0.8520000000000001	56	45	UCS	BEVACIZUMAB	Approved in same tumor type	PIK3CA|KRAS|TP53	1342.2308473283122	-252.10017906125995
1416.2675830780177	30.691700106706946	0.8520000000000001	56	45	UCS	DABRAFENIB	Approved in cancer	PIK3CA|KRAS|TP53	1328.8435680720286	-160.24324889978706
1386.3757503809202	16.620182696207394	0.8320000000000001	56	45	UCS	IRINOTECAN	Approved in cancer	PIK3CA|KRAS|TP53	1316.2843977182742	151.8020590665094
1426.4629907015199	-87.67888958852541	0.8540000000000001	56	45	UCS	TRAMETINIB	Approved in cancer	KRAS|TP53|NF1	1358.184119290725	-72.36619583677108
1174.2054558556804	-0.9277338589913882	0.6819999999999999	56	45	UCS	DASATINIB	Approved in other pathologies and in clinical trials in cancer	PIK3CA|KRAS|TP53	1129.092818943288	117.18678157113612
1145.1822453596865	15.039795783262406	0.652	56	45	UCS	SIROLIMUS	Approved in other pathologies and in clinical trials in cancer	PIK3CA|KRAS|TP53	1101.8266335688377	-33.33073135365109
994.0534762088002	5.3182116939289585	0.552	56	45	UCS	NVP-CGM097	Clinical trials in cancer	PIK3CA|KRAS|TP53	946.2008360653572	-60.97041748273078
836.1115214375632	71.08094212658864	0.432	56	45	UCS	DEMCIZUMAB	Clinical trials in cancer	PIK3CA|KRAS|TP53	738.3718593385495	200.3493672035691
861.6697935825244	49.978648756908484	0.452	56	45	UCS	PIMASERTIB	Clinical trials in cancer	KRAS|TP53|NF1	815.2867582626359	240.4853005207862
1409.7810916291176	-34.913203592930756	0.8420000000000001	56	43	UCS	TOPOTECAN	Approved in same tumor type	PIK3CA|TP53|PTEN	1349.708249282301	-185.06854139454867
1466.2540264848622	-8.178403980236084	0.8720000000000001	56	43	UCS	DOCETAXEL	Approved in cancer	PIK3CA|KRAS|TP53	1391.3061620425829	262.0971602640944
248.39365970031915	4.452852327995259	0.0004	56	43	UCS	1173900-33-8	Experimental	PIK3CA|TP53|PTEN	136.70556990287707	-76.43993500548957
1438.6460907689466	-23.09760884893845	0.8620000000000001	56	42	UCS	DUVELISIB	Approved in cancer	PIK3CA|TP53	1352.1014677497274	-122.85894307990921
1355.1136265655173	-91.98836457918479	0.8220000000000001	56	42	UCS	RALOXIFENE	Approved in cancer	PIK3CA|TP53	1278.006527210873	-108.12053752818841
1442.456476264892	12.25694484532562	0.8620000000000001	56	42	UCS	TAMOXIFEN	Approved in cancer	RRAS2|PIK3CA|TP53	1361.4125742068875	160.81513597574605
905.9902703743386	4.031663262191813	0.472	56	42	UCS	RESVERATROL	Clinical trials in cancer	PIK3CA|TP53	829.0171263290372	-45.693613469587206
814.8216863678895	-66.04839213266544	0.422	56	42	UCS	TANESPIMYCIN	Clinical trials in cancer	PIK3CA|TP53	746.7480756932177	57.337498070666385
579.1211945193614	10.232195480649835	0.242	56	42	UCS	GEMCITABINE	Approved in other pathologies	KRAS|TP53|PTEN	544.2787794666872	-90.80650608968843
295.77882379231164	-10.277386769783277	0.032	56	42	UCS	EMODIN	Clinical trials	ERBB2|PIK3CA|TP53	348.29932323040117	-121.71070723604626
1463.824290893984	-40.56158322774593	0.8720000000000001	56	41	UCS	ENCORAFENIB	Approved in cancer	KRAS|TP53|PTEN	1395.248364953402	-66.51174925298508
1382.3938832888568	-47.68298517779897	0.8420000000000001	56	39	UCS	ABEMACICLIB	Approved in cancer	ERBB2|KRAS|TP53	1311.4247319153612	8.702278552300271
1398.7175463055748	-101.51369949325905	0.8420000000000001	56	39	UCS	VORINOSTAT	Approved in cancer	RB1|TP53|PTEN	1338.0784843498577	258.2228301636122
1383.3628913530476	47.467701157468696	0.8420000000000001	56	39	UCS	VEMURAFENIB	Approved in cancer	PIK3CA|TP53|PTEN	1337.039731155501	21.985778141400658
1373.802992881304	109.2735730647708	0.8320000000000001	56	39	UCS	CRIZOTINIB	Approved in cancer	ERBB2|KRAS|TP53	1280.9831199873072	121.61263279512053
1405.5341163175435	-64.91499687158128	0.8520000000000001	56	39	UCS	PAZOPANIB	Approved in cancer	KRAS|TP53	1373.5109767638733	55.43103191911041
831.782471684438	40.387414659952185	0.432	56	39	UCS	ADAVOSERTIB	Clinical trials in cancer	KRAS|TP53	767.4612948020255	0.9166230914682956
846.077907761727	-56.646682638306984	0.442	56	39	UCS	BERZOSERTIB	Clinical trials in cancer	KRAS|TP53	751.3255189192641	-135.48625288605018
277.3575848926751	13.309540571426425	0.022	56	39	UCS	LY3009120	Clinical trials	KRAS|TP53	335.045621326131	128.09059426025777
251.8770636689565	34.53802866123007	0.0004	56	39	UCS	PF-477736	Experimental	KRAS|TP53	174.2899781431408	140.2852263494526
1352.015773955807	90.95028847136376	0.8220000000000001	56	38	UCS	TEMOZOLOMIDE	Approved in cancer	TP53|PTEN	1182.7718826488456	-37.610359217358194
823.317218166469	9.713320611111982	0.422	56	38	UCS	ONC201	Clinical trials in cancer	TP53|PTEN	749.145370683741	-20.916485401964252
1360.0741589251645	31.61489778077049	0.8220000000000001	56	37	UCS	LORLATINIB	Approved in cancer	RB1|TP53	1312.3980421211918	-24.066021234085753
1381.426752692796	-79.38304794374596	0.8320000000000001	56	37	UCS	METHOTREXATE	Approved in same tumor type	RB1|TP53	1339.3343182533395	-29.23530004875775
1097.5177063510582	-49.47601219024375	0.622	56	37	UCS	MERCAPTOPURINE	Approved in other pathologies and in clinical trials in cancer	RB1|TP53	1059.5213486725759	-68.33418222687598
891.8452277572711	47.35047416361664	0.463	56	37	UCS	SELICICLIB	Clinical trials in cancer	RB1|TP53	858.826673700465	-6.470379801719901
1357.9275033405145	58.57462102341714	0.8220000000000001	56	36	UCS	CAPMATINIB	Approved in cancer	TP53	1226.6790272439468	33.24666146259668
1360.0202129771017	2.635316946592013	0.8320000000000001	56	36	UCS	CICLOPHOSPHAMIDE	Approved in cancer	ERBB2|TP53	1419.8622929589628	58.2273821630078
1337.315673920277	17.075667985958802	0.8220000000000001	56	36	UCS	DAUNORUBICIN HYDROCHLORIDE	Approved in cancer	TP53	1236.8908153145471	-127.92125794857614
1327.8934905839692	-82.45770972720833	0.8220000000000001	56	36	UCS	DOXORUBICIN HYDROCHLORIDE	Approved in cancer	TP53	1286.9792881802252	148.74345965997537
1322.7187758765333	-32.397575401137516	0.8220000000000001	56	36	UCS	ETOPOSIDE	Approved in cancer	TP53	1227.9560802771623	-180.45782262021473
1313.4331191798221	29.024777311279877	0.812	56	36	UCS	IFOSFAMIDE	Approved in cancer	TP53	1159.5445934686672	-216.730853490625
1298.8455342624814	-20.579383297356628	0.812	56	36	UCS	MECHLORETHAMINE HYDROCHLORIDE	Approved in cancer	TP53	1165.5948318354574	202.04727357585256
1335.7554582043256	43.68169215923888	0.8220000000000001	56	36	UCS	MELPHALAN	Approved in cancer	TP53	1204.6229422856368	-222.19781354521706
1333.9071150071545	-56.49423154262094	0.8220000000000001	56	36	UCS	METHYLPREDNISOLONE	Approved in cancer	TP53	1309.5030804322364	-183.40813146396178
1307.4115624002507	-54.24331525905815	0.8220000000000001	56	36	UCS	MITOXANTRONE	Approved in cancer	TP53	1239.6879690416833	229.6389743962365
1336.3256439721192	-9.50187844072559	0.8220000000000001	56	36	UCS	MITOXANTRONE HYDROCHLORIDE	Approved in cancer	TP53	1204.4370544978747	-0.2846166338006526
1311.6639290776773	55.6221219084168	0.812	56	36	UCS	RITUXIMAB	Approved in cancer	TP53	1231.7844449096847	-57.33228186290256
1359.6405896661765	-63.51365957942561	0.8220000000000001	56	36	UCS	TAMOXIFEN CITRATE	Approved in cancer	TP53	1312.4554813729458	-55.30604887082349
1312.4203566176377	2.42631861461291	0.812	56	36	UCS	TRABECTEDIN	Approved in cancer	TP53	1200.1532908186978	71.60715427036865
1333.9492825678697	70.35669572521209	0.8220000000000001	56	36	UCS	TRIFLURIDINE	Approved in cancer	ERBB2|TP53	1246.592744095959	81.8187196008472
1278.8951924344108	0.3893853764545838	0.762	56	36	UCS	ASPIRIN	Approved in other pathologies and in clinical trials in cancer	TP53	1165.0891706294174	96.25725585463658
1089.66302486444	57.99266457099898	0.622	56	36	UCS	CLADRIBINE	Approved in other pathologies and in clinical trials in cancer	TP53	1060.7320872733658	7.298627450921572
1073.5242428892998	-36.97466269237847	0.622	56	36	UCS	AZACITIDINE	Approved in other pathologies and in clinical trials in cancer	TP53	999.2876988326313	-115.24557884518414
1071.5688967247384	-10.316438975141352	0.622	56	36	UCS	CHLORAMBUCIL	Approved in other pathologies and in clinical trials in cancer	ERBB2|TP53	1031.1430973799233	90.54189244441915
1119.55581042931	-33.750126198997776	0.632	56	36	UCS	DAUNORUBICIN	Approved in other pathologies and in clinical trials in cancer	TP53	1095.114276219458	-104.30802065258186
1117.685629529094	-6.91280358808595	0.632	56	36	UCS	ENALAPRIL	Approved in other pathologies and in clinical trials in cancer	TP53	1037.3436947964576	20.21081372050918
1091.6263708787997	31.373254929471898	0.622	56	36	UCS	FENOFIBRATE	Approved in other pathologies and in clinical trials in cancer	TP53	1072.115005452692	167.59646570331347
1113.7200015464155	46.35387967261644	0.632	56	36	UCS	FLUPHENAZINE	Approved in other pathologies and in clinical trials in cancer	TP53	1096.1630505046733	58.77648759142747
1115.6774673639964	19.728341800069387	0.622	56	36	UCS	HALOPERIDOL	Approved in other pathologies and in clinical trials in cancer	TP53	1002.3738769816683	-88.70860348473892
1047.5240554365198	1.3171224536580155	0.612	56	36	UCS	HYDRALAZINE HYDROCHLORIDE	Approved in other pathologies and in clinical trials in cancer	TP53	1025.3132342618842	64.47005605875242
1069.5904583088131	16.336745646609415	0.622	56	36	UCS	LOPERAMIDE	Approved in other pathologies and in clinical trials in cancer	TP53	1079.4690001598062	-51.89934856099592
1049.4937677252265	-25.3065540523626	0.612	56	36	UCS	METHYLENE BLUE CATION	Approved in other pathologies and in clinical trials in cancer	TP53	1045.5056818955643	169.97940552407601
1067.5688811694313	42.9616024380023	0.612	56	36	UCS	THIAMAZOLE	Approved in other pathologies and in clinical trials in cancer	TP53	1045.684646920367	215.64095517816833
1093.6210226384087	4.6900211895673465	0.622	56	36	UCS	THIORIDAZINE HYDROCHLORIDE	Approved in other pathologies and in clinical trials in cancer	TP53	1028.952031200759	-55.729126712029654
1095.5875711008505	-21.953502270707816	0.622	56	36	UCS	WARFARIN	Approved in other pathologies and in clinical trials in cancer	TP53	1043.0080421953228	-88.75574957433601
864.3042474156995	-35.67514329165604	0.452	56	36	UCS	GENISTEIN	Clinical trials in cancer	TP53	843.0428093251238	91.18486916275498
964.7600083926848	-0.8216288100023235	0.532	56	36	UCS	KEVETRIN	Clinical trials in cancer	TP53	912.0428954180742	-137.3768542320256
809.6247605277432	57.17003504807866	0.412	56	36	UCS	1026680-07-8	Clinical trials in cancer	TP53	669.4748889772115	-50.45210229113431
883.1817385817124	21.70213833955512	0.452	56	36	UCS	2-PHENYLETHYL ISOTHIOCYANATE	Clinical trials in cancer	TP53	788.4241626367451	-179.69907731826314
785.7828367057294	-18.803823131986064	0.412	56	36	UCS	ALVESPIMYCIN	Clinical trials in cancer	TP53	695.8395986700759	156.8704430577962
798.2194806291722	-42.435991175710086	0.412	56	36	UCS	AVASTIN	Clinical trials in cancer	TP53	718.5031286898209	38.33058389617182
784.7846152049594	47.33012091912812	0.412	56	36	UCS	CARBENDAZIM	Clinical trials in cancer	TP53	690.5198945394263	111.2774307549559
775.232709679406	22.387035716941938	0.412	56	36	UCS	FENRETINIDE	Clinical trials in cancer	TP53	678.7001788540927	-8.72348204388939
812.2883916634921	-15.375643112155586	0.422	56	36	UCS	GANETESPIB	Clinical trials in cancer	TP53	674.3341165213583	48.06225433967589
824.7327150144781	-38.96832652448066	0.422	56	36	UCS	NORDIHYDROGUAIARETIC ACID	Clinical trials in cancer	TP53	709.6385467717918	13.128403827322472
805.7271299204115	30.745780593432443	0.432	56	36	UCS	QUINACRINE DIHYDROCHLORIDE	Clinical trials in cancer	TP53	715.6108815589707	-38.62191208863513
796.1387072488127	5.8097262653467965	0.422	56	36	UCS	TIRAPAZAMINE	Clinical trials in cancer	TP53	753.0081107834719	85.50298172971753
711.8188954541231	0.4393989777547347	0.3320000000000001	56	36	UCS	ZINC	Approved in other pathologies	TP53	627.3042331752715	-31.25877191006336
685.0945973792411	0.4401019152699064	0.3320000000000001	56	36	UCS	ZINC ACETATE	Approved in other pathologies	TP53	629.6097257570946	21.140237149372666
698.450492804495	23.575624002409484	0.3320000000000001	56	36	UCS	ZINC CHLORIDE	Approved in other pathologies	TP53	625.659687246753	-88.71144786585911
698.449276818767	-22.696123201127875	0.3320000000000001	56	36	UCS	ZINC SULFATE	Approved in other pathologies	TP53	620.5559708699536	-3.9948688641776755
561.6888812476589	-12.765600457161696	0.2329999999999999	56	36	UCS	TRIFLUOPERAZINE	Approved in other pathologies	TP53	508.49657119610526	-22.1226033479756
536.4281073473612	0.39642504313030713	0.212	56	36	UCS	(S)-FLUOXETINE	Approved in other pathologies	TP53	472.704630456767	48.19480233894532
1400.5098212155679	19.48573337549817	0.8520000000000001	80	72	UVM	TRAMETINIB	Approved in cancer	FGFR2|GNAQ|GNA11	1429.2796847498912	4.573838561842564
1428.8979493165562	-4.2461815011917565	0.8720000000000001	80	72	UVM	BINIMETINIB	Approved in cancer	GNAQ|GNA11	1412.6757874652128	-306.96910311981776
1384.435130186431	-13.840612952647632	0.8420000000000001	80	72	UVM	EVEROLIMUS	Approved in cancer	GNAQ|GNA11	1336.1231876893278	193.04141479695102
1130.1793201414125	0.43071874597703186	0.652	80	72	UVM	SELUMETINIB	Approved in other pathologies and in clinical trials in cancer	FGFR2|GNAQ|GNA11	1130.3955154005453	7.527978899534759
850.1686856398667	13.168465230433213	0.442	80	72	UVM	TAK-733	Clinical trials in cancer	GNAQ|GNA11	767.461518298708	-99.62996711153937
852.61626619374	-23.755977851102415	0.442	80	72	UVM	NVP-CGM097	Clinical trials in cancer	GNAQ|GNA11	762.0970247202514	158.1569787477817
813.316434120646	16.5204021530962	0.422	80	72	UVM	SOTRASTAURIN	Clinical trials in cancer	GNAQ|GNA11	724.6937901777471	-103.34058158947322
1076.1479633734384	0.4299234291389098	0.612	80	38	UVM	VISUDYNE (TN)	Approved in other pathologies and in clinical trials in cancer	GNAQ	1032.1178787446504	-161.94572282820315
829.779346896447	-6.748563253718231	0.432	80	38	UVM	ENZASTAURIN	Clinical trials in cancer	GNAQ	748.6305206903806	20.89012447567484
810.4389957851783	-11.842439719835397	0.422	80	38	UVM	MIRDAMETINIB	Clinical trials in cancer	GNAQ	730.9717246406428	-56.21940031164981
276.0149362125158	1.1074137542173048	0.022	80	38	UVM	REFAMETINIB	Clinical trials	GNAQ	279.0906859080342	113.52202016051774
295.9843060252689	0.0008299436466927546	0.032	80	38	UVM	OMIPALISIB	Clinical trials	GNAQ	338.0078106207557	-55.21236255098067
1359.2669711819533	0.4043503823617698	0.8220000000000001	80	1	UVM	ALPELISIB	Approved in cancer	FGFR2	1286.7036477421564	13.045677124359884
1504.1403876315815	0.4320228250028322	0.93	80	1	UVM	INFIGRATINIB	Approved in cancer	FGFR2	1497.2310706671049	-55.040912940199405
1502.6403876322645	0.4319775584838226	0.928	80	1	UVM	NINTEDANIB	Approved in cancer	FGFR2	1505.1165731459796	-41.3026029577706
1496.8813695467156	0.4323560011817449	0.924	80	1	UVM	REGORAFENIB	Approved in cancer	FGFR2	1428.0149535539065	-25.898113663519524
1485.1953972688073	-0.25578135103071986	0.916	80	1	UVM	ERDAFITINIB	Approved in cancer	FGFR2	1491.1938080590758	26.847810090017816
1485.5556417776859	1.2010735280720155	0.916	80	1	UVM	PEMIGATINIB	Approved in cancer	FGFR2	1443.7979612868803	76.20808594660463
1483.7539957426688	-0.6682804651180732	0.914	80	1	UVM	THALIDOMIDE	Approved in cancer	FGFR2	1452.6024833742108	-123.29358841186064
1483.0391613400661	1.83074993032713	0.913	80	1	UVM	LENVATINIB	Approved in cancer	FGFR2	1405.360424421001	-17.672807883580276
1481.597670118673	1.4181499383949188	0.912	80	1	UVM	NINTEDANIB ESYLATE	Approved in cancer	FGFR2	1504.0778785668542	-50.40892963543084
1481.232486055831	-0.0368897195441491	0.912	80	1	UVM	PRALSETINIB	Approved in cancer	FGFR2	1501.7382897646173	7.438666776359099
1482.312086057295	-1.0800639399179772	0.912	80	1	UVM	SELPERCATINIB	Approved in cancer	FGFR2	1500.2975684947758	92.14181045882987
1346.8377069865464	-1.1434332757922334	0.812	80	1	UVM	CETUXIMAB	Approved in cancer	FGFR2	1309.405893072364	122.3307276166422
1346.5122467979224	0.3190460886513904	0.812	80	1	UVM	GEFITINIB	Approved in cancer	FGFR2	1266.5771403993813	40.995414140031016
1347.6151370096807	1.3336710608213878	0.812	80	1	UVM	LAPATINIB	Approved in cancer	FGFR2	1268.1903202393576	5.635826710425221
1345.4060466943486	-0.6917534885243981	0.812	80	1	UVM	PAZOPANIB	Approved in cancer	FGFR2	1309.7065197470226	50.00907189571018
1346.1857857880957	1.7860129081761045	0.812	80	1	UVM	SUNITINIB	Approved in cancer	FGFR2	1291.3723832644778	-11.971532704111212
1345.080690191364	0.7717330100917934	0.812	80	1	UVM	TRABECTEDIN	Approved in cancer	FGFR2	1246.540611439198	95.91880499275447
1237.8208235179243	0.43196793830790625	0.7320000000000001	80	1	UVM	FOSTAMATINIB	Approved in other pathologies and in clinical trials in cancer	FGFR2	1154.2318059997306	-1.7178329369048981
1231.0678663179865	0.4370103604502731	0.7270000000000001	80	1	UVM	PONATINIB	Approved in other pathologies and in clinical trials in cancer	FGFR2	1174.240442263244	20.388709339046585
1224.775101567061	1.2940460595570755	0.7220000000000001	80	1	UVM	SEMULOPARIN	Approved in other pathologies and in clinical trials in cancer	FGFR2	1173.5903104913364	-25.996457630517654
819.2526508655567	-1.7980910580411091	0.422	80	1	UVM	PICTILISIB	Clinical trials in cancer	FGFR2	764.964821467567	15.324696051282558
827.7715423472215	3.811577127618051	0.422	80	1	UVM	BUPARLISIB	Clinical trials in cancer	FGFR2	765.5801235406858	-18.573763325887057
955.418825525903	0.4209584293501223	0.523	80	1	UVM	XL228	Clinical trials in cancer	FGFR2	885.6448779632796	13.701698792572301
953.9188257935843	0.4200623027165591	0.522	80	1	UVM	MASITINIB	Clinical trials in cancer	FGFR2	888.0555661438511	15.004316234069307
946.6929257107614	0.39660378724391876	0.517	80	1	UVM	DOVITINIB	Clinical trials in cancer	FGFR2	900.7744466098467	57.96003928943762
943.6741869491871	1.4616862269956812	0.514	80	1	UVM	ENMD-2076	Clinical trials in cancer	FGFR2	886.6622212738215	14.412580613324934
942.3975248614171	0.6746282907536454	0.513	80	1	UVM	LUCITANIB	Clinical trials in cancer	FGFR2	919.9991841326922	80.84276442760563
942.4425941365372	-0.8255025005226457	0.513	80	1	UVM	LY2874455	Clinical trials in cancer	FGFR2	901.5458956569914	43.246760246802324
941.0730116451648	-0.21703682405157565	0.511	80	1	UVM	497839-62-0	Clinical trials in cancer	FGFR2	879.8110511308683	28.27583687104658
801.296654168496	1.4809958882278806	0.413	80	1	UVM	BRIVANIB	Clinical trials in cancer	FGFR2	774.3650699780202	13.511098336510258
805.6727934238091	-2.225369076678305	0.413	80	1	UVM	DERAZANTINIB	Clinical trials in cancer	FGFR2	759.6597605867075	13.535629950696432
807.0339968281087	-1.6441639179557797	0.413	80	1	UVM	FUTIBATINIB	Clinical trials in cancer	FGFR2	749.0952642387781	-45.3103050386014
804.4138356964024	-2.9682454330865085	0.413	80	1	UVM	ROGARATINIB	Clinical trials in cancer	FGFR2	739.9832888144259	-50.298136387271455
803.2204078293156	-3.8536734082371424	0.412	80	1	UVM	AZD4547	Clinical trials in cancer	FGFR2	710.4727984093383	-51.93901876324094
803.7540802473893	-0.1617936649663818	0.412	80	1	UVM	CEDIRANIB	Clinical trials in cancer	FGFR2	762.8014417838589	-28.044724129223113
802.437377609388	-0.9151730237770153	0.412	80	1	UVM	FP-1039	Clinical trials in cancer	FGFR2	760.9408332374961	-57.994004192450845
802.4827381033499	0.5912803098715642	0.412	80	1	UVM	ORANTINIB	Clinical trials in cancer	FGFR2	738.4862401722776	43.50790543531744
802.1923378157666	-4.945055884942207	0.412	80	1	UVM	PI-88	Clinical trials in cancer	FGFR2	690.9294203884263	-81.9059178740741
803.7435707540411	-1.6581000215255983	0.412	80	1	UVM	TASURGRATINIB	Clinical trials in cancer	FGFR2	771.0928504541205	-15.668799557168029
802.5231251003065	-2.5301727795672946	0.412	80	1	UVM	TYROSINE KINASE-IN-1	Clinical trials in cancer	FGFR2	749.842114203307	-45.54016740564592
281.0359752302793	10.614262037663451	0.022	80	1	UVM	RO4987655	Clinical trials	FGFR2	224.93669858571974	49.60622707319496
401.2985859466246	0.43353701522545407	0.112	80	1	UVM	TRAFERMIN	Clinical trials	FGFR2	375.988561044465	5.513495820775432
265.26924272578754	1.2671572361884387	0.012	80	1	UVM	BRIVANIB ALANINATE	Clinical trials	FGFR2	218.5727218056536	30.708949191160144
265.35162419098555	-0.23057882005718966	0.012	80	1	UVM	ZOLIGRATINIB	Clinical trials	FGFR2	239.23890424322673	-14.750293430267675
250.6116259438015	2.827343910968125	0.0008	80	1	UVM	3-[4-(1-FORMYLPIPERAZIN-4-YL)-BENZYLIDENYL]-2-INDOLINONE	Experimental	FGFR2	189.13045599926735	75.0853494376081
253.15197303111313	-0.21837138481726015	0.0008	80	1	UVM	4-ARYL-2-PHENYLAMINO PYRIMIDINE	Experimental	FGFR2	220.13391531677587	-21.018113027473305
250.19547907929842	0.2670214749899458	0.0008	80	1	UVM	APRUTUMAB	Experimental	FGFR2	242.44235401229326	41.035661042774876
252.0886890221266	2.587850298537745	0.0008	80	1	UVM	BEMARITUZUMAB	Experimental	FGFR2	266.89929424680804	5.811846781349232
253.5689831158657	2.334437383861058	0.0008	80	1	UVM	FORESKIN FIBROBLAST (NEONATAL)	Experimental	FGFR2	201.7393760536468	81.72691257590469
251.67274319846203	0.02205522085893108	0.0008	80	1	UVM	FORESKIN KERATINOCYTE (NEONATAL)	Experimental	FGFR2	263.88552906859564	79.44457269489061
252.6209380199945	1.1811079972565324	0.0008	80	1	UVM	MK-2461	Experimental	FGFR2	209.9130352892006	0.9248798442288262
252.20402685217468	-1.378764903487621	0.0008	80	1	UVM	SUCROSOFATE	Experimental	FGFR2	185.26211300173856	-90.57939146279257
251.24501135311766	-2.536530117461382	0.0004	80	1	UVM	867331-82-6	Experimental	FGFR2	164.32026385155615	63.75375569330919
249.24626034325541	-0.8933850749869521	0.0004	80	1	UVM	882531-87-5	Experimental	FGFR2	239.0136649757186	-14.810100525455624
248.7187775892109	0.506963248757387	0.0004	80	1	UVM	CP-459632	Experimental	FGFR2	205.27569895591532	-2.1153206666214714
250.72623741876535	-1.1313584671731292	0.0004	80	1	UVM	GSK3052230	Experimental	FGFR2	237.67183233792835	20.38986135365576
251.14398998558428	1.4241461268222224	0.0004	80	1	UVM	PHA-665752	Experimental	FGFR2	233.7136263122996	-15.151767238701865
1484.1173300999287	0.7869635315155392	0.914	80	1	UVM	ABIRATERONE	Approved in cancer	CYP17A1	1375.3239350719641	-74.8346461725849
1482.6751235300874	0.3746042101628859	0.913	80	1	UVM	ABIRATERONE ACETATE	Approved in cancer	CYP17A1	1380.5592258570623	8.043983235865255
1224.1598770106414	-0.07519862557433044	0.7220000000000001	80	1	UVM	PROGESTERONE	Approved in other pathologies and in clinical trials in cancer	CYP17A1	1160.1549327936827	-20.437740692162293
1225.6522434988697	0.0759379509161704	0.7220000000000001	80	1	UVM	SPIRONOLACTONE	Approved in other pathologies and in clinical trials in cancer	CYP17A1	1174.4168107115804	-25.401132413282596
1211.492475415728	0.42878760642068414	0.7120000000000001	80	1	UVM	KETOCONAZOLE	Approved in other pathologies and in clinical trials in cancer	CYP17A1	1154.844209081099	25.002382815211945
943.7184777888162	-0.03762540544536819	0.514	80	1	UVM	ORTERONEL	Clinical trials in cancer	CYP17A1	901.975340654178	58.80690894213666
941.0263247816358	1.2822364449874613	0.511	80	1	UVM	SEVITERONEL	Clinical trials in cancer	CYP17A1	925.6860013268055	-39.34614066181149
805.0705429714458	-0.8641962364404776	0.414	80	1	UVM	GALETERONE	Clinical trials in cancer	CYP17A1	739.8950077189835	42.86232266591995
698.3935546774089	0.41976490912983877	0.3320000000000001	80	1	UVM	CANNABIDIOL	Approved in other pathologies	CYP17A1	631.9307654427746	6.347004473631074
441.5773634434779	0.4325429995804484	0.142	80	1	UVM	MEDICAL CANNABIS	Clinical trials	CYP17A1	398.7325063902433	14.44792472417268
428.19226006986975	0.4327802163919614	0.132	80	1	UVM	NABIXIMOLS	Clinical trials	CYP17A1	389.2556907726387	-10.41498521094357
399.7985859602121	0.4333351179134297	0.111	80	1	UVM	CFG920	Clinical trials	CYP17A1	374.58222915677374	6.033359850742471
249.66418927157335	1.66948231352805	0.0008	80	1	UVM	NADH	Experimental	CYP17A1	285.9682136630779	-50.02425795449284
